---
document_datetime: 2023-09-21 21:24:15
document_pages: 177
document_pathfilename: www.ema.europa.eu/en/documents/variation-report/jakavi-h-c-2464-ii-0053-epar-assessment-report-variation_en.pdf
document_name: jakavi-h-c-2464-ii-0053-epar-assessment-report-variation_en.pdf
version: success
processing_time: 266.7023626
conversion_datetime: 2025-12-22 22:37:35.44189
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

24 March 2022 EMA/231935/2022 Committee for Medicinal Products for Human Use (CHMP)

## Assessment report

## Jakavi

International non-proprietary name: ruxolitinib

Procedure No. EMEA/H/C/002464/II/0053

## Note

Variation assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted.

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Table of contents

| 1. Background information on the procedure                                                                                  | ..............................................7                                                         |
|-----------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------|
| 1.1. Type II variation ..................................................................................................7  |                                                                                                         |
| 1.2. Steps taken for the assessment of the product.........................................................8                |                                                                                                         |
| 2. Scientific discussion                                                                                                    | ................................................................................8                       |
| 2.1. Introduction.........................................................................................................8 |                                                                                                         |
| 2.1.1. Problem statement                                                                                                    | ............................................................................................9           |
| 2.1.2. Management...................................................................................................11      |                                                                                                         |
| 2.1.3. About the product............................................................................................12      |                                                                                                         |
| 2.1.4. The development programme/compliance with CHMP guidance/scientific advice                                            | ......12                                                                                                |
| 2.1.5. General comments on compliance with GCP                                                                              | .......................................................13                                               |
| 2.2. Quality aspects                                                                                                        | ..................................................................................................13    |
| 2.3. Non-clinical aspects                                                                                                   | ............................................................................................14          |
| 2.3.1. Pharmacology                                                                                                         | .................................................................................................14     |
| 2.3.2. Ecotoxicity/Environmental risk assessment                                                                            | .........................................................14                                             |
| 2.3.3. Conclusion on the non-clinical aspects................................................................14             |                                                                                                         |
| 2.4. Clinical aspects                                                                                                       | ..................................................................................................15    |
| 2.4.1. Introduction....................................................................................................15   |                                                                                                         |
| 2.4.2. Pharmacokinetics.............................................................................................16      |                                                                                                         |
| 2.4.3. PK/PD modelling..............................................................................................24      |                                                                                                         |
| 2.4.4. Discussion on clinical pharmacology...................................................................28             |                                                                                                         |
| 2.4.5. Conclusions on clinical pharmacology.................................................................30              |                                                                                                         |
| 2.5. Clinical efficacy                                                                                                      | ..................................................................................................30    |
| 2.5.1. Dose-selection rationale                                                                                             | ...................................................................................30                   |
| 2.5.2. Main studies                                                                                                         | ...................................................................................................31   |
| 2.5.3. Steroid refractory acute GvHD...........................................................................31           |                                                                                                         |
| 2.5.4. Steroid refractory chronic GvHD........................................................................75            |                                                                                                         |
| 2.5.5. Discussion on clinical efficacy..........................................................................            | 117                                                                                                     |
| 2.5.6. Conclusions on the clinical efficacy...................................................................              | 123                                                                                                     |
| 2.6. Clinical safety                                                                                                        | .................................................................................................. 124  |
| 2.6.1. Discussion on clinical safety ............................................................................           | 157                                                                                                     |
| 2.6.2. Conclusions on clinical safety ..........................................................................            | 160                                                                                                     |
| 2.6.3. PSUR cycle                                                                                                           | ................................................................................................... 160 |
| 2.7. Risk management plan......................................................................................             | 160                                                                                                     |
| 2.8. update of the Product Information......................................................................                | 162                                                                                                     |
| 2.8.1. User consultation...........................................................................................         | 162                                                                                                     |
| 3. Benefit-Risk Balance............................................................................163                      |                                                                                                         |
| 3.1. Therapeutic Context                                                                                                    | ......................................................................................... 163           |
| 3.1.1. Disease or condition.......................................................................................          | 163                                                                                                     |
| 3.1.2. Available therapies and unmet medical need.....................................................                      | 164                                                                                                     |
| 3.1.3. Main clinical studies                                                                                                | ....................................................................................... 164             |
| 3.2. Favourable effects ............................................................................................        | 164                                                                                                     |
| 3.3. Uncertainties and limitations about favourable effects...........................................                      | 165                                                                                                     |
| 3.4. Unfavourable effects.........................................................................................          | 167                                                                                                     |

<div style=\"page-break-after: always\"></div>

3.5. Uncertainties and limitations about unfavourable effects ....................................... 169

3.6. Effects Table  ....................................................................................................  169

3.7. Benefit-risk assessment and discussion  ............................................................... 175

3.7.1. Importance of favourable and unfavourable effects  ............................................ 175

3.8. Conclusions .....................................................................................................  176

4. Recommendations ...............................................................................  176

5. EPAR changes  ......................................................................................  177

<div style=\"page-break-after: always\"></div>

## List of abbreviations

ADR

Adverse Drug Reaction

AE

Adverse Event

AESI

Adverse Event of Special Interest

aGvHD

Acute Graft vs. Host Disease

alloSCT

Allogeneic Stem Cell Transplantation

ALL

Acute Lymphoblastic Leukemia

ALP

Alkaline Phosphatase

ALT

Alanine aminotransferase

AML

Acute Myeloid Leukemia

ANC

Absolute Neutrophils Count

AST

Aspartate aminotransferase

ATC

Anatomical Therapeutic Chemical

ATG

Anti-Thymocyte Globulin

BID

bis in diem/twice a day

BALT

Bone Alkaline Phosphatase

BAT

Best Available Therapy

b.i.d.

bis in diem/twice a day

BOR

Best Overall Response

CAS

Cross over Analysis Set

cGvHD

chronic Graft vs. Host Disease

CIBMTR

Center for International Blood and Marrow Transplant Research

CMH

Cochrane-Mantel-Haenszel

CMV

Cytomegalovirus

CNI

Calcineurin Inhibitor

CV

Coefficient of variation

COVID-19

COVID-19

CR

Complete response

CRF

Case Report/Record Form; the term CRF can be applied to either EDC or Paper

CSR

Clinical Study Report

CTCAE

Common Terminology Criteria for Adverse Events

Ctrough

Minimum concentration

CYP3A

Cytochrome P450, family 3, subfamily A

CYP450

Cytochrome P450

EDTA

Ethylenediaminetetraacetic acid

DILI

Drug-Induced Liver Injury

DLI

Donor Lymphocyte Infusion

DMC

Data Monitoring Committee

DOR

Duration of Response

EBV

Epstein-Barr Virus

ECOG

Eastern Cooperative Oncology Group

ECP

Extracorporeal Photopheresis

eCRF

Electronic Case Report/Record Form

EDC

Electronic Data Capture

EFS

Event-Free Survival

EOS

End of Study

EOT

End of treatment

FACT-BMT

Functional Assessment of Cancer Therapy - Bone Marrow Transplantation

<div style=\"page-break-after: always\"></div>

| FAS                             | Full Analysis Set                              |
|---------------------------------|------------------------------------------------|
| FFS                             | Failure-Free Survival                          |
| GGT                             | Gamma-Glutamyl Transferase                     |
| GI                              | Gastro-Intestinal                              |
| GvHD                            | Graft vs. Host Disease                         |
| GvL                             | Graft vs. Leukemia                             |
| HLA                             | Human leukocyte antigen                        |
| HBV                             | Hepatitis B Virus                              |
| HCV                             | Hepatitis C Virus                              |
| HCT                             | Hematopoietic Cell Transplantation             |
| HDL                             | High Density Lipoprotein                       |
| HHV-6                           | Human Herpes Virus                             |
| HIV                             | Human Immunodeficiency Virus                   |
| HLA                             | Human Leukocyte Antigen                        |
| HR                              | Heart rate                                     |
| HSCT                            | Hematopoietic stem cell transplantation        |
| ICF                             | Informed consent form                          |
| ICH                             | International Council on Harmonization         |
| ICU                             | Intensive Care Unit                            |
| IEC                             | Independent Ethics Committee                   |
| IFN                             | Interferon                                     |
| IL                              | Interleukin                                    |
| IRB                             | Institutional Review Board                     |
| interactive Web Response System | interactive Web Response System                |
| ITT                             | Intent To Treat                                |
| JAK                             | Janus kinase                                   |
| K-M                             | Kaplan-Meier                                   |
| LDL                             | Low Density Lipoprotein                        |
| LC-MS/MS                        | Liquid Chromatography-tandem Mass Spectrometry |
| LLOQ                            | Lower limit of quantification                  |
| LMWH                            | Low molecular weight heparin                   |
| MCH                             | Mean Corpuscular Hemoglobin                    |
| MDS                             | Myelodysplastic Syndromes                      |
| MedDRA                          | Medical dictionary for regulatory activities   |
| MMF                             | Mycophenolate mofetil                          |
| MF                              | Myelofibrosis                                  |
| MPNs                            | Myeloproliferative Neoplasms                   |
| MR                              | Malignancy Relapse/Progression                 |
| MSC                             | Mesenchymal Stromal Cells                      |
| mTOR                            | Mammalian Target of Rapamycin                  |
| MTX                             | Methotrexate                                   |
| NCA                             | Non-compartmental analysis                     |
| NIH                             | National Institutes of Health                  |
| NMSC                            | Non-Melanoma Skin Cancer                       |
| NRM                             | Non Relapse Mortality                          |
| NSAID                           | Nonsteroidal anti-inflammatory drug            |
| o.d.                            | omnia die/once a day Odds ratio / Overall      |
| OR                              | Response                                       |

<div style=\"page-break-after: always\"></div>

| ORR      | Overall Response Rate                                        |
|----------|--------------------------------------------------------------|
| OS       | Overall Survival                                             |
| PAS      | Pharmacokinetic analysis set                                 |
| PGIC     | Patient global impression of change                          |
| PGIS     | Patient global impression of severity                        |
| PK       | Pharmacokinetics                                             |
| PPS      | Per-Protocol Set                                             |
| PV       | polycythemia vera                                            |
| PR       | Partial response                                             |
| PRO      | Patient Reported Outcomes                                    |
| PT       | Preferred term                                               |
| PTT      | Partial thromboplastin time                                  |
| PTY      | Patient treatment years (instead of Subject treatment years) |
| QD       | quaque die, once a day                                       |
| QC       | Quality control                                              |
| QOL      | Quality of Life                                              |
| RAEB     | Refractory anemia with excess blasts                         |
| RBC      | Red blood cell                                               |
| RDI      | Relative Dose Intensity                                      |
| ROW      | Rest of the World                                            |
| SAE      | Serious Adverse Event                                        |
| SAP      | Statistical analysis plan                                    |
| SCT      | Stem cell transplantation                                    |
| SD       | standard deviation                                           |
| SMQ      | Standardized MedDRA Queries                                  |
| SOC      | System organ class                                           |
| SOS      | Sinusoidal Obstructive Syndrome                              |
| SR-cGvHD | Steroid refractory chronic Graft vs. Host Disease            |
| TNC      | Total nucleated dose                                         |
| TNF      | Tumor Necrosis Factor                                        |
| TSS      | Total symptom score                                          |
| ULN      | Upper limit of normal                                        |
| US       | United States of America                                     |
| ULOQ     | Upper limit of quantification                                |
| WBC      | White Blood Cells                                            |

<div style=\"page-break-after: always\"></div>

## 1. Background information on the procedure

## 1.1. Type II variation

Pursuant to Article 16 of Commission Regulation (EC) No 1234/2008, Novartis Europharm Limited submitted to the European Medicines Agency on 2 February 2021 an application for a variation.

The following changes were proposed:

| Variation requested   | Variation requested                                                                                                            | Type    | Annexes affected   |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a               | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of patients with GvHD aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies for Jakavi; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8. 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives for The Netherlands in the Package Leaflet.

The requested variation proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Information on paediatric requirements

Pursuant to Article 8 of Regulation (EC) No 1901/2006, the application included EMA Decisions P/0172/2021 (EMEA-000901-PIP03-16-M02) and P/0384/2019 (EMEA-000901-PIP04-17-M01) on the agreement of a paediatric investigation plan (PIP).

At the time of submission of the application, the P/0172/2021 (EMEA-000901-PIP03-16-M02) and P/0384/2019 (EMEA-000901-PIP04-17-M01) were not yet completed as some measures were deferred.

## Information relating to orphan market exclusivity

## Similarity

Pursuant to Article 8 of Regulation (EC) No. 141/2000 and Article 3 of Commission Regulation (EC) No 847/2000, the MAH did not submit a critical report addressing the possible similarity with authorised orphan medicinal products because there is no authorised orphan medicinal product for a condition related to the proposed indication.

## Scientific advice

Scientific Advice was sought at the CHMP on clinical development for the Phase III study D2301 protocol in chronic GvHD (Procedure No: EMEA/H/SA/1155/2/2016/II).

<div style=\"page-break-after: always\"></div>

## 1.2. Steps taken for the assessment of the product

The Rapporteur and Co-Rapporteur appointed by the CHMP were:

Rapporteur:

Filip Josephson

Co-Rapporteur:

Paula Boudewina van Hennik

| Timetable                                                                                       | Actual dates                     |
|-------------------------------------------------------------------------------------------------|----------------------------------|
| Submission date                                                                                 | 2 February 2021                  |
| Start of procedure:                                                                             | 26 April 2021                    |
| CHMP Co-Rapporteur's preliminary assessment report circulated on                                | 25 May 2021                      |
| CHMP/PRAC Rapporteurs preliminary joint assessment report circulated on                         | 26 May 2021                      |
| Updated PRAC Rapporteur's assessment report circulated on                                       | 3 June 2021                      |
| PRAC RMP advice and assessment overview adopted by PRAC on                                      | 10 June 2021                     |
| Updated CHMP Rapporteur's assessment report circulated on                                       | 18 June 2021                     |
| Request for supplementary information adopted by the CHMP on                                    | 24 June 2021                     |
| Summary report of the inspection as issued on MAH's responses submitted to the CHMP on          | 22 December 2021 14 October 2021 |
| CHMP/PRAC Rapporteurs preliminary 'joint assessment report on the MAH's responses circulated on | 16 November 2021                 |
| Updated PRAC Rapporteur's assessment report on the MAH's responses circulated on                | 26 November 2021                 |
| PRAC RMP advice and assessment overview adopted by PRAC on                                      | 2 December 2021                  |
| Updated CHMP Rapporteur's assessment report on the MAH's responses circulated on                | 9 December 2021                  |
| Request for supplementary information adopted by the CHMP on                                    | 16 December 2021                 |
|                                                                                                 | 20 January                       |
| MAH's responses submitted to the CHMP on                                                        | 2022                             |
| responses circulated on                                                                         |                                  |
| PRAC RMP advice and assessment overview adopted by PRAC on                                      | 10 March 2022                    |
| Updated CHMP Rapporteur's assessment report on the MAH's responses circulated on                | 17 March 2022                    |

## 2. Scientific discussion

## 2.1. Introduction

Ruxolitinib (Jakavi®/Jakafi®, INC424, INCB018424 phosphate) is an oral selective inhibitor of the Janus kinases (JAKs) JAK1 and JAK2. Ruxolitinib (Jakavi®) is currently indicated in EU and more than 100 countries for the treatment of disease-related splenomegaly or symptoms in adult patients with PMF, PPV-MF or PET-MF and for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.

<div style=\"page-break-after: always\"></div>

The target indication subject to this Type II variation, is to extend the indications for ruxolitinib, as follows:

- Jakavi is indicated for the treatment of patients with GvHD aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies.

## 2.1.1. Problem statement

Allogeneic hematopoietic stem cell transplantation (alloSCT) is a well-established procedure for the treatment of malignant and non-malignant hematological diseases (Copelan 2006). However, despite the curative potential of alloSCT, graft versus host disease (GvHD) is a major barrier to the efficacious outcome.

GvHD is an immunologically mediated, multi-organ disorder that occurs when donor-derived immune cells recognize the transplant recipient cells, organs and tissues as non-self, thereby initiating an adverse immune reaction leading to tissue damage, organ failure, or even death (Jagasia et al 2018, Greinix et al 2011, Ferrara et al 2009). GvHD It is the major cause of transplant-related morbidity and mortality, affecting up to 70% of HSCT recipients and accounting for 21-31% of deaths post-alloSCT among patients who received human leukocyte antigen (HLA)-matched sibling and 31-40% of deaths in patients receiving unrelated donor transplants (D'Souza and Fretham 2019, Jagasia et al 2018, Hill et al 2018, Zeiser and Blazar 2017, Pavletic and Fowler 2012).

GvHD is categorized into two main clinical forms namely acute GvHD (aGvHD) and chronic GvHD (cGvHD); although patients may also have disease characteristics of both, acute and chronic GvHD. Overlap syndrome, although infrequent, may occur with the presence of one or more features of aGvHD in patients with diagnosis of cGvHD or may develop clinical features of aGvHD after diagnosis of cGvHD (Jagasia et al 2015).

## Acute GvHD

Acute GvHD is mainly characterized by mature donor T cell-mediated inflammatory disease (Hill et al 2018, Zhang et al 2006). It usually presents early after engraftment, with a median time to onset (grade II-IV) of 20-25 days (Axt et al 2019, Flowers et al 2011). The clinical manifestations are seen primarily in three organs: the skin (maculopapular erythematous skin rash, erythroderma), the liver (cholestasis, hyperbilirubinemia, and/or jaundice), and the lower and upper gastrointestinal tract (nausea, abdominal pain, vomiting, anorexia with weight loss, secretory diarrhea, GI bleeding and/or ileus) (Schoemans et al 2018, Harris et al 2016, Dignan et al 2012, Jacobsohn and Vogelsang 2007).

The overall severity of aGvHD is graded from I (mild) to IV (life-threatening) according to the degree of involvement of the individual organs (Schoemans et al 2018). The diagnosis and clinical staging are assessed using a comprehensive and systematic approach for the determination of GvHD onset, confidence in the attribution of symptoms to aGvHD, and quantification of clinical severity of aGvHD in each target organ (The MAGIC criteria, Harris et al 2016). The extent of individual organ staging and overall grade of aGvHD is an important prognostic factor.

Among all patients who had alloSCT, the occurrence of aGvHD ranges from 30% to 50%, with 14% to 36% developing severe (grade III to IV) aGvHD (Malard et al 2020, Zeiser and Blazer 2017). The incidence of grade II-IV aGvHD in pediatric patients (2-12 years old) is lower than in adults, but adolescent patients (13-17 years old) can present higher rates, closer to that seen in adults (Gatza et al 2020, Qayed et al 2018).

The occurrence and severity of aGvHD depends on various factors including donor type (i.e., matched or unmatched, related or unrelated), older patient/donor age, gender disparity, multiparous female

<div style=\"page-break-after: always\"></div>

donors, intensity of transplant conditioning regimen, and absence of or suboptimal GvHD prophylaxis (Nassereddine et al 2017, Ringden et al 2009).

The likelihood of response to treatment decreases with increasing disease severity (Hill et al 2018). The overall aGvHD grade has major impact on the survival post HSCT. Adult and pediatric patients with grade III-IV aGvHD have a high mortality risk with a 2-year survival rate of 27-35% (Khoury et al 2017).

Acute GvHD is one of the most consistently reported risk factors for development of cGvHD. It is estimated that approximately 30-50% of the patients with aGvHD will develop cGvHD despite the treatment received (Pagliuca et al 2021, Ringden et al 2018).

## Chronic GvHD

According to the current knowledge of cGvHD pathophysiology it begins with activation of host antigen-presenting cells (APC) expressed by damaged tissues and/or pathogens (Dhir et al 2014). Activated host APC then present host antigens to donor immune cells, leading to donor T-cell proliferation and inflammatory cytokine production. Cytokine dysregulation has also been implicated through observations that high levels of interleukin (IL)1β, IFNγ, and tumor necrosis factor (TNF) -α are associated with more severe cGvHD (Socie and Ritz 2014). These inflammatory cytokines then recruit and induce proliferation of additional immune effector cells, thereby perpetuating an adverse cycle of alloreactive tissue injury and inflammation (Paczesny et al 2010).

Chronic GvHD is a major long-term complication after alloSCT (Jagasia et al 2015), occurring most frequently after 100 days post-transplant with a median time to onset reported as 162 days posttransplant (Flowers et al 2011). While aGvHD is mainly a mature donor T cell-mediated inflammatory disease, cGvHD is characterized by the activation of complex signaling pathways in both T and B cells, reduced levels of circulating regulatory B cells (Bregs) and CD4+ Tregs (Hill et al 2018, Zhang et al 2006).

Chronic GvHD usually involves not only the epithelial target tissues affected in classic aGvHD (GI tract, liver, skin,) but also additional organ systems including lungs, muscles, fascia, joints, genitalia, eyes, and nails, (Jagasia et al 2015, Dhir et al 2014, Greinix et al 2011). The signs and symptoms include rash, raised or discoloured skin, thickening or tightening of skin, dry mouth, yellow discoloration of skin/eyes dry eyes, shortness of breath, weight loss, difficulty swallowing, fatigue, and muscle weakness (Pavletic et al 2006).

Chronic GvHD is classified into mild, moderate, and severe based on degree and number of organs or sites involved according to standard criteria (Schoemans et al 2018, Jagasia et al 2015).

Among patients who undergo alloSCT, cGvHD occurs in 30% to 70% of patients. The occurrence of cGvHD varies depending on the donor type, with 40% of recipients from matched sibling donor (Zeiser and Blazar 2017a, Lazaryan et al 2016). Approximately 30% of cGvHD are de novo without any preceding aGvHD (Lee 2017). The rates of cGvHD are lower in paediatric and adolescent patients as compared to adults (Dhir et al 2014, Flowers et al 2011, Kernan et al 1993).

Chronic GvHD is a leading cause of non-relapse mortality and morbidity in patients surviving more than 2 years after transplantation. Chronic GvHD adversely affects physical and functional well-being as well as quality of life of most of the patients who are otherwise cured for their underlying disease after HSCT (Lee 2017, Arai et al 2015). The risk factors including grafting with growth factor mobilized blood cells and use of female donor for male recipients and unrelated donors associated with chronic GvHD were not changed after adjustment for prior aGvHD, suggesting that chronic GvHD is not simply an evolution of preceding acute GvHD (Flowers et al 2011).

<div style=\"page-break-after: always\"></div>

It is important to realize that the NIH diagnostic criteria (Jagasia 2015) were devised for clinical trials to ensure that study participants had unequivocal chronic GVHD. Many patients with signs and symptoms encountered in practice will not meet the NIH diagnostic criteria for chronic GVHD but nevertheless have active allo-immunity requiring systemic immunosuppression to improve symptoms and prevent ongoing organ damage.

## 2.1.2. Management

There are no optimal or standard preventive methods for GvHD defined and treatments vary across institutions. Prophylaxis is mainly based on suppressing the donor T-cell function using immunosuppression regimens (calcineurin inhibitors (CNI), methotrexate (MTX), mycophenolate mofetil (MMF), anti-thymocyte globulin (ATG), rituximab or T-cell depletion) (Hamilton 2018, Ruutu et al 2014), but often at the risk of underlying disease relapse or rejection (Ruutu et al 2012).

Treatment for GvHD is based on the severity of the disease and the number of organs affected (please refer to aGvHD target organ staging below (Please refer to assessor's comment, section 4.5.3.1.1. for aGcHD and the assessor's comment, section 4.5.5.1.4 for cGvHD). Topical therapies including corticosteroids or CNI are recommended for patients with grade I aGvHD and mild cGvHD, whose disease is localized to the skin (Nassereddine et al 2017, Garnett et al 2013). Systemic treatments with corticosteroids are the standard first-line treatment for grade II to IV aGvHD and moderate to severe cGvHD.

## Management Acute GvHD

In aGvHD, high dose systemic corticosteroids (methylprednisolone 2 mg/kg/day or prednisone 2.0-2.5 mg/kg/day) is the standard initial treatment of grade II to IV aGvHD (Penack et al 2020, Ruutu et al 2014, Martin et al 2012).

However, approximately 50% of patients with grade II to IV aGvHD do not show adequate response to corticosteroids and often become steroid resistant/refractory or fail to taper corticosteroids (Schoemans et al 2018, Jamil and Mineishi 2015). In addition, less than 50% of responding patients treated with steroids present a sustained response (Garnett et al 2013). Patients with aGvHD refractory to steroid therapy are at a high mortality risk with an estimated 2-year survival rate below 20% (Malard et al 2020).

## Management chronic GvHD

In cGvHD, systemic steroids (prednisone 1 mg/kg) with or without addition of CNIs are the recommended first-line therapy for patients with moderate to severe cGvHD (Penack et al 2020). Approximately 50% to 60% of patients do not respond or have inadequate control of disease with steroid treatment and require addition of another systemic therapy or fail to taper corticosteroids (Axt et al 2019, Inamoto et al 2014, Garnett et al 2013). Among patients who respond to treatment, responses were durable in 20% to 40% patients, and remaining patients were considered either resistant or refractory to steroids (Mawardi et al 2019, Garnett et al 2013). The estimated median duration of treatment with immunosuppressive therapy was 2 to 3 years (Jamil and Mineishi 2015). The long-term immunosuppressive treatment along with the disease associated immunodeficiency further increases the risk of serious and life-threatening infections.

For patients with cGvHD who do not respond to steroids or are unable to taper steroids, the prognosis remains poor with a 5-year survival rate of 50 to 70%, necessitating the addition of other agents (Mawardi et al 2019, Wolff D et al 2011).

<div style=\"page-break-after: always\"></div>

Tapering of corticosteroids is recommended in patients with clinical improvements to minimize the risk of infection and other toxicities. First-line treatment with a combination of steroids and other agents had failed so far to improve the outcomes and are associated with increased mortality or only suboptimal response rates. Adding additional therapy to prophylaxis and/or first line therapy is generally recommended for patients who fail to respond to corticosteroids, do not tolerate or fail to taper corticosteroids. The term 'steroid intolerance' has not been formally validated but refers to the emergence of unacceptable toxicity (e.g. uncontrolled infections, avascular necrosis, arterial hypertension, diabetes mellitus, myopathy, osteoporosis, etc.) attributed to corticosteroids, as evaluated by a healthcare professional.

Due to the lack of large scale, positive randomized prospective studies to compare the efficacy and safety of second-line therapy for GvHD, no standard second-line treatment is defined in the EU. However, the most common used second-line agents recommended in both acute and chronic GvHD include ruxolitinib, extracorporeal photopheresis (ECP), low-dose MTX, MMF, mTOR inhibitors (everolimus or sirolimus), or infliximab. These agents may be used alone or in combinations with steroids (Penack et al 2020, Ruutu et al 2014, Wolff et al 2011). Anti-thymocyte globulin (ATG), etanercept, and mesenchymal stromal cells (MSC) are also recommended for use as second line treatment of aGVHD. Additional treatments in cGvHD include rituximab, imatinib, pentostatin, and ibrutinib. A need exists for novel therapies in this hard-to-treat population.

Ruxolitinib was first approved (treatment of MF) under the trade name of Jakafi® in Nov-2011 in the USA. Ruxolitinib is since 2019 registered for the treatment of SR-aGvHD in the USA, based on the data from single-arm, multi-centre, Phase II Study 18424-271 (REACH 1; supportive study for this submission; hereafter referred to as Study 271) (Jagasia et al 2020). Furthermore, the BTK inhibitor ibrutinib, is also approved in the USA and Canada since 2017, for the treatment of patients with cGvHD who had failed one to three lines of prior systemic therapy, based on the results from a Phase Ib/II single arm study (n=42).

## 2.1.3. About the product

Ruxolitinib (Jakavi®/Jakafi®, INC424, INCB018424 phosphate) is a potent and selective inhibitor of Janus Kinases (JAKs), JAK1 and JAK2, mutated JAK2V617F, with moderate and minimal inhibitory activity against TYK2 and JAK3. Ruxolitinib interferes with the signalling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. The JAK-STAT pathway plays a critical role in cytokine signalling and the development of several immune cell types, leading to T-cell proliferation, tissue damage and is a promising target for GvHD treatment (Schwartz et al 2016).

Inhibition of JAK1/2 signalling results in reduced proliferation of donor effector T cells, suppression of pro-inflammatory cytokine production in response to alloantigen, as well as impairment of antigen presenting cells, based on in vitro and in mouse models. Data from murine and mice models suggest that graft-versus-leukaemia effect of alloreactive T cells was maintained after ruxolitinib administration.

## 2.1.4. The development programme/compliance with CHMP guidance/scientific advice

Scientific Advice was sought in the EU for the Phase III study D2301 protocol in chronic GvHD (Procedure No.: EMEA/H/SA/1155/2/2016/II). The CHMP acknowledged that a placebo-controlled study would not be possible considering the differences between the best available therapies (BAT) allowed in the comparator arm. The listing of acceptable BAT was endorsed but it was noted that the many options will add to the heterogeneity of the control group. The CHMP suggested to consider

<div style=\"page-break-after: always\"></div>

limitation of cross-over to 'early-progressors'. Regarding the proposed study population, it was noted that adolescents aged ≥12 years might significantly differ in terms of underlying disease, prior antineoplastic treatment, type of donor and stem cell source used and overall immunotolerance with unknown impact on study outcomes. Moreover, preclinical safety data in juvenile rats suggested bone effects of ruxolitinib with unknown consequences for safety in children. Next, it was advised to restrict the trial participation to true steroid-refractory patients according to NIH consensus on criteria for clinical trials in cGvHD, i.e. excluding steroid-dependent GvHD patients that are not able to taper the corticosteroid dose. Alternatively, steroid-refractoriness/steroid-dependency according to NIH definition should at least be considered for inclusion as stratification factor. With regard to the proposed endpoints, CHMP stated that clinically significant and statistically compelling results in favour of ruxolitinib in terms of ORR and failure free survival (FFS), if supported by consistent findings in relevant secondary endpoints, without detrimental effects on OS and the cumulative incidence of relapse of the underlying malignancy, could be sufficient to conclude on clinical benefit. The use of the Lee Chronic GVHD Symptom Scale instrument (Lee 2002), FACT-BMT, and EQ-5D to characterize patients reported outcomes and symptom burden improvement was accepted.

Pre-submission meetings with Rapporteur and Co-Rapporteur were held in November 2020.

A Paediatric Investigation Plan (PIP) has been agreed with the Paediatric Committee for aGvHD (EMEA000901-PIP03-16-M01) and cGvHD (EMEA-000901-PIP04-17-M01).

## 2.1.5. General comments on compliance with GCP

The clinical studies included in this application were, as claimed by the applicant, conducted in full compliance with current Good Clinical Practices (ICH E6). Nevertheless, during assessment a GCP inspection has been performed due to the concerns raised by the high numbers of protocol deviations. Further details and impact of the inspection is provided in section 2.5.5 discussion on clinical efficacy. Overall, according to the inspectors, the observed findings are unlikely to have a significant impact on data integrity within the inspected clinical trials. The inspection team did not identify any restrictions on the usability of the reported trial data, and therefore it was the recommendation of the inspectors that the data of the REACH-2 and REACH-3 clinical trials could be used for evaluation and assessment of the application. The Committee/Rapporteurs shares this view and therefore concludes that the findings are unlikely to have had any significant impact on the benefit-risk balance with regard to both aGvHD and cGvHD.

## 2.2. Quality aspects

This variation does not include any specific quality variation application and the already approved formulations, 5, 10, 15 and 20 mg tablets for adults, are proposed for the paediatric population from 12 years of age. The 5 and 10 mg tablets are round curved tablets, 7.5 and 9.3 mm in diameter respectively. The 15 and 20 mg tablets are ovaloid or elongated tablets of approximately 15 x 7 mm and 17 x 7 mm respectively. The tablets contain the excipients microcrystalline cellulose, magnesium stearate, colloidal anhydrous silica, sodium starch glycolate, povidone, hydroxypropylcellulose and lactose monohydrate.

Suitability of the formulation for the paediatric population from 12 years of age.

Since the variation concerns an introduction of a paediatric population, the suitability of the proposed formulation in the proposed age group should be addressed, in line with the Guideline on pharmaceutical development of medicines for paediatric use EMA/CHMP/QWP/805880/2012 Rev.2. No such justification has been provided but this can be accepted since the proposed adult formulation only

<div style=\"page-break-after: always\"></div>

contains commonly used excipients in amounts for which no safety issues are foreseen in the proposed target age group. The proposed adult formulation is considered acceptable from a quality point of view.

## 2.3. Non-clinical aspects

With this submission, the MAH has provided data pharmacology non clinic studies with ruxolitinib in acute and chronic Graft versus Host Disease (GvHD). All other aspects in of the nonclinical program remain unchanged, since the submission of the original dossier.

## 2.3.1. Pharmacology

Ruxolitinib oral administration in an MHC-mismatched allo-HSCT mouse model resulted in the decreased expression of inflammatory cytokines, reduced immune-cell infiltration in diseased colon tissue, reduced GvHD scores and body weight loss, preserved engraftment, and improved survival. Ruxolitinib inhibited pSTAT3 and pSTAT5 phosphorylation in T cells and in the inflamed colon tissue, consistent with JAK-STAT pathway inhibition. Ruxolitinib was efficacious in ameliorating disease severity in steroid-refractory mice with acute GvHD, leading to significant improvements in percent body weight loss, GvHD score, and increased survival.

Additionally, ruxolitinib was efficacious in ameliorating disease severity in a MHC-matched, miHAmismatched chronic GvHD mouse model, leading to reduced GvHD scores, weight gain, significant survival benefits, improved skin integrity, and reduced incidence of skin and lung inflammation.

## 2.3.2. Ecotoxicity/Environmental risk assessment

For this new indication, the MAH has calculated a PECsw incorporating the previously approved indications.

Total PECsurfacewater

| Indication              |   PECSURFACEWATER(μg.L-1) |
|-------------------------|---------------------------|
| GraftversusHost Disease |                  0.00047  |
| Polycythemiavera        |                  0.0075   |
| Myelofibrosis           |                  0.000625 |
| TotalPECSURFACEWATER    |                  0.008    |

It is concluded that PECsw remains below the trigger value and no further steps are taken. Previous assessment has demonstrated ruxolitinib not be a PBT substance.

## 2.3.3. Conclusion on the non-clinical aspects

The presented non clinical data have provided proof of concept support for the clinical development of ruxolitinib in treatment of acute and chronic GvHD. The clinical data further developed has then provided the necessary safety and efficacy data to support the extension of indication. No further nonclinical data have been provided which is considered acceptable. The updated data submitted in this application do not lead to a significant increase in environmental exposure further to the use of ruxolitinib in the new indication.

<div style=\"page-break-after: always\"></div>

## 2.4. Clinical aspects

## 2.4.1. Introduction

Two pivotal, open label Phase III studies, REACH2 [CINC424C2301] for aGvHD and REACH3 [CINC424D2301] for chronic graft-versus-host disease (cGvHD) are conducted to support the submission. In both studies, a dose of ruxolitinib 10 mg orally b.i.d was used. The 10 mg b.i.d dose was the same in adolescents as in adult patients.

## GCP

The Clinical trials were performed in accordance with GCP as claimed by the MAH.

The MAH has provided a statement to the effect that clinical trials conducted outside the community were carried out in accordance with the ethical standards of Directive 2001/20/EC.

- Tabular overview of clinical studies included in the submission and their status

| Studyl Design                                                                                                                                                                                                                | Number ofpatients enrolled/treated                                                     | Study population/ Primary endpoint                                                                           | Status/ Cut-off date                                                                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|
| Acute GvHD                                                                                                                                                                                                                   | Acute GvHD                                                                             | Acute GvHD                                                                                                   | Acute GvHD                                                                                       |
| StudyC2301(Registration study)/ Phase Ill, open-label, randomized,multicenter study comparing the efficacy and safety ofruxolitinib vs.BAT (as selected by theInvestigator) added to the patient's immunosuppressive regimen | N=309/302 Ruxolitinib:n=154/152 BAT: n=155/150 11 Ruxolitinib after cross- over: n= 49 | Adults and adolescents (212years old)with grade I1 to IVSR-aGvHD after alloSCT/ ORR at Day 28                | Ongoing/ Primary analysis cut-off date: 25- Jul-2019 Secondary analysis cut-off date:06-Jan-2020 |
| Study271（Supportivestudy) Phase ll,open-label, single cohort,multicenter study evaluating the efficacy and safety of ruxolitinib in combination with corticosteroids                                                         | N=71                                                                                   | Adult and adolescents （212years old）with grade ItoIVSR-aGvHDafter alloSCT/ ORR at Day 28                     | Completed/ Final analysis cut- off date:05-Jun- 2019                                             |
| Chronic GvHD                                                                                                                                                                                                                 | Chronic GvHD                                                                           | Chronic GvHD                                                                                                 | Chronic GvHD                                                                                     |
| StudyD2301(Registration study) Phase Ill, open-label, randomized,multicenter study comparing the efficacy and safetyofruxolitinibvs.BAT(as selected by the Investigator) added to the patient's immunosuppressive regimen    | N=329/323 Ruxolitinib:n=165/165 BAT:n=164/158 Ruxolitinib after cross- over: n= 61     | Adults and adolescents (≥ 12 years old) with moderate or severe SR- cGvHDafteralloSCT/ ORR at Cycle 7 Day 1. | Ongoing/ Interim analysis cut-off date: 09- Jul-2019 Primary analysis cut-off date: 08- May-2020 |

[1 310 patients were randomized but one patient was excluded from analysis as study consent was not signed prior to receiving BAT.

ACyclewas definedas4weeks (28days).

BAT= best available therapy; SR=steroid refractory; aGvHD= acute graft versus host disease; cGvHD= chronic graft versushostdisease ORR=overallresponserate

<div style=\"page-break-after: always\"></div>

## 2.4.2. Pharmacokinetics

No new drug strength was developed to support this submission.

## Bioanalysis

The previously validated method DMB-07.111.2 (Incyte) was used for samples from study 271 /REACH 1. Standard curve and QCs accuracy and precision in the within study validation were within pre-set acceptance criteria. Incurred sample reanalysis was performed for 77 samples (10.3%). All (77/77 or 100%) of the results for INCB018424 agreed within 20% of the original results. The oldest plasma sample was 296 days old prior to analysis, which was within the long term stability of at least 372 days stored at -60 to -80°C.

Two new liquid chromatography tandem mass spectrometry (LC-MS/MS) methods were fully validated for the determination of ruxolitinib in plasma. The method validated at SGS [DMPK R1701012] was employed for the quantitative analysis of ruxolitinib in human plasma samples (with Ethylenediaminetetraacetic acid (EDTA) as anticoagulant) collected in the Study C2301 as well as in the Study D2301, while the method validated at WuXi AppTec [DMPK R1100270a-02] supported the long term stability of ruxolitinib, but was not used to analyse study samples. The long-term stability period of 813 days (at ≤ -70 °C) covered the maximum length of time from specimen collection to analysis for the two studies.

In both methods, 50 µL K2-EDTA plasma samples were subjected to liquid-liquid extraction, evaporation of the supernatant to dryness, and analysis of the reconstituted sample residue by LCMS/MS. Validation parameters are summarised in Table 1.

Summary of validation parameters for ruxolitinib methods DMPK R1701012 &amp; R1100270a

| Key validation parameters                             | DMPK R1701012                                            | DMPK R1100270a and amendments 01 and 02                  |
|-------------------------------------------------------|----------------------------------------------------------|----------------------------------------------------------|
| Analyte                                               | Ruxolitinib, INC424-D9 stable labelled internal standard | Ruxolitinib, INC424-D9 stable labelled internal standard |
| Use in current application                            | Clinical studies C2301, D2301                            | Long term stability only                                 |
| Site                                                  | SGS (France)                                             | WuXi (China)                                             |
| Standard curve range (ng/mL)                          | 0.500 ng/mL to 500 ng/mL                                 | 0.500 ng/mL to 500 ng/mL                                 |
| Inter-day accuracy (Bias %)                           | From -2.67% to -2.00%                                    | From -6.4% to -3.3%                                      |
| Inter-day precision (CV%)                             | From 0.86% to 4.78%                                      | From 1.7% to 8.1%                                        |
| Post-preparative stability in extracts (Auto sampler) | 83 hours at 10°C                                         | 149 hours at 4°C                                         |
| Short-term stability in spiked human plasma at RT     | 24 hours at RT                                           | 24 hours at RT                                           |
| Freeze-thaw stability                                 | 3 freeze-thaw cycles at -75°C±10°C                       | 5 freeze-thaw cycles at ≤-15°C and ≤-70°C                |
| Long-term stability when frozen                       | Not performed*                                           | 354 days at ≤-15°C                                       |

<div style=\"page-break-after: always\"></div>

## *performed under DMPK R1100270a and its subsequent amendment DMPK R1100270a-01

In the method validation DMPK R1701012, all following parameters were within pre-set acceptance criteria: no interference with fluconazole was demonstrated, no matrix effect (6 individual plasma lots), specificity (8 individual plasma lots), no effect of haemolysis or lipaemia, and dilution linearity upon 10 fold dilution. Certificates of analysis for analytes and internal standard were provided.

The within study validation showed that the standard curve and QCs accuracy and precision were within pre-set acceptance criteria. Incurred sample reanalysis was performed in 47 of study samples from study C2301 and 95.7% of samples met the pre-specified criteria, and in 110 of study samples from study D2301 and 99.1% of samples met the pre-specified criteria.

## Study INCB 18424-271 (REACH 1 or 271)

Study 271 was a prospective, open-label, single-cohort, multicenter Phase 2 study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory Grades II to IV aGVHD.

Seventy-one participants began treatment at ruxolitinib 5 mg b.i.d; if hematologic parameters were stable and no treatment-related toxicity was observed after the first 3 days of treatment, the dose could be increased to 10 mg b.i.d.

PK samples were taken on Days 1, 7, and 14 (predose and 1 h (±15 min), 2 h (±30 min), and 4 -8 h post-dose). PK parameters were calculated from the plasma concentrations of ruxolitinib according to a population PK approach, see below.

## Study C2301 (REACH 2)

Two versions of the clinical study report were submitted, the Primary CSR dated 9.3.2020 with data cutoff 25.7.19 with its amendment, dated 12.08.2020 and the Secondary CSR dated 29.07.20 with data cutoff 6.1.2020. Only the primary CSR contained PK data and is presented here.

Study C2301 was a randomized (1:1) Phase III, open label study of ruxolitinib compared to Investigator choice BAT in allogeneic stem cell transplant recipients (adults and adolescents ( ≥ 12 years old) with Grade II-IV aGVHD. The assessment of PK of ruxolitinib in SR-aGvHD patients was a secondary endpoint.

Ruxolitinib was administered at a starting dose of 10 mg twice daily (as 2x 5 mg with or without food) until Week 4. Thereafter patients who had complete or partial response continued to receive ruxolitinib up to Week 24. Adolescents received the same ruxolitinib dose as adults. Dose reductions were allowed when given with strong CYP3A4 or dual CYP2C9 and CYP3A4 inhibitors. Dose and frequency of best available therapy (BAT) was based the Investigator's opinion.

The Pharmacokinetic analysis set (PAS) included a total of 200 patients, 152 of whom were patients randomized to ruxolitinib arm, and 48 patients who crossed over to ruxolitinib from BAT. PK parameters from patients with 'extensive PK' sampling were available from 22 adult patients and 5 adolescent patients. The sampling was as follows: days 1 and 7 at pre-dose and 0.5 h, 1.0 h, 1.5 h, 2.0 h, 4.0 h, 6.0 h and 9 h (±15 min) post -dose; day 14, 28, 56 and 168: predose and 2 h postdose (± 15 min) for complete and partial responders. Sparse PK sampling was performed for all the other adult patients predose and postdose 2 h (± 15 min) on Days 1, 7, 14, 28, 56, and 168.

<div style=\"page-break-after: always\"></div>

PK data was analysed by non-compartmental analysis (NCA), as detailed here, and included in the population PK analysis. The NCA PK parameters were as follows:

After a single dose of 10 mg ruxolitinib, mean plasma concentrations increased rapidly reaching the peak concentration at approximately 1.6 h followed by rapid distribution and elimination phases. On Cycle 1 Day 1, the geometric mean (Geo-mean) peak plasma concentration (Cmax) was 118 (CV 70.4%) ng/mL; AUCinf and AUClast were 470 (CV 71.2%) ng*h/mL and 511 (CV 95.7%) ng*h/mL respectively.

After multiple dosing at Day 7, the accumulation ratio was low (1.2), indicating minimal accumulation of ruxolitinib with continuous dosing. After 7 days of continuous dosing, geometric mean Cmax was 137.1 ng/mL and AUCtau was 713.4 ng.h/mL.

Oral plasma clearance at steady state (CLss/F) of ruxolitinib after oral dosing at 10 mg twice daily was estimated as 23.3 L/h, which was comparable to the CL/F obtained from AUCinf after a single 10 mg oral dose. This suggested that clearance is not expected to change with time. Similarly, geometric mean terminal T1/2 appeared to be independent of time and ranged from 1.9-2.0 h after both single and repeated doses.

Most of the patients in the ruxolitinib arm (134/152) received concomitant CYP3A4 inhibitors during the study. The most frequently administered CYP3A4 inhibitors were cyclosporin (61.2%), posaconazole (48.0%) and voriconazole (20.4%) which are known to be moderate or strong inhibitor of CYP3A4. Though a large fraction of the ruxolitinib-treated population received CYP3A4 inhibitors, PK parameters on Day 7 could be estimated only for 22 patients from whom extensive PK samples were collected. Of these 22 patients, only 4 patients were without a strong or moderate concomitant CYP3A4 inhibitor and the PK variability in these 4 patients was high.

PK parameters at Day 1 in adolescent patients could be computed for only 5 patients, however, within the ambit of the available data, the exposure in adolescent patients was within the range observed in adult patients (Table below).

## Individual observed PK parameters in adolescent patients with acute GvHD after single and repeated dosing

| Patient                               | Age (years)                           | BSA (m 1 )                            | BW (kg)                               | Cmax (ng/mL) Day 1   | Cmax (ng/mL) Day 7   | AUClast* (ng*h/mL) Day 1   | AUClast* (ng*h/mL) Day 7   |
|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|----------------------|----------------------|----------------------------|----------------------------|
| patient 1                             | 15                                    | 1.43                                  | 45                                    | 128                  | NA                   | 366                        | NA                         |
| patient 2                             | 13                                    | 1.45                                  | 46                                    | 111                  | 146                  | 489                        | 733                        |
| patient 3                             | 16                                    | 2.16                                  | 97                                    | 156                  | NA                   | 963                        | NA                         |
| patient 4                             | 12                                    | 1.03                                  | 28.5                                  | 357                  | 165                  | 809                        | 555                        |
| patient 5                             | 13                                    | 1.19                                  | 32.9                                  | 149                  | 363                  | 710                        | 2010                       |
| Min-Max range observed in adolescents | Min-Max range observed in adolescents | Min-Max range observed in adolescents | Min-Max range observed in adolescents | 111-357              | 146-363              | 366-963                    | 555-2010                   |
| Min-Max range observed in adults      | Min-Max range observed in adults      | Min-Max range observed in adults      | Min-Max range observed in adults      | 20.8-580             | 33.8-744             | 63.8-4484                  | 116-3064                   |

*PK samples were collected up to approximately 9 hours post-dose

## Study D2301 (REACH 3)

<div style=\"page-break-after: always\"></div>

Study D2301 was a randomized, open-label, multi-center study of ruxolitinib vs. BAT in patients (adults and adolescents ( ≥ 12 years old) with moderate or severe cGvHD after allogeneic stem cell transplantation. The assessment of PK of ruxolitinib in SR-cGvHD patients was a secondary endpoint. Ruxolitinib vs. BAT was added to the patient ' s immunosuppressive regimen corticosteroids ± calcineurin inhibitor (CNI). Dose and frequency of BAT was based the Investigator's opinion.

Ruxolitinib was administered at a dose of 10 mg b.i.d daily, (as 2x 5 mg with or without food) for a minimum of 6 (28 day) cycles until cycle 7 Day 1. Thereafter patients who had complete or partial response continued to receive ruxolitinib up to Cycle 39. Dose modifications (reductions and/or interruptions) and delays were permitted to address safety concerns related to haematological (primarily, cytopenias) or non-haematological reasons, or to avoid under- or over-exposure of ruxolitinib when combined with CYP450 modulators. Adolescents received the same ruxolitinib dose as adults.

The Pharmacokinetic analysis set (PAS) included a total of 221 patients, 164 of whom were patients randomized to ruxolitinib arm, and 57 patients who crossed over to ruxolitinib from BAT. PK parameters from patients with 'extensive PK' sampling were available from 17 adult patients and 4 adolescent patients who received a dose of 10 mg ruxolitinib twice daily. PK parameters at Day 1 in adolescent patients could be computed for only 2 or 3 available samples for one of the adolescents.

For the extensive PK dataset, on days 1 and 15 of Cycle 1 samples were taken pre-dose (0 h), postdose (0.5 h, 1 h, 1.5 h (±15 min), 4 h, 6 h, 9 h (±1 hr) ; at Cycle 2, 7 and 39, one pre-dose and onepost dose 1.5 hr (±15 min). Sparse PK sampling was available for all the other patients: predose and postdose 1.5 h (± 15 min) on Day 1 of Cycle 1, Day 15 of Cycle 1, and Day 1 of Cycle 2, 7 and 39. Sparse PK samples for cross-over patients from BAT to ruxolitinib were taken only at the time of a scheduled visit.

PK data was analysed by non-compartmental analysis, as detailed here, and included in the population PK analysis.

After a single dose of 10 mg ruxolitinib, median Tmax was 0.833 h; geo mean Cmax was 167 (39.3%) ng/mL; AUCinf and AUClast were 642 (32.7%) ng.h/mL and 636 (40.8%) ng.h/mL respectively; elimination half-life (T1/2) was 2.40h in patients receiving ruxolitinib at a dose of 10 mg.

After multiple dosing at Day 15, ruxolitinib PK profile was similar to that at Day 1. A slightly higher peak plasma concentration level was observed in the Day 15 profile; however, large variability was noted. On Day 15, geo mean AUCtau was 656 (20.4%) ng.h/mL; AUClast was 945 (56.1%) ng.h/mL and Cmax was 215 (48.8%) ng/mL in patients receiving ruxolitinib at a dose of 10 mg b.i.d.

Oral plasma clearance at steady state (CLss/F) of ruxolitinib after oral dosing at 10 mg twice daily was estimated as 15.2 L/h. The geometric mean terminal half-life (T1/2) appeared to be independent of time and ranged from 2.3 to 2.4 h.

Within the ambit of the available data, the exposure in adolescent patients was within the range observed in adult patients (Table below).

## Individual observed PK parameters in adolescent patients with chronic GvHD after single and repeated dosing

| Patient   |   Age (years) |   BSA (M 2 ) |   BW (kg) |   Cmax (ng/mL) Day 1 |   Cmax (ng/mL) Day 15 |   AUClast* (ng*h/mL) Day 1 |   AUClast* (ng*h/mL) Day 15 |
|-----------|---------------|--------------|-----------|----------------------|-----------------------|----------------------------|-----------------------------|
| patient 1 |            13 |         1.37 |      45   |                  249 |                   253 |                        773 |                         711 |
| Patient 2 |            15 |         1.2  |      32.5 |                  152 |                   286 |                        595 |                         849 |

<div style=\"page-break-after: always\"></div>

| Patient 3                             | 16                                    | 2.31                                  | 107                                   | 190      | 274      | 783      | 1120     |
|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|----------|----------|----------|----------|
| Min-Max range observed in adolescents | Min-Max range observed in adolescents | Min-Max range observed in adolescents | Min-Max range observed in adolescents | 152-249  | 253-286  | 595-783  | 711-1120 |
| Min-Max range observed in adults      | Min-Max range observed in adults      | Min-Max range observed in adults      | Min-Max range observed in adults      | 67.8-312 | 95.5-451 | 313-1400 | 450-2720 |

*PK samples were collected up to approximately 9 hours post-dose

## Population Pharmacokinetic analysis

The applicant has submitted three model based pharmacokinetic analysis reports.

1. Report DMPK R1800133 (Projected Pharmacokinetic Parameters and Anticipated Therapeutic Dose of Ruxolitinib (INC424) in Paediatric population) describes dose selection in children from 0 years and is out of the scope for this application. Therefore, it is not reviewed.
2. Report DMB-18.34.1 (Population Pharmacokinetic Analysis of the JAK Inhibitor Ruxolitinib Tablets in Combination with Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease INCB 18424-271) only includes GvHD patient data from Reach 1 (phase 2 study). The report below is updated with additional phase 3 data, has similar objectives, and includes a re-assessment of the final model presented in this report. Therefore, this model is not assessed in dept or described in this assessment.
3. Report named Population pharmacokinetics of ruxolitinib in steroidrefractory (SR) acute and chronic (a+c) Graft versus Host Disease (GvHD) adult and adolescent patients Modeling Report (Final, 27 Nov 2020) includes GvHD patients' data from Reach 1, 2 and 3 and an update of the model from Report DMB-18-34-1. This report is considered to include the pivotal analysis of ruxolitinib in the GvHD population and is described below.

## Methods

The objective was to characterize PK in acute and chronic GvHD patients and investigate the covariates in this population which explain the inter-patient variability.

## Software

The analysis is performed using the Monolix software system, Monolix 2019R2 (Lixoft, Paris, France) utilizing the DaVinci high performance computing environment accessed from GPSII. All model building was performed using Stochastic Approximation Expectation Maximization (SAEM) method).

## Data

The final model included data from the studies Reach 1, 2 and 3, added during model development in a staggered manner. 11.6% of data were censored (below quantification limit).

## Model

The model was a two-compartment model with first-order absorption and linear elimination, with a lag time, and an exponential residual error structure (additional error model, with log-normal IIV distributions). Inter-individual variability (IIV) was estimated for all parameters apart from lag time and inter-compartmental clearance. Administration of CYP3A4-inhibitors (moderate and potent vs weak and none), aGvHD disease grade at each assessment (MAGIC score, &lt;4 vs. 4), and liver involvement in aGvHD at each assessment (liver score &gt;=1, Y/N), all included on apparent clearance, and aGvHD disease grade at each assessment (MAGIC score &lt;=1 vs. &gt;1) on the absorption rate. A covariance term was added for the IIV on apparent central volume and clearance.

<div style=\"page-break-after: always\"></div>

Components of this model were reassessed to determine whether simpler or alternative models could better describe the PK data in aGvHD patients. In particular, according to [PK Report DMB-18 341], high IIV was observed on V2 and ka, which was attributed to the composition of the data used for model building, notably the limited dense PK sampling for REACH 1 (and also 1 of the MF studies).

The original model incorporates an additive error model, with log-normal distributions implemented on the IIV terms. A normal distribution will be implemented in place of a log-normal distribution.

The model was reassessed first by adding data from study Reach 2, and subsequently reassessed again adding data from study Reach 3. All comparisons will be made using the BIC, since models will not be nested and therefore a likelihood ratio test cannot be performed. A reduction of &gt;3 BIC units constitutes a significant model improvement.

Relevant covariates will be assessed with the aGvHD final base model, along with additional potential candidates that may be expected to impact ruxolitinib PK. Forward selection will be implemented and correlated covariates will be tested separately and the more appropriate covariate will then be included individually. Eighty percent of the datasets were used for covariate model building, with the remaining 20% used for validation. The data was split with a random Bernoulli variable. Patients with missing/unknown levels of a covariate of interest (e.g. Race) were also excluded from the model building dataset and added to the external validation dataset provided they were not a significant covariate in the final model. All data (with valid covariate information as per the final model) was used for simulations.

## Final Model

The final model is a 2-compartment, 1st order absorption model, with a lag time and linear elimination. Additional IIV was placed on CL/F and Vc/F.

Median scaled BSA had a significant impact on Vc/F and Cl/F, with an increase in Vc/F observed with increasing BSA (as expected), and decreased Cl/F with increasing BSA. Lower GI involvement to the GvHD at baseline had a significant impact on primarily on the peripheral volume, but also on the absorption rate. The presence of lower GI involvement of the disease at baseline indicated a lower absorption rate and an increase in the peripheral volume. The reduction in absorption rate is expected, since ruxolitinib is orally administered, and therefore any indication of GI disease would logically impact the absorption of the drug. The indication of chronic GvHD (compared to acute GvHD) has a significant impact on Ka, Cl/F and Vc/F, resulting in an increased Ka, decreased Cl/F and decreased Vc/F. All of these impacts result in overall higher exposures in cGvHD patients compared to aGvHD patients, as previously indicated by the initial VPC (for the final aGvHD model on the cGvHD data).

The final parameter estimates, after running the model with an increased number of simulations, are given below and the models ability to predict the observed data, stratified on acute and chronic GvHD is presented in Figure 1, and BSA &lt;1.5 mf vs &gt;=1.5 m2 is presented in Figure 2. The impact of BSA and other covariates is graphically presented in Figure 3 and Figure 4.

## Final parameter estimates

<div style=\"page-break-after: always\"></div>

| Parameter                                   | Population Estimate   | Population Estimate   | Population Estimate   | IIV (Omega)   | IIV (Omega)   | IIV (Omega)   |
|---------------------------------------------|-----------------------|-----------------------|-----------------------|---------------|---------------|---------------|
|                                             | Mean                  | SE                    | RSE (%)               | Mean (SD)     | SE            | RSE (%)       |
| Ka (h-1)                                    | 3.35                  | 0.951                 | 28.4                  | 1.16          | 0.128         | 11            |
| Involvement of lower Gl at baseline onKa    | -1.06                 | 0.291                 | 27.5                  |               |               |               |
| cGvHD on Ka                                 | 0.636                 | 0.34                  | 53.4                  |               |               |               |
| Tlag (h)                                    | 0.195                 | 0.0376                | 19.3                  | 0.858         | 0.126         | 14.7          |
| Vc/F (L) for a patient with BSA=1.83        | 17.5                  | 1.16                  | 6.59                  | 0.145         | 0.00724.99 1  |               |
| BSA/1.83on Vc/F                             | 1.35                  | 0.0648                | 4.8                   |               |               |               |
| cGvHD on Vc/F                               | -0.103                | 0.019                 | 18.4                  |               |               |               |
| CI/F (L/h) for a patient with BSA=1.83      | 6.57                  | 1.47                  | 22.4                  | 0.508         | 0.02474.86    |               |
| BSA/1.83onCI/F                              | 0.46                  | 0.219                 | 47.7                  |               |               |               |
| cGvHD on CI/F                               | -0.286                | 0.0641                | 22.4                  |               |               |               |
| Vp/F (L)                                    | 4.89                  | 4                     | 81.8                  | 4.99          | 0.487         | 9.75          |
| Involvement of lower Gl at baseline on Vp/F | 2.9                   | 0.954                 | 32.8                  |               |               |               |
| Q (Lh)                                      | 13.8                  | 0.586                 | 4.25                  | NA            |               |               |
| Residual variability (CV)                   | 0.487                 | 0.00771               | 1.58                  | NA            | NA            | NA            |
| Correlation between CI/F, Vc/F              | 0.999                 | 0.000613              | 0.0613                | NA            | NA            | NA            |

Figure 1. Visual Predictive Check of patients with aGvHD (left plot, from REACH 1 or 2) and cGvHD (right plot, from REACH 3)

<!-- image -->

Solid lines display observed 10th, 50th, 90th percentiles Blue/Pink regions show 90% prediction interval around the percentiles Circled dots show observed percentiles outside of the prediction interval

<div style=\"page-break-after: always\"></div>

Figure 2. Visual Predictive Check of patients stratified on BSA (1-1.25m2 (n=9), 1.25-1.5m2 (n=47), 1.5-1.75m2 (n=133), &gt;1.75m2 (n=293))

<!-- image -->

Solid lines display observed 10th, 50th, 90th percentiles Blue/Pink regions show 90% prediction interval around the percentiles Circled dots show observed percentiles outside of the prediction interval

Figure 3. Simulated AUC 0-12 (A) and Cmax (B) on day 1 by indication, across the BSA range

Figure 4. Forest Plot of covariate effects on PK parameters, including BSA

<!-- image -->

<div style=\"page-break-after: always\"></div>

| Parameter   | Ref.: LGI=N           |   % diff |
|-------------|-----------------------|----------|
| C12h D1     | aGvHDvs.cGvHD         |   -25.86 |
| Ctrough D7  | aGvHD VS.CGvHD        |   -32.65 |
| Cmax        | aGvHD Vs. CGvHD       |   -12.88 |
| AUC0-12     | aGvHD vs. cGvHD       |   -17.52 |
| C12h D1     | LGI=Y vS. LGI=N       |    -0.32 |
| Ctrough D7  | LGI=Y VS.LGI=N        |     5.84 |
| Cmax        | LGI=Y VS. LGI=N       |   -10.75 |
| AUC0-12     | LGI=Y vS. LGI=N       |    -9.57 |
| C12h D1     | BSA=1.06 Vs.BSA=1.79  |    -3.58 |
| Ctrough D7  | BSA=1.06VS.BSA=1.79   |    -7.9  |
| Cmax        | BSA=1.06 VS.BSA=1.79  |    55.35 |
| AUC0-12     | BSA=1.06 VS.BSA=1.79  |    30.72 |
| C12h D1     | BSA=2.23 VS.BSA=1.79  |    -2.4  |
| CtroughD7   | BSA=2.23 VS.BSA=1.79  |     2.66 |
| Cmax        | BSA=2.23 VS. BSA=1.79 |   -24.37 |
| AUC0-12     | BSA=2.23VS.BSA=1.79   |   -17.25 |

<!-- image -->

## 2.4.3. PK/PD modelling

## Exposure-Response

Data from the two phase 3 studies (C2301 for aGvHD and D2301 for cGvHD) were used and analysed separately. Time-averaged AUC0-12h was the exposure metrics that was used. Cmax was not considered for safety endpoints, since the safety endpoints selected were chosen based on underlying disease and systemic treatments. Several demographic and disease related covariates were investigated in the analysis. If there were more than 10% missing values for a covariate then the covariate was not included in the covariate selection.

Overall response rate (ORR), durable response rate (DRR) and modified Lee symptoms score at Cycle 7 Day 1 were analysed with logistic regression models. Overall Survival (OS), duration of response (DoR) and failure free survival (FFS) were analysed with Cox regression models. The PK-efficacy set included 150 patients each from Study C2301 (up to the data cut-off date of 06-Jan-2020) and Study D2301 (up to the data cut-off date of 15-May-2020).

Only adverse events of special interest (AESI) that were reported in adequate numbers (at least 10% and no more than 90% of the patients in the PK Safety Set of each AESI) of patients were analysed. If there was a considerable portion of patients with several occurrences of the same AESI (e.g. if the median number of AESI per patient is 2 or more), this AESI in question was analysed with a count regression model. The PK-safety set included 194 patients from Study C2301 (up to the data cut-off date of 06- Jan-2020) and 150 patients from Study D2301 (up to the data cut-off date of 15-May2020)

## Results

There was an absence of a strong relationship between the exposure metric (time-averaged AUC0-12) and the efficacy and safety endpoints for patients with aGvHD and cGvHD. This may be due to the limited exposure range observed with a dosing regimen of 10mg bid.

<div style=\"page-break-after: always\"></div>

## Population pharmacokinetic/pharmacodynamic relationship of ruxolitinib and platelet count in GvHD patients

There were two main objectives with the below presented analysis

1. To characterize exposure-response relationship of ruxolitinib and longitudinal platelet count, in the context of thrombocytopenia, in GvHD (acute+chronic) patients and investigate the covariates in this population which could explain a part of the inter-patient variability

2. Quantify and qualify the impact of ruxolitinib dose on the ruxolitinib induced thrombocytopenia in acute and chronic GvHD population through simulations of patient platelet profiles, for fixed dosing regimens of 5mg bid and 10mg bid, accounting for predictors of platelets counts identified during model building.

## Methods

Average predicted concentration between platelet measurements was used instead of observed concentrations (derived from the final pop PK model).

A previously developed base semi-mechanistic life span model was modified in order for model to be able to capture the typically very low (&lt;50 Gi/L) baseline platelet counts seen in acute GvHD patient. A small set of covariates were tested in the final acute and chronic GvHD model. The number of patients, platelet and transfusion observations per study in the corresponding modelling datasets is listed below. The modelling datasets included platelet and transfusion observations for the first 168 days of treatment.

## Number if platelet observations and platelet transfusions by study in the modelling datasets

| Indication/Modeling dataset   |   Numberof patients |   Number of platelet observations |   Number ofpatients with platelet transfusions |   Numberof transfusions |
|-------------------------------|---------------------|-----------------------------------|------------------------------------------------|-------------------------|
| acute,testdata                |                  39 |                               292 |                                             22 |                     212 |
| acute,training data           |                 153 |                              1448 |                                             84 |                     862 |
| chronic,testdata              |                  45 |                               393 |                                              3 |                       6 |
| chronic, training data        |                 172 |                              1416 |                                             12 |                      67 |

Distinct differences between the two studies were observed with baseline platelet count, as well as overall profiles whilst receiving ruxolitinib treatment (Figure 5). This is largely due to a longer time since stem cell transplant in the cGvHD indication, by definition, &gt;100 days. For the aGvHD patients (from study C2301), there is limited trend. This is in general due to the fact that all patients are &lt;100 days since transplant, and therefore have not fully achieved platelet recovery.

<div style=\"page-break-after: always\"></div>

Figure 5. Boxplot of baseline platelet counts stratified by study

<!-- image -->

Given the differences observed between the two studies, and in particular, the fact that study D2301 (cGvHD patients) have generally normal platelet levels, the analysis moving forward will be conducted only on study C2301 (aGvHD patients).

## Final model

The final base model therefore incorporated a chain of 5 compartments, including 1 precursor compartment with proliferative cells, such as stem cells and other progenitor cells, three transit compartments with maturating cells, and one compartment for circulating platelets. A feedback mechanism was incorporated to reproduce proliferation regulation based on ratio between normal baseline value and actual platelet count. In the acute GvHD population most patients start with extremely low platelet counts due to the short time since transplantation, and the inclusion of timevarying baseline platelet count is needed to capture these observations. Plasma concentrations of ruxolitinib (averaged between platelet measurements) were assumed to inhibit the proliferation rate by a linear slope model. Platelet transfusion events were incorporated in the model to account for resulting quick elevations in platelet counts. Only the covariate 'effect of time since the engraftment with the respect to the first dose' (TTRANSDOS1) on projected platelet count at engraftment time (PLTT) was carried into the final model.

The parameter estimates for the final model are shown in Table below. The final fit of the model is displayed in Figure 6, with a further validation component to fit the model to a separate test dataset (20% of the original dataset) and is displayed in Figure 7. The VPC for the covariate model improves the fit towards the end of the treatment period, suggesting that by adjusting for time since transplant (relative to first dose) on the platelet count, allows a better description of the recovery phase.

<div style=\"page-break-after: always\"></div>

## Parameter estimates for the final acute semi-mechanistic platelet model

| Parameter (units)    | Population Estimate   | Population Estimate   | Population Estimate   | Randomeffects   | Randomeffects   | Randomeffects   |
|----------------------|-----------------------|-----------------------|-----------------------|-----------------|-----------------|-----------------|
|                      | Mean                  | SE                    | RSE (%)               | Mean (SD)       | SE              | RSE (%)         |
| ktr12                | 0.257                 | 0.0207                | 8.06                  | 0.1 FIX         |                 |                 |
| α (10°/L)            | 40.6                  | 3.79                  | 9.34                  | 0.1 FIX         |                 |                 |
| iLAG (hr)            | 18.9                  | 0.666                 | 3.52                  |                 |                 |                 |
| MMT (hr)             | 191                   | 22.1                  | 11.6                  | 0.631           | 0.0817          | 12.9            |
| V (-)                | 0.29                  | 0.0223                | 7.66                  |                 |                 |                 |
| PLTT0(10°/L)         | 79.2                  | 7.67                  | 9.68                  | 0.583           | 0.0429          | 7.35            |
| PLTTO~TTRANDOS 1     | -0.000132             | 3.86e-5               | 29.3                  |                 |                 |                 |
| SLOPE                | 4.1e-5                | 4.94e-6               | 12                    | 0.764           | 0.105           | 13.8            |
| w (10°/L)            | 142                   | 12.2                  | 8.64                  | 0.3 FIX         |                 |                 |
| t50(days)            | 260                   | 20.1                  | 7.74                  | 0.553           | 0.0808          | 14.6            |
| j(-)                 | 10 FIX                |                       |                       |                 |                 |                 |
| Corr(PLTT,MMT)       | 0.583                 | 0.118                 | 20.3                  |                 |                 |                 |
| Residual error model |                       |                       |                       |                 |                 |                 |
| a                    | 5.38                  | 0.952                 | 17.7                  | NA              | NA              | NA              |
| b                    | 0.332                 | 0.0125                | 3.76                  | NA              | NA              | NA              |

Ktr12=kout: first-order platelet count removal rate constant, a: bioavailability of platelets for transfusion

Y: coefficient associated with feedback mechanism

PLTTO:projectedplateletcount atengraftment time;SLOPE:proportionaldrugeffect onprecursor cells; w: the maximum possible increase of baseline platelet count since engraftment t50:timesinceengraftmentwithhalfofrecovery

i: Hill coefficient

Figure 6. Visual predictive check of the final aGvHD platelet model in the training dataset

<!-- image -->

Solidlinesdisplayobserved10th，50th,90thpercentiles Blue/Pinkregionsshow90%predictionintervalaroundthepercentiles Circleddotsshowobservedpercentilesoutsideofthepredictioninterval

<div style=\"page-break-after: always\"></div>

Figure 7. Visual predictive check of the external validation dataset

<!-- image -->

time(h)

Solidlinesdisplayobserved10,50th,90tpercentiles Blue/Pinkregionsshow90%predictionintervalaroundthepercentiles Circleddotsshowobservedpercentilesoutsideofthepredictioninterval

The model well captures the initial reduction of platelet count, initiated from a very low baseline, and gradual recovery of platelet function (recovery is defined as &gt;100,000/mm3) which is observed while still receiving ruxolitinib (within 4032 hours, which corresponds to Day 168 of study). Extrapolation of this model to high platelet count is somewhat optimistic in the early phase. The full recovery generally occurs before 100 days (by 2400 hours, 3 cycles) which is during the taper period. The results suggest that for aGvHD patients, there is an initial reduction of platelet count with initiation of ruxolitinib, but this can generally be managed well by short term dose reductions/interruptions and platelet transfusions as per protocol.

## 2.4.4. Discussion on clinical pharmacology

The bioanalytical method used for study 271 / REACH1 was previously assessed in procedure EMEA/H/C/002464/II/16. Within study validation for study 271 is adequate. Both methods DMPK R1701012 &amp; R1100270a have demonstrated acceptable sensitivity, specificity, selectivity and stability for the quantification of ruxolitinib. Within study validation was also adequate. Methods DMPK R1701012 &amp; R1100270a are not cross-validated. This is acceptable since method R1100270a is only used to support the long term stability of samples and is itself adequately validated.

Single and repeated PK data following a 10 mg ruxolitinib were obtained in acute GvHD and chronic GvHD subjects. In both groups, ruxolitinib was absorbed rapidly, with a tmax of approximately 1.5 hour. After multiple dosing, the accumulation ratio was low (1.2), indicating minimal accumulation of ruxolitinib with continuous dosing. Terminal t1/2 was approximately 1.9-2.0h in aGvHD subjects and 2.3-2.4h in cGvHD subjects. Further, ruxolitinib PK appeared to be independent of time. Clearance was 10.4 l/h in patients with acute GvHD and 7.8 l/h in patients with chronic GvHD, with a 49% inter subject variability. No relationship was apparent between oral clearance and gender, patient age or race, based on a population pharmacokinetic evaluation in GvHD patients.

## Special populations &amp; interactions

Compared to the dedicated studies, no mechanistic or physiological difference is expected in the GvHD population for patients that have hepatic impairment (HI) or when combined with CYP3A4 inhibitors that would result in a different outcome with respect to PK. Therefore, a similar magnitude of

<div style=\"page-break-after: always\"></div>

interaction is expected in GvHD patients and this is aligned to the recommendation for CYP3A4 inhibition and for hepatic impairment not due to GvHD with prior recommendation.

Dual CYP3A4/CYP2C9 inhibitors. In line with the MF and PV indications and partly based on the popPK analysis where visual predictive checks suggested that administration of fluconazole in patients increased ruxolitinib concentration levels approximately 2-fold, the 50% dose reduction in patients with GvHD when co-administered with dual inhibitors of CYP2C9 and CYP3A4 enzymes is considered acceptable.

Hepatic impairment. Based on the observed and predicted plasma exposures across all hepatic impairment categories (total bilirubin and AST levels) in the PopPK analyses no dose adjustment appears necessary in GvHD patients with mild, moderate, or severe hepatic impairment. Nevertheless, considering the  numbers of aGvHD and cGvHD patients included in each hepatic impairment subgroup (as classified by total bilirubin and AST levels) in the popPK analysis and the data collected, the proposed conservative approach and the advice that the starting dose of ruxolitinib in patients with liver impairment not related to GvHD should be reduced by 50%, in line with the current advice in MF and PV patients, is agreed.

Renal impairment. In the popPK study, GvHD patients with moderate renal impairment had very similar observed and predicted plasma exposures to those who had no renal impairment at baseline. This provides support that the current posology advice for MF and PV patients with mild or moderate renal impairment patients, i.e. no dose adjustment is recommended, is also valid for GvHD patients belonging to the same special subpopulation.

Considering the proposed recommendation on dosing of GvHD subjects with ESRD and in absence of further modelling and simulation data the SmPC has been updated including  the proposed text that no data are available for ESRD.

The pharmacokinetics profile observed in adolescent patients with acute or chronic GvHD was comparable to the overall patient population

## Population PK

The main objective of the model-based population PK analysis was to assess relevant covariates to explain the exposure in patients with acute and chronic GvHD and have a model adequate for simulation of post-hoc PK parameters to be used in exposure-response analysis. Adolescent subjects are expected to have a lower, or much lower, BSA than the average adult. In addition, the GvHD population is more sensitive to haematological side effects. It is of importance that the starting dose in the subjects with lowest BSA is appropriate. The presented VPCs indicate that the model can capture the general trend in the analysed population (no major deviations between observed and predicted data points), and the goodness-of-fit plots to not indicate any obvious major trends of model misspecification. There is a concern regarding the potential overparameterization of the final model. However, the VPCs adequately predict the data with respect to BSA and acute and chronic GvHD population and the final model parameters seem reasonable (i.e. not large RSEs or unreasonable parameter estimates). Therefore, given the application of the model (inform the suitability of the dose in subjects with low BSA) and that there is sufficient clinical efficacy and safety data, a new model is not requested. The safety and efficacy data are mainly represented by subjects with a BSA &gt;1.5m 2 . (BSA 1.03-1.25m 2  n=9; BSA 1.25-1.5 m 2 , n=47; BSA 1.5-1.75 m 2 , n=133; BSA &gt;1.75 m 2  n=293). All subjects included in the study received the same starting dose, which was adjusted based on safety and efficacy. BSA is the covariate that has the highest impact on exposure of ruxolitinib, however there is a considerable overlap of exposures. The impact of BSA on ruxolitinib exposure is presented in the SmPC section 5.2.

<div style=\"page-break-after: always\"></div>

## PK/PD modelling

The exposure-response analysis was sufficiently explored, however the results from the analysis are inconclusive and should be interpreted with caution. This is because all subjects included in the exposure-response analysis received 10 mg b.i.d. which results in a limited exposure range. There is sufficient clinical patient efficacy and safety data to overcome the inconclusive data from Modelling. (see Clinical Efficacy and Clinical Safety sections).

The applicant developed a model to characterize the relationship of ruxolitinib and longitudinal platelet count, in the context of thrombocytopenia, in acute GvHD patients. Only data from the phase 3 C2301 study (aGvHD) study was used in the model development. There is limited information on impact of starting dose and subsequently exposure, because all patients had a starting dose of 10 mg b.i.d. Therefore, information available is too limited to answer the second objective (i.e. impact of starting dose on thrombocytopenia) and results of the simulations should be interpreted with caution.

PD. For the pivotal clinical Phase 3 trials, PD related endpoints were defined to explore cytokines and GvHD biomarkers were planned to be collected and included as exploratory endpoint in both pivotal trials. Results of these exploratory endpoints have not been presented. No conclusion on predictive values of the biomarkers from the selected panels can be drawn at this point. Evaluations for the association of selected marker with response are continuing as the data matures and are expected to be reported when available.

## 2.4.5. Conclusions on clinical pharmacology

Overall, ruxolitinib PK in GvHD subjects is clarified to a sufficient extent.

Population PK model adequately characterize the PK of ruxolitinib in the GvHD population. Body surface area was the covariate with highest impact on ruxolitinib exposure. Subjects with lower BSA have a higher exposure, which is reflected in the SmPC. The results from the exposure-response analysis are inconclusive and should be interpreted with caution because all subjects included received 10 mg b.i.d. which results in a limited exposure range. The applicant developed a model to characterize the relationship of ruxolitinib and longitudinal platelet count in acute GvHD patients using only data from the phase 3 C2301 study (aGvHD), however, there is no information on impact of a different starting dose.

## 2.5. Clinical efficacy

## 2.5.1. Dose-selection rationale

No formal dose finding study has been presented. Ruxolitinib dose selection was based on the published data on preliminary efficacy and safety generated in patients with SR-GvHD and from the supportive study INCB 18424-271 (A Single-Cohort, Phase 2 Study of ruxolitinib in combination with corticosteroids for the treatment of steroid-refractory acute Graft-Versus-Host Disease [REACH1])(Zeiser et al 2015). The dose administered in this study was lower than that generally administered in myelofibrosis patients (i.e. 15-20 mg bid), due to that alloSCT patients with SR-aGvHD would routinely be treated with concurrent CNI and azole prophylaxis that can inhibit the metabolism (via CYP3A4) of ruxolitinib, potentially increasing its exposure. The usage of same dose of ruxolitinib 10 mg b.i.d. in adolescents in Study C2301 and D2301 was supported by the published literature showing similar toxicity profiles, maximum tolerated doses, and ruxolitinib PK parameters in both adolescents

<div style=\"page-break-after: always\"></div>

and adults (Loh et al 2015). The dose selection seems adequate, based on preclinical and clinical publications and Pk analysis.

## 2.5.2. Main studies

There are two pivotal Phase III Studies (CINC424C2301 and CINC424D2301, hereafter referred to as study C2301 and study D2301 or REACH2 and REACH3) presented in the present dossier, designed as randomized, multi-centre, open-label studies to investigate the efficacy and safety of ruxolitinib (RUX) compared to Investigator's choice of best available therapy (BAT) in patients with SR-aGvHD and SRcGvHD, respectively.

## 2.5.3. Steroid refractory acute GvHD

Title of Study: A phase III randomized open-label multi-centre study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation (INC424C2301).

Name of product:

ruxolitinib/INC424

Study number: CINC424C2301 (EudraCT number: 2016-002584-33). Study identifier: REACH2 Participating countries/regions and (number of sites): EU (65, incl. UK and Norway), Australia (4), Canada (8), Hong Kong (1), Israel (4), Japan (14), Republic Of Korea (2), Russian Federation (1), Saudi Arabia (1), Taiwan (1), Turkey (4).

## Study period

Study initiation date: 10-Mar-2017 (first patient first visit)

Data cut-off date: 25-Jul-2019 (data cut-off date for primary analysis) and 06-Jan-2020 (data cut-off date for second analysis); study is ongoing. The final analysis will occur once all patients have completed the Long-Term Follow-Up period to 24 months. All available data from all patients up to EOS, inclusive of OS, will be reported in a final CSR.

Phase of development (phase of this clinical study): Phase III

## Methods

## Study participants

## Inclusion criteria

Patients eligible for inclusion in the study had to meet all of the following criteria:

1. Written screening informed consent and/or assent from the patient, parent, or guardian at the time of Screening, i.e. at the time of aGvHD Grade II-IV diagnosis.
2. Written  study  informed  consent  and/or  assent  from  the  patient,  parent,  or  guardian  once SRaGvHD was confirmed.
3. Male or female patients aged 12 or older at the time of screening informed consent.
4. Able to swallow tablets.
5. Had undergone alloSCT from any donor source (matched unrelated donor, sibling, haploidentical) using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non-myeloablative, myeloablative, and reduced intensity conditioning were eligible.

<div style=\"page-break-after: always\"></div>

6. Clinically diagnosed Grades II to IV acute GvHD as per standard criteria occurring after alloSCT requiring  systemic  immune suppressive therapy. Biopsy of involved organs with aGvHD was encouraged but not required for study screening.
7. Evident myeloid and platelet engraftment (confirmed within 48h prior to study treatment start):
3. o Absolute neutrophil count (ANC) &gt; 1000/mm3 and
4. o Platelets ≥ 20,000/ mm3

Note: Use of growth factor supplementation and transfusion support was allowed.

8. Confirmed diagnosis of SR-aGvHD

## Key exclusion criteria: Patients eligible for this study should not have met any of the following key criteria:

- Received more than one systemic treatment for SR-aGvHD.
- Clinical presentation resembling de novo chronic GvHD or GvHD overlap syndrome with both acute and chronic GvHD features (as defined by Jagasia et al 2015).
- Failed prior alloSCT within the past 6 months.
- Presented with active uncontrolled infection requiring treatment.
- Presented with relapsed primary malignancy, or patients who were treated for relapse after the alloSCT was performed, or who may require rapid immune suppression withdrawal as preemergent treatment of early malignancy relapse.
- SR-aGvHD occurring after non-scheduled donor lymphocyte infusion (DLI) administered for pre-emptive treatment of malignancy recurrence.
- Significant respiratory disease including patients who were on mechanical ventilation or who have resting O2 saturation &lt;90% by pulse-oximetry
- Severely impaired renal function defined by serum creatinine &gt;2 mg/dL (&gt;176.8 μ mol/L), renal dialysis requirement, or have estimated creatinine clearance &lt;30 mL/min measured or calculated by Cockroft Gault equation.
- Clinically significant or uncontrolled cardiac disease including any of the following:
- Acute myocardial infarction within 6 months from Day 1 of study treatment administration
- Uncontrolled hypertension
- New York Heart Association Class III or IV congestive heart failure
- Unstable angina within last 6 months from screening
- Clinically significant (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, and clinically significant second or third degree atrio-ventricular block without a pacemaker, circulatory collapse requiring vasopressor or inotropic support, or arrhythmia requiring therapy).
- Cholestatic disorders, or unresolved sinusoidal obstructive syndrome/veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to aGvHD and ongoing organ dysfunction).
- Any corticosteroid therapy for indications other than aGvHD at doses &gt;1 mg/kg/day methylprednisolone (or equivalent prednisone dose 1.25 mg/kg/day) within 7 days of Screening. Routine corticosteroids administered during conditioning or cell infusion is allowed.
- Current therapy with medications that interfere with coagulation or platelet function including but not limited to aspirin and related drugs, heparin, and warfarin (to minimize risk of bleeding). Note: Heparin or Low Molecular Weight Heparin was allowed as per protocol amendment 2, if used at sub-therapeutic dose (e.g. for prophylaxis of sinusoidal obstructive syndrome/veno-occlusive disease of the liver).
- History of progressive multifocal leuko-encephalopathy.

<div style=\"page-break-after: always\"></div>

- Patients who received JAK inhibitor therapy for any indication after initiation of current alloSCT conditioning.
- Previous participation in a study of any investigational treatment agent within 30 days of randomisation or within 5 half-lives of the investigational treatment agent, whichever is longer.
- Known allergies, hypersensitivity, or intolerance to systemic immunosuppressive therapy.
- Pregnant or nursing (lactating) women.

Grading of GvHD according to MAGIC criteria (Harris et al 2016), is a tool to standardize the collection of complex clinical data for acute GvHD (not advising treatment in clinical practice), and to collect a quantification of symptoms (extent of skin rash, total bilirubin level, volume of diarrhea etc) and still valid and used in most EU transplant centres and recommended by the EBMT.

The choice of aGvHD grading according to Harris et al 2016 is appropriate and presently the most commonly used grading instrument. However, the adherence may vary between centres due to the meticulousness demanded and time-consuming task of grading. The applicant has presented means taken to ensure the reliability and integrity of the data. The high number of PD have been highlighted, however the actual numbers of PD with respect to efficacy assessment for the timepoint of primary and key secondary endpoints were relatively low. Furthermore, a post-hoc sensitivity analysis, based on data from the secondary analysis cut-off, has been conducted excluding patients with PDs related to aGvHD efficacy assessment on the primary and key secondary endpoints showing similar results to those reported in the overall patient population (FAS).

## Treatments

Patients were randomized 1:1 to receive either best available therapy (BAT) or ruxolitinib.

Test and reference therapies, dose- and mode of administration:

Patients were randomised to receive:

- RUX 10 mg orally twice daily or
- Best available therapy (BAT) identified by the Investigator prior to patient randomisation among the following treatments: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted. Within the first 28 days after randomisation, the initiation or addition of another BAT was allowed for patients meeting criteria of disease progression, mixed response, no response but was considered a treatment failure for both the primary and key secondary objectives.

## Dose modifications

RUX dose modifications (reductions and/or interruptions) and delays were permitted to address safety concerns related to haematological (primarily, cytopenias) or non-haematological reasons, or to avoid under- or over-exposure of RUX when combined with strong CYP3A4 inhibitors or dual CYP2C9 and CYP3A4 inhibitors. RUX dose could be re-escalated to a maximum of 10 mg bid when the safety concern was resolved. The permitted daily dose range for RUX was 5 mg to 10 mg bid.

In the BAT arm, dose adjustment was based on manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines.

## Treatment duration and tapering

<div style=\"page-break-after: always\"></div>

All eligible patients randomised to study treatment were planned to receive treatment from the day of randomisation up to approximately 24 weeks (6 months), or up to approximately 2 years from randomisation, in case the end of RUX taper is delayed due to an aGvHD flare or other safety concerns or the patient met any discontinuation criteria, whichever was earlier.

Tapering of immunosuppression therapy in responding patients was performed in two steps:

1. Taper of corticosteroids: initiated not earlier than Day 7 and performed per institutional guidelines
2. Taper of CNI and/or RUX once the patient stopped corticosteroids as follows: CNI taper was performed as per institutional guidelines. RUX taper was initiated after Day 56, and performed based on condition of the patient, current dosing regimen and clinical judgement of the investigator.

The taper of corticosteroids, CNI, and RUX had to be completed by Week 96.

Special guidelines for cessation or interruption of immunosuppression, in case of an aGvHD flare, were in place.

The variety of therapies in the control arm is acceptable, as a result of differences in national and local guidelines. The most commonly used BAT treatment was ECP. Approximately 20% were treated with more than 1 concomitant BAT treatment.

## Initial BAT treatment C2301, REACH 2

<!-- formula-not-decoded -->

|                                    | BAT N=150   |
|------------------------------------|-------------|
| InitialBAT-n（&)                    |             |
| Extracorporeal photopheresis (EcP) | 41 (27.3)   |
| Mycophenolate mofetil (MMF)        | 25 (16.7)   |
| Etanercept                         | 22 (14.7)   |
| Anti-thymocyte globulin (ATG)      | 20 (13.3)   |
| Infliximab                         | 17 (11.3)   |
| Mesenchymal stromal cells (Msc)    | 15 (10.0)   |
| Low-dose Methotrexate (MTx)        | 5 (3.3)     |
| Sirolimus                          | 3 (2.0)     |
| Everolimus                         | 2 (1.3)     |
| NumberofBAT-n (%)                  |             |
| 1                                  | 119 (79.3)  |
| 2                                  | 27 (18.0)   |
| >2                                 | 4 (2.7)     |

<!-- formula-not-decoded -->

Patients continued to receive systemic corticosteroids with or without continued CNI with or without other systemic treatment for aGvHD per standard of care by the Investigator during the Screening period. Systemic medications for aGvHD other than corticosteroids +/- CNI could be continued after randomization only if used for aGvHD prophylaxis (i.e. started before the diagnosis of aGvHD)

The continued treatment with systemic corticosteroids with or without continued CNI with or without other systemic treatment, after randomisation, is according to standard procedure, and RUX or BAT treatment is considered an add on treatment at randomisation.

## Concomitant treatment

<div style=\"page-break-after: always\"></div>

Supportive treatments per institutional guidelines for management of alloSCT patients with SR-aGvHD were allowed, including systemic corticosteroids, CNI (cyclosporine or tacrolimus), and topical corticosteroid therapy, however, close monitoring of potential drug-drug interactions effects was recommended. Furthermore, antibiotics, anti-infectives, and immunizations could be used as prophylactic therapies for infections. Dose adjustments of ruxolitinib might be required particularly in patients treated with strong CYP3A4 inhibitors or dual CYP2C9 and CYP3A4 inhibitors due to potential for drug-drug interactions leading to under- or over-exposure.

In line with the MF and PV indications, a 50% dose reduction should be considered in patients with GvHD when co-administered with dual inhibitors of CYP2C9 and CYP3A4 enzymes. The concomitant use of ruxolitinib with fluconazole doses of greater than 200 mg daily was to be avoided. Due to the high risk of bleeding in alloSCT patients with SR-aGvHD, aspirin, NSAIDs, and related medications that would expectedly reduce platelet function and/or heparin, warfarin or related medication that would adversely affect blood coagulation, were prohibited.

A new immunosuppressive agent could be added to RUX or BAT treatment regimen if the patient met the criteria for disease progression, no response, or mixed response, or aGvHD flare failure; this was, then, considered treatment failure.

## Objectives

The primary and key secondary objectives were analysed when all patients completed Day 56 or discontinued from study participation earlier with a cut-off date of 25-Jul-2019 and the results were presented in the Primary analysis CSR. The second analysis with a cut-off date of 06-Jan-2020 includes data when all patients have completed approximately 6 months of treatment or discontinued from study participation earlier.

The Primary analysis included the primary endpoint and key secondary endpoint (cut-off date of 25Jul-2019)

Primary objective was to compare the efficacy of ruxolitinib vs. Best Available Therapy (BAT) in patients with Grade II-IV SR-aGvHD assessed by Overall Response Rate (ORR) at Day 28.

<div style=\"page-break-after: always\"></div>

The key secondary objective was to compare the rate of durable ORR (proportion of all patients in each arm who achieved a CR or PR at Day 28 and maintained a CR or PR at Day 56) between RUX and BAT.

## Outcomes/endpoints

## Summary of efficacy endpoints Study C2301, 271 and D2301

<!-- image -->

| Endpoint                 | Aeute GvHD                                                                                                                                                                                                                                                                                                                   | Aeute GvHD                                                                                                                                                                                                                                                          | Chronie GvHD                                                                                                                                                                                                                                                                                                                                                                                                             |
|--------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                          | Study C2301 (REACH2)                                                                                                                                                                                                                                                                                                         | Study 271 (REACH1)                                                                                                                                                                                                                                                  | Study D2301 (REACH3)                                                                                                                                                                                                                                                                                                                                                                                                     |
| Primary endpoint         | Overall response rate (ORR) at Day 28 after randomization, defined as the proportion of patients in each aim demonstrating a complete ue aoj saedeueg snuesAs jeuogppe aoj uewaumbai earlier peogression, mixed response or non- response. Sconing of response was relative to the organ stage at the time of randomization. | ORR at Day 28, defined as the proportion of patients demonstrating a complete response (CR), very good partial response (VGPR), or partial response (PR)                                                                                                            | Overallresponserate[ORR)onCycle7Day1 after randomization, defined as the proportion of patents in each arm demonstrating acomplete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mooed response or non-response. Scoring of response was neltive to the organ score uoqezwopues je                                                         |
| Key secondary endpoint   | Durable ORR at Day S6, defined as the proportion of all patients in each arm who achieve a complele response (CR) or partial response (PR) at Day 28 and maintain a CR or PR at Day 56.                                                                                                                                      | Six-month duration of response (DOR), dehned ars the time from frst response unel GVHD progression or death. DOR was assessed when all patients who are still on study complete the Day 180 visit.                                                                  | Fallure-Free Survival (FF S), composite time to event endpoint incorporating the following FFS events: ij relapse or recurrence of underlying disease or death due to underying disease, i) NRM, or j addition or initiapon of another systemic therapy for cGvHD Modified Lee symptom score, Rate of patients with dinically relevant improvement in modified Lee symptoms score at Cycle 7 Day 1 relative to baseline. |
| Other Aepuoses endpoints | ORR at Day 14, defined as the proportion of patients who achieved ORR (CR+PR) at Day 14.                                                                                                                                                                                                                                     | ORRat Days 14, 56, and 100, deined as The proportion of patients demonstrating a CR, VGPR, or PR at Days 14, 56, and 100.                                                                                                                                           | ORR on Cycle 4 Day 1, defined as the proportion of patients who achieved overall response (CR+PR) at Cyde 4 Day 1.                                                                                                                                                                                                                                                                                                       |
|                          | Best Overall Response (BOR), defined as the proportion of patients who achieve Overall pe o dn uod aw Aue e (td+) asuodsai including Day 28 and before the start of additional systemic therapy for aGvHD.                                                                                                                   | Best ORR, defined as the proportion of patents demonstrating a CR,VGPR,or PR per the CIBMTR Criteria at any time point and before the start of new anti- aGVHD therapy                                                                                              | Best overall response (BOR), defined as the proportion of patients who achieved overall response (CR+PR) at any time point (up Cycle 7 day 1 or the start of additional systemic therapy for cGvHD)                                                                                                                                                                                                                      |
|                          | opsassooodsouong responders only and is defined as the time from first response until aGvHD progression or the date of additional systemic therapies for aGvHD, Onset of cGvHD, or death without prior observation of aGvHD progression are considered as competing risks.                                                   | Three-month DORdefinedas the tim tromfirstresponseuntlGVHD progression or death, wten al parents who wrere still on study complete the Day 84 visi.                                                                                                                 | responders only. DOR is defined as the time from first response unti cOvHD progression, death, or the date of change/addition of systemic therapies for cGvHD.                                                                                                                                                                                                                                                           |
|                          | Cumullative steroid dosing until Day 56 Weekdy cumulative steroid dose for each patient up to Day 56 or end of treatment was calculated                                                                                                                                                                                      | Average and cumulative corticosteroid dote at Days 28,56 100, and 180                                                                                                                                                                                               | Proportion of patients successfully tapered off all cortioosteroids at Cycle 7 Day 1                                                                                                                                                                                                                                                                                                                                     |
|                          | Non-relapse mortality (NRM), defined as the time from date of randomization to date of death not preceded by hematologic disease relapse/progression.                                                                                                                                                                        | Non-relapse mortality (NRM), defined ns the proportion of patients who died due to cause other than malignancy relapse at months 6, 9, 12, & 24                                                                                                                     | Non-relapse mortality (NRM), defined as the time from date of randomization to dabe of death not preceded by underlying disease relapse/recurrence.                                                                                                                                                                                                                                                                      |
|                          | OverallSurvival(OS).defined asthe time from thwt date of randomization to the dale of death due to any cause.                                                                                                                                                                                                                | Overall Survval (OS). defined as the time from study enrollment (first dose of ruxolitinib treatment) to death due to any cause.                                                                                                                                    | Overalli Survival(OS),defined as the tme from the date of randomization to the date of death due to any cause.                                                                                                                                                                                                                                                                                                           |
|                          | Failure-Free Survival (FF S), defined as the time from the date of randomization lo date of hematologic disease relapse/progression, NRM or addioon of new systemic aGvHD treatment.                                                                                                                                         | Failure-Free Survival (FFS). delined as the time lrom first dose of ruxolitinib lo the earlest date that a patient died, had a relapse/ progression of the underlying malignancy, required additional therapy for aGVHD, or demonstrated signs or symptoms of cGVHD | awoqe pireiep pue Arepuooes Aao e st Sd                                                                                                                                                                                                                                                                                                                                                                                  |
|                          | Ewent-Free Survivall (EFS), defined as the time from the date of randomization to the date of hematologic disease relapse/progression, graft failure, or death due to amy cause.                                                                                                                                             | NA                                                                                                                                                                                                                                                                  | NA.                                                                                                                                                                                                                                                                                                                                                                                                                      |
|                          | Malignancy Relapse/Progression (MR), defined as the time from date of randomization to hematologic maignancy relapse/progression. Calculated for panents with underlying hematologic maignant disease.                                                                                                                       | NA                                                                                                                                                                                                                                                                  | Malignaney Relapse/ Reeurrence (MR), defined as the time from date of randomization to hematologic malignancy relapse/recurrence.Calculated for patients with underlying hematologic malignant disease.                                                                                                                                                                                                                  |
|                          | Incidence rate of cGvHD cGvHD, defined as the diagnosis of any cGvHD including mild moderate,sewere.                                                                                                                                                                                                                         | Incidence rate of cGVHD (Days 180 and 365 and overal)                                                                                                                                                                                                               | NA                                                                                                                                                                                                                                                                                                                                                                                                                       |

ORR=verallresponse rate, EOT=end of treatment, OS=overall survival EFS=event-ree survival; FFS=tailure fee survival; NRM=non-relapse mortality, BOR=best overall response; cGvHD=chronic graft versus host disease; FACT=lunctional assessment of cancer therapy; BMT=bone marrow transplantation

## Efficacy analysis/ Criteria for evaluation

Acute GvHD assessment: Acute GvHD grading was performed by the investigator at every visit during the treatment period and at EOT visit. aGvHD was graded using standard staging criteria for aGvHD (Harris et al 2016): measures of body surface area aGvHD skin rash, stool volumes or frequency per 24 h time period, and serum bilirubin levels, staging by organ (skin; liver; upper gastrointestinal; lower gastro-intestinal) and overall grading at the time of the evaluation. In addition, biopsy of the organ involved could be performed per institutional practices at Investigator's discretion for aGvHD management. Once randomized, response to study treatment was assessed by the Investigator at every visit during the Treatment Period according to study protocol definition.

<div style=\"page-break-after: always\"></div>

CR : defined as a score of 0 for the aGvHD grading in all evaluable organs that indicates complete resolution of all signs and symptoms of aGvHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response or non-response of aGvHD.

PR: defined as improvement of 1 stage in 1 or more organs involved with aGvHD signs or symptoms without progression in other organs or sites without administration of additional systemic therapies for an earlier progression, mixed response or non-response of aGvHD.

Lack of response was defined as no response, mixed response, or progression.

No response: defined as absence of improvement in any organ involved by aGvHD, without worsening in any involved organ.

Mixed response : defined as improvement of at least 1 stage in the severity of aGvHD in at least one organ accompanied by progression in another organ or development of signs or symptoms of aGvHD in a new organ.

Progression : defined as worsening in 1 or more organs by 1 or more stages without improvement in any involved organ.

Patients were also monitored for occurrence of aGvHD flares occurring during steroid, CNI, and ruxolitinib taper. Additional aGvHD assessment could be performed as per institutional guidelines at investigator's discretion.

Chronic GvHD assessment: Occurrence of definitive and possible manifestations of cGvHD was assessed monthly from Day 1 to Day 56 and at every visit thereafter during the treatment period, at the time of last dose if before Week 24, in responding patients, and at EOT (or Crossover EOT). After EOT (or Crossover EOT), patients were assessed for occurrence of cGvHD at the Safety Follow-up visit if applicable, and at Month 6, at Month 9, at Month 12, at Month 18 and at Month 24 during the LongTerm Follow-up period. Occurrence of cGvHD was not considered an adverse event (AE). cGvHD was graded as per NIH consensus guidelines for cGvHD, as mild, moderate, or severe at the time of cGvHD diagnosis. Note: Clinical presentation resembling de novo chronic GvHD or GvHD overlap syndrome with both acute and chronic GvHD features were exclusion criteria, however a mixed picture can occur after randomization.

Graft failure monitoring: Patients were monitored for any evidence of secondary graft failure at each visit from Day 1 during the Treatment, at the time of last dose if before Week 24, in responding patients, at EOT (or Crossover EOT), Safety Follow-up if applicable, and Long- Term Follow-up periods. Occurrence of graft failure was reported as an event and also as an AE. Graft failure was defined as initial whole blood or marrow donor chimerism &gt;5% declining to &lt;5% on subsequent measurements. Donor chimerism was closely monitored to detect graft failure.

Chimerism: Donor chimerism after a hematopoietic stem cell transplant involves identifying the genetic profiles of the recipient and of the donor pre-transplant, and then evaluating the ratio of donor to recipient cells in the recipient's blood, or bone marrow. Chimerism testing using peripheral blood mononuclear cells or bone marrow (or peripheral blood selected CD3+ T cells) was performed during screening (prior to study treatment start), at Day 28 and at Day 56. In addition, for patients who Crossover from BAT to ruxolitinib, chimerism was also performed at Crossover Week 1. Additional chimerism testing could be performed at any time during study (Treatment and Long-Term Follow-up period) at the treating Investigator's discretion according to local institutional practice as indicated.

Hematologic disease relapse/progression assessment: Patients were monitored for any evidence of underlying hematologic disease relapse or progression during the study. Patients were assessed at each visit from Day 1 during the Treatment period, including during crossover period if applicable, at

<div style=\"page-break-after: always\"></div>

the time of last dose if before Week 24, in responding patients, at EOT (or Crossover EOT), Safety Follow-Up if applicable, and the Long-Term follow-up period.

- -The relapse and progression of the underlying hematologic disease were assessed by the Investigator as per the definitions outlined in protocol. Evaluation and/or evidence of malignancy relapse/progression was conducted according to local institutional practices. Per protocol, study treatment was discontinued underlying hematological disease progression or relapse.

Safety: Safety was monitored by assessing physical examination, vital signs, height and weight, and laboratory assessments including urinalysis, assessment of pregnancy and fertility, clinical chemistry and hematology. Adverse event data was collected at every visit.

Special safety assessments included:

- -Pulmonary function test (PFT), if indicated clinically at investigator's discretion per local practices.
- -Bleeding, due to the potential complications of thrombocytopenia and/or coagulopathy in the setting of alloSCT.
- -Infection monitoring identified as a risk associated with ruxolitinib and BAT for aGvHD therapy.
- -Viral reactivation monitoring for hepatitis B and C (HBV viral DNA-PCR and HCV RNA-PCR), Cytomegalovirus (CMV viral DNA quantification), Epstein Barr Virus (EBV viral load), Human Herpes virus (HHV-6 viral load).
- -Second primary malignancy monitoring defined as any new malignancy other than the underlying hematologic disease.

Pharmacokinetics: Blood sampling for PK of ruxolitinib was performed in all patients enrolled in the study and treated with ruxolitinib to characterize the PK parameters in aGvHD patients.

Extensive PK sampling schedule: 'Extensive PK' sampling schedule was followed for approximately the first twenty-five (25) adult patients and all adolescent patients enrolled. The 'Extensive PK' sampling scheme includes a pre-dose and seven (7) post-dose samples on Day 1 and Day 7 thereafter, two (2) samples (1 pre-dose and 1 post-dose) per scheduled visit.

Sparse PK sampling schedule: Adult patients randomized to ruxolitinib after the Extensive PK samples were collected, and any patients crossing over from BAT to ruxolitinib after Day 28, would follow the 'Sparse PK' sampling schedule and had a total of two (2) samples (1 pre-dose and 1 postdose) per scheduled visit. The plasma samples from all patients were assayed for ruxolitinib concentrations using validated liquid chromatography-tandem mass spectrometry method.

Resource Utilization was captured for use in post-study Health Economics analysis.

Patient-reported outcomes: In order to measure Quality-of-Life (QoL) among aGVHD patients, and potential changes over time, two patient-reported outcome (PRO) instruments were administered: FACT-BMT and EQ-5D-5L. FACT-BMT is a 50-item self-report questionnaire that measures in adult patients only, the effect of a therapy on domains including physical, functional, social/family, and emotional wellbeing, together with additional concerns relevant for bone marrow transplantation patients. EQ-5D-5L descriptive classification consists of five dimensions of health: mobility, self-care, usual activities, anxiety/depression, and pain/discomfort (Brooks 1996). Each dimension of health has five levels of severity (Herdman et al 2011).

<div style=\"page-break-after: always\"></div>

These PRO instruments were planned to be administered on randomization day and every week during the first 2 months, and every 4 weeks thereafter until the end of treatment (EOT).

PRO instruments were not used for adolescents.

## Sample size

A study with a total of 308 patients and 1:1 randomization (ruxolitinib vs. BAT) stratified on aGvHD grade (Grade II vs. Grade III vs. Grade IV) would have 90% power to test for the primary endpoint (ORR at Day 28) and approximately 90% power to test for the key secondary endpoint (durable ORR at Day 56) . The family wise α -level would be controlled at 0.025 overall for the two comparisons. Specifically, this study would claim to have achieved the efficacy objective when the primary endpoint ORR at Day 28 shows a significant treatment effect at onesided α = 0.025. Conditional on significance of the primary endpoint, the key secondary endpoint durable ORR at Day 56 would be tested at onesided α = 0.025.

The sample size calculation was based on the primary variable ORR at Day 28. Based on Martin P. et al BBMT 2013, the ORR at Day 28 in the BAT arm was expected to be 58%. The stratum specific rates (Grade II 69%, Grade III 59%, Grade IV 50%) were obtained assuming that the ratio of aGvHD Grade II: III: IV is 0.2:0.4:0.4. It was expected that treatment with ruxolitinib would result in an 18% increase in the ORR, i.e., an expected odds ratio of 2.25 (which corresponds to an increase in ORR to 75%). Power for the CMH test, stratifying on aGvHD grade, was calculated using software package East V6. In order to ensure 90% power a total sample size of 308 patients is needed. With a sample size of 154 patients in each treatment arm, an observed odds ratio greater than or equal to 1.63 would achieve statistical significance for the primary endpoint. Assuming that the observed response rates in Grades II/III/IV in BAT arm are 69%/59%/50% (overall 57%), observed response rates ≥ 78%/70%/62% (overall 68%) in the ruxolitinib arm would achieve statistical significance. approximately 35%. It is expected that treatment with ruxolitinib would result in a 20% increase in the

Based on [Van Groningen 2016], the durable ORR at Day 56 in the BAT arm was expected to be ORR, i.e., an expected odds ratio of 2.25 (which corresponds to an increase in durable ORR to 55%). With these assumptions and sample size of 308 patients, the power for the key secondary endpoint is at least 90%. With sample size 154 patients in each treatment arm, an observed odds ratio greater than or equal to 1.59 for durable ORR at Day 56 would achieve statistical significance. Assuming that the observed durable response rates in Grades II/III/IV in BAT arm are 45%/36%/30% (overall 35%), observed durable response rates ≥ 57%/47%/41% (overall 47%) in the ruxolitinib arm w ould achieve statistical significance.

## Randomisation

A stratified 1:1 randomisation was conducted, and patients received either ruxolitinib or BAT. They were stratified by aGvHD grade (Grade II vs. III vs. IV). Before randomization, BAT was selected by the Investigator.

## Blinding (masking)

As these BATs vary from administered tablets to cellular therapy and photopheresis, the open label design of these studies was inevitable. This has been acknowledged by the CHMP at the time of the Scientific Advice sought in 2016 for cGvHD (CHMP Scientific Advice). The open label strategy is, therefore, acceptable.

<div style=\"page-break-after: always\"></div>

The BAT treatment was allocated before randomization took place, i.e., the treatment/s which would be standard treatment/s at the specific site.

## Treatment phases/study conduct

<!-- image -->

## Screening period

## Definition of steroid refractory aGvHD:

During the screening period, patients were monitored for a diagnosis of Steroid-refractory aGvHD, which was defined as patients who had high-dose systemic corticosteroids (methylprednisolone 2 mg/kg/day [or equivalent prednisone dose 2.5 mg/kg/day]), given alone or combined with CNI, who either:

- a) Progressed based on organ assessment after at least 3 days compared to organ stage at the time of initiation of high-dose systemic corticosteroid +/- CNI for the treatment of Grade II-IV aGvHD,

OR

OR

OR

- b) Failed to achieve at a minimum a partial response based on organ assessment after 7 days compared to organ stage at the time of initiation of high-dose systemic corticosteroid +/- CNI for the treatment of Grade II-IV aGvHD,
- c) Failed corticosteroid taper defined as fulfilling either one of the following criteria:
- Requirement for an increase in the corticosteroid dose to methylprednisolone ≥ 2 mg/kg/day (or equivalent prednisone dose ≥ 2.5 mg/kg/day)
- Failure to taper the methylprednisolone dose to &lt;0.5 mg/kg/day (or equivalent prednisone dose &lt;0.6 mg/kg/day) for a minimum 7 days.

<div style=\"page-break-after: always\"></div>

The Screening Phase should not exceed 28 days. The period from suspicion of SR-aGvHD and urgent need of additional treatment is usually short and treatment delay is not desirable.

## Randomized treatment phase

Duration of treatment: The End of Treatment (EOT) visit occurred when the patient completed the study treatment period or earlier if the patient met any of the criteria for discontinuation of study treatment.

Patients'  treatment period was up to 6 months (Week 24). However, ruxolitinib taper could be delayed up to 2 years from randomization due to an aGvHD flare or other safety concerns.

Patients meeting the primary endpoint at Day 28 will continue ruxolitinib at 10 mg BID until Day 56. Ruxolitinib will then be tapered in responding patients who have completed steroid taper starting Day 56 to complete treatment by Week 24, while patients responding to BAT will be managed as per institutional practices.

For patients not meeting the primary endpoint at Day 28: Patients who are randomized to ruxolitinib, will discontinue treatment and be treated per Investigator's judgement.

## Crossover treatment phase

Patients who are randomized to BAT, and who meet cross-over criteria after Day 28, may cross over to the ruxolitinib treatment arm and follow the same treatment duration and taper schedule as patients originally randomized to ruxolitinib treatment.

Corticosteroids and CNI for aGvHD treatment are allowed to be continued, with cessation required of any other systemic immunosuppressive treatment prior to crossover.

Cross-over to ruxolitinib during the Treatment Period for patients randomized to BAT was an option between Day 28 and Week 24 if they:

- Failed to meet the primary endpoint response definition (CR or PR) at Day 28

OR

- Lost the response thereafter and met criteria for progression, mixed response, or no response, necessitating new additional systemic immunosuppressive treatment for aGvHD.

## AND

- Did not have signs/symptoms of chronic Graft vs. Host Disease (cGvHD) (overlap syndrome, progressive, or de novo cGvHD). Patients who crossed over to ruxolitinib were followed until completion of treatment with ruxolitinib and received the same treatment and tapering schedule as patients randomized to ruxolitinib treatment.

## Safety Follow-Up (last dose + 30 days)

A 30-day Safety Follow-up visit was performed for all patients after the last dose of ruxolitinib (administered during Treatment Period or after Crossover) or BAT.

## Long-Term Follow-Up Period (From EOT to Month 24)

As SR-aGvHD often leads to death within 2 years after the transplant, and assessment of long-term safety and durable efficacy is clinically relevant, all patients (responders and non-responders in both arms, regardless of when treatment was discontinued) would be followed up for long-term observation up to 24 months from randomization.

<div style=\"page-break-after: always\"></div>

During this period, long-term data was collected: survival, any relapse/progression of the underlying hematologic disease for which the alloSCT procedure was performed, non-relapse mortality (NRM), any occurrence of graft failure, event-free survival (EFS), any occurrence of cGvHD, and occurrence of any second primary malignancies. Visits for these assessments occurred after EOT or Crossover EOT, at 6, 9, 12, 18, and 24 months.

## Statistical methods

Multiple analyses were performed:

- -The first analysis of the primary and key secondary endpoints was performed with the cut-off date as 25-Jul-2019 after all patients have completed their Day 56 visit or have discontinued study. The results were summarized in the so called 'primary' clinical study report (CSR).
- -Further analyses on secondary endpoints were performed when all patients have completed 6 months treatment or discontinued from study participation earlier, using all data collected in the database up to the data cut-off at 06-Jan-2020.

The final analysis will occur once all patients have completed the study (up to 24 months from randomization). All available data from all patients up to end of study will be reported in a final CSR. No formal interim efficacy analysis was planned in this study.

## Analysis sets

Full Analysis Set (FAS) comprises all patients to whom study treatment has been assigned by randomization. According to the intent to treat principle, patients were analysed according to the treatment and strata they have been assigned to during the randomization procedure.

The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant with requirements of the clinical study protocol. The following list of protocol deviations lead to exclusion of the patient from the PPS:

- Not steroid refractory aGvHD
- More than one prior systemic therapy for the treatment of aGvHD other than corticosteroids +/- CNI (prophylaxis or treatment)
- Missing or incorrect aGvHD grade at randomization
- Taking any prohibited medication as specified in the protocol after start of study treatment and before end of study treatment
- Study treatment received different from treatment arm assigned by randomization.

The Safety Set includes all patients who received at least one dose of study treatment. Patients were analysed according to the study treatment received, where treatment received was defined as the randomized treatment if the patient took at least one dose of that treatment, or the first treatment received if the randomized treatment was never received during the randomized treatment period.

The Crossover Analysis Set (CAS) comprises all patients randomized to and received BAT who then crossed over and received at least one dose of ruxolitinib. This analysis set was used for all analyses for crossover patients.

## Primary analysis

The primary endpoint, ORR at Day 28, was defined as the proportion of patients with CR or PR at Day 28 according to standard criteria [Harris 2016]. Note that response is relative to the assessment of aGvHD at randomization. Lack of response is defined as no response, mixed response, or progression.

<div style=\"page-break-after: always\"></div>

For definitions of these events, see section Outcomes/Endpoints. A patient was not considered a responder at Day 28 if any of the following events occurs:

- Missing aGvHD assessment at baseline or Day 28
- No CR or PR at Day 28
- Additional systemic therapy for aGvHD prior to Day 28.

The primary analysis was performed at the time when all patients have completed their Day 56 visit or discontinued earlier. The Cochrane-Mantel-Haenszel (CMH) chi-square test, stratified by the randomization stratification factor (i.e., aGvHD Grade II vs III vs. IV), was used to compare ORR between the two treatment groups, at the one-sided 2.5% level of significance, using the analysis the FAS. The statistical hypotheses tested were:

H0: ORRrux ≤ ORRBAT vs. H1: O RRrux &gt; ORRBAT

where ORRrux and ORRBAT are the overall response rates at Day 28 in the ruxolitinib and BAT group, respectively.

One-sided p-value, odds ratio and 95% Wald confidence limits calculated from the stratified CMH test were presented. ORR was also summarized using descriptive statistics (N, %) by treatment arm along with two-sided exact binomial 95% CIs [Clopper and Pearson 1934].

As a supportive analysis, the primary endpoint was analysed in the same way as in the primary analysis based on patients in PPS. A supportive analysis was also conducted using logistic regression model to estimate the treatment effect adjusting for key baseline and prognostic factors based on patients in FAS. The model included the followings covariates: age, gender, race, aGvHD grade, source of grafts, criteria for SR-aGvHD, prior aGvHD therapy in addition to treatment as one of the covariates.

As a sensitivity analysis, the two treatment groups were compared using Fisher's exact test.

Subgroup analyses were performed for the primary efficacy endpoint to examine the homogeneity of treatment effect. For each of the subgroups, the following statistics were presented:

- Proportion of patients with ORR using descriptive statistics (N, %) along with two-sided exact binomial 95% CIs.

- Odds ratio with 95% CI from a logistic regression model with treatment and stratification factors as covariates.

Efficacy analyses in subgroups were purely exploratory and were intended to explore the consistency of treatment effect. No inferential statistics (p-values) were to be produced for the subgroups.

## ORR at Crossover Day 28

ORR at Crossover Day 28 was defined as proportion of crossover patients with CR or PR at Crossover Day 28. Note that response is relative to the last assessment of aGvHD prior to or at the start date of crossover treatment (ruxolitinib). A patient was not considered a responder at Crossover Day 28 if any of the following events occurs:

- Missing aGvHD assessment at Crossover baseline or Crossover Day 28
- No CR or PR at Crossover Day 28
- Additional systemic therapy for aGvHD prior to Crossover Day 28.

ORR at Crossover Day 28 was summarized using descriptive statistics (N, %) along with two-sided exact binomial 95% CIs [Clopper and Pearson 1934] based on the CAS.

## Analysis of the key secondary endpoint

The key secondary endpoint was Durable ORR at Day 56, an tested only if the primary endpoint was statistically significant. If a patient was a CR at Day 28 and a PR at Day 56, he/she was considered as

<div style=\"page-break-after: always\"></div>

a durable responder. A patient was not considered a durable responder at Day 56 if any of the following events occurs:

- Not a responder at Day 28
- Missing aGvHD assessment at Day 56
- No CR or PR at Day 56.
- Additional systemic therapy for aGvHD prior to Day 56.

The patients randomized to BAT who met cross-over criteria and crossed-over to ruxolitinib were considered to have the additional systemic therapy for aGvHD and were not considered as a responder afterwards. Durable ORR at Day 56 was analyzed using the same method as in the primary analysis.

## Durable ORR at Crossover Day 56

Durable ORR at Crossover Day 56 was defined as the proportion of all crossover patients who achieved a CR or PR at Crossover Day 28 and maintained a CR or PR at Crossover Day 56. Note that response is relative to the last assessment of aGvHD prior to or at the start date of crossover treatment (ruxolitinib). A patient was not considered a durable responder at Crossover Day 56 if any of the following events occurs:

- Not a responder at Crossover Day 28
- Missing aGvHD assessment at Crossover Day 56
- No CR or PR at Crossover Day 56.
- Additional systemic therapy for aGvHD prior to Crossover Day 56.

Durable ORR at Crossover Day 56 was summarized using descriptive statistics (N, %) along with twosided exact binomial 95% CIs [Clopper and Pearson 1934] based on the CAS.

## Analyses of other secondary endpoints

Other secondary endpoints were not part of the hierarchical testing. ORR at Day 14 and BOR were analysed only at the data cut-off date of 25-Jul-2019. The rest of the endpoints were re-analysed at the second analysis, i.e. when all patients have completed 6 months treatment or discontinued from study participation earlier (data cut-off date 06-Jan-2020). These secondary efficacy endpoint analyses were non-comparative in nature and analysed based on the FAS.

Safety and PRO endpoints were analysed using descriptive statistics.

## Handling of missing values/censoring/discontinuations

Patients with missing assessments that prevent the evaluation of the primary endpoint were considered non-responders on that treatment arm. This includes missing aGvHD response assessments at baseline and Days 28 and 56. Duration of response was not censored based on a treatment discontinuation. No data imputation was to be applied.

## Multiplicity

The primary and the key secondary endpoint were tested hierarchically. That is, if the ORR at Day 28 was statistically significant, the durable ORR at Day 56 would be tested.

The two endpoints were tested hierarchically controlling alpha at 2.5 % one-sided. As this is the only analysis of these two endpoints and included all patients, no further adjustment for multiplicity was required then the hierarchical procedure used.

## Data Monitoring Committee (DMC)

<div style=\"page-break-after: always\"></div>

A DMC has been added as a part of study protocol amendment 2, in order to limit potential bias in study conduct in the context of this ongoing open label trial. The DMC is responsible for assessing the safety data defined as SAEs/death and graft failures obtained in the study and ensuring that the event rates are balanced between the treatment arms.

## Changes from the planned analyses

Compared to the protocol version 00 (dated 01-Sep-2016), 'discontinuation from randomized treatment' has been dropped as reason. Since some BATs have fixed duration which is less than 8 weeks, to avoid bias, discontinuation from randomized treatment will not be used to disqualify the response or durable response. Also, duration of response was not censored based on a treatment discontinuation.

According to the protocol version 00, patients who discontinued randomized treatment prior to or at Day 28 would be considered as ORR non-responders. Similar rule was to be applied for the durable ORR for the period prior to or at Day 56.

There were very few substantial changes from the protocol specified analysis, and the analyses were actually performed in accordance to the original protocol (version 00). Handling of discontinuations from randomized treatment, which was identified as a change from the protocol specified analysis, is addressed in a separate question. It was noted that at the time of the second analysis (data cut-off date 06-Jan-2020), due to the data cleaning activities, one subject in each treatment arm has changed from a non-responder to responder at Day 28. Although there is no change to the odds ratio and the conclusion, it was of concern at what time-period the data cleaning was performed for the first (and second) analysis. Dates for the database locks, data cleaning period and SAP versions are provided for the two data cut-offs.

According to the SAP, the one change to the analysis described in the original protocol was that treatment discontinuations would not be used to disqualify the response or durable response, which is not obvious to have been followed as all treatment discontinuations were treated as non-responders in the primary and the key secondary analysis. Among non-responders, the rates of early discontinuations appear to be well-balanced between the treatment groups, but together with death and missing visits, this may add to the uncertainty in the estimated outcome.

Of note, for the interpretation of the phase III study results, the convention is to use 2-sided tests and p-values. For that reason, 2-sided p-values are included in the SmPC.

## Protocol amendments

There were 2 protocol amendments. The key features of each amendment are presented below:

Amendment 1 (31- May-2017): The main purpose of Amend 1 was to clarify the exclusion criterion #5 and other eligibility criteria to follow standard medical practice. At the time of randomization, the investigator assessed if the patient presented with a viral infection or not based on his/her medical judgement and without waiting for viral load test results for CMV, EBV, HHV-6, HBV, HCV performed at screening in order not to delay the initiation of aGvHD treatment in this life-threatening condition.

Amendment 2 (21- Jun-2018): The main purpose of the amendment was to allow for more flexibility in the tapering of corticosteroids, calcineurin inhibitors (CNI) and ruxolitinib; and if needed, for this taper to be completed safely beyond Week 24. This change included clarification that institutional guidelines for the tapering of corticosteroids and CNI could be followed. Additionally, the physician could tailor the tapering strategy to each patient's condition, including stopping ruxolitinib more slowly in case of an acute Graft vs. Host Disease (aGvHD) flare or other safety concerns which may prevent the taper from

<div style=\"page-break-after: always\"></div>

being completed by Week 24. Patients, who met the protocol criteria for treatment discontinuation were not eligible to continue receiving ruxolitinib within the study but were given the possibility to continue/receive ruxolitinib outside the study (provided they met specified criteria), would not enter the Long-Term Follow-Up period. -Alignment with medical practices in managing adolescent patients, other systemic medications for aGvHD prophylaxis in addition to CNI could be maintained after randomization for all patients. To be allowed, these additional prophylactic medications start date must precede the diagnosis date of aGvHD. This change is anticipated to primarily improve adolescent enrolment but its impact on overall patient homogeneity is limited. -Simplifying the PK sampling. Alignment of the secondary endpoint BOR to aGVDH publications. A DMC was added to address the Study Steering Committee's request to be informed on the balance of safety events between treatment arms. The DMC was added to maintain the Study Steering Committee blinding during their review of pooled safety data, in order to preserve the integrity of the trial.

## CSR amendment

In addition to protocol amendments above, the Clinical Study Report was amended 12-Aug-2020 due to the following reasons

- -Correction of the cumulative corticosteroids dosing results in the primary analysis CSR because the doses of methylprednisolone were not converted to equivalent prednisone doses. The conversion factor (1.25 to convert methylprednisolone dose in prednisone) was mistakenly omitted in the programming data specification document (PDS) and statistical analysis plan (SAP), which now has been added. Correction and update of the biochemistry results
- -Furthermore, Correction and update of the lipase biochemistry results has been added and a conversion issue was detected for creatinine, magnesium and phosphate where few cases were reported as CTCAE grade 1 instead of grade 0. Some laboratory listings have been reformatted for more clarity and a clarification was added as a footnote in the outputs to a category of a protocol deviation related to the screening informed consent in order to align with its definition in the study specification documents.

The protocol amendments 1 and 2 are not expected to interfere with the integrity of the study. It is not expected that the amendments of the CSR, with regard to the recalculation of corticosteroids and biochemistry data, will affect the interpretation of data.

<div style=\"page-break-after: always\"></div>

## Results

## Recruitment

Table 14.1-2.1 (Page 1 of 1)

Screening phase disposition

All Screened Subjects

|                                                            |     | All Subjects N=620 n (8)   |
|------------------------------------------------------------|-----|----------------------------|
| Screened                                                   | 620 | (100)                      |
| Completed screening phase, randomized                      | 309 | (49.8)                     |
| Completed screening, not randomized                        | 1   | (0.2)                      |
| Did not complete screening                                 |     | 310 (50.0)                 |
| Primary reason for not completing screening Screen failure | 296 | (47.7)                     |
| Death                                                      | 7   | (1.1)                      |
| Subject/guardian decision                                  | 4   | (0.6)                      |
| Physician decision                                         | 2   | (0.3)                      |
| Technical problems                                         | 1   | (0.2)                      |
| Adverse event                                              |     | 0                          |
| Disease relapse                                            |     | 0                          |
| Failure to meet protocol continuation criteria             |     | 0                          |
| Graft loss                                                 |     | 0                          |
| Lack of efficacy                                           |     | 0                          |
| Lost to follow-up                                          |     | 0                          |
| Pregnancy                                                  |     | 0                          |
| Protocol deviation                                         |     | 0                          |
| Study terminated by sponsor                                |     | 0                          |

## Participant flow

<!-- image -->

A high rate of screen failures was seen, 310 out of a total of 620 aGvHD screened patients (50%) did not complete screening. A majority of these were screen failures, with the primary reason for not

<div style=\"page-break-after: always\"></div>

meeting eligibility criteria was that patients did not become steroid refractory (42.9%) according to study criteria.

Due to the low acceptance of a lag period in these patients from the time of SR-aGvHD has occurred until treatment should start, screening activities and assessment of inclusion and exclusion criteria began once the patient was diagnosed with aGvHD, i.e., before a possible conversion to SR-aGvHD. Out of the 309 patients included in the FAS, 154 were in the ruxolitinib arm (including 5 adolescent patients) and 155 in the BAT arm (including 4 adolescent patients).

Any occurrence of SR-aGvHD was monitored closely.

## Disposition of patients

Study treatment was discontinued due to following reasons: Lack of efficacy of aGvHD treatment, i.e. not achieving PR or CR at Day 28 or Crossover Day 28 and/or requiring additional systemic therapy for aGvHD, at any time; development of signs or symptoms of cGvHD including de novo, overlap, or progressive onset; underlying haematological disease progression or relapse; evidence of graft failure necessitating rapid taper of immunosuppression, administration of non-scheduled DLI, stem cell boost, chemotherapy, or other treatment that would expectedly affect aGvHD; adverse events leading to study treatment discontinuation.

A majority of patients discontinued from the randomized treatment phase (24 weeks) in both arms. The median duration of exposure to RUX treatment and BAT treatment were 63 days (6.0 - 463.0 days) and 29 days (1.0 - 188.0 days) respectively.

## Randomized treatment phase at the secondary analysis, data cut-off 06 Jan 2020

Table10-1 Patient disposition (FAS)

* Ongoing at the time of the data cut-off date 06-Jan-2020

|                                                              | RUX N=154 n (%)   | BAT N=155 n (%)   | AII Patients N=309 n (%)   |
|--------------------------------------------------------------|-------------------|-------------------|----------------------------|
| Subjectsrandomized                                           |                   |                   |                            |
| Treated                                                      | 152 (98.7)        | 150 (96.8)        | 302 (97.7)                 |
| Not treated                                                  | 2 (1.3)           | 5 (3.2)           | 7 (2.3)                    |
| Treatment ongoing*                                           | 3 (1.9)           | 0                 | 3 (1.0)                    |
| Completedtreatmentperiod                                     | 35 (22.7)         | 21 (13.5)         | 56 (18.1)                  |
| Discontinued fromtreatmentperiod                             | 116 (75.3)        | 134 (86.5)        | 250 (80.9)                 |
| Reasonfordiscontinuation                                     |                   |                   |                            |
| Lackofefficacy                                               | 32 (20.8)         | 69 (44.5)         | 101 (32.7)                 |
| Adverse event                                                | 27 (17.5)         | 6 (3.9)           | 33 (10.7)                  |
| Death                                                        | 25 (16.2)         | 21 (13.5)         | 46 (14.9)                  |
| Failure to meet protocol continuation criteria               | 12 (7.8)          | 9 (5.8)           | 21 (6.8)                   |
| Diseaserelapse                                               | 8 (5.2)           | 13 (8.4)          | 21 (6.8)                   |
| Physician decision                                           | 6 (3.9)           | 9 (5.8)           | 15 (4.9)                   |
| Subject/guardian decision                                    | 4 (2.6)           | 6 (3.9)           | 10 (3.2)                   |
| Graft loss                                                   | 2 (1.3)           | 0                 | 2 (0.6)                    |
| Lost to follow-up                                            | 0                 | 0                 | 0                          |
| Pregnancy                                                    | 0                 | 0                 | 0                          |
| Protocol deviation                                           | 0                 | 0                 | 0                          |
| Studyterminatedbysponsor                                     | 0                 | 0                 | 0                          |
| Technicalproblems                                            | 0                 | 1 (0.6)           | 1 (0.3)                    |
| Continued into next phase at the end of randomized treatment |                   |                   |                            |
| Crossovertreatment                                           | 0                 | 49 (31.6)         | 49 (15.9)                  |
| Enteredlong-termfollow-up                                    | 96 (62.3)         | 51 (32.9)         | 147 (47.6)                 |

<div style=\"page-break-after: always\"></div>

The study had three phases: Randomization treatment phase (n=309), crossover treatment phase (n=49) and long-term follow-up phase into which 87 patients entered (56.5%) in the RUX arm and 45 (29.0%) patients in the BAT arm. In addition, 24 patients from the cross-over phase entered the longterm follow-up phase.

In the randomization treatment phase, thirty-five (22.7%) patients completed the treatment period in the RUX arm compared to 21 (13.5%) in the BAT arm. A total of 116 (75.3%) patients in RUX arm and 134 (86.5%) patients in BAT arm discontinued during the randomized treatment period and the most common reasons for discontinuation were lack of efficacy (20.8% in ruxolitinib arm vs. 44.5% in BAT arm), death (16.2% in ruxolitinib arm vs. 13.5% in BAT arm) and AEs (17.5% in ruxolitinib arm vs. 3.9% in BAT arm). Among the 14 patients (6 in ruxolitinib arm and 8 in BAT arm) who discontinued due to physician decision, one patient in ruxolitinib arm and two patients in BAT arm were reported to be responders. In the RUX arm, 62.3% entered the long-term follow up phase compared to 32.9% in the BAT arm.

Due to the option for patients in the BAT arm to switch to a second BAT within the first 28 days (i.e., the timepoint for the analysis of the primary endpoint and also the option for BAT patients to crossover to RUX treatment), without discontinuing from the main treatment period, indicate no difference between treatment arms until this timepoint but a quick drop, for the BAT arm, was thereafter seen.

The K-M plot over treatment discontinuations indicate similar and rather quick drop out in both treatment arms already from the study start, and a sharp drop in the BAT arm after day 28.

<!-- image -->

The most frequent reasons for discontinuations during the first 28 days were lack of efficacy, death, and adverse events in ruxolitinib arm (13, 12 and 7 patients, respectively), and lack of efficacy and death in the BAT arm (26 and 9 patients, respectively). The sharp drop after day 28 was not surprising since per study design patients were expected to remain in the initial treatment at least until Day 28.

<div style=\"page-break-after: always\"></div>

## CINC424C2301-SecondaryCSR

## Treatment:Bestavailabletherapy

|                                              | Dayssincetreatmentstart   | Dayssincetreatmentstart   | Dayssincetreatmentstart   | Dayssincetreatmentstart   | Dayssincetreatmentstart   | Dayssincetreatmentstart   | Dayssincetreatmentstart   |             |            |
|----------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------|------------|
| Reason                                       | <=28                      | >28 -56                   | >56-112                   | >112-168                  | >168-336                  | >336-672                  | >672                      | Not treated | any        |
| Primaryreasonfor discontinuation             |                           |                           |                           |                           |                           |                           |                           |             |            |
| Adverse event                                | 3                         | 0                         | 2                         | 0                         | 1                         | 0                         | 0                         | 0           | 6 (3.9%)   |
| Death                                        | 6                         | 5                         | 5                         | 0                         | 0                         | 0                         | 0                         | 2           | 21 (13.5%) |
| Diseaserelapse                               | 2                         | 2                         | 5                         | 4                         | 0                         | 0                         | 0                         | 0           | 13 ( 8.4%) |
| Failure tomeetprotocol continuation criteria | 0                         | 1                         | 3                         | 3                         | 1                         | 0                         | 0                         | 1           | 9 ( 5.8%)  |
| Graft loss                                   | 0                         | 0                         | 0                         | 0                         | 0                         | 0                         | 0                         | 0           | 0          |
| Lack of efficacy                             | 26                        | 30                        | 8                         | 5                         | 0                         | 0                         | 0                         | 0           | 69 (44.5%) |
| Physician decision                           | 3                         | 3                         | 2                         | 0                         | 0                         | 0                         | 0                         | 1           | 9 ( 5.8%)  |
| Subject/guardian decision                    | 3                         | 1                         | 0                         | 1                         | 0                         | 0                         | 0                         | 1           | 6 (3.9%)   |
| Technical problems                           | 1                         | 0                         | 0                         | 0                         | 0                         | 0                         | 0                         | 0           | 1 (0.6%)   |

No patients discontinued due to protocol deviations.

## Cross over patients

Forty-nine patients (31.6%) discontinued BAT and crossed over to RUX treatment of whom 55.1% entered the long-term follow-up phase. The median time to cross-over was 34 days (range 28.0162.0). At the secondary analysis data cut-off, 36 (73.5%) of patients discontinued the cross-over treatment period. The most common reason for discontinuation were AEs (24.5%), death (16.3%) and lack of efficacy (12.2%).

TableHA2 14.1-1.4

Discontinuationreasonsbytimeintervalforthemainstudyperiod,bytreatment

## Treatment:Ruxolitinib10mgBlD

|                                              | Dayssincetreatmentstart   | Dayssincetreatmentstart   | Dayssincetreatmentstart   | Dayssincetreatmentstart   | Dayssincetreatmentstart   | Dayssincetreatmentstart   | Dayssincetreatmentstart   |             |            |
|----------------------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|---------------------------|-------------|------------|
| Reason                                       | <=28                      | >28-56                    | >56-112                   | >112-168                  | >168-336                  | >336-672                  | >672                      | Not treated | any        |
| Primaryreasonfordiscontinuation              |                           |                           |                           |                           |                           |                           |                           |             |            |
| Adverse event                                | 7                         | 6                         | 7                         | 3                         | 1                         | 0                         | 0                         | 0           | 27 (17.5%) |
| Death                                        | 12                        | 7                         | 5                         | 1                         | 0                         | 0                         | 0                         | 0           | 25 (16.2%) |
| Disease relapse                              | 1                         | 1                         | 3                         | 2                         | 1                         | 0                         | 0                         | 0           | 8 ( 5.2%)  |
| Failure tomeetprotocol continuation criteria | 0                         | 2                         | 3                         | 3                         | 4                         | 0                         | 0                         | 0           | 12 ( 7.8%) |
| Graft loss                                   | 0                         | 1                         | 1                         | 0                         | 0                         | 0                         | 0                         | 0           | 2 ( 1.3%)  |
| Lack of efficacy                             | 13                        | 12                        | 6                         | 1                         | 0                         | 0                         | 0                         | 0           | 32 (20.8%) |
| Physician decision                           | 0                         | 3                         | 3                         | 0                         | 0                         | 0                         | 0                         | 0           | 6 (3.9%)   |
| Subject/guardian decision                    | 0                         | 1                         | 0                         | 0                         | 1                         | 0                         | 0                         | 2           | 4 (2.6%)   |
| Technical problems                           | 0                         | 0                         | 0                         | 0                         | 0                         | 0                         | 0                         | 0           | 0          |

CINC424C2301-SecondaryCSR

<!-- formula-not-decoded -->

<!-- formula-not-decoded -->

Full analysisset

<div style=\"page-break-after: always\"></div>

## Conduct of the study

## Protocol deviations

Table 14.1-4.1 (Page 1 of 2) Protocol deviations Full Analysis Set

| Category Protocol deviation                                                                                                | RUX N=154 n (%)   | BAT N=155 n (%)   | All Patients N=309 n (%)   |
|----------------------------------------------------------------------------------------------------------------------------|-------------------|-------------------|----------------------------|
| Any protocol deviation                                                                                                     | 131 (85.1)        | 135 (87.1)        | 266 (86.1)                 |
| Any exclusion criteria deviation                                                                                           | 4 (2.6)           | 3 (1.9)           | 7 (2.3)                    |
| exclusion criteria of concomitant meds not met                                                                             | 2 (1.3)           | 0                 | 2 (0.6)                    |
| Exclusion criterion of absence of chronic                                                                                  | 1 (0.6)           | 1 (0.6)           | 2 (0.6)                    |
| GvHD(denovo or overlap syndrome) met. exclusion criteria of absence of significant or uncontrolled cardiac disease not met | 1 (0.6)           | 0                 | 1 (0.3)                    |
| Exclusion criteria of absence of severely                                                                                  | 0                 | 1 (0.6)           | 1 (0.3)                    |
| impaired renal function not met exclusion criteria of absence of relapsed primary maligancy not met                        | 0                 | 1 (0.6)           | 1 (0.3)                    |
| Any inclusion criteria deviation                                                                                           | 56 (36.4)         | 61 (39.4)         | 117 (37.9)                 |
| viral Load assessment at screening or Day 1 is beyond protocol acceptable window.                                          | 26 (16.9)         | 25 (16.1)         | 51 (16.5)                  |
| Chimerism at Screening or Day 1 is beyond protocol acceptable window.                                                      | 20 (13.0)         | 18 (11.6)         | 38 (12.3)                  |
| Study Informed Consent not obtained                                                                                        | 8 (5.2)           | 7 (4.5)           | 15 (4.9)                   |
| Steroid refractory aGvHD criteria not met                                                                                  | 7 (4.5)           | 15 (9.7)          | 22 (7.1)                   |
| acute GvHD grade criteria not met                                                                                          | 6 (3.9)           | 3 (1.9)           | 9 (2.9)                    |
| Myeloid platelet engraftment not confirmed                                                                                 | 3 (1.9)           | 6 (3.9)           | 9 (2.9)                    |
| Screening Informed Consent not obtained                                                                                    | 2 (1.3)           | 0                 | 2 (0.6)                    |
| Other Deviation                                                                                                            | 95 (61.7)         | 101 (65.2)        | 196 (63.4)                 |
| OTHER DEVIATION                                                                                                            | 95 (61.7)         | 101 (65.2)        | 196 (63.4)                 |
| Prohibited Concomitant Medication                                                                                          | 31 (20.1)         | 28 (18.1)         | 59 (19.1)                  |

Numbers (n) represent counts of subjects. A Subject can have more than one deviation.

/csr\\_1/pgm/saf/tprtdev.sas@@/main/4-23JAN2020:16:44

<!-- formula-not-decoded -->

| Category                                                            | RUX N=154   | BAT N=155   | All Patients N=309   |
|---------------------------------------------------------------------|-------------|-------------|----------------------|
| Protocol deviation                                                  | n (%)       | n (%)       | n (%)                |
| Prohibited Concomitant Medication prohibited concomitant medication | 31 (20.1)   | 28 (18.1)   | 59 (19.1)            |
| Subject Not Withdrawn As Per Protocol                               | 10 (6.5)    | 19 (12.3)   | 29 (9.4)             |
| Study treatment continued whereas a withdrawal criterion was met    | 6 (3.9)     | 0           | 6 (1.9)              |
| study treatment withdrawal criteria not met                         | 5 (3.2)     | 19 (12.3)   | 24 (7.8)             |
| Treatment Deviation                                                 | 44 (28.6)   | 60 (38.7)   | 104 (33.7)           |
| Investigational study treatment dispensing error                    | 43 (27.9)   | 60 (38.7)   | 103 (33.3)           |
| criteria for dose reduction/interruption not followed               | 3 (1.9)     | 3 (1.9)     | 6 (1.9)              |

The high rate of protocol deviations did, overall, not differ between the 2 study arms. The most common deviation belonged to the category 'Other deviations' (61.7% and 65.2%) which included: Different aGvHD overall grades used for randomization between e-CRF and IRT; missing two consecutive monthly scheduled viral load testing; missing aGvHD assessment at day 28 or day 56; organ Staging assessment done per investigator criteria/judgement rather than MAGIC criteria (Harris et al); response assessment done per investigator criteria/judgement rather than protocol definition; protocol amendment 2 implemented before patient's re-consent obtained. 'Prohibited drugs' were taken by 19.1% patients (20.1% in ruxolitinib arm and 18.1% in BAT arm). Deviations in these categories were the most common reasons for exclusion of patients from the PPS (see below).

With the exception of protocol deviation 'organ staging assessment done per investigator criteria/judgement rather Harris' (18.8% with RUX vs. 34.2% with BAT), no imbalances in

Final

<div style=\"page-break-after: always\"></div>

subcategories of 'other deviations' have been observed. It is acknowledged that above-described exception was reported with similar rates at key time points (baseline, Day 28 and Day 56).

## Baseline data

Demographics and baseline characteristics (FAS)

|                             | RUX          | BAT           | All Patients   |
|-----------------------------|--------------|---------------|----------------|
| Demographic variable        | N=154        | N=155         | N=309          |
| Age (years)                 |              |               |                |
| n                           | 154          | 155           | 309            |
| Mean (SD)                   | 48.1 (16.30) | 50.9 (14.97)  | 49.5 (15.69)   |
| Median                      | 52.5         | 54.0          | 54.0           |
| 01-03                       | 32.0-61.0    | 41.0-63.0     | 38.0-62.0      |
| Min - Max                   | 12:0-73.0    | 13.0-71.0     | 12.0-73.0      |
| Age calegory -n (%)         |              |               |                |
| Adolescents, 12 - c18 yoars | 5 (3.2)      | 4 (2.6)       | 9 (2.9)        |
| 18 - 65 years               | 128 (83.1)   | 126 (81.3)    | 254 (82.2)     |
| >65 yoars                   | 21 (13.6)    | 25 (16.1)     | 46 (14.9)      |
| (%]0-X09                    |              |               |                |
| Female                      | 62 (40.3)    | 64 (41.3)     | 126 (40.8)     |
| Malo                        | 92 (59.7)    | 91 (58.7)     | 183 (59.2)     |
| Raco -n (%)                 |              |               |                |
| While                       | 111 (72.1)   | 102 (65.8)    | 213 (68.9)     |
| Black or African American   | 0            | 1 (0.6)       | 1 (0.3)        |
| Asian                       | 19 (12.3)    | 29 (18.7)     | 48 (15.5)      |
| Other                       | 8 (5.2)      | 4 (2.6)       | 12 (3.9)       |
| Unknown                     | 16 (10.4)    | 19 (12.3)     | 35 (11.3)      |
| Eihnicity -n (%)            |              |               |                |
| Hispanic/Latino             | 8 (5.2)      | 12 (7.7)      | 20 (6.5)       |
| Not Hispanie/Latino         | 94 (61.0)    | (8'99)88      | 182 (58.9)     |
| Not Reported                | 29 (18.8)    | 36 (23.2)     | 65 (21.0)      |
| Unknown                     | 23 (14.9)    | 19 (12.3)     | 42 (13.6)      |
| Weight (kg)                 |              |               |                |
| n                           | 150          | 152           | 302            |
| Mean (SD)                   | 67.5 (14.04) | 66.2 (14.78)  | 66.9 (14.41)   |
| Median                      | 67.7         | 66.2          | 67.0           |
| 01-03                       | 58.0-78.0    | 54.6-74.5     | 55.6-75.6      |
| Min - Max                   | 28.5-97.0    | 32.9-115.5    | 28.5-115.5     |
| Height (em)                 |              |               |                |
| n                           | 148          | 144           | 292            |
| Mean (SD)                   | 169.7 (9.86) | 170.0 (10.16) | 169.9 (9.99)   |
| Median                      | 170.0        | 170.0         | 170.0          |
| Q1-03                       | 161.9-177.5  | 163.0-177.0   | 162.0-177.0    |
| Min - Max                   | 128.7-195.0  | 146.0-200.0   | 128.7-200.0    |
| Body mass index (kg/m²)     |              |               |                |
| n                           | 146          | 142           | 288            |
| Mean (SD)                   | 23.4 (4.24)  | 22.7 (4.15)   | 23.1 (4.20)    |
| Median                      | 23.3         | 977           | 23.1           |
| Q1-Q3                       | 20.4-26.2    | 19.9-24.7     | 20.1-25.5      |
| Mln - Max                   | 13.5-34.4    | 13.9-35.7     | 13.5-35.7      |

Body Mass Index (kg/m²) = weight (kg) / (height (m)*2)

<div style=\"page-break-after: always\"></div>

## Underlying disease history/transplant and GvHD related history

## Disease history by treatment (FAS)

| Disease history                                                | RUX N=154    | BAT N=155    | All Patients N=309   |
|----------------------------------------------------------------|--------------|--------------|----------------------|
| Primary diagnosis classification-n (%)                         |              |              |                      |
| Malignant-leukemia/MDS                                         | 129 (83.8)   | 121 (78.1)   | 250 (80.9)           |
| Malignant-lymphoproliferative                                  | 18 (11.7)    | 26 (16.8)    | 44 (14.2)            |
| Non-malignant                                                  | 1 (0.6)      | 5 (3.2)      | 6 (1.9)              |
| Other                                                          | 6 (3.9)      | 3 (1.9)      | 9 (2.9)              |
| Diagnosis of underlying malignant disease-n (%)                |              |              |                      |
| Acute lymphoblastic leukemia (ALL)                             | 25 (16.2)    | 16 (10.3)    | 41 (13.3)            |
| Acutemyelogenousleukemia(AML)                                  | 58 (37.7)    | 63 (40.6)    | 121 (39.2)           |
| Chronic myelogenous leukemia (CML)                             | 6 (3.9)      | 2 (1.3)      | 8 (2.6)              |
| Excessblasts 2,developed fromFanconi                           | 1 (0.6)      | 0            | 1 (0.3)              |
| syndrome                                                       |              |              |                      |
| Hodgkin's lymphoma                                             | 6 (3.9)      | 2 (1.3)      | 8 (2.6)              |
| Multiple myeloma                                               | 2 (1.3)      | 5 (3.2)      | 7 (2.3)              |
| Myelodysplastic disorder                                       | 26 (16.9)    | 29 (18.7)    | 55 (17.8)            |
| Non-Hodgkin's lymphoma                                         | 9 (5.8)      | 19 (12.3)    | 28 (9.1)             |
| Other acute leukemia                                           | 4 (2.6)      | 3 (1.9)      | 7 (2.3)              |
| Otherleukemia                                                  | 6 (3.9)      | 8 (5.2)      | 14 (4.5)             |
| Other                                                          | 4 (2.6)      | 0            | 4 (1.3)              |
| Diagnosis of underlying non-malignant disease-n (%)            |              |              |                      |
| Histiocytic disorders                                          | 0            | 1 (0.6)      | 1 (0.3)              |
| Sickle cell disease                                            | 1 (0.6)      | 1 (0.6)      | 2 (0.6)              |
| Other                                                          | 0            | 3 (1.9)      | 3 (1.0)              |
| Diagnosis of underlying disease Other -n (%)                   |              |              |                      |
| Blasticneoplasmofplasmacytoiddentriticcells                    | 0            | 1 (0.6)      | 1 (0.3)              |
| Multiple myeloma and secondary acutemyeloid                    | 0            | 1 (0.6)      | 1 (0.3)              |
| leukemia                                                       |              |              |                      |
| Myelofibrosis                                                  | 2 (1.3)      | 0            | 2 (0.6)              |
| Myeloma                                                        | 0            | 1 (0.6)      | 1 (0.3)              |
| Myeloproliferativeneoplasm                                     | 1 (0.6)      | 0            | 1 (0.3)              |
| Post polycythemia vera myelofibrosis                           | 1 (0.6)      | 0            | 1 (0.3)              |
| Primary myelofibrosis                                          | 1 (0.6)      | 0            | 1 (0.3)              |
| Septic granulomatosis                                          | 1 (0.6)      | 0            | 1 (0.3)              |
| Time from diagnosis of underlying disease to screening (years) |              |              |                      |
| n                                                              | 154          | 154          | 308                  |
| Mean (SD)                                                      | 2.16 (3.195) | 1.72 (2.170) | 1.94 (2.735)         |
| Median                                                         | 1.04         | 0.86         | 0.94                 |
| Min-Max                                                        | 0.2 - 25.7   | 0.2-15.1     | 0.2 - 25.7           |
| CIBMTRrisk assessment-n (%)                                    |              |              |                      |
| Low                                                            | 46 (29.9)    | 46 (29.7)    | 92 (29.8)            |
| Intermediate                                                   | 43 (27.9)    | 48 (31.0)    | 91 (29.4)            |
| High                                                           | 61 (39.6)    | 55 (35.5)    | 116 (37.5)           |
| Unknown                                                        | 4 (2.6)      | 6 (3.9)      | 10 (3.2)             |

Table 14.1-7.2 (Page 1 of 2)

Transplant related disease history by treatment Full Analysis Set

| Disease history                                  | RUX N=154   | BAT N=155   | All Patients N=309   |
|--------------------------------------------------|-------------|-------------|----------------------|
| Conditioning regimen type-n (&)                  |             |             |                      |
| MYELOABLATIVE                                    | 85 (55.2)   | 65 (41.9)   | 150 (48.5)           |
| NON-MYELOABLATIVE                                | 31 (20.1)   | 41 (26.5)   | 72 (23.3)            |
| REDUCED INTENSITY                                | 38 (24.7)   | 49 (31.6)   | 87 (28.2)            |
| Total HcT-specific co-morbidityindex score-n (%) |             |             |                      |
| 0                                                | 70 (45.5)   | 63 (40.6)   | 133 (43.0)           |
| 1                                                | 30 (19.5)   | 27 (17.4)   | 57 (18.4)            |
| 2                                                | 24 (15.6)   | 19 (12.3)   | 43 (13.9)            |
| 3                                                | 6 (5.8)     | 26 (16.8)   | 35 (11.3)            |
| 4                                                | 12 (7.8)    | 6 (3.9)     | 18 (5.8)             |
| >=5                                              | 6(3.9)      | 6 (3.9)     | 12 (3.9)             |
| Missing                                          | 3 (1.9)     | 8(5.2)      | 11 (3.6)             |

<div style=\"page-break-after: always\"></div>

<!-- formula-not-decoded -->

|                                                                                          |                                                                                          |                | All Patients       |
|------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------|----------------|--------------------|
| Disease history                                                                          | RUX N=154                                                                                | BAT N=155      | N=309              |
| Stem cell type-n (&)                                                                     |                                                                                          |                |                    |
| BONE MARROW                                                                              | 19 (12.3)                                                                                | 30 (19.4)      | 49( (15.9)         |
| PERIPHERALBLOOD                                                                          | 134 (87.0)                                                                               | 118 (76.1)     | 252 (81.6)         |
| SINGLE CORD BLOOD                                                                        | 1 (0.6)                                                                                  | (4.5)          | 8(2.6)             |
| Cytomegalovirus status at time of transplant-n (&) NEGATIVE                              | 73 (47.4)                                                                                | 68 (43.9)      | 141 (45.6)         |
| POSITIVE                                                                                 | 81 (52.6)                                                                                | 87 (56.1)      | 168 (54.4)         |
| Table 14.1-7.3 (Page 1 of 3) Transplant donor information by treatment Full Analysis Set | Table 14.1-7.3 (Page 1 of 3) Transplant donor information by treatment Full Analysis Set |                |                    |
|                                                                                          | RUX                                                                                      | BAT N=155      | All Patients N=309 |
| Disease history Number of Donors                                                         | N=154 157                                                                                | 158            | 315                |
| Donor age (years)                                                                        |                                                                                          |                |                    |
| n                                                                                        | 152                                                                                      | 145            | 297                |
| Mean (SD)                                                                                | 36.2 (12.80)                                                                             | 37.3 (12.86)   | 36.7 (12.82)       |
| Median Min-Max                                                                           | 35.0 11.0 - 68.0                                                                         | 36.0 14.0-73.0 | 35.0 11.0 -73.0    |
| Donor sex-n                                                                              |                                                                                          |                |                    |
| Female                                                                                   | 54 (34.4)                                                                                | 55 (34.8)      | 109 (34.6)         |
| Male                                                                                     | 102 (65.0)                                                                               | 99 (62.7)      | 201 (63.8)         |
| Missing                                                                                  | 1 (0.6)                                                                                  | 4(2.5)         | 5 (1.6)            |
| HLA typing method-n (&)                                                                  |                                                                                          |                |                    |
| HIGH LEVEL DNA                                                                           | 105 (66.9)                                                                               | 89 (56.3)      | 194 (61.6)         |
| LOCI A，B， C, DQ: LOW LEVEL DNA, LOCUS DRB1: HIGH LEVEL                                   | 18 (11.5)                                                                                | 22 (13.9)      | 40 (12.7)          |
| DNA.                                                                                     |                                                                                          |                |                    |
| LOCI A, B， C: LOW LEVEL DNA,LOCUS DRB1: HIGH LEVEL DNA                                   | 1 0.6)                                                                                   | 5 (3.2)        | 9 1.9)             |
| LOCI A, B: LOW LEVEL DNA,LOCUS DRB1: HIGH LEVEL DNA                                      | 3 1.9)                                                                                   | 1 (0.6)        | 4 1.3)             |
| LOCI A, B: SEROLOGIC, LOCUS DRB1: HIGH LEVEL DNA                                         | 1 0.6)                                                                                   | 1 (0.6)        | 2 0.6)             |
| LOCI A, B： SEROLOGIC, LOCUS DRB1: LOW LEVEL DNA                                          | 1 0.6)                                                                                   | 1 (0.6)        | 2 0.6)             |
| LOW LEVEL DNA                                                                            | 14 8.9)                                                                                  | 11 (7.0)       | 25 7.9)            |
| SEROLOGIC                                                                                | 10                                                                                       | 19 (12.0)      | 29 9.2)            |
| Missing                                                                                  | 6.4) 0                                                                                   | (0.6)          | 0.3)               |
| HLA match score-n （)                                                                     |                                                                                          |                |                    |
| 10/10                                                                                    | 77 (49.0)                                                                                | 74 (46.8)      | 151 (47.9)         |
| 9/10                                                                                     | 29 (18.5)                                                                                | 18 (11.4)      | 47 (14.9)          |
| 8/8                                                                                      | 12 (7.6)                                                                                 | 13(8.2)        | 25 (7.9)           |

Percentages are based on the number of donors.

Baseline demographics were well-balanced between the two treatment arms

In the general population that had undergone allo-transplantation, the incidence of Grade II-IV aGvHD in adolescent patients aged 12-18 years approximates 5% of that observed in adults &gt;18 years (data Center for International Blood and Marrow Transplant Research [CIBMTR] data - unpublished data). In the present study, the proportion of adolescents was 2.9%.

Few patients had other than underlying malignant disease (0.6% and 3.2%). The predominant malignant diagnoses (AML, ALL, MDS) were generally balanced between the treatment arms. In addition, the CIBMTR risk categories (a validated tool to categorize groups of patients undergoing allogeneic stem cell transplantation, intended for research purposes to stratify patients in broad disease risk categories for retrospective or prospective studies), were also balanced between the treatment arms.

Furthermore, the majority of conditioning regiments were myeloablative, however, a slight imbalance was noted, 55.2% of subjects in the RUX arm received myelo-ablative conditioning prior to transplant compared to 41.9% in the BAT arm. Consequently, fewer patients in ruxolitinib arm received the less intense forms of conditioning therapy (non-myelo-ablative: 20.1% and reduced intensity: 24.7%)

<div style=\"page-break-after: always\"></div>

compared to BAT arm (non-myelo-ablative: 26.5% and reduced intensity: 31.6%). T-cell depletion was performed in 39 patients overall.

The transplant donor median age was 35 years, and the majority were male (balance between arms). The HLA match score was 10/0 or 9/10 in most cases.

Most patients (75.3%) entered the study with low hematopoietic cell transplantation (HCT)comorbidity scores (between 0 and 2).

|                                                                           | Table 14.1-7.4a (Page 1 of 3)                        | Table 14.1-7.4a (Page 1 of 3)   | Table 14.1-7.4a (Page 1 of 3)   | Table 14.1-7.4a (Page 1 of 3)   |
|---------------------------------------------------------------------------|------------------------------------------------------|---------------------------------|---------------------------------|---------------------------------|
|                                                                           | aGvHD disease history by treatment Full Analysis Set |                                 |                                 |                                 |
| Disease history                                                           | RUX N=154                                            | BAT N=155                       |                                 |                                 |
| Time from transplant to diagnosis of aGvHD grade>=2 (day)                 |                                                      |                                 |                                 |                                 |
| n                                                                         | 154                                                  | 155                             | 309                             | 309                             |
| Mean (SD)                                                                 | 54.77 (62.813)                                       | 58.25 (58.680)                  | 56.52 (60.701)                  | 56.52 (60.701)                  |
| Median                                                                    | 33.50                                                | 34.00                           | 34.00                           | 34.00                           |
| Min-Max                                                                   | 3.0-380.0                                            | 6.0-412.0                       | 3.0-412.0                       | 3.0-412.0                       |
| Time from diagnosis of aGvHD grade>=2 to randomization (day)              |                                                      |                                 |                                 |                                 |
| n                                                                         | 154                                                  | 155                             | 309                             | 309                             |
| Mean (SD)                                                                 | 29.57 (43.612)                                       | 23.26 (31.392)                  | 26.41 (38.046)                  | 26.41 (38.046)                  |
| Median                                                                    | 14.00                                                | 14.00                           | 14.00                           | 14.00                           |
| Min-Max                                                                   | 2.0 -332.0                                           | 1.0 -293.0                      | 1.0 -332.0                      | 1.0 -332.0                      |
| aGvHD grade when diagnosis of grade >=2 -n (&)                            |                                                      |                                 |                                 |                                 |
| Grade II                                                                  | 68 (44.2)                                            | 74 (47.7)                       | 142 (46.0)                      | 142 (46.0)                      |
| Grade III                                                                 | 68 (44.2)                                            | 62 (40.0)                       | 130 (42.1)                      | 130 (42.1)                      |
| Grade IV                                                                  | 18 (11.7)                                            | 19 (12.3)                       | 37 (12.0)                       | 37 (12.0)                       |
| Steroid refractory aGvHD criteria met -n ()                               |                                                      |                                 |                                 |                                 |
| Progression after at least 3 days                                         | 35 (22.7)                                            | 43 (27.7)                       | 78 (25.2)                       | 78 (25.2)                       |
| Failure to achieve a response after 7days                                 | 72 (46.8)                                            | 63 (40.6)                       | 135 (43.7)                      | 135 (43.7)                      |
| Failure on steroid taper                                                  | 47 (30.5)                                            | 49 (31.6)                       | 96 (31.1)                       | 96 (31.1)                       |
| aGvHD disease history by treatment Full Analysis Set                      | Table 14.1-7.4a (Page 2 of 3)                        |                                 |                                 |                                 |
|                                                                           | RUX                                                  | BAT                             |                                 |                                 |
| Prior aGvHD therapy -n                                                    | N=154                                                | N=155                           |                                 |                                 |
| Disease history                                                           |                                                      |                                 |                                 |                                 |
| Steroid only Steroid + CNI Steroid + CNI + Other systemic aGvHD treatment | 12 (7.8) 77 (50.0) 56 (36.4)                         | (11.6) 76 (49.0) 49 (31.6)      |                                 |                                 |
| Steroid + CNI + only aGvHD prophylaxis +                                  | 41 (26.6)                                            | 30 (19.4)                       | 71 (23.0)                       | 71 (23.0)                       |
| Steroid + CNI only aGvHD treatment                                        | 8 (5.2)                                              | 12 7.7)                         | 20 (6.5)                        | 20 (6.5)                        |
| Steroid + CNI I+ both aGvHD prophylaxis and treatment                     | 7 （ 4.5)                                             | 7 4.5)                          | 14 (4.5)                        | 14 (4.5)                        |
| Steroid + other  systemic aGvHD treatment                                 | 6 5.8)                                               | 12 7.7)                         | 21 ( 6.8)                       | 21 ( 6.8)                       |
| Steroid + only aGvHD prophylaxis                                          | 8 （ 5.2)                                             | 8 5.2)                          | 16 5.2)                         | 16 5.2)                         |
| Steroid + only aGvHD treatment                                            | 1 (0.6)                                              | 4 2.6)                          | 5 1.6)                          | 5 1.6)                          |
| Time from steroid refractory aGvHD to randomization (day)                 | 154 3.38 3(5.940)                                    | 155                             | 309                             | 309                             |
| n Mean (SD)                                                               |                                                      | 3.14 ( 5.130)                   |                                 |                                 |
|                                                                           |                                                      | 1.00                            |                                 |                                 |
| Median                                                                    | 1.00                                                 |                                 |                                 |                                 |
|                                                                           | 47.0 24.0                                            |                                 |                                 |                                 |
|                                                                           | 0.0                                                  |                                 |                                 |                                 |
|                                                                           | 0.0                                                  |                                 |                                 |                                 |
| Min-Max                                                                   |                                                      |                                 |                                 |                                 |

<div style=\"page-break-after: always\"></div>

Table 14.1-7.4a (Page 3 of 3)

Full Analysis Set aGvHD disease history by treatment

<!-- image -->

| Disease history                                                   | RUX N=154            | BAT N=155      | All Patient N=309        |
|-------------------------------------------------------------------|----------------------|----------------|--------------------------|
| Time from diagnosis of aGvHD grade>=2 to steroid refractory (day) |                      |                |                          |
| n                                                                 | 154                  | 155 10.00      | 309 23.15 (37.547) 10.00 |
| Mean (SD) Median                                                  | 26.19 (43.159) 11.00 | 20.13 (30.831) |                          |
| Min-Max                                                           | 1.0 331.0            | 1.0 -293.0     | 1.0 331.0                |
| Overall aGvHD grade at baseline -n ()                             |                      |                |                          |
| Grade 0                                                           | 4 (2.6)              | 0.6)           | 5 (1.6)                  |
| Grade I                                                           | 2 1.3)               | 0              | 2 0.6)                   |
| Grade II                                                          | 50 (32.5)            | 54 (34.8)      | 104 (33.7)               |
| Grade III                                                         | 68 (44.2)            | 68 (43.9)      | 136 (44.0)               |
| Grade IV                                                          | 30 (19.5)            | 32 (20.6)      | 62 (20.1)                |
| aGvHD organ involvement at baseline -n(&)                         |                      |                |                          |
| skin                                                              | 93 (60.4)            | 74 (47.7)      | 167 (54.0)               |
| Liver                                                             | 36 (23.4)            | 26 (16.8)      | 62 (20.1)                |
| Upper GI                                                          | 28 (18.2)            | 37 (23.9)      | 65 (21.0)                |
| Lower GI                                                          | 96 (62.3)            | 115 (74.2)     | 211 (68.3)               |
| Missing                                                           | 4 (2.6)              | 1 0.6)         | 5 1.6)                   |
| Steroid dose at randomization (mg)                                |                      |                |                          |
| n                                                                 | 149                  | 151            | 300                      |
| Mean (SD)                                                         | 152.48 (112.555)     | 149.45(90.704) | 150.95 (101.983)         |
| Median                                                            | 150.00               | 150.00         | 150.00                   |
| Min-Max                                                           | 20.0 -1250.0         | 20.0 850.0     | 20.0-1250.0              |

Note: Corticosteroid dose (bw) methylprednisolonedose (mg) x1.25+prednisone dose (5u)

The median time to conversion from grade 2 to 4 aGvHD to SR-aGvHD was 10 days (range: 1.0 to 331.0 days).  The median time, from aGvHD grad ≥2 diagnosis and randomization was 14 days. The median time from diagnosis of SR-aGvHD to randomization was 1 day.

The number of patients randomized at baseline with grade II, III, and IV aGvHD was 104 (33.7%), 136 (44.0%), and 62 (20.1%), respectively.

Prior aGvHD therapy was steroids + Calcineurin inhibitor (CNI) in 50.0% in RUX arm and 49.0% in BAT arm. Second most common prior aGvHD treatment was steroids as aGvHD prophylaxis.

Prophylactic aGvHD treatments (systemic and/or locally active) were balanced between the two treatment arms. The most commonly used prior treatment for a GvHD was a combination of steroids and CNI and the most common reason for SR-aGvHD was failure to achieve a response after 7 days of treatment with steroids (46.8% in ruxolitinib arm and 40.6% in BAT arm).

Current medical conditions were (except for medical history consistent with study indication) mostly related to post allo-HSCT and symptoms of aGvHD and/or use of high-dose steroid complications. Most conditions were reported in, more or less, the same frequency in both study arms.  However, CMV infections were reported more frequently among patients randomized to RUX arm than to BAT arm (CMV infection 23.4% vs 18.1%, CMV colitis 1.9% vs 0; CMV enteritis 1.3% vs 0.6%; and CMV viremia 1.3% vs 0). In addition, CMV test positive was reported in medical history for 3.9% in ruxolitinib arm and 9.7% in BAT arm.

The most common organs involved were skin (54.0%) and lower GI tract (68.3%). More patients in the RUX arm had symptoms of skin (60.4%) and liver (23.4%), than BAT arm (skin: 47.7% and liver: 16.8%). Upper GI symptoms and lower GI symptoms were less frequent in RUX arm (18.2% and 62.3%) than in BAT arm (23.9% and 74.2%).

## Concomitant therapies

From randomization up to the data cut-off date, concomitant medications were taken by 98.7% and 100% patients in ruxolitinib and BAT arm, respectively. The overall profile of concomitant medications was, overall, similar between the two treatment arms. In addition to corticosteroids and CNIs, the

<div style=\"page-break-after: always\"></div>

frequent concomitant medications also included agents for treatment of infections, gastric motility enhancers and electrolytes.

Up to the data cut-off, more patients in the BAT arm (53.5%) received additional systemic aGvHD treatments than ruxolitinib arm (22.1%) during the treatment period. The most frequent additional systemic aGvHD treatment in BAT arm was ruxolitinib (39.4%) where most patients were crossing over, and etanercept (6.5%). No single additional systemic aGvHD treatment was given to &gt;10% patients in the ruxolitinib arm. The most common by PT in ruxolitinib arm was ECP (5.8%).

## Prohibited medications

Prohibited medication was taken by 29 (19.1%) and 21 (14.0%) of subjects (at least one medication or non-drug therapy in the RUX arm and the BAT arm, respectively.

## Transfusions

A total of 79.6% patients in ruxolitinib arm and 80.0% patients in BAT arm underwent transfusion after start of randomized study treatment, the most common being packed red blood cells (RBC). Furthermore, 87.8% of the patients underwent transfusion in the Crossover period.

## Numbers analysed

Efficacy analyses used the Full Analysis Set (FAS), following the Intent-to-Treat (ITT) principle, comprising all patients to whom study treatment has been assigned by randomisation. All 309 randomised patients (except one patient who was randomised but did not sign the study consent) were included in the FAS: n=154 in the RUX arm and n=155 in the BAT arm.

Supportive analyses were performed using the Per Protocol Set comprised of patients compliant with the requirements of the study. Fifty-six (36.4%) patients in the RUX arm and 68 (43.9%) patients in the BAT arm were excluded from the PPS, mainly due to intake of prohibited medications (20.1% and 18.1%) and due to different aGvHD overall grades used for randomisation between CRF and IRT (18.2% and 17.4%).

## Outcomes and estimation

The primary analysis comprised of analyses of the primary and key secondary endpoint and was performed in all patients who completed Day 56 or who discontinued from study participation earlier and had a cut-off date of 25-Jul-2019. Most endpoints were either updated at time of the second analysis or analysed only at the second analysis 17-Jan-2020.

## Primary efficacy results

The primary endpoint, ORR at Day 28, assessed by local investigator (INV) using protocol advised criteria (according to Harris et al), was met (see table).

According to the SAP, a patient was not be considered a responder at Day 28 if any of the following events occurs; in case of missing aGvHD assessment at baseline or Day 28, no CR or PR at Day 28 or in case there was use of Additional systemic therapy for aGvHD prior to Day 28. It has been clarified that missing data in the primary analysis are presented in category 'unknown', while the category 'missing visits' actually refers to invalid aGvHD assessments at Day 28.

<div style=\"page-break-after: always\"></div>

## Overall response rate at Day 28 (FAS) by INV (primary analysis)

|                                    | RUX N = 154   | RUX N = 154   | BAT N =155   | BAT N =155   |           |              |          |
|------------------------------------|---------------|---------------|--------------|--------------|-----------|--------------|----------|
|                                    | n (%)         | 95%CI         | n (%)        | 95% CI       | (RUX/BAT) | 95% CI       | P- value |
| Overall response                   |               |               |              |              |           |              |          |
| Responders                         |               |               |              |              |           |              |          |
| Complete Response                  | 53 (34.4)     |               | 30 (19.4)    |              |           |              |          |
| Partial Response                   | 43 (27.9)     |               | 31 (20.0)    |              |           |              |          |
| Non-responders                     |               |               |              |              |           |              |          |
| No Response                        | 7 (4.5)       |               | 10 (6.5)     |              |           |              |          |
| Mixed response                     | 10 (6.5)      |               | 17 (11.0)    |              |           |              |          |
| Progression                        | 4 (2.6)       |               | 13 (8.4)     |              |           |              |          |
| Other *                            | 1 (0.6)       |               | 7 (4.5)      |              |           |              |          |
| Unknown                            | 36 (23.4)     |               | 47 (30.3)    |              |           |              |          |
| Death                              | 15 (9.7)      |               | 22 (14.2)    |              |           |              |          |
| Early discontinuation              | 17 (11.0)     |               | 16 (10.3)    |              |           |              |          |
| Missing visits                     | 4 (2.6)       |               | 9 (5.8)      |              |           |              |          |
| Overall Response Rate (ORR: CR+PR) | 96 (62.3)     | (54.2, 70.0)  | 61 (39.4)    | (31.6, 47.5) | 2.64      | (1.65, 4.22) | .0001    |

N: The total number of subjects in the treatment group. It is the denominator for percentage (%) calculation.

n: Number of patients who were at the corresponding category.

The 95% Cl for the response rate was calculated using Clopper Pearson exact method.

One-sided p-value, odds ratio and 95% Cl were calculated using stratified Cochrane-Mantel-

Haenszel test.

*Other: patient with additional systemic therapies along with CR/PR per investigator assessment.

The number of patients who received a new systemic treatment for aGvHD prior to Day 28 was 10 (6.5%) in the ruxolitinib arm and 39 (25.2%) in the BAT arm. The requested sensitivity analysis used actual response instead of imputed non-response, for patients who received a new systemic treatment for aGvHD prior to Day 28. The number of responders in this sensitivity analysis was higher in the ruxolitinib arm (98 patients; 63.6%) compared to the BAT arm (69 patients; 44.5%); the difference was statistically significant (p=0.0005) with an odds ratio of 2.22 (95% CI: 1.40, 3.53), i.e., supportive for the primary endpoint result.

No response or progression were seen in 4,5% and 2,6% in the RUX arm and 6,5% and 8,4% in the BAT arm, respectively.

Unknow responses were 23,4% and 30,3% in the RUX arm and BAT arm respectively, in this category deaths accounted for 9,7% and 14,2%, early discontinuations for 11,0% and 10,3% and missing visits for 2,6% and 5,8% in respective RUX and BAT arm. With respect to the imbalance in numbers between the two arms, it is apparently more non-response imputations in the BAT arm than in the ruxolitinib arm, but further analyses were not specifically requested.

## Subgroup analyses

Efficacy showed that the subgroup analyses (Day 28) were overall consistent with results for the primary endpoint, as demonstrated by the odds ratio (at Day 28) ranging from 1.55 to 12.28 in subgroups with evaluable data. Results favouring the BAT arm was only seen for patients &gt;65 years, patients with unknown race and patients who received prior 'steroid+CNI+Other' systemic aGvHD treatment. The results in these subgroups cannot, however, be definitively concluded due to the wide confidence intervals and limited sample size and wide confidence intervals.

The subgroup analysis demonstrated an advantage for the RUX arm compared to the BAT arm with an odds ratio (RUX/BAT) for ORR of 2.96 (Grade 2), 2.15 (Grade 3) and 3.76 (Grade 4), respectively.

<div style=\"page-break-after: always\"></div>

## Forest plot of odds ratio with 95% confidence interval at Day 28 from subgroup analysis (FAS) -(A)

<!-- image -->

X-axisvaluesarerepresentedinnaturallogscale

Dotted linesshowsnoeffectpoint,and(new)bold lineshowsoverall treatmenteffectpoint(Oddsratio =2.64).Thearea oftheboxindicates theweightof thesubgroup,measured bythesizeof subpopulation.

## Forest plot of odds ratio with 95% confidence interval for ORR at Day 28 from subgroup analysis (FAS)-(B)

<!-- image -->

<div style=\"page-break-after: always\"></div>

<!-- image -->

X-axisvalues are represented in natural log scale.Dotted lines shows no effect point. The area of the box indicates the weight of the sub group,measured by the size of subpopulation.

## Subgroup adolescents (12-18 years)

<!-- image -->

The odds ratio in adolescent patients were inconclusive due to low number of evaluable patients (N=9).

A sensitivity analysis was performed using Fisher's exact test to compare ORR at Day 28 between the two treatment groups. The result was supportive of the primary analysis (odds ratio 2.55, with 95% CI (1.61, 4.03); p-value &lt;0.0001) in favour of the RUX arm.

## Supportive analysis for ORR at Day 28 (PPS population)

ORR in the PPS population  showed similar results compared to the ORR rate in the FAS population (63.9% in the RUX arm vs 39.1% in the BAT arm in the PPS population and 62,3% in the RUX arm vs 39.4% in the BAT arm in the FAS population), indicating robustness of the results.

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Overall Response Rate (ORR) by initial Best Available Therapy (BAT) subgroups

Table 8. REACH-2: ORR at Day 28 by initial BAT

<!-- image -->

|              | Insufficient BAT compliance monitoring (worst ease) per inspeetion report   | N BAT *(%)   | ORR BAT at day 28   | ORR BAT at day 28   | N Rux   | ORR RUX at day 28   | ORR RUX at day 28   |
|--------------|-----------------------------------------------------------------------------|--------------|---------------------|---------------------|---------|---------------------|---------------------|
|              |                                                                             |              | ORR (%)**           | 95% CI              |         | ORR (%)             | I0 %56              |
| Total        | 16***                                                                       | 155          | 61 (39.4)           | 31.647.5            | 154     | 96 (62.3)           | 54.270.0            |
| ATG          | 0                                                                           | 20 (12.9)    | 6 (30)              | 11.9-45.3           |         |                     |                     |
| Etanercept   | 2                                                                           | 22 (14.2)    | 10 (45.5)           | 24.4-67.8           |         |                     |                     |
| Everolimus   | 2                                                                           | 2 (1.3)      | 0                   | 0-84.2              |         |                     |                     |
| ECP          | Q                                                                           | 41 (26.5)    | 18 (43.9)           | 28.5-60.3           |         |                     |                     |
| Infliximab   | 0                                                                           | 17 (11.0)    | 6 (35.3)            | 14.2-61.7           |         |                     |                     |
| Low-dose MTX | 0                                                                           | 5 (3.2)      | 2 (40.0)            | 5.3-85.3            |         |                     |                     |
| MSC          | 0                                                                           | 15 (9.7)     | 9 (60.0)            | 32.3-83.7           |         |                     |                     |
| MMF          | 10***                                                                       | 25 (16.1)    | 8 (32.0)            | 14.9-53.5           |         |                     |                     |
| Sirolimus    | 2                                                                           | 3 (1.9)      | 2 (66.6)            | 9.4-99.2            |         |                     |                     |

ATG anti-thymocyte globulin, ECP: extracorporeal photopheresis, MMF mycophenolate mofetil MSC mesenchymal stromal cells, MTX methotrexate, RUX: ruxolitinib, * uses all patients randomised to BAT as reference (denominator), **ORR within subgroup defined by initial BAT treatment, *** in REACH2 study, 2 patients flagged as having insufficient compliance monitoring in the inspector report were counted twice: Subjects 1 and 2 taking MMF were counted for both categories 'administrated at home' and 'administrated at home or hospitalized'. Thus, the overall count is now 16 and not 18 as noted in inspector report

1Zeiser R, von Bubnoff N, Butler J, et al (2020) Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med; 382:1800-1810 - Supplementary material .

## Shift in aGvHD by organ staging from baseline to Day 28

The trend of improvements favors the RUX arm in all assessed organs, although some baseline imbalances were detected, more patients in the RUX arm had acute GvHD involving skin (60.4%) and liver (23.4%), compared to the BAT arm (skin: 47.7% and liver: 16.1%). Organ staging data was missing for 23.4% patients in the ruxolitinib arm and 30.3% patients in BAT arm at Day 28, due to missing visits, discontinuation, or death.

<div style=\"page-break-after: always\"></div>

## Overall response rate at Crossover Day 28

Among the 49 patients who crossed over to RUX treatment between Day 28 and Week 24, the ORR at Crossover Day 28 was consistent with the primary analysis in the RUX arm: 67.3% (95% CI: 52.5, 80.1). The CR rate was higher compared with the primary analysis: 46.9%.

## Secondary efficacy results

## Durable ORR at Day 56 (key secondary endpoint)

Duration of response (DOR) is assessed for responders only and is defined as the time from first response until aGvHD progression or the date of additional systemic therapies for aGvHD. Onset of chronic GvHD, or death without prior observation of aGvHD progression were considered as competing risks.

Since the primary endpoint, ORR Day 28 was statistically significant at the primary analysis, the key secondary endpoint was also tested for significance at the primary analysis.

The drop in Durable ORR at day 56 compared to ORR Day 28 indicates that almost half of the responses, in both treatment arms, at Day 28 are no longer recorded at Day 56.

## Durable overall response rate at Day 56 (FAS). Primary analysis.

|                                  | RUX N= 154   | RUX N= 154   | BAT N =155   | BAT N =155   |                |                   |          |
|----------------------------------|--------------|--------------|--------------|--------------|----------------|-------------------|----------|
|                                  | n (%)        | 95% CI       | n (%)        |              | 95%CI(RUX/BAT) | 95% CI            | P- value |
| Overall response                 |              |              |              |              |                |                   |          |
| Responders                       |              |              |              |              |                |                   |          |
| Complete Response                | 41 (26.6)    |              | 25 (16.1)    |              |                |                   |          |
| Partial Response                 | 20 (13.0)    |              | 9 (5.8)      |              |                |                   |          |
| Non-responders                   |              |              |              |              |                |                   |          |
| No Response                      | 1 (0.6)      |              | 1 (0.6)      |              |                |                   |          |
| Mixed response                   | 5 (3.2)      |              | 4 (2.6)      |              |                |                   |          |
| Progression                      | 0            |              | 0            |              |                |                   |          |
| Other *                          | 0            |              | 1 (0.6)      |              |                |                   |          |
| Unknown                          | 29 (18.8)    |              | 21 (13.5)    |              |                |                   |          |
| Death                            | 7 (4.5)      |              | 2 ( 1.3)     |              |                |                   |          |
| Early discontinuation            | 13 (8.4)     |              | 15 (9.7)     |              |                |                   |          |
| Missing visits                   | 9 (5.8)      |              | 4 (2.6)      |              |                |                   |          |
| OverallResponseRate (ORR: CR+PR) | 61 (39.6)    | (31.8, 47.8) | 34 (21.9)    | (15.7, 29.3) | 2.38           | (1.43,3.94)0.0005 |          |

N: The total number of subjects in the treatment group. Itis the denominator for percentage (%) calculation.

n: Number of patients who were at the corresponding category.

The 95% Cl for the response rate was calculated using Clopper Pearson exact method.

One-sided P-value, odds ratio and 95% Cl were calculated using stratified Cochrane-MantelHaenszel test.

Durable ORR at Day 56 is defined as the proportion of all patients who achieve a complete response (CR) or partial response (PR) at Day 28 and maintained a CR or PR at Day 56.

*Other: patient with additional systemic therapies along with CR/PR per investigator assessment.

## Durable overall response rate at Crossover Day 56 (Crossover Analysis Set) (Second analysis)

Durable ORR at Crossover Day 56 was also tested for the crossover analysis set (the proportion of all crossover patients who achieved a CR or PR at Crossover Day 28 and maintained a CR or PR at Crossover Day 56). Among the 49 patients who crossed over, the durable ORR at Crossover Day 56

<div style=\"page-break-after: always\"></div>

was 42.9% (95% CI: 28.8, 57.8). Thirty-six (73.5%) of these patients discontinued the cross-over treatment period with the most frequent reason for discontinuation being AEs (24.5%).

The durable ORR at Day 56 (FAS) during the randomized phase was consistent with the durable ORR for Crossover Day 56.

|                                | RUX N= 49   | RUX N= 49   |
|--------------------------------|-------------|-------------|
|                                | n (%)       | 95%CI       |
| Overall response               |             |             |
| Responders                     |             |             |
| CompleteResponse(CR)           | 19 (38.8)   |             |
| Partial Response (PR)          | 2 (4.1)     |             |
| Non-responders                 |             |             |
| No Response                    | 1 (2.0)     |             |
| Mixed response                 | 0           |             |
| Progression                    | 1 (2.0)     |             |
| Other *                        | 0           |             |
| Unknown                        | 10 (20.4)   |             |
| Death                          | 4 (8.2)     |             |
| Early discontinuation          | 4 (8.2)     |             |
| Missing visits                 | 2 (4.1)     |             |
| OverallResponseRate(ORR:CR+PR) | 21 (42.9)   | (28.8,57.8) |

N:Thetotal number of patients in the treatmentgroup.It isthe denominator forpercentage(%) calculation.

n:Numberofpatientswhoareatthecorrespondingcategory.

The95%ClfortheresponserateiscalculatedusingClopperPearsonexactmethod

DurableORRatCrossoverDay56isdefinedastheproportionofallcrossoverpatientswhoachieve a completeresponse(CR)orpartial response(PR)at Crossover Day28andmaintaina CRorPRat

CrossoverDay56

*Other:patientwithadditionalsystemictherapiesalongwithCR/PRperinvestigatorassessment

- Other secondary endpoints descriptive, not formally tested

## Overall response rate at Day 14

The ORR at Day 14 at the Primary analysis data cut-off was higher in RUX arm (63.0%; 95% CI: 54.8, 70.6) compared to BAT (47.1%; 95% CI: 39.0, 55.3; p&lt;0.0029) with the OR for response in RUX arm compared to BAT arm being 1.98 and 95% CI: 1.24, 3.17.

## Best overall response by Day 28

The BOR up to Day 28 at the Primary analysis data cut-off was higher in the RUX arm (81.8%) than in the BAT arm (60.6%; p&lt;0.0001) with the odds ratio 3.07 and 95% CI: 1.80, 5.25 in favour of RUX.

The response rates at Day 14, 63% in the RUX arm and 39% in the BAT, compared to ORR Day 28 arm, 62.3% in the RUX arm and 39.4% indicate that the responses occur at an early timepoint after start of treatment. However, the BOR up to Day 28, 81.8% in the RUX arm and 60.6% in the BAT arm, also indicate that 19.5% and 21.2% of responses achieved up to Day 28, are no longer recorded. These 'lost responses' are accounted for below, please refer to endpoint DoR and competing risks.

## Duration of response

DoR was evaluated in patients who achieved a CR or PR at or before Day 28.

<div style=\"page-break-after: always\"></div>

## Duration of response (FAS set)

|                                              | RUX N=97            | BAT N=62             |
|----------------------------------------------|---------------------|----------------------|
| Number of patients with events               | 9 (9.3)             | 22 (35.5)            |
| Number of patients with competing risks      | 66 (68.0)           | 26 (41.9)            |
| Death                                        | 34 (35.1)           | 14 (22.6)            |
| Incidence of cGvHD                           | 32 (33.0)           | 12 (19.4)            |
| Number of patients censored                  | 22 (22.7)           | 14 (22.6)            |
| Duration of response (day)                   |                     |                      |
| Median                                       | 163.0               | 101.0                |
| Q1-Q3                                        | 78.0-246.0          | 46.0 - 181.0         |
| Min-Max                                      | 22.0 - 623.0        | 10.0-456.0           |
| Estimated cumulative incidence and 95% Cl at |                     |                      |
| 1 month                                      | 2.06 (0.39, 6.58)   | 12.97 (6.01, 22.66)  |
| 2 months                                     | 5.20 (1.92, 10.96)  | 21.38 (12.05, 32.47) |
| 6months                                      | 8.73 (4.03, 15.68)  | 37.34 (24.95, 49.71) |
| 12 months                                    | 10.16 (4.91, 17.64) | 37.34 (24.95, 49.71) |
| 18 months                                    | 10.16 (4.91, 17.64) | NE (NE , NE)         |

N: number of patients whose overall response is CR or PR at Day 28.

The start date is the date of first documented response of CR or PR, which could be prior to or at Day 28

The event is defined as the progression of aGvHD or addition of systemic therapies for aGvHD after Day 28

The competing risks include death without prior observation of aGvHD progression and onset of cGvHD.

Duration of response is censored at the lastresponse assessment

Median and Quartiles are provided using Kaplan-Meier method.

## Cumulative incidence curve of loss of response (FAS)

<!-- image -->

The competing risks include death without prior observation of aGvHD progression and onset of CGvHD.

NA - Not Applicable

The median duration of response was longer in ruxolitinib arm (163 days, range: 22.0 to 623.0) compared to the BAT arm (101 days, range: 10.0 to 456.0).

<div style=\"page-break-after: always\"></div>

The probability of an event (progression or addition of systemic therapy for aGvHD) and 95% CIs at all estimated timepoints months, was lower in ruxolitinib arm compared to the BAT arm.

## Overall survival

At the primary analysis, an interim OS analysis was performed with 72 (46.8%) deaths in the ruxolitinib arm and 79 (51.0%) deaths in the BAT arm. At the second analysis, there were 82 (53.2%) deaths in the ruxolitinib arm and 88 (56.8%) deaths in the BAT arm. OS median follow-up time was longer in ruxolitinib arm (7.34 months), compared to BAT arm (3.81 months).

Time-to-event analysis of OS stratified by aGvHD grade, suggested greater benefits of RUX for patients with lower baseline aGvHD grades, as shown by HRs closer to zero at lower grades. Patients with grade II aGvHD were shown to benefit most by RUX treatment (HR: 0.6; 95% CI: 0.34, 1.04). For patients with grade III the HR was 0.92, and in patients with grade IV the HR was 1.06.

Kaplan-Meier Curves of Overall survival (FAS)

<!-- image -->

p-value is obtained from the log-rank test.

## Hazard ratio for overall survival (FAS)

<div style=\"page-break-after: always\"></div>

|                  | Event/N (%)   | Log-rankTest Median Time (95% CI) (day)(2)   | Cox Model Hazard Ratio (3)   | 95% CI      |
|------------------|---------------|----------------------------------------------|------------------------------|-------------|
| All Subjects (1) |               |                                              |                              |             |
| RUX              | 82/154 (53.2) | 326 (182,547)                                | 0.83                         | (0.62,1.13) |
| BAT              | 88/155 (56.8) | 177 (115,392)                                |                              |             |
| Grade II         |               |                                              |                              |             |
| RUX              | 22/ 53 (41.5) | 547 (339,NE)                                 | 0.60                         | (0.34,1.04) |
| BAT              | 29/ 53 (54.7) | 280 (116,NE)                                 |                              |             |
| Grade IlI        |               |                                              |                              |             |
| RUX              | 42/ 71 (59.2) | 249 (85,617)                                 | 0.92                         | (0.60,1.41) |
| BAT              | 42/ 72 (58.3) | 150 (87,458)                                 |                              |             |
| Grade IV         |               |                                              |                              |             |
| RUX              | 18/ 30 (60.0) | 83 (50,NE)                                   | 1.06                         | (0.54,2.06) |
| BAT              | 17/ 30 (56.7) | 197 (38,NE)                                  |                              |             |

(1) Cox PH model are stratified by aGvHD grade at randomization per IRT.

(2) Median (time to event) and its 95% Cl are generated by KM estimation.

(3) Hazard Ratio of Rux versus BAT.

NE -Non Evaluable

There was no statistically significant impact on OS. The Kaplan-Meier (K-M) estimated median OS, was longer in RUX arm (10.71 months), compared to BAT arm (5.82 months). However, the cumulative incidence of OS event rates was similar, for the two treatment arms, over time, indicating no major difference in survival in the treatment arms. Longer follow-up of OS data up to the end of study may provide better understanding of the data.

Given the study design, OS is primarily viewed as a safety endpoint. The allowance of cross-over creates a bias towards unity. In REACH-2 study, 49 (31.6%) out of 155 BAT subjects switched to ruxolitinib on or after Day 28. The rank-preserving structural failure time (RPSFT) model was applied post-hoc to investigate what would have been the OS analysis had patients not crossed over to ruxolitinib. After adjustment for cross-over with the RPSFT model, the HR estimate was 0.779 (95% CI: 0.515, 1.177) compared to 0.833 (95% CI: 0.616, 1.126) obtained in the pre-planned ITT analysis. Thus, the RPSFT results do not indicate any impact of cross-over on overall survival.

## Event free survival

EFS was defined as the time from the date of randomization to the date of i) hematologic disease relapse/progression, ii) graft failure or death due to any cause. The EFS analysis at time of the second analysis cut-off date included 87 (56.5%) events in the RUX arm and 95 (61.3%) events in the BAT arm.

The K-M estimated median EFS was longer in RUX arm (8.18 months), compared to BAT arm (4.17 months). However, at DCO the difference in events between the arms have decreased and furthermore, a decreasing K-M probability estimates for survival at 2 months, 6 months, 12 months, 18 months and 24 months in both treatment arms, was seen.

<div style=\"page-break-after: always\"></div>

## Kaplan-Meier Curves of Event free survival (FAS)

<!-- image -->

p-value is obtained from the log-rank test.

The event includes hematologic diseaserelapse/progression.graft failure or death due to any cause.

## Hazard ratio for event free survival (FAS)

|                  |              | Log-rank Test                 | Cox Model        | Cox Model   |
|------------------|--------------|-------------------------------|------------------|-------------|
|                  | Event/N (%)  | Median Time (95% CI) (day)(2) | Hazard Ratio (3) | 95% CI      |
| All Subjects (1) |              |                               |                  |             |
| RUX              | 87/154(56.5) | 249 (153,412)                 | 0.80             | (0.60,1.08) |
| BAT              | 95/155(61.3) | 127 (92,254)                  |                  |             |
| Grade II         |              |                               |                  |             |
| RUX              | 25/53(47.2)  | 547 (207,NE)                  | 0.63             | (0.38,1.07) |
| BAT              | 32/53(60.4)  | 177 (94,512)                  |                  |             |
| Grade Ill        |              |                               |                  |             |
| RUX              | 44/71(62.0)  | 182 (79,412)                  | 0.87             | (0.57,1.32) |
| BAT              | 45/72(62.5)  | 118 (66,264)                  |                  |             |
| Grade IV         |              |                               |                  |             |
| RUX              | 18/30(60.0)  | 83(43,NE)                     | 0.96             | (0.50,1.85) |
| BAT              | 18/30(60.0)  | 92(37,592)                    |                  |             |

(1) Cox PH model are stratified by aGvHD grade at randomization per IRT.

(2) Median (lime to event) and its 95% Cl are generated by KM eslimation.

(3) Hazard Ratio of Rux versus BAT.

Event-free survival is defined as the time from the date of randomization to the date of hematologic

disease relapse/progression, graft failure or death due to any cause.

NE - Non Evaluable

Sensitivity analysis for EFS including aGvHD progression as an event of interest produced similar results as primary analysis.

Time to event, EFS, stratified by GvHD grade, indicate a higher benefit for the RUX arm with lower aGvHD grade.

There reduction in risk of EFS event in the RUX arm relative to the BAT arm was not statistically significant and was also not corrected for multiplicity.

## Failure free survival

FFS, which is a composite endpoint of (i) relapse or recurrence of underlying disease or death due of underlying disease, (ii) non-relapse mortality, or (iii) addition or initiation of another systemic therapy for aGvHD and the competing risk was cGvHD. Median FFS in the RUX arm was longer than in the BAT arm (4.86 months vs. 1.02 months; HR: 0.49, 95% CI: 0.37, 0.63; p&lt;0.0001). The formal comparison using Log rank test was, however, not mentioned in the SAP and is considered only descriptively. As

<div style=\"page-break-after: always\"></div>

anticipated, FFS is driven by item (iii), while there is no indication of any impact of treatment on items (i) and (ii). FFS is not considered readily interpretable and these data are generated in an open-label study. Given these concerns, the FFS endpoint is not included in the product information.

## Failure free survival (FAS)

|                                              | RUX N=154            | BAT N=155            |
|----------------------------------------------|----------------------|----------------------|
| Numberofpatientswithevents                   | 91 (59.1)            | 121 (78.1)           |
| Numberofpatientswithcompetingrisks           | 36 (23.4)            | 15 (9.7)             |
| IncidenceofcGvHD                             | 36 (23.4)            | 15 (9.7)             |
| Numberofpatientscensored                     | 27 (17.5)            | 19 (12.3)            |
| Estimated cumulative Incidence and 95% Cl at |                      |                      |
| 1 month                                      | 18.47 (12.74, 25.04) | 49.13 (40.94, 56.80) |
| 2 months                                     | 35.82 (28.21,43.48)  | 61.32 (53.00, 68.61) |
| 6 months                                     | 54.07 (45.69, 61.71) | 80.17 (72.52, 85.90) |
| 12 months                                    | 59.59 (51.02, 67.14) | 80.97 (73.37,86.60)  |
| 18 months                                    | 60.76 (52.06, 68.38) | 83.41 (74.17,89.57)  |
| 24 months                                    | NE (NE, NE)          | 83.41 (74.17, 89.57) |

The competing risk includes onset of cGvHD.

Failure Free Survival includes hematologic disease relapse/progression, non-relapse mortality or addition of new systemic aGvHD treatment.

NE - Non Evaluable

## Failure free survival by treatment (FAS)

Treatment:Ruxolitinib10mgBID

Probability of Events (%)

Additionofnewsystemic aGvHD treatment Hematologic disease relapse/progression Non-RelapseMortality IncidenceofcGvHD

Monthsfrominitialtreatment

<!-- image -->

%0 17%20%21%22%22%22%22%22%22%22%22%22%22%22% %0 4% 6% 7% 8% %6 11%12%12%12%12%12%12%12%12% %0 15% 23% 25%25%26%27%27%27%27%27%33%33%33%33% %0 1% 4% 13%19%23%25%26%26%26%26%26%26%26%26%

<div style=\"page-break-after: always\"></div>

## Treatment:Bestavailabletherapy

<!-- image -->

## Incidence of malignancy relapse/progression (updated at second analysis)

Out of 309 randomized patients, there were 147 subjects in each treatment arm with an underlying hematologic malignant disease at baseline.

The probability of malignancy relapse/progression was relatively low in both treatment arms, namely 16/147; 10.9% in ruxolitinib arm and 25/147; 17.0% in the BAT arm.

## Incidence of Malignancy relapse/progression (FAS)

|                                              | RUX N=147           | BAT N=147            |
|----------------------------------------------|---------------------|----------------------|
| Number of patients with events               | 16 (10.9)           | 25 (17.0)            |
| Number of patients with competing risks      | 65 (44.2)           | 66 (44.9)            |
| Death                                        | 65 (44.2)           | 66 (44.9)            |
| Number of patients censored                  | 66 (44.9)           | 56 (38.1)            |
| Estimated cumulative incidence and 95% Cl at |                     |                      |
| 1 month                                      | 0.69 (0.06,3.51)    | 2.80 (0.92, 6.54)    |
| 2 months                                     | 4.21(1.73,8.46)     | 4.29 (1.75, 8.60)    |
| 6 months                                     | 8.49 (4.62,13.83)   | 13.49 (8.32, 19.91)  |
| 12 months                                    | 11.12 (6.47, 17.17) | 15.13 (9.61, 21.82)  |
| 18 months                                    | 12.40 (7.29, 18.93) | 19.02 (12.36, 26.79) |
| 24 months                                    | 12.40 (7.29.18.93)  | 20.93 (13.56, 29.40) |

N = number of patients with underlying hematologic malignant disease.

The competing risk includes death with non-relapse mortality for patients with underlying hematologic malignant disease.

<div style=\"page-break-after: always\"></div>

<!-- image -->

NA - Not Applicable

Number of patients at risk is the number of patients who may develop malignancy relapse / progression at the given time point. Patients may experience event, competing risk, or become censored.

## Non-relapse mortality

The analysis of NRM among all FAS patients included 69 (44.8%) patients with events in RUX arm and 70 (45.2%) patients in BAT arm. The cumulative incidence curves for NRM were overlapping for the RUX and BAT arms, indicating similar event rates over time. The competing risk (hematological disease relapse/progression) was low in both treatment arms (11.0% and 16.1%, respectively). However, censoring was high in both treatment arms (44.2% and 38.7%), implying a high proportion of patients who were alive and who had no relapse/progression of underlying malignancy.

## Cumulative incidence curve of non-relapse mortality (FAS)

<!-- image -->

Death occurring after start of new systemic aGVHD therapy was not counted as an FFS event, if the patient already experienced an FFS event at the start of new systemic acute GvHD therapy. In other

<div style=\"page-break-after: always\"></div>

words, NRM death was only counted as FFS event if it occurred before the other FFS events (hematologic disease relapse/progression and addition of new systemic aGvHD). For NRM as sole endpoint, all NRM deaths were counted as events, as start of new therapy would not interfere with this endpoint. Based on this, it is understood that the cumulative incidence of NRM is generally higher than the probability of NRM in the analysis of FFS, which was also the case in in this study. Moreover, NRM appears to be higher for ruxolitinib versus BAT in the FFS analysis because in the BAT arm many more patients had FFS events due to start of new systemic acute GvHD therapy than in the ruxolitinib arm.

## Cumulative steroid dosing until Day 56

A successful tapering of steroids is a crucial step for the wellbeing of a patient after an allo-HSCT.

Tapering of steroids preceded any tapering of other immunosuppressants and should, according to the protocol, not be initiated before Day 7.

At Day 56, a numerically larger proportion of patients in RUX arm (21.4%; 95% CI: 15.2, 28.8) had tapered off corticosteroids than in BAT arm (14.8%; 95% CI: 9.6, 21.4) in the Primary analysis. Similar results were shown at the Secondary analysis (22.1% vs. 14.8%). The relative dose intensity and cumulative dose of steroids were similar between the RUX and BAT arms at all assessments.

## Average weekly steroid dosing (FAS)

|                                                                                     | Time RUX N=154                                                                      | BAT N=155                                                                           | o                                                                                   |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|
| Completelytapered offbyDay56-n（%) (95%C1)                                           | 34(22.1)(15.8,29.5)                                                                 | 23 (14.8)(9.6,21.4)                                                                 |                                                                                     |
| ≤50%RDI                                                                             | 45 (29.2) (22.2,37.1)                                                               | 37(23.9) (17.4,31.4)                                                                |                                                                                     |
| >50% RD1                                                                            | 106(68.8)(60.9,76.0)                                                                | 117(75.5) (67.9,82.0)                                                               |                                                                                     |
| Doseintensityandrelativedoseintensityincludedaysofzerodoseinthecalculation          | Doseintensityandrelativedoseintensityincludedaysofzerodoseinthecalculation          | Doseintensityandrelativedoseintensityincludedaysofzerodoseinthecalculation          | Doseintensityandrelativedoseintensityincludedaysofzerodoseinthecalculation          |
| Theplanneddoseintensityofsteroidisthestartingdosedefinedatthetimeofrandomizationper | Theplanneddoseintensityofsteroidisthestartingdosedefinedatthetimeofrandomizationper | Theplanneddoseintensityofsteroidisthestartingdosedefinedatthetimeofrandomizationper | Theplanneddoseintensityofsteroidisthestartingdosedefinedatthetimeofrandomizationper |

<!-- image -->

A similar proportion of patients in both treatment arms were receiving ≤ 50% of RDI at Day 56 (29.2% and 23.9%).

Tapering of CNI and/or ruxolitinib would be initiated once the patient stopped corticosteroids. CNI taper was performed as per institutional guidelines.

## Primary analysis: Duration of CNI:s from time of randomization

<div style=\"page-break-after: always\"></div>

<!-- formula-not-decoded -->

<!-- image -->

Table above, indicate a substantially longer use of CNI in the RUX arm. However, concomitant medications, such as CNI, were only captured in the study database up to 30 days after the last dose of the study treatment, thus including patients that that crossed over from BAT to ruxolitinib arm whose exposure to CNI was only collected until BAT discontinuation/the time of crossover. Hence, the reported shorter use of CNIs in the BAT arm reflects the study design rather than the actual exposure time to CNIs.

## Incidence of cGvHD

## Cumulative incidence of cGvHD (FAS)

<!-- image -->

ThecompetingriskincludesdeathswithoutprioronsetofcGvHDandhematologicdisease relapse/progression.NA-NotApplicable

A total of 45 (29.2%) patients in the RUX arm and 29 (18.7%) patients in BAT arm had developed cGvHD at DCO, i.e. more patients in the RUX arm had experienced an event of cGvHD. However, the difference in favor for the BAT arm, was seen mainly in Grade II aGvHD at randomization, while the cGVHD events were similar between the two treatment arms with respect to those with an aGvHD Grade 3 and 4 at randomization.

<div style=\"page-break-after: always\"></div>

Competing events (deaths without prior onset of cGvHD and hematologic disease relapse/progression) were similar between the treatment arms.

The median time to onset of cGvHD was longer in the RUX arm (181.0 days) than the BAT arm (142.0 days). A majority of cGvHD events were reported mild at time of onset in both treatment arms.

## Health related Quality of Life outcomes analysis

EQ-5D-5L questionnaire and FACT-BMT completion rates as a percentage of available patients were similar between the two arms throughout the study. Baseline scores were similar between both treatment arms. In both the randomized treatment and crossover periods, there was an overall improvement in all aspects of EQ-5D-5L and FACT-BMT questionnaires in both arms and no statistical analyses were performed.

## Graft failure (Chimerism)

Occurrence of graft failure was reported as an event and also as an AE.

A small proportion of patients (9/309), 5 patients in ruxolitinib arm and 4 patients in BAT arm, experienced graft failure by the time of Second analysis cut-off date (no change in these numbers from the Primary analysis cut-off). In the ruxolitinib arm, 3/5 graft failures were detected by a drop in chimerism, and two patients discontinued due to graft loss. In the BAT arm, 1/4 graft failures were detected by a drop in chimerism, and one patient discontinued due to graft loss.

In the present study, the rate of graft failure is low and also comparable in the RUX arm and the BAT arm.

## Supportive study

Title of Study: A Single-Cohort, Phase 2 Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft Versus-Host Disease

Study number: INCB 18424-271, REACH-1

Study period: This study was conducted at 26 study centres in the United States and the study period was 27 Dec 2016 to 05 Jun 2019 (final DCO).

Treatment for an individual participant could continue for as long as benefit was being observed and/or until treatment withdrawal criteria were met. The study ended, and the final analysis occurred when 75% of participants achieved 2-year NRM, died or were lost to follow-up.

## Statistical methods

No formal statistical tests were performed. All CIs were 95%.

## Outcomes/endpoints

All efficacy analyses were conducted in the efficacy evaluable population, defined as all patients enrolled in the study (N=71).

<div style=\"page-break-after: always\"></div>

The primary objective was to evaluate the efficacy of ruxolitinib in combination with corticosteroids in participants with Grades II to IV SR-aGVHD as assessed by ORR at Day 28 (CR, VGPR or PR) based on CIBMTR response criteria and before the start of new anti-aGvHD therapy, if applicable.

## Treatments

Patients received ruxolitinib at a starting dose of 5 mg b.i.d and the dose could be increased to 10 mg b.i.d if hematologic parameters were stable and no treatment-related toxicity was observed after the first 3 days of treatment. Dose-selection was based on publications (Spoerl et al, 2014 and Zeiser et al 2015), both using ruxolitinib as an add on treatment in SR-GvHD.

Participants received prednisone 2.5 mg/kg per day PO or methylprednisolone 2.0 mg/kg per day IV. Participants who previously began corticosteroid therapy at a different dose were permitted to remain on that dose if considered appropriate by the treating physician. Corticosteroids were tapered as per institutional guidelines at a rate commensurate with resolution of GVHD manifestations.

## Study participants

Inclusion and exclusion criteria were similar to those for Study C2301. In the original protocol male or female, 18 years of age or older was an inclusion criterion, which was amended in Sept 2016, (Amend. 1) to include male or female, 12 years of age or older. No patients &lt; 18 years of age were, however, included.

The majority of participants were &lt; 65 years of age, with a median age of 58 years (range: 18-73 years) and 49.3% males and 50.7% females.

At baseline, mean donor chimerism was 95.3% (median: 100.0%; range 0%-100%).

## Outcomes and estimation

## Primary endpoint

## Summary of Overall Response Rate at Day 28 (Efficacy Evaluable Participants)

| Variable                                          | Ruxolitinib (N = 71)   |
|---------------------------------------------------|------------------------|
| Number(%)ofparticipantswhohad an overallresponsea | 40 (56.3)              |
| 95%CIforORR                                       | (44.0, 68.1)           |
| Responders                                        |                        |
| CR                                                | 19 (26.8)              |
| VGPR                                              | 6 (8.5)                |
| PR                                                | 15 (21.1)              |
| Nonresponders                                     |                        |
| MR                                                | 3 (4.2)                |
| NR                                                | 2 (2.8)                |
| PD                                                | 2 (2.8)                |
| Other                                             | 1 (1.4)                |
| Missingb                                          | 23 (32.4)              |
| Death                                             | 10 (14.1)              |
| Discontinuation                                   | 12 (16.9)              |
| Missing visits                                    | 1 (1.4)                |

Day28.on orbefore thestart of newanti-GVHD therapy(if applicable).

aParticipants who had a CR,VGPR,or PR at Day 28response assessment or other response assessments within ± 2 days of

bParticipants with missing assessment were considered nonresponders.

The 6-month DOR was the key secondary endpoint of the study. The median DOR for the 56.3% of patients who had response at Day 28 was 669.0 days, and for 76.1% of patients who had response at

<div style=\"page-break-after: always\"></div>

any time point was 345.0 days. The 6-month event-free probability estimate for DOR based on response at Day 28 and response at any time point was 68.2% and 62.1%, respectively.

NRM: A total of 40 participants (56.3%) died from causes other than relapse of the underlying malignancy. The cumulative incidence rates at 6, 9, and 12 months were 44.3% (95% CI: 32.5, 55.5), 47.3% (95% CI: 35.2, 58.5), and 53.4% (95% CI: 40.9, 64.3), respectively.

Relapse rate: Five participants (7.0%) had a relapse of the underlying malignancy; the relapse had a fatal outcome in 4 of those participants (5.6%).

FFS: A total of 11 participants (15.5%) were still alive and had not had a relapse/progression of the underlying malignancy, had not required additional therapy for aGVHD, and had not demonstrated signs or symptoms of cGVHD. The median FFS time was 85.0 days (95% CI: 42.0, 158.0).

OS: A total of 44 participants (62.0%) had died, and 27 participants (38.0%) were censored at the last date known to be alive. The median OS time was 232.0 days (95% CI: 93.0, 675.0). At Months 3 and 6 the OS probability was &gt;50%, and at Months 9 and 12, the OS probability was &gt;40%.

## 2.5.4. Steroid refractory chronic GvHD: title of Study

Title of study: A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogeneic stem cell transplantation.

Study number: CINC424D2301. Study identifier: REACH3.

Participating countries/regions and (number of sites): EU (177, including Norway and UK), Switzerland (5), Turkey (15), United States (34) Saudi Arabia (10), Australia (6) India (6), Israel (18), Japan (37), Jordan (3), Republic of Korea (4), Canada (6) and Russia (8).

Study period: Study initiation date: 29-Jun-2017 (first patient first visit)

Data cut-off date: 08-May-2020 (data cut-off date for the primary analysis); study is ongoing.

The final analysis will occur once all patients have completed the study (up to 39 cycles/3 years from randomization). All available data from all patients up to end of study will be reported in a final CSR.

## Phase of development (phase of this clinical study): Phase III

Study CINC424D2301 (study D2301, REACH3)) was performed to evaluate pharmacokinetics, efficacy and safety of ruxolitinib versus investigator-choice best available therapy (BAT) in adults and adolescents from 12 to less than 18 years old with moderate or severe SR-cGvHD following allogeneic HSCT.

## Schematic Study design

<div style=\"page-break-after: always\"></div>

<!-- image -->

Patientswhocrossed over toruxolitinibtreatment formed astand-aloneCross-over analysissetforefficacy and safetyassessment,notpooledwithdatafromrandomizedruxolitinibtreatment

## Methods

The present report presents the results of the primary analysis, which includes data up to the cut-off date of 08-May-2020, when all 329 patients randomized and completed the Cycle 7 Day 1 visit or discontinued from the study earlier.

At the time of that the COVID-19 pandemic occurred, most patients had completed Cycle 7 Day 1 visit or discontinued earlier. The impact of the pandemic on efficacy and safety assessment was reported as minimal.

## Study participants

## Inclusion criteria

- Male or female patients aged 12 or older at the time of screening informed consent.
- Had undergone alloSCT from any donor source (matched unrelated donor, sibling, haploidentical) using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non-myeloablative, myeloablative, and reduced intensity conditioning were eligible.
- Clinically diagnosed cGvHD staging of moderate to severe according to NIH Consensus Criteria prior to Cycle 1 Day 1.
- -Moderate cGvHD: At least one organ (not lung) with a score of 2, 3 or more organs involved with a score of 1 in each organ, or lung score of 1
- -Severe cGvHD: at least 1 organ with a score of 3, or lung score of 2 or 3
- Evident myeloid and platelet engraftment (ANC &gt;1,000/mm 3  and platelet count &gt;25,000/mm 3 )
- Patients received systemic or topical corticosteroids for the treatment of cGvHD for a duration of &lt;12 months prior to Cycle 1 Day 1, and had a confirmed diagnosis of corticosteroid refractory cGvHD defined per 2014 NIH consensus criteria (Martin et al 2015) irrespective of the concomitant use of a calcineurin inhibitor, as follows:

<div style=\"page-break-after: always\"></div>

- -A lack of response or disease progression after administration of minimum prednisone 1 mg/kg/day for at least 1 week (or equivalent)

or

- -Disease persistence without improvement despite continued treatment with prednisone at &gt;0.5 mg/kg/day or 1 mg/kg/every other day for at least 4 weeks (or equivalent) or
- -Increased prednisone dose to &gt;0.25 mg/kg/day after two unsuccessful attempts to taper the dose (or equivalent) (criteria corresponding to steroid dependency)
- ECOG performance status of 0-2 OR Karnofsky Performance Score (KPS) OR Lansky Performance Score (LPS) of 60-100%.
- Patient accepted to be treated with only one of the following BAT options on Cycle 1 Day 1 (Additions and changes are allowed during the study, but only with BAT from the BAT options used in the study.)

Note: Concomitant use of CNI and steroids was allowed. If any medication included in the BAT list was used as prophylaxis for underlying malignancy relapse, it was required to be discontinued prior to randomisation and entered into the eCRF. For patients randomised to either the RUX or BAT treatment arm, rituximab was allowed to be administered postrandomisation for the treatment of EBV. This EBV infection was captured either into the Medical History or Adverse Event eCRF. If any medication included in the BAT list was used as prophylaxis for cGvHD before entering this study, it was allowed to be continued postrandomisation and was captured on the Concomitant Medication eCRF.

## Exclusion criteria

- Received two or more systemic treatments (BAT) for cGvHD in addition to corticosteroids ± CNI for cGvHD
- Patients that transition from active aGvHD to cGvHD without tap ering off corticosteroids ± CNI and any systemic treatment
- -Patients receiving up to 30 mg by mouth once a day of hydrocortisone (i.e., physiologic replacement dose) of corticosteroids were allowed.
- Patients who were treated with prior JAK inhibitors for aGvHD; except when the patient achieved complete or partial response and had been off JAK inhibitor treatment for at least 8 weeks prior to Cycle 1 Day 1
- Failed prior alloSCT within the past 6 months from Cycle 1 Day 1
- Patients with relapsed primary malignancy, or who were treated for relapse after the alloSCT was performed.
- SR-cGvHD occurring after a non-scheduled DLI administered for pre-emptive treatment of malignancy recurrence.
- History of progressive multifocal leuko-encephalopathy (PML)
- Active uncontrolled bacterial, fungal, parasitic, or viral infection
- Patients on mechanical ventilation or had a resting O2 saturation &lt;90% by pulse oximetry
- History or current diagnosis of cardiac disease indicating significant risk of safety for patients participating in the study such as uncontrolled or significant cardiac disease.
- Presence of severely impaired renal function defined by serum creatinine &gt; 2 mg/dL (&gt; 176.8μmol/L), renal dialysis requirement, or have estimated creat inine clearance &lt;30 ml/min measured or calculated by Cockcroft Gault equation
- Cholestatic disorders, or unresolved sinusoidal obstructive syndrome/veno-occlusive disease of the liver (defined as persistent bilirubin abnormalities not attributable to aGvHD and ongoing organ dysfunction) or

Total bilirubin &gt;2mg/dL attributable to GvHD.

<div style=\"page-break-after: always\"></div>

- Impairment of gastrointestinal (GI) function (unrelated to GvHD) or GI disease (unrelated to GvHD) that may significantly alter the absorption of oral Rux (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection) Or

Diarrhoea attributable to GvHD.

- Any corticosteroid therapy for indications other than cGvHD at doses &gt;1 mg/kg/day methylprednisolone or equivalent within 7 days of Cycle 1 Day 1.
- Patient was receiving treatment with medications that interfere with coagulation or platelet function including, but not limited to, heparin or warfarin sodium (Coumadin®). Use of low molecular weight heparin is allowed. In patients in whom aspirin was indicated for secondary cardiovascular disease prevention, aspirin daily dose not exceeded 150 mg/day.
- Patient was receiving fluconazole at daily doses higher than 200 mg.
- Known allergies, hypersensitivity, or intolerance to systemic immunosuppressive therapy.
- Pregnant or nursing (lactating) women

## Treatments

Patients were randomized 1:1 to receive either best available therapy (BAT, please see below) or ruxolitinib. The dose-selection is based on the same data as presented for study C2301 (aGvHD).

- Ruxolitinib 10 mg orally twice daily or
- Best available therapy (BAT) identified by the Investigator prior to patient randomisation among the following treatments: extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib or ibrutinib. Addition or initiation of a new systemic therapy in the BAT arm was allowed only after documented lack of response intolerable toxicity, or cGvHD flare and was considered a treatment failure for both the primary and key secondary objectives.

Cycle length is 28 days.

Following randomization, change or addition of a new systemic therapy in the BAT arm due to documented lack of response or toxicity was allowed in the first 6 cycles, but was considered a treatment failure. At Cycle 7 Day 1 or later after randomization, patients randomized to BAT that did not achieve or maintain a CR or PR, or who developed toxicity to BAT were allowed to cross over from BAT to ruxolitinib.

The protocol defined BAT were based on a selection of therapies used as institutional standards since there is none uniformly used standard second line therapy in SR-cGvHD. Ibrutinib, included in the arsenal for the treatment of cGvHD after the protocol finalisation (however not an authorized indication in EU) was included as an of the electable choices of BAT, as a consequence of Amendment 1.

<div style=\"page-break-after: always\"></div>

## Initial BAT treatment D2301, REACH 3

```
Table 14.3-1.3 (Page 1 of 1) Initial BAT treatment and number of BATs started before Cycle 7 Day 1 Safety set BAT N=158 Initial BAT treatment -n (%) Extracorporeal photopheresis (EcP) 55 (34.8) Mycophenolatemofetil (MMF) 35 (22.2) Ibrutinib 27 (17.1) Low-dose Methotrexate (MTx) 10 (6.3) Imatinib 8 (5.1) Sirolimus 7 (4.4) Rituximab 6 (3.8) Everolimus 5 (3.2) Infliximab 5 (3.2) Number of BAT treatments started before Cycle 7 Day 1 -n(%) 1 127 (80.4) 2 28 (17.7) >2 3 (1.9) CINC424D2301- PrimarY CSR
```

## Tapering of concomitant immunosuppression

Tapering of immunosuppression therapy in responding patients was performed in two steps:

1. Taper of corticosteroids was attempted approximately 2 weeks after achieving a CR, based on protocol guidelines.
2. Taper of CNI and/or ruxolitinib was not initiated until the patient was off corticosteroids AND completed the assessments for Cycle 7 Day 1. Ruxolitinib was not be tapered prior to Cycle 7 Day 1 for patients initially randomized to the ruxolitinib arm.

## Concomitant treatment

Supportive treatments per institutional guidelines for management of alloSCT patients with SRcGvHD were allowed. Patients may have received other cGvHD medications administered either as cGvHD prophylaxis or as treatment prior to randomization which could include CNI (cyclosporine or tacrolimus), and corticosteroids. Viral prophylaxis and antibiotics were allowed as needed for prevention and treatment of any infections.

Change or addition of new systemic immunosuppressive therapy after randomization and up to completion of Cycle 7 Day 1 was considered a treatment failure.

Ruxolitinib dose adjustments might be required particularly in patients treated with CYP450 modulators due to potential for drug-drug interactions leading to under- or over-exposure.

Permitted/prohibited medication according to the protocol are in line with Jakavi SmPC.

## Cross-over

Patients randomised to BAT, and not achieving PR or better on or after Cycle 7 Day 1 were allowed to cross-over to the RUX treatment arm and were to follow the same treatment schedule as patients originally randomised to RUX treatment.

## Duration of treatment

The End of Treatment (EOT) visit occurred when the patient permanently discontinued the study treatment and entered the Long-term survival follow-up, or completed the Randomized treatment period (ruxolitinib arm, or BAT patients not crossing over) or the Crossover period (BAT arm only). The total duration on study for an individual patient was 39 Cycles (156 weeks or 3 years).

<div style=\"page-break-after: always\"></div>

## Objectives

## Primary objective

- To compare the efficacy of ruxolitinib vs. Investigator's choice Best Available Therapy (BAT) in patients with moderate or severe SR-cGvHD assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 visit.

## Outcomes/endpoints

Endpoints according to Statistical Analysis Plan

## Primary endpoint

Overall response rate (ORR) on Cycle 7 Day 1 after randomization, defined as the proportion of patients in each arm demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier progression, mixed response or nonresponse. Scoring of response was relative to the organ score at randomization, using the established NIH consensus criteria.

## Secondary endpoints

Key secondary endpoint-Composite time to event endpoint

-First key secondary endpoint defined as the time from date of randomization to the earliest of the following FFS events:

- i) relapse or recurrence of underlying disease or death due to underlying disease or
2. ii) non-relapse mortality, or
3. iii) addition or initiation of another systemic therapy for cGvHD.

-The second key secondary objective was to assess the rate of patients with clinically relevant improvement of the modified Lee symptoms score at Cycle 7 Day 1 relative to baseline, as assessed by the rate of responders as per improvement ≥ 7 points of total symptom score (TSS) from baseline of the modified Lee Symptom Scale (mLSS).

Other secondary endpoints- please also refer to table in section 2.5.3.1.4

-Best overall response (BOR): Proportion of patients who achieved OR (CR+PR) at any time point (up Cycle 7 day 1 or the start of additional systemic therapy for cGvHD).

- Proportion of patients who achieved OR (CR+PR) at Cycle 4 Day 1.
- Duration of response (DOR) is assessed for responders only. DOR is defined as the time from first response until cGvHD progression, death, or the date of change/addition of systemic therapies for cGvHD.
- Overall survival (OS), defined as the time from the date of randomization to the date of death due to any cause.
- Non-relapse mortality (NRM), defined as the time from date of randomization to date of death not preceded by underlying disease relapse/recurrence.
- -To assess proportion of patients with ≥ 50% reduction in daily corticosteroid dose at Cycle 7 Day1
- -To assess proportion of patients successfully tapered off all corticosteroids at Cycle 7 Day 1

<div style=\"page-break-after: always\"></div>

-To assess Malignancy Relapse/Recurrence (MR) is defined as the time from date of randomization to hematologic malignancy relapse/recurrence. Calculated for patients with underlying hematologic malignant disease.

- Change in FACT-BMT from baseline to each visit where measured. Change in EQ-5D from baseline to each visit where measured.

## Efficacy analysis/ Criteria for evaluation

The severity of cGvHD at screening was assessed based on the number and degree of organ involvement according to the established NIH consensus criteria. For the definition of SR-CGvHD, please refer to inclusion criteria since the patient had to have a confirmed diagnosis of corticosteroid refractory cGvHD defined per 2014 NIH consensus criteria (Lee 2015).

The most frequently involved organs in patients with chronic GVHD are skin, mouth, and liver, with less frequent involvement of eye, lung, GI tract, joint/fascia, and genital tract.

Global and organ-specific cGvHD clinician assessments were performed at baseline, weekly for the first 4 weeks, and then every 28 days until Cycle 7 Day 1 according to the NIH Consensus Criteria described above. Following Cycle 7 Day 1, response was assessed on Cycle 9 Day 1 and every 12 weeks thereafter.

CR was defined as complete resolution of all signs and symptoms of cGvHD in all evaluable organs without additional therapies.

PR was defined as an improvement in at least one organ (e.g., improvement of 1 or more points on a 4 to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, or addition/initiation of new systemic treatment.

Lack of response was defined as unchanged, mixed response, or progression.

PD was defined as worsening of at least one organ and no improvement (CR or PR) in any other organ

Mixed response was a CR or PR in at least 1 organ accompanied by progression in another organ

Unchanged response was defined as stable disease or absence of improvement in any organ involved by cGvHD

cGvHD Flare was defined as any increase in symptoms during taper of any immunosuppressive therapy for cGvHD, after an initial response (CR or PR). A cGvHD flare was not considered a treatment failure unless severity requires addition and/or change of another systemic immunosuppressive treatment.

cGvHD Recurrence was defined as the return of cGvHD symptoms after tapering off study treatment due to response. Following completion of a taper of systemic therapy, if worsening of cGvHD symptoms occur, the patient was allowed to resume treatment for cGvHD as per local institutional practice. However, this was to be documented as a recurrence of cGvHD.

Graft failure monitoring Patients will be monitored for any evidence of graft failure at each visit after Cycle 1 Day 1. In addition, considering that Graft failure is defined as initial whole blood or marrow donor chimerism &gt;5% declining to &lt;5% on subsequent measurements, donor chimerism will be also closely monitored. Donor chimerism after a hematopoietic stem cell transplant involves identifying the genetic profiles of the recipient and of the donor pre-transplant, and then evaluating the ratio of donor to recipient cells in the recipient's blood, or bone marrow.

<div style=\"page-break-after: always\"></div>

## Sample size

In a meta-analysis, Olivieri et al (2015) obtained an estimated pooled effect size for ORR for systemic treatment of SR-cGvHD of 0.66 (95% CI: 0.62-0.70). Sample size calculations were performed to achieve 90% power for different scenarios, assuming a targeted odds ratio of 2.35 and 2.5, respectively. A sample size of 324 patients was considered reasonable for this study based on stratified one-sided CMH test (alpha=2.5%, assuming same ORR and 50% of patients in each stratum).

With a sample size of 162 patients in each treatment (e.g., ORR=0.66 on Cycle 7 Day 1 for BAT for each stratum), an observed odds ratio greater than or equal to 1.68 is expected to result in statistically significant differences between the arms.

The sample size calculation seems appropriate. However, it is noted that the observed ORR rates are considerably lower than what was anticipated in the calculation. The ORR for Ruxolitinib estimated in the study is approximately 50%, i.e., only a fraction of the expected 82% as indicated above. The expected BAT effect (ORR of 66%) was not achieved in the study.

## Randomisation

A stratified 1:1 randomisation was conducted, and patients received either ruxolitinib or BAT. They were stratified by cGvHD grade (Grade cGvHD moderate vs severe). Before randomization, BAT was selected by the Investigator.

## Blinding (masking)

No blinding was performed due to the variety of treatments for SR cGvHD with different severity in the BAT arm.

## Treatment phases/study conduct

-Screening period (Day -28 to Day -1): Prospective patients diagnosed with moderate or severe SRcGvHD and who meet the inclusion and exclusion criteria will be consented prior to beginning screening assessments. The screening period can last 28 days (Day -28 to Day -1).

-Main treatment period (Day 1 to EOT): The total duration on study for an individual patient will be 39 Cycles (156 weeks or 3 years), inclusive of the randomized treatment period, cross over treatment period, and long-term survival follow-up.

-Crossover Treatment Phase: Patients randomized to the BAT arm who experience disease progression, have a mixed response, experience cGvHD flare, or experience toxicity to BAT are permitted to cross over to the ruxolitinib arm following completion of all assessments at Cycle 7 Day 1, or thereafter.

A maximum of 39 cycles of study treatment and follow-up is completed, inclusive of the randomized treatment period, cross over treatment period, and long-term survival follow up (i.e. patients who cross over on Cycle 9 will only complete visits until Cross-Over Cycle 30).

Primary efficacy period The Primary Efficacy Endpoint assessment will be conducted on Cycle 7 Day 1 of the randomized treatment period with a window of +/- 7 days.

<div style=\"page-break-after: always\"></div>

## Overall cGvHD Response assessment vs baseline (prior to Cycle 7 Day 1)

Section 6.1.5.1 refers to Appendix 16.1.1-Protocol-Section 6.1.5.1

<!-- image -->

Extension period (Cycle 7 to Cycle 39)

-Safety follow-up (Last Dose + 30 days): All patients must have safety evaluations at least 30 days (+ 3 days) after the last dose of study treatment. During the safety follow up, adverse events, concomitant medications, transfusions, and monitoring of infections will be recorded. If an adverse event or a serious adverse event is detected, it should be followed until its resolution or until it is judged to be permanent.

-Long-term survival follow-up (EOT to 39 cycles on study): Patients who permanently discontinue the study treatment prior to the completion of 39 cycles on study for reasons other than achieving a CR or PR will enter the Long-Term Survival Follow-Up, and may be treated per Institutional practice. They will be followed approximately every 3 months by telephone call for survival, reporting of new cGvHD therapies until 39 cycles on study is completed, inclusive of randomized treatment, cross over treatment (BAT patients only), and long-term survival follow up.

## Statistical methods

The primary efficacy variable, ORR at Cycle 7 Day 1, was planned to be analysed at the time when all patients have completed their Cycle 7 Day 1 visit or discontinued earlier. The data cut-off date for the primary analysis was 08-May-2020. An interim analysis on the primary endpoint ORR and key secondary endpoints FFS and mLSS, based on cut-off date 9-Jul-2019, was performed in October 2019.

The final analysis will occur once all patients have completed the study (up to 39 cycles/3 years from randomization).

## Analysis sets

The Full Analysis Set (FAS) comprises all patients to whom study treatment has been assigned by randomization. According to the intent to treat principle, patients were analyzed according to the treatment and strata they have been assigned to during the randomization procedure.

The Per-Protocol Set (PPS) consists of a subset of the patients in the FAS who are compliant with requirements of the clinical study protocol (CSP).

<div style=\"page-break-after: always\"></div>

The Safety Set includes all patients who received at least one dose of study treatment. Patients were analysed according to the study treatment received, where treatment received was defined as the randomized treatment if the patient took at least one dose of that treatment, or the first treatment received if the randomized treatment was never received.

The Cross-over Analysis Set (CAS) comprises all patients randomized to and who receive BAT, who then crossed over and received at least one dose of ruxolitinib. This analysis set was used for all analyses for crossover patients.

## Primary analysis

The primary endpoint of the study was ORR at Cycle 7 Day 1 defined as the proportion of patients with CR or PR, according to the NIH Consensus Criteria. Note that response is relative to the assessment of cGvHD at randomization. A patient was not considered a responder if any of the following events occurs prior to the Cycle 7 Day 1 visit:

- -Missing overall cGvHD response assessment at Cycle 7 Day 1
- -No CR or PR at Cycle 7 Day 1
- -Addition of or start of new systemic therapy for cGvHD.

The statistical hypotheses and method of analysis was similar to the primary analysis of the REACH 2 study. The Cochrane-Mantel-Haenszel (CMH) chi-square test, stratified by the randomization stratification factor (i.e., cGvHD moderate vs. severe), was used to compare ORR between the two treatment groups. The primary analysis was performed on the FAS according to ITT principle. Onesided p-value, odds ratio (OR) and 95% Wald confidence limits calculated from the stratified CMH test were presented. ORR was also summarized using descriptive statistics (N, %) by treatment arm along with two-sided exact binomial 95% CIs [Clopper and Pearson 1934].

Supportive analyses included re-run of the primary efficacy analysis on the PPS, and detailed descriptions of response rates and organ specific responses at Cycle 7 Day 1.

Subgroup analysis was performed for the primary efficacy endpoint to assess the homogeneity of treatment effect across demographic and baseline disease characteristics. Efficacy analyses in subgroups were purely exploratory and intended to explore the consistency of treatment effect.

ORR at Crossover Cycle 7 Day 1 was defined as the proportion of crossover patients with CR or PR at Crossover Cycle 7 Day 1. ORR was summarized using descriptive statistics (N, %) along with two-sided exact binomial 95% CIs [Clopper and Pearson 1934] using local investigators' overall response assessed at the Crossover Cycle 7 Day 1 visit and taking into account initiation or addition of new systemic therapy before this time point. Note that response was relative to the last assessment of cGvHD prior to or at the start date of crossover treatment (ruxolitinib). A patient was not considered a responder at Crossover Cycle 7 Day 1 if any of the following events occurs prior to Crossover Cycle 7 Day 1:

- -Missing overall cGvHD response assessment at crossover or Crossover Cycle 7 Day 1
- -No CR or PR at Crossover Cycle 7 Day 1
- -Addition of or start of new systemic therapy for cGvHD.

## Analysis of the key secondary endpoints

The first key secondary endpoint was Failure free survival (FFS), in line with the CHMP/PMDA's recommendation and defined as the time from date of randomization to the earliest of: i) relapse or recurrence of underlying disease or death due to underlying disease, ii) non-relapse mortality, or iii) addition or initiation of another systemic therapy for cGvHD. If a patient did not experience any of these events, FFS were censored at the latest contact data (on or before the cut-off date). A stratified

<div style=\"page-break-after: always\"></div>

one-sided log-rank test was used to test if FFS hazard ratio (ruxolitinib arm versus BAT arm) was lower than 1. The stratification was based on the randomization stratification factors (i.e. cGvHD moderate vs severe).

No data imputation was performed for key secondary endpoints when missing values, censoring, or discontinuations occurred.

The second key secondary objective was to assess the improvement of symptoms based on the total symptom score (TSS) using the modified Lee Symptom Scale. A responder was defined as having achieved a clinically relevant reduction by ≥7 scores from baseline of the TSS. A patient was not considered a responder at Cycle 7 Day 1 if any of the following events occurs prior to or at the Cycle 7 Day 1 visit:

- -Missing or insufficient data to calculate TSS at baseline or Cycle 7 Day 1
- -No clinically relevant reduction of TSS at Cycle 7 Day 1
- -Additional systemic therapy for cGvHD.

The Cochrane-Mantel-Haenszel chi-square test, stratified by the randomization stratification factor (i.e., cGvHD moderate vs severe), was used to compare the response rates between the two treatment groups.

## Handling of missing values/censoring/discontinuations

Patients with missing assessments that prevent the evaluation of the primary endpoint were considered non-responders on that treatment arm. This includes missing overall cGvHD response assessments at baseline and Cycle 7 Day 1. The same rule was applied for the evaluation of the ORR at Cycle 4 Day 1 and BOR, including missing cGvHD assessments at Cycle 4 Day 1.

No data imputation was to be applied. Addition or initiation of a new systemic therapy before Cycle 7 Day 1 in any arm was considered a treatment failure, and patients were counted as non-responder in the primary analysis.

## Multiplicity

A fixed sequence hierarchical testing strategy has initially been planned for the primary and the two key secondary endpoints, with all tests being one-sided with significance level alpha=2.5%. With protocol amendment 1, an efficacy and safety interim analysis (IA) was added based on a 2-look group-sequential study design, and a hierarchical testing procedure was implemented to control the familywise error rate (FWER) at the one-sided 2.5% level of significance for the primary and the two key secondary endpoints at the IA and the primary CSR analysis (see figure below). (In line with the CHMP/PMDA's recommendation, FFS was used as the first key secondary endpoint for all regions except the US. A different testing sequence was used for the US (FDA), where mLSS was tested before testing FFS.)

Figure 8. Hierarchical testing strategy used for all regions except for the US (RoW)

<div style=\"page-break-after: always\"></div>

<!-- image -->

ORR: overall response rate; FFS: Failure-free survival; mLSS refers to responder rate based on the modified Lee symptom score (mLss)

RoW:Rest of the world

The first efficacy look was planned when 194 (60% of the targeted 324 patients) had completed the Cycle 7 Day 1 visit or discontinued from the study earlier and data of assessments are available.

Interim analysis was performed based on efficacy data of the first 196 patients (60.5% of the targeted 324 patients) on cut-off date 9-Jul-2019. The resulting significance level alpha was 0.01176 for the interim analysis. With N=329 for the primary analysis the targeted alpha to re-test the hypotheses (if not rejected at the IA) was 0.01858. Following the overall hierarchical testing procedure, the hypotheses that were not rejected at the IA are to be tested again in this this CSR analyses spending the remaining alpha, i.e. IA results have to be taken into account when interpreting CSR results.

## Interim analysis

One early safety interim analysis and an interim efficacy and safety analysis (both added in protocol amendment 1) were planned. An early safety analysis was generated when safety data on the first 80 randomized patients who have completed Cycle 4 Day 1 were available. The interim analysis was to be performed by an independent statistician and programmer when 194 (60% of the targeted 324 patients) have completed the Cycle 7 Day 1 visit or discontinued from the study earlier and data of assessments were available. Following a 2-look group sequential design a rho-spending function with parameter rho=1.5 was used as alpha spending function, for which operational characteristics were given in the amended protocol (dated 20-Dec-2017). If the number of patients at the IA is not exactly 194 at the time of the interim cut-off, the efficacy stopping bound would be recalculated based on the pre-specified alpha spending function.

The interim analysis was performed based on efficacy data of the first 196 patients (60.5% of the targeted 324 patients) on the significance level alpha of 0.01176. With N=329 for the primary analysis the targeted alpha to re-test the hypotheses (if not rejected at the IA) was 0.01858. The interim analysis p-values for the primary and the key secondary endpoints were: 0.0003, &lt;0.0001 and 0.0151. At the CSR primary analysis, the corresponding p-values were &lt;0.0001, &lt;0.0001 and 0.0011. The 3 rd  endpoint (proportion of responders based on the TSS) was according to the applied hierarchical testing procedure not significant at the interim analysis but could be re-tested at the primary CSR analysis on 0.01858 alpha level and therefore was statistically significant.

## Changes from the planned analyses

No relevant changes were made between the (amended) protocol statistical section and the SAP.

However, an error was detected in the programmed derivation of some of the mLSS subscales caused by an incorrect description in the SAP Amendment 2. The corrected description of the scoring is

<div style=\"page-break-after: always\"></div>

documented in the SAP Addendum to Amendment 2. The programs were updated for the respective analysis data and all outputs for mLSS were re-produced. The impact of these updates on the overall results for mLSS was low, the key secondary endpoint remained statistically significant.

The addition of an interim efficacy and safety analysis in the protocol amendment 1 was made early during the study conduct (at the time when 15 subjects were screened and randomized) and is not likely to have been influenced by any observed study data. The analyses were performed in accordance with the amended protocol.

Of note, for the interpretation of the phase III study results, the convention is to use 2-sided tests and p-values. For that reason, 2-sided p-values are included in the SmPC.

## Protocol amendments

The original protocol was dated 14-MAR-2017 and an amended protocol version 01 was effective from 20-DEC-2017; issued after 15 patients had been randomized.

The main purpose of the amendment was to extend the available patient population. Due to protracted enrolment and feedback from health authorities and investigators, several inclusion and exclusion criteria were revised. Additionally, following the approval of ibrutinib, the original protocol-defined list of BAT options would not allow for a complete comparative assessment versus ruxolitinib. Therefore, adding ibrutinib to the list of eligible BAT was necessary to reflect the complete list of treatment options for this patient population. Lastly, a Data Monitoring Committee was been added based on health authority feedback to include an independent review group.

At the time of the amendment finalization, 15 patients had been screened and all 15 had been randomized, and none of these patients had reached the 6-month visit that was used for the primary endpoint.

With regards to amendments concerning inclusion and exclusion criteria, please also refer to section 2.4.5.1.1.

There was one protocol amendment, issued 20-DEC-2017, after 15 patients had been randomized in study D2301, REACH3. There were several changes including revision of some inclusion and exclusion criteria as well as some secondary endpoints. Most of the changes being of clarifying nature, however, some of more clinically relevant character. The updated number of patients for extensive PK sampling is acknowledged as well as the important update of the window for patients receiving systemic or topical corticosteroids for the treatment of cGvHD, which was extended from six months to twelve months. Furthermore, patients who had received two or more systemic therapies for cGvHD were excluded, thus only patients who had received one prior replacement dose range was allowed. The amendment allowing a broader inclusion population, i.e. updated definition of overlap syndrome might have facilitated the inclusion rate.

With regard to the added DMC, interim analysis and the SAP addendum, these are endorsed. The addition of DMC and interim efficacy and safety analysis in the protocol amendment 1 was made early during the study conduct and is not likely to have been influenced by any observed study data. The scoring for mLSS was corrected prior to the CSR, and the key secondary endpoint remained statistically significant.

<div style=\"page-break-after: always\"></div>

## Results

This clinical study report (CSR) presents the results of the interim analysis and the primary analysis, which includes data up to the cut-off date of 08-May-2020, when all 329 patients randomized and completed the Cycle 7 Day 1 visit or discontinued from the study earlier.

## Recruitment

## Screening failures

Table 14.1-1.3 (Page 1 of 1) Screening phase disposition All screened subjects

|                                                |     | All Subjects N=404 n (%)   |
|------------------------------------------------|-----|----------------------------|
| Screened                                       | 404 | (100)                      |
| Completed screening phase, randomized          | 329 | (81.4)                     |
| Completed screening, not randomized            | 1   | (0.2)                      |
| Did not complete screening                     | 74  | (18.3)                     |
| Primary reason for not completing screening    |     |                            |
| Screen failure                                 | 72  | (17.8)                     |
| Subject/guardian decision                      | 2   | (0.5)                      |
| Adverse event                                  |     | 0                          |
| Death                                          |     | 0                          |
| Disease relapse                                |     | 0                          |
| Failure to meet protocol continuation criteria |     | 0                          |
| Graft loss                                     |     | 0                          |
| Lack of efficacy                               |     | 0                          |
| Lost to follow-up                              |     | 0                          |
| Physician decision                             |     | 0                          |
| Pregnancy                                      |     | 0                          |
| Protocol deviation                             |     | 0                          |
| Study terminated by sponsor                    |     | 0                          |
| Technical problems                             |     | 0                          |

## Disposition of patients

## Participant flow

<!-- image -->

<div style=\"page-break-after: always\"></div>

## Patient disposition - End of randomized treatment (FAS)

|                                                              | RUX N=165 n (%)   | BAT N=164 n (%)   | AllPatients N=329 n (%)   |
|--------------------------------------------------------------|-------------------|-------------------|---------------------------|
| Subjectsrandomized                                           |                   |                   |                           |
| Treated                                                      | 165 (100)         | 158 (96.3)        | 323 (98.2)                |
| Not treated                                                  | 0                 | 6 (3.7)           | 6 (1.8)                   |
| Treatmentongoing*                                            | 83 (50.3)         | 42 (25.6)         | 125 (38.0)                |
| Discontinuedfromtreatmentperiod                              | 82 (49.7)         | 122 (74.4)        | 204 (62.0)                |
| Primaryreasonfordiscontinuation                              |                   |                   |                           |
| Adverseevent                                                 | 28 (17.0)         | 8 (4.9)           | 36 (10.9)                 |
| Lack of efficacy                                             | 24 (14.5)         | 70 (42.7)         | 94 (28.6)                 |
| Diseaserelapse                                               | 9 (5.5)           | 7 (4.3)           | 16 (4.9)                  |
| Death                                                        | 8 (4.8)           | 7 (4.3)           | 15 (4.6)                  |
| Failuretomeetprotocolcontinuationcriteria                    | 4 (2.4)           | 5 (3.0)           | 9 (2.7)                   |
| Physician decision                                           | 4 (2.4)           | 14 (8.5)          | 18 (5.5)                  |
| Subject/guardiandecision                                     | 4 (2.4)           | 11 (6.7)          | 15 (4.6)                  |
| Lost to follow-up                                            | 1 (0.6)           | 0                 | 1 (0.3)                   |
| Continued into next phase at the end of randomized treatment |                   |                   |                           |
| Crossovertreatment                                           | 0                 | 61 (37.2)         | 61 (18.5)                 |
| Entered survival follow-up                                   | 61 (37.0)         | 37 (22.6)         | 98 (29.8)                 |

*Ongoing treatment and/or assessments during theMaintreatmentperiod at cut-offdateof08-May-2020

Reasonofdiscontinuationwasalsoreportedforsubjectsnottreated

The median duration of exposure to RUX treatment and BAT treatment were 41.3 weeks (0.7-127.3) and 24.1 weeks (0.6-108.4) for RUX treatment and BAT treatment, respectively.

As illustrated in the K-M plot, treatments were discontinued at similar pace up to the measurement timepoint for the primary endpoint (Cycle 7 Day 1), after which there is a sharp drop in the BAT arm, explained by the study design as it was targeted to keep patients in the main treatment period at least until the Cycle 7 Day 1 visit.

A total of 82 (49.7%) and 122 (74.4%) patients discontinued the randomized treatment period in the ruxolitinib and BAT arm, respectively. The most frequent reasons for discontinuations during period up

<div style=\"page-break-after: always\"></div>

to the Cycle 7 Day 1 visit were adverse events and lack of efficacy in ruxolitinib arm (21 and 13 patients, respectively), and lack of efficacy in the BAT arm (29 patients).

<!-- image -->

## CINC424D2301-PrimaryCSR

Discontinuationreasonsbytimeintervalforthemainstudyperiod,bytreatment

## Treatment:Ruxolitinib10mgBID

|                                           | Weekssincetreatmentstart   | Weekssincetreatmentstart   | Weekssincetreatmentstart   | Weekssincetreatmentstart   | Weekssincetreatmentstart   | Weekssincetreatmentstart   |     |            |
|-------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|-----|------------|
| Reason                                    | >0-8                       | >8-16                      | >16-24                     | >24-32                     | >32-40                     | >40-48                     | >48 | any        |
| Primaryreasonfordiscontinuation           |                            |                            |                            |                            |                            |                            |     |            |
| Adverse event                             | 8                          | 8                          | 5                          | 3                          | 1                          | 1                          | 2   | 28 (17.0%) |
| Death                                     | 2                          | 3                          | 1                          | 0                          | 1                          | 1                          | 0   | 8 (4.8%)   |
| Diseaserelapse                            | 1                          | 1                          | 1                          | 2                          | 1                          | 0                          | 3   | 9 ( 5.5%)  |
| Failuretomeetprotocolcontinuationcriteria | 1                          | 0                          | 0                          | 0                          | 0                          | 2                          | 1   | 4 (2.4%)   |
| Lack of efficacy                          | 1                          | 7                          | 5                          | 6                          | 1                          | 1                          | 3   | 24 (14.5%) |
| Lost to follow-up                         | 0                          | 0                          | 0                          | 0                          | 0                          | 0                          | 1   | 1(0.6%)    |
| Physician decision                        | 1                          | 0                          | 1                          | 1                          | 0                          | 0                          | 1   | 4 (2.4%)   |
| Subject/guardian decision                 | 0                          | 3                          | 1                          | 0                          | 0                          | 0                          | 0   | 4 ( 2.4%)  |

## CINC424D2301-PrimaryCSR

TableHA2 14.1-1.4

Fullanalysisset

TableHA2 14.1-1.4

Discontinuationreasonsbytimeintervalforthemainstudyperiod,bytreatment Fullanalysisset

## Treatment:Best available therapy

|                                           | Weekssincetreatmentstart   | Weekssincetreatmentstart   | Weekssincetreatmentstart   | Weekssincetreatmentstart   | Weekssincetreatmentstart   | Weekssincetreatmentstart   |     |            |
|-------------------------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|----------------------------|-----|------------|
| Reason                                    | >0-8                       | >8-16                      |                            |                            | >16-24>24-32>32-40         | >40-48                     | >48 | any        |
| Primary reason for discontinuation        |                            |                            |                            |                            |                            |                            |     |            |
| Adverse event                             | 2                          | 0                          | 3                          | 2                          | 0                          | 0                          | 1   | 8 (4.9%)   |
| Death                                     | 4                          | 0                          | 1                          | 2                          | 0                          | 0                          | 0   | 7 (4.3%)   |
| Diseaserelapse                            | 1                          | 2                          | 1                          | 3                          | 0                          | 0                          | 0   | 7 (4.3%)   |
| Failuretomeetprotocolcontinuationcriteria | 1                          | 1                          | 1                          | 0                          | 1                          | 0                          | 0   | 5 (3.0%)   |
| Lack of efficacy                          | 3                          | 8                          | 18                         | 29                         | 7                          | 3                          | 2   | 70 (42.7%) |
| Lost to follow-up                         | 0                          | 0                          | 0                          | 0                          | 0                          | 0                          | 0   | 0          |
| Physician decision                        | 0                          | 2                          | 3                          | 5                          | 0                          | 0                          | 1   | 14 ( 8.5%) |
| Subject/guardian decision                 | 3                          | 2                          | 3                          | 0                          | 0                          | 0                          | 1   | 11 (6.7%)  |

## Cross-over patients

At the end of Cycle 6, 61 (37.2%) patients in the BAT arm crossed over to RUX treatment and 37 (22.6%) entered the Survival follow-up phase. No patient completed the Cross-over treatment period with RUX at the time of data cut-off, and 46 (75.4%, out of 61 patients) were still receiving RUX. Therefore, efficacy data for the cross-over treatment population are not presented in the present CSR.

<div style=\"page-break-after: always\"></div>

Fifteen (24.6%) patients discontinued the Cross-over treatment period with RUX due to AEs: lack of efficacy each in 4 (6.6%) patients, physician decision and patient/guardian decision each in 3 (4.9%) patients and death in one patient.

## Conduct of the study

## Protocol changes

The original study protocol dated 14 Mar 2017 was amended once on 20-Dec-2017. The main purpose of the amendment was to extend the available patient population. Due to protracted enrollment and feedback from health authorities and investigators, several inclusion and exclusion criteria were revised:

- The window for patients currently receiving systemic or topical corticosteroids for the treatment of cGvHD was extended from six months to twelve months prior to Cycle 1 Day 1.
- Instead of excluding patients that received any systemic treatment for cGvHD in addition to corticosteroids ± CNI, patients who have received one prior systemic treatment in addition to corticosteroids ± CNI were eligibl e as well.
- The criterion regarding overlap syndrome was clarified to exclude those patients with active acute progressive disease.
- The definition of severely impaired renal function was updated by adding the text 'having estimated creatinine clearance &lt;30 ml/min measured or calculated by Cockroft Gault equation (confirmed within 48 hours prior to study treatment start)'. This criterion was updated to provide a more sensitive measure of mild or moderate kidney injury at study entry.
- Updated cholestatic criterion to add total bilirubin &gt;2mg/dL attributable to GvHD. This criterion was added as a more specific exclusion of patients with ongoing hepatic acute-like GvHD
- Added impairment of GI function example of diarrhea attributed to GvHD. This criterion was added as a more specific exclusion of patients with ongoing acute-like GI GvHD.

Additionally, with the recent approval of ibrutinib by the FDA the original protocol-defined list of BAT options would not allow for a complete comparative assessment versus RUX. Therefore, ibrutinib was added to this list to reflect the complete list of treatment options for this patient population.

The Patient Global Impression of Severity (PGIS) and the Patient Global Impression of Change (PGIC) patient-reported outcomes have been added as exploratory endpoint.

Lastly, a Data Monitoring Committee was added to include an independent review group.

## Protocol deviations

Protocol deviations were observed in 63% of patients in the RUX arm and 66.5% in BAT arm. The most common deviation category was 'other deviations'(32.7% vs. 37.2%), primarily consisting of Lee Symptom Scale not collected (13.9% vs. 17.1%) and HBV and/or HCV viral load testing value missing at Cycle 1 Day 1 (9.7% vs. 7.9%).

## Protocol deviations due to COVID-19 pandemic

The study was fully recruited before the out brake of the COVID-19 pandemic and all, except 6, patients had completed Cycle 7 Day 1 visit (primary endpoint). The conduct of the clinical trial during the COVID-19 pandemic followed the guidance of FDA and EMA. One of the changes was allowing

<div style=\"page-break-after: always\"></div>

assessments to be done remotely (video, telephone) or at non-conventional location such as outside of site, when no other option was available.

Deviations were noted with respect to drug supply (5.5%), visits conducted outside of study site (8,2%), cGVHD staging assessment missing (2,7%), assessment / procedure changed (2,7%), missing cGvHD assessment for cycle 6 and 7, resulting in 'PD' (1.8%, 2 and 4 patients in the RUX arm and BAT arm, respectively). Due to challenges to assess GvHD patients, especially with regard to the staging of skin and lung involvement in cGvHD for patients with remote visits (video or telephone) during the COVID-19 pandemic, the applicant has declared that the majority of patients had already reached the time for primary endpoint assessment before the WHO declared COVID-19 as a pandemic. For the 8 patients, for whom the Cycle 7 Day 1 visit could have been impacted due to the pandemic, measures were taken to ensure a reliable assessment. Other visits done outside of study site due to COVID-19 were handled the same way.

## Baseline data

## Demographics and baseline characteristics (FAS)

| Demographic variable             | RUX N=165    | BAT N=164     | AllPatients N=329   |
|----------------------------------|--------------|---------------|---------------------|
| Age (years)                      |              |               |                     |
| n                                | 165          | 164           | 329                 |
| Mean (SD)                        | 45.9 (15.68) | 47.2 (16.17)  | 46.5 (15.92)        |
| Median                           | 49.0         | 50.0          | 49.0                |
| Q1-Q3                            | 33.0-57.0    | 34.5-61.0     | 34.0-60.0           |
| Min -Max                         | 13.0-73.0    | 12.0-76.0     | 12.0-76.0           |
| Age category -n (%)              |              |               |                     |
| Adolescents, 12-<18 years        | 4 (2.4)      | 8 (4.9)       | 12 (3.6)            |
| 18 -65 years                     | 143 (86.7)   | 134 (81.7)    | 277 (84.2)          |
| >65 years                        | 18 (10.9)    | 22 (13.4)     | 40 (12.2)           |
| Sex -n (%)                       |              |               |                     |
| Female                           | 56 (33.9)    | 72 (43.9)     | 128 (38.9)          |
| Male                             | 109 (66.1)   | 92 (56.1)     | 201 (61.1)          |
| Race -n (%)                      |              |               |                     |
| White                            | 116 (70.3)   | 132 (80.5)    | 248 (75.4)          |
| Black or African American        | 2 (1.2)      | 0             | 2 (0.8)             |
| Asian                            | 33 (20.0)    | 21 (12.8)     | 54 (16.4)           |
| American Indian or Alaska Native | 2 (1.2)      | 0             | 2 (0.6)             |
| Other                            | 9 (5.5)      | 4 (2.4)       | 13 (4.0)            |
| Unknown                          | 3 (1.8)      | 7 (4.3)       | 10 (3.0)            |
| Ethnicity -n (%)                 |              |               |                     |
| Hispanic/Latino                  | 13 (7.9)     | 13 (7.9)      | 26 (7.9)            |
| Not Hispanic/Latino              | 118 (71.5)   | 115 (70.1)    | 233 (70.8)          |
| Not Reported                     | 26 (15.8)    | 25 (15.2)     | 51 (15.5)           |
| Unknown                          | 8 (4.8)      | 11 (6.7)      | 19 (5.8)            |
| Weight (kg)                      |              |               |                     |
| n                                | 165          | 163           | 328                 |
| Mean (SD)                        | 68.5 (18.29) | 67.9 (16.71)  | 68.2 (17.50)        |
| Median                           | 66.0         | 67.0          | 66.1                |
| Q1-Q3                            | 55.0-78.9    | 55.0-78.5     | 55.0-78.6           |
| Min -Max                         | 32.0-128.0   | 37.0-128.5    | 32.0-128.5          |
| Height (cm)                      |              |               |                     |
| n                                | 143          | 150           | 293                 |
| Mean (SD)                        | 169.7 (9.77) | 169.4 (10.05) | 189.6 (9.90)        |
| Median                           | 169.0        | 170.0         | 170.0               |
| Q1-Q3                            | 162.0-178.0  | 160.0-177.0   | 162.0-177.5         |
| Min -Max                         | 145.0-191.0  | 144.3-196.0   | 144.3-196.0         |
| Body mass index (kg/m2)          |              |               |                     |
| n                                | 143          | 150           | 293                 |
| Mean (SD)                        | 23.4 (5.35)  | 23.5 (4.92)   | 23.4 (5.13)         |

<div style=\"page-break-after: always\"></div>

Body Mass Index (kg/m2) = weight(kg) / (height(m))²

<!-- image -->

| Demographic variable                    | RUX N=165   | BAT N=164   | All Patients N=329   |
|-----------------------------------------|-------------|-------------|----------------------|
| Median                                  | 22.5        | 22.8        | 22.7                 |
| Q1-Q3                                   | 19.2-26.3   | 19.8-26.2   | 19.6-26.2            |
| Min-Max                                 | 13.0-38.7   | 14.7-42.9   | 13.0-42.9            |
| Assessment of performsnce status -n (%) |             |             |                      |
| ECOG                                    | 153 (92.7)  | 148 (90.2)  | 301 (91.5)           |
| Kamofsky                                | 41 (24.8)   | 43 (26.2)   | 84 (25.5)            |
| Lansky                                  | 11 (6.7)    | 14 (8.5)    | 25 (7.6)             |
| Missing                                 | 0           | 1 (0.6)     | 1 (0.3)              |
| ECOG performance status-n (%)           |             |             |                      |
| 0                                       | 39 (23.8)   | 42 (25.6)   | 81 (24.6)            |
| 1                                       | 92 (55.8)   | 82 (50.0)   | 174 (52.9)           |
| 2                                       | 22 (13.3)   | 22 (13.4)   | 44 (13.4)            |
| 3                                       | 0           | 2 (1.2)     | 2 (0.6)              |
| Missing                                 | 12 (7.3)    | 16 (9.8)    | 28 (8.5)             |
| Karnofsky performance status-n (%)      |             |             |                      |
| 290                                     | 24 (14.5)   | 17 (10.4)   | 41 (12.5)            |
| 70 -80                                  | 16 (9.7)    | 19 (11.6)   | 35 (10.6)            |
| 50-60                                   | 1 (0.6)     | 7 (4.3)     | 8 (2.4)              |
| Missing                                 | 124 (75.2)  | 121 (73.8)  | 245 (74.5)           |
| Lansky perfomance status -n (%)         |             |             |                      |
| 28                                      | 9 (5.5)     | 4 (2.4)     | 13 (4.0)             |
| 70 -80                                  | 2 (1.2)     | 9 (5.5)     | 11 (3.3)             |
| 50 -60                                  | 0           | 1 (0.6)     | 1 (0.3)              |
| Missing                                 | 154 (93.3)  | 150 (91.5)  | 304 (92.4)           |

## Underlying disease history/transplant and GvHD related history

The most frequently reported underlying diseases were AML (36.5%), ALL (15.8%) and MDC 13.4%. The fraction of patients with a non-malignant underlying disease was low.

Using the CIBMTR risk assessment tool (a validated tool to categorize groups of patients undergoing allogeneic stem cell transplantation, intended for research purposes, to stratify patients in broad disease risk categories for retrospective or prospective studies) approximately 25% were graded in each of the Low, Intermediate and High-risk groups. ~21% was missing or unknown.

Median time from transplant to cGvHD diagnosis was 235.00 days (range: 20.0 - 8047.0) overall and similar between two arms.

The median time since diagnosis to randomization was 2.33 years.

The stem cell source was bone marrow in 13.3% and 18.9% of the patients in the RUX arm and the BAT arm, respectively and peripheral blood in 85.5% and 79.9% of the patients in the RUX arm and the BAT arm, respectively. Only two patients in each arm received cord blood. Most patients received grafts from identical HLA-matched donors (57.5%; 192/329). T-cell depletion was performed in 38 (11.4%) patients overall.

<div style=\"page-break-after: always\"></div>

## Graft versus Host disease history (Full analysis set)

| Disease history                                   | RUX N=165        | BAT N=164         | AllPatients N=329   |
|---------------------------------------------------|------------------|-------------------|---------------------|
| Prior aGvHD-n (%)                                 |                  |                   |                     |
| Any                                               | 92 (55.8)        | 88 (53.7)         | 180 (54.7)          |
| Grade l                                           | 25 (15.2)        | 30 (18.3)         | 55 (16.7)           |
| Grade II                                          | 53 (32.1)        | 43 (26.2)         | 96 (29.2)           |
| Grade II                                          | 14 (8.5)         | 12 (7.3)          | 26 (7.9)            |
| Grade IV                                          | 0                | 3 (1.8)           | 3 (0.9)             |
| Steroid-refractory aGvHD                          | 18 (10.9)        | 17 (10.4)         | 35 (10.6)           |
| Time from aGvHD diagnosis to resolution (days)    |                  |                   |                     |
| n                                                 | 90               | 83                | 173                 |
| Mean (SD)                                         | 143.12 (241.795) | 105.78 (173.747)  | 125.21 (212.118)    |
| Median                                            | 63.50            | 50.00             | 52.00               |
| Min-Max                                           | 4.0-1675.0       | 5.0 - 1227.0      | 4.0-1675.0          |
| Time from aGvHD diagnosis to randomization (days) |                  |                   |                     |
| n                                                 | 92               | 87                | 179                 |
| Mean (SD)                                         | 578.76 (485.490) | 631.05 (1110.281) | 604.17 (846.623)    |
| Median                                            | 454.00           | 370.00            | 416.00              |
| Min-Max                                           | 110.0-2558.0     | 57.0- 9981.0      | 57.0-9981.0         |
| OverallseverityofcGvHDatinitialdiagnosis          |                  |                   |                     |
| Mild                                              | 33 (20.0)        | 41 (25.0)         | 74 (22.5)           |
| Moderate                                          | 77 (46.7)        | 77 (47.0)         | 154 (46.8)          |
| Severe                                            | 53 (32.1)        | 45 (27.4)         | 98 (29.8)           |
| Unknown                                           | 1 (0.6)          | 0                 | 1 (0.3)             |
| Missing                                           | 1 (0.6)          | 1 (0.6)           | 2 (0.6)             |
| Time from transplant to cGvHD diagnosis (days)    |                  |                   |                     |
| n                                                 | 165              | 164               | 329                 |
| Mean (SD)                                         | 371.44           | 404.53            | 387.94              |
|                                                   | (378.120)        | (749.580)         | (592.439)           |

<div style=\"page-break-after: always\"></div>

| Disease history                                                                                                                                                  | RUX N=165           | BAT N=164           | All Patlents N=329   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------|---------------------|----------------------|
| Medlan Min-Max                                                                                                                                                   | 247.00 20.0 -2360.0 | 230.00 35.0 -8047.0 | 235.00 20.0 - 8047.0 |
| Time from cGvHD diagnosis to randomization (days)                                                                                                                |                     |                     |                      |
| n                                                                                                                                                                | 165                 | 164                 | 329                  |
| Mean (SD)                                                                                                                                                        | 232.62 (282.843)    | 227.24 (287.471)    | 229.94 (284.737)     |
| Median                                                                                                                                                           | 174.00              | 149.50              | 154.00               |
| Min-Max                                                                                                                                                          | 7.0-2017.0          | 10.0- 1947.0        | 7.0-2017.0           |
| SR-cGvHD diagnosis-n (%)                                                                                                                                         |                     |                     |                      |
| SR criteria met (any)*                                                                                                                                           | 165 (100)           | 164 (100)           | 329 (100)            |
| A: lack of response or disease progression after prednisone ≥ 1 mg/kg/day for at least 1 week (or equivalent)                                                    | 62 (37.6)           | 73 (44.5)           | 135 (41.0)           |
| B: Disease persistence without improvement despite continued treatment with prednisone>0.5mq/kq/dayor1mq/kq/everv other day for at least 4 weeks (or equivalent) | 58 (35.2)           | 42 (25.6)           | 100 (30.4)           |
| C: Increase prednlsone dose to >0.25 mg/kq/day after two unsuccessful attempts to taper the dose (or equlvalent)                                                 | 45 (27.3)           | 49 (29.9)           | 94 (28.6)            |
| Tlme from Inltial cGvHD to dlagnosls of SR cGvHD (days)                                                                                                          |                     |                     |                      |
| ni                                                                                                                                                               | 165                 | 164                 | 329                  |
| Mean (SD)                                                                                                                                                        | 200.84 (259.325)    | 186.87 (242.706)    | 193.88 (250.892)     |
| Median                                                                                                                                                           | 125.00              | 106.00              | 111.00               |
| Min-Max                                                                                                                                                          | 3.0-2009.0          | 2.0-1540.0          | 2.0-2009.0           |
| Overall severity of SR-cGvHD at study entry                                                                                                                      |                     |                     |                      |
| Mild                                                                                                                                                             | 0                   | 1 (0.6)             | 1 (0.3)              |
| Moderate                                                                                                                                                         | 68 (41.2)           | 73 (44.5)           | 141 (42.9)           |
| Severe                                                                                                                                                           | 97 (58.8)           | 90 (54.9)           | 187 (56.8)           |
| Prior systemic cGvHD / SR-cGvHD therapy-n (%)                                                                                                                    |                     |                     |                      |
| Sterold only                                                                                                                                                     | 70 (42.4)           | 81 (49.4)           | 151 (45.9)           |
| Sterold + CNI                                                                                                                                                    | 68 (41.2)           | 69 (42.1)           | 137 (41.6)           |
| Sterold + CNI + other systemlc therapy                                                                                                                           | 10 (6.1)            | 4 (2.4)             | 14 (4.3)             |
| Sterold + other systemic therapy                                                                                                                                 | 14 (8.5)            | 9 (5.5)             | 23 (7.0)             |
| Missing                                                                                                                                                          | 3 (1.8)             | 1 (0.6)             | 4 (1.2)              |

-Analyses of lime to variables' are given for patients with available start and end dates only

*: Data were reported by investigator.

-Prior treatment for cGvHD as documented in the prior medication data, topical or local treatments not counted

|                                   | Table 14.1-7.5 (Page 1 of 1) Chronic GvHD Staging at screening Full analysis set   | Table 14.1-7.5 (Page 1 of 1) Chronic GvHD Staging at screening Full analysis set   | Table 14.1-7.5 (Page 1 of 1) Chronic GvHD Staging at screening Full analysis set   | Table 14.1-7.5 (Page 1 of 1) Chronic GvHD Staging at screening Full analysis set   | Table 14.1-7.5 (Page 1 of 1) Chronic GvHD Staging at screening Full analysis set   | Table 14.1-7.5 (Page 1 of 1) Chronic GvHD Staging at screening Full analysis set   |
|-----------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|------------------------------------------------------------------------------------|
|                                   |                                                                                    | RUX N=165                                                                          |                                                                                    | BAT N=164                                                                          |                                                                                    | All Patients N=329                                                                 |
| Overall cGvHD Severity -n (%) [1] |                                                                                    |                                                                                    |                                                                                    |                                                                                    |                                                                                    |                                                                                    |
| Mild                              | 1                                                                                  | (0.6)                                                                              |                                                                                    | (0.6)                                                                              | 2                                                                                  | (0.6)                                                                              |
| Moderate                          | 67                                                                                 | (40.6)                                                                             | 74                                                                                 | (45.1)                                                                             | 141                                                                                | (42.9)                                                                             |
| Severe                            | 97                                                                                 | (58.8)                                                                             | 89                                                                                 | (54.3)                                                                             | 186                                                                                | (56.5)                                                                             |
| Organ involvement -n (8)[2]       |                                                                                    |                                                                                    |                                                                                    |                                                                                    |                                                                                    |                                                                                    |
| Mouth                             | 97                                                                                 | (58.8)                                                                             | 103                                                                                | (62.8)                                                                             | 200                                                                                | (60.8)                                                                             |
| Gastrointestinal                  | 39                                                                                 | (23.6)                                                                             | 36                                                                                 | (22.0)                                                                             | 75                                                                                 | (22.8)                                                                             |
| Lung                              | 74                                                                                 | (44.8)                                                                             | 67                                                                                 | (40.9)                                                                             | 141                                                                                | (42.9)                                                                             |
| Eyes                              | 97                                                                                 | (58.8)                                                                             | 92                                                                                 | (56.1)                                                                             | 189                                                                                | (57.4)                                                                             |
| Joints And Fascia                 | 48                                                                                 | (29.1)                                                                             | 42                                                                                 | (25.6)                                                                             | 06                                                                                 | (27.4)                                                                             |
| Liver                             | 42                                                                                 | (25.5)                                                                             | 40                                                                                 | (24.4)                                                                             | 82                                                                                 | (24.9)                                                                             |
| Skin                              | 121                                                                                | (73.3)                                                                             | 113                                                                                | (68.9)                                                                             | 234                                                                                | (71.1)                                                                             |
| Genital Tract                     | 14                                                                                 | (8.5)                                                                              | 17                                                                                 | (10.4)                                                                             | 31                                                                                 | (9.4)                                                                              |
| Missing                           | 0                                                                                  |                                                                                    | 1                                                                                  | (0.6)                                                                              | 1                                                                                  | (0.3)                                                                              |

With regard to prior aGVHD diagnosis, this was documented for in total 189 (54.7%) patient with 38% with Grade ≥2. Out of these, 10.6% had a history of SR -aGvHD. The median time form aGvHD diagnosis and resolution was 52 days and the median time form resolution of aGvHD to randomization was 416 d.

<div style=\"page-break-after: always\"></div>

## Medical history and cGvHD disease history

Most reported ongoing medical conditions were consistent with the study indication and the complications of treatment (transplantation and GvHD treatment).

Prior prophylaxis -Among the 329 patients randomised, 33.9% of patients in RUX arm and 31.1% of patients in BAT arm received prior prophylaxis treatment for cGvHD. CNIs were the most frequently (24.0%) reported prophylactic therapy for cGvHD in both arms (23.6% and 24.4%, respectively), including cyclosporine (14.5% and 17.1%) and tacrolimus (9.1% and 7.9%). Use of glucocorticoids in the prophylactic treatment for cGvHD was reported in 10.0% of all patients.

Prior treatment -Almost all patients reported a prior treatment for cGvHD or SR-cGvHD (RUX arm: 98.2% and BAT arm: 95.7%). The most frequently used prior systemic therapy was steroid alone (42.4% in RUX arm and 49.4% in BAT arm) or steroids + CNI (41.2% vs. 42.1%).

Concomitant cGvHD treatments Almost all (≥99%) patients in both treatment arms used concomitant immunosuppressive medications on treatment (starting on or after the start of study treatment and no more than 30 days after EOT). Corticosteroids were used by 59.4% of patients in the RUX arm and 55.1% in the BAT arm. Calcineurin inhibitors were taken in 27.3% vs. 19%, respectively.

## Transfusions

A total of 26.7% patients in the ruxolitinib arm and 21.5% patients in the BAT arm underwent transfusion starting on or after the start of study treatment (packed red blood cells in 23.6% and 18.4% in each respective arm) and platelets (13.9% in each arm).

## Numbers analysed

## Analysis sets (all randomized patients)

Efficacy analyses used the Full Analysis Set (FAS), following the Intent-to-Treat (ITT) principle, comprising all patients to whom study treatment has been assigned by randomisation. All 329 randomised patients were included in the Full Analysis Set (FAS) for the primary analysis with data cut-off date 08-May-2020: n=165 in the RUX arm and n=164 in the BAT arm.

Supportive analyses were performed using the Per Protocol Set comprised of patients compliant with the requirements of the study (n=96 [58.2%] in the RUX arm, and n=92 [56.1%] in the BAT arm).

Results of the interim analysis (IA) for the primary and key secondary efficacy endpoints were based on the first 196 patients who completed Cycle 7 Day 1 visit (by data cut-off on 09-Jul-2019), after which the DMC recommended to proceed the study with primary analysis for all 329 randomized patients who completed Cycle 7 Day 1 visit or discontinued earlier (data cut-off on 08-May-2020).

## Outcomes and estimation

Statistical tests of the primary and the two key secondary endpoints at the interim analysis and the primary analysis were performed according to an overall hierarchical testing procedure (please refer to Statistical methods).

<div style=\"page-break-after: always\"></div>

## Primary efficacy results

Primary endpoint, overall response rate (ORR) at Cycle 7 Day 1, as assessed by local investigators' review of cGvHD response according to the NIH response criteria for IA (interim analysis) and primary analysis.

Overall response rate at Cycle 7 Day 1 (Full analysis set - Interim Analysis)

|                                    | RUX N = 97   | RUX N = 97   | BAT N=99   | BAT N=99     | Odds ratio   | 10%56        | P-value   |
|------------------------------------|--------------|--------------|------------|--------------|--------------|--------------|-----------|
|                                    | n (%)        | 95% CI       | n (%)      | 15 %96       |              |              |           |
| Responders                         |              |              |            |              |              |              |           |
| CompleteResponse (CR)              | 8 (8.2)      |              | 3 (3.0)    |              |              |              |           |
| Partial Response (PR)              | 41 (42.3)    |              | 23 (23.2)  |              |              |              |           |
| Non-responders                     |              |              |            |              |              |              |           |
| Unchanged Response                 | 5(5.2)       |              | 8 (8.1)    |              |              |              |           |
| Mixed response                     | 7 (7.2)      |              | 11 (11.1)  |              |              |              |           |
| Progression                        | 2 (2.1)      |              | 15 (15.2)  |              |              |              |           |
| Other *                            | 3 (3.1)      |              | 4 (4.0)    |              |              |              |           |
| Unknown                            | 31 (32.0)    |              | 35 (35.4)  |              |              |              |           |
| Death                              | 9 (9.3)      |              | 7 (7.1)    |              |              |              |           |
| Early discontinuatlon              | 18 (18.6)    |              | 21 (21.2)  |              |              |              |           |
| Missing visits                     | 4 (4.1)      |              | 7 (7.1)    |              |              |              |           |
| Overall Response Rate (ORR: CR+PR) | 49 (50.5)    | (40.2. 60.8) | 26 (26.3)  | (17.9. 36.11 | 2.98         | (1.62. 5.48) | 0.0003    |

n: Number of subjects who are at the corresponding category.

N: The total number of subjecls in the treatment group. It is the denominator for percentage (%) calculation.

The 95% Cl for the response rate was calculated using Clopper Pearson exact method.

* Other: subjects with additional systemic therapies along with CR/PR per investigator assessment

One-sided p-value, odds ratio and 95% Cl are calculated using stratified CMH tesl.

The results were confirmed at the primary analysis (data cut-off date 08-May-2020, N=329).

Overall response rate at Cycle 7 Day 1 (Full analysis set- Primary analysis)

|                                  | RUX N= 165   | RUX N= 165   | BAT N = 164   | BAT N = 164   | sppo ratio   | 95% CI       | P-value   |
|----------------------------------|--------------|--------------|---------------|---------------|--------------|--------------|-----------|
|                                  | n (%)        | 95% CI       | n (%)         | 95% CI        |              |              |           |
| Overall response                 |              |              |               |               |              |              |           |
| Responders                       |              |              |               |               |              |              |           |
| Complete Response (CR)           | 11 (6.7)     |              | 5 (3.0)       |               |              |              |           |
| Partial Response (PR)            | 71 (43.0)    |              | 37 (22.6)     |               |              |              |           |
| Non-responders                   |              |              |               |               |              |              |           |
| Unchanged Response               | 9 (5.5)      |              | 15 (9.1)      |               |              |              |           |
| Mixed response                   | 10 (6.1)     |              | 17 (10.4)     |               |              |              |           |
| Progression                      | 4 (2.4)      |              | 21 (12.8)     |               |              |              |           |
| Other *                          | 5 (3.0)      |              | 9 (5.5)       |               |              |              |           |
| Unknown                          | 55 (33.3)    |              | 60 (36.6)     |               |              |              |           |
| Death                            | 16 (9.7)     |              | 11 (6.7)      |               |              |              |           |
| Early discontinuation            | 33 (20.0)    |              | 33 (20.1)     |               |              |              |           |
| Missing visits                   | 6 (3.6)      |              | 16 (9.8)      |               |              |              |           |
| OverallResponseRate (ORR: CR+PR) | 82 (49.7)    | (41.8, 57.6) | 42 (25.6)     | (19.1, 33.0)  | 2.99         | (1.86, 4.80) | <0.0001   |

N: The total number of subjects in the treatment group. It is the denominator for percentage (%) calculation.

The 95% Cl for the response rate was calculated using Clopper Pearson exact method.

n: Number of patients who are at the corresponding category.

One-sided p-value, odds ratio and 95% Cl are calculated using stratified CMH test.

It is noticed that ORR rates are considerably lower than what was anticipated in the sample size calculation.

The P-value of the stratified CMH test (P&lt;0.0001) is given for descriptive purpose only, as significance was shown at the interim analysis.

The proportion of complete responders was low in both arms (6.7% vs. 3%).

<div style=\"page-break-after: always\"></div>

Sensitivity analysis using PPS (N=188), ORR at Cycle 7 Day 1 evaluated with the same analysis conventions as for the primary efficacy analysis, was consistent with the primary analysis using FAS.

## Overall response at Cycle 7 Day 1 - (Per Protocol Set, primary analysis)

|                                 | RUX N = 96   | RUX N = 96   | BAT N = 92   | BAT N = 92   |            |              |         |
|---------------------------------|--------------|--------------|--------------|--------------|------------|--------------|---------|
|                                 | n (%)        | 15%96        | n (%)        | 95% CI       | sppo ratio | 95% CI       | p-value |
| Overallresponse                 |              |              |              |              |            |              |         |
| Responders                      |              |              |              |              |            |              |         |
| CompleteResponse(CR)            | 6 (6.3)      |              | 2 (2.2)      |              |            |              |         |
| Partial Response (PR)           | 47 (49.0)    |              | 20 (21.7)    |              |            |              |         |
| Non-responders                  |              |              |              |              |            |              |         |
| Unchanged Response              | 5 (5.2)      |              | 12 (13.0)    |              |            |              |         |
| Mixed response                  | 5 (5.2)      |              | 10 (10.9)    |              |            |              |         |
| Progression                     | 2 (2.1)      |              | 13 (14.1)    |              |            |              |         |
| Other*                          | 3 (3.1)      |              | 5 (5.4)      |              |            |              |         |
| Unknown                         | 28 (29.2)    |              | 30 (32.6)    |              |            |              |         |
| Death                           | 9 (9.4)      |              | 8 (8.7)      |              |            |              |         |
| Early discontinuation           | 15 (15.6)    |              | 15 (16.3)    |              |            |              |         |
| Missing visits                  | 4 (4.2)      |              | 7 (7.6)      |              |            |              |         |
| OverallResponseRate(ORR: CR+PR) | 53 (55.2)    | (44.7. 65.4) | 22 (23.9)    | (15.6. 33.9) | 4.08       | (2.16, 7.69) | ≤0.0001 |

N: The total number of subjects in the treatment group. It is the denominator for percentage (%) calculation.

The 95% Cl for the response rate was calculated using Clopper Pearson exact method.

n: Number of patients who are at the corresponding category.

One-sided p-value, odds ralio and 95% Cl are calculated using stratified CMH test.

* Other: patient with additional systemic therapies along with CR/PR per investigator assessment

According to the SAP, a patient was not considered a responder at Cycle 7 Day 1 if any of the following events occur in case of missing cGvHD assessment at Cycle 7 Day 1, or in case there was use of Additional systemic therapy for cGvHD. It has been clarified that missing data in the primary analysis are presented in category 'unknown', while the category 'missing visits' actually refers to invalid cGvHD assessments. There were 19 (11.5%) and 49 (29.9%) patients in the ruxolitinib and BAT arm, respectively, who started new or additional systemic cGvHD treatment up to the pre-specified time window used to define a valid Cycle 7 Day 1. Sensitivity analysis was requested to use the actual response instead of imputed non-response for patients who received a new systemic treatment for cGvHD prior to Cycle 7 Day 1 visit. The analysis was not provided as done in REACH-2 study; instead, only frequency of the overall response was presented per treatment group: 87 (52.7%) and 51 (31.1%) patients with overall response in the ruxolitinib and BAT arm, respectively. With nonresponder imputation in the primary analysis, the corresponding numbers were 82 (49.7%) and 42 (25.6%) patients with overall response in the ruxolitinib and BAT arms, respectively, thus, potentially overestimating efficacy of ruxolitinib.

## Initial BAT treatment, assigned before randomization

<!-- formula-not-decoded -->

|                                                            | BAT N=158   |
|------------------------------------------------------------|-------------|
| Initial BAT treatment -n(%)                                |             |
| Extracorporeal photopheresis (ECP)                         | 55 (34.8)   |
| Mycophenolate mofetil (MMF)                                | 35 (22.2)   |
| Ibrutinib                                                  | 27 (17.1)   |
| Low-dose Methotrexate (MTx)                                | 10 (6.3)    |
| Imatinib                                                   | 8 (5.1)     |
| Sirolimus                                                  | 7 (4.4)     |
| Rituximab                                                  | 6 (3.8)     |
| Everolimus                                                 | 5 (3.2)     |
| Infliximab                                                 | 5 (3.2)     |
| Number of BAT treatments started before Cycle 7 Day 1-n(%) |             |
| 1                                                          | 127 (80.4)  |
| 2                                                          | 28 (17.7)   |
| >2                                                         | 3 (1.9)     |

<div style=\"page-break-after: always\"></div>

## ORR at Cycle 7 Day 1 by initial BAT 2

<!-- image -->

|              | Insufficient BAT compliance monitoring (worst case) per inspection report   | N BAT (96)*   | ORR BAT at Cycle 7 Day 1   | ORR BAT at Cycle 7 Day 1   | N Rux   | ORR RUX at Cycle 7 Day 1   | ORR RUX at Cycle 7 Day 1   |
|--------------|-----------------------------------------------------------------------------|---------------|----------------------------|----------------------------|---------|----------------------------|----------------------------|
|              | Insufficient BAT compliance monitoring (worst case) per inspection report   | N BAT (96)*   | ORR (%)**                  | 95% CI                     | N Rux   | ORR. (%)                   | 10%56                      |
| Total        | 66                                                                          | 164           | 42 (25.6)                  | 19.1-33.0                  | 165     | 82 (49.7)                  | 41.8-57.6                  |
| Everolimus   | 4                                                                           | 5 (3.0)       | 1 (20.0)                   | 0.5-71.6                   |         |                            |                            |
| ECP          | 2                                                                           | 55 (33.5)     | 16 (29.1)                  | 17.6-42.9                  |         |                            |                            |
| Ibrutinib    | 13                                                                          | 27 (16.5)     | 6(22.2)                    | 8.6-42.3                   |         |                            |                            |
| Imatinib     | 5                                                                           | 8 (4.9)       | 2 (25.0)                   | 3.2-65.1                   |         |                            |                            |
| Infliximab   | 0                                                                           | 5 (3.0)       | 1 (20.0)                   | 0.5-71.6                   |         |                            |                            |
| Low dose MTX | 9                                                                           | 10 (6.1)      | 3 (30.0)                   | 6.7-65.2                   |         |                            |                            |
| MMF          | 26                                                                          | 35 (21.3)     | 10 (28.6)                  | 14.646.3                   |         |                            |                            |
| Riluximab    | 0                                                                           | 6(3.7)        | 1 (16.7)                   | 0.464.1                    |         |                            |                            |
| Sirolimus    | 7                                                                           | 7 (4.3)       | 2 (28.6)                   | 3.7-71.0                   |         |                            |                            |

ATG anti-thymocyte globulin, ECP: extracorporeal photopheresis, MMF mycophenolate mofetil MSC mesenchymal stromal cells, MTX methotrexate, RUX: ruxolitinib,* uses all patients randomised to BAT as reference (denominator).

2 Supplement to: Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus host disease. N Engl J Med 2021;385:228-38. DOI: 10.1056/NEJMoa2033122.

According to the SAP, a patient was not considered a responder at Cycle 7 Day 1 if any of the following events occurs in case of missing cGvHD assessment at Cycle 7 Day 1, or in case there was use of Additional systemic therapy for cGvHD. It has been clarified that missing data in the primary analysis are presented in category 'unknown', while the category 'missing visits' actually refers to invalid cGvHD assessments. There were 19 (11.5%) and 49 (29.9%) patients in the ruxolitinib and BAT arm, respectively, who started new or additional systemic cGvHD treatment up to the pre-specified time window used to define a valid Cycle 7 Day 1. Sensitivity analysis was requested to use the actual response instead of imputed non-response for patients who received a new systemic treatment for cGvHD prior to Cycle 7 Day 1 visit. The analysis was not provided as done in REACH-2 study; instead, only frequency of the overall response was presented per treatment group: 87 (52.7%) and 51 (31.1%) patients with overall response in the ruxolitinib and BAT arm, respectively. With nonresponder imputation in the primary analysis, the corresponding numbers were 82 (49.7%) and 42 (25.6%) patients with overall response in the ruxolitinib and BAT arms, respectively, thus, potentially overestimating efficacy of ruxolitinib.

For the subgroup analyses, the odds ratio remained favorable for ruxolitinib, demonstrated by consistent odds ratio &gt;1 in most subgroups. Subgroups with odds ratio &lt;1 (Asian region, Steroid+ CNI+ other systemic therapy and steroid+ other systemic therapy), where all hampered by wide CI and small size. Point estimate of the treatment effect and 95% confidence intervals was provided.

In subgroup age 12- &lt;18 years, there were in total 12 patients randomized, 4 patients in the RUX arm and 8 in the BAT treatment arm. Seventy five percent (3/4) and 25% (2/8) in the RUX arm and the BAT arm, respectively, showed a PR response. The odds ratio in subgroup adolescent patients were inconclusive due to the low number of evaluable patients.

<div style=\"page-break-after: always\"></div>

## Forest plot of odds ratio with 95% confidence interval for ORR at Cycle 7 Day 1 from subgroup analysis (Full analysis set - Primary analysis)

<!-- image -->

X-axis values are represented in natural log scale. Dotted lines shows no effect point. The area of the box indicates the weight of the sub group, measured by the size of subpopulation. Criteria for SR-cGvHD:

B. Disease persistence without improvement despite continued treatment with prednisone at &gt;0.5 mg/kg/day or 1mg/kg/everyotherdayforatleast4weeks;

A. Lack of response or disease progression after administration of minimum prednisone 1 mg/kg/day for at least 1week;

C.Increase prednisone dose to&gt;0.25 mg/kg/day after two unsuccessful attempts to taper the dose

Baseline organ involvement are overall balanced between the two treatment arms, with the exception of lung involvement (42.4% in the RUX arm and 29.9% in the BAT arm). Response assessments, i.e., responders at Cycle 7 Day 1, generally shows a higher response rate for all assessed organs in the RUX arm compared to the BAT arm.

Table 9. Individual Organ Response at Cycle 7 Day 1

<div style=\"page-break-after: always\"></div>

|                   | Ruxolitinib n=165     | Ruxolitinib n=165   | BAT n=164             | BAT n=164      |
|-------------------|-----------------------|---------------------|-----------------------|----------------|
| Organ             | Baseline involvementa | Organresponseb      | Baseline involvementa | Organresponseb |
|                   | n(%)                  | m/n(%)              | n(%)                  | m/n(%)         |
| Skin              | 119 (72.1)            | 49/119(41.2)        | 110(67.1)             | 17/110(15.5)   |
| Eye               | 96(58.2)              | 25/96(26.0)         | 93(56.7)              | 10/93(10.8)    |
| Mouth             | 96(58.2)              | 48/96(50.0)         | 99(60.4)              | 25/99(25.3)    |
| Esophagus         | 18(10.9)              | 9/18(50.0)          | 17(10.4)              | 5/17(29.4)     |
| UpperGl tract     | 20(12.1)              | 8/20 (40.0)         | 21(12.8)              | 8/21(38.1)     |
| LowerGltract      | 15(9.1)               | 8/15(53.3)          | 10(6.1)               | 3/10(30.0)     |
| Liver             | 86(52.1)              | 21/86 (24.4)        | 83(50.6)              | 18/83(21.7)    |
| Lung              | 70(42.4)              | 6/70(8.6)           | 49(29.9)              | 3/49 (6.1)     |
| Joints and fascia | 45(27.3)              | 17/45(37.8)         | 44(26.8)              | 7/44(15.9)     |
| Overall response  |                       | 82(49.7)            |                       | 42(25.6)       |

<!-- image -->

## Cross-over population

At the primary analysis data cut-off (last patient enrolled could have reached the Cycle 7 Day 1 visit), 61 patients had crossed over from the BAT arm and started treatment with ruxolitinib, and treatment with ruxolitinib was still ongoing for 46 patients [Study D2301 PA Table 10-2]. Since not all of the 46 ongoing patients have reached the Cross-over Cycle 7 day 1 visit at the data cut-off, the analysis was performed again with longer follow-up based on the data cut-off 25-Jun-2021 used for the later OS analysis performed. In total 69 patients crossed-over from BAT to ruxolitinib; 33 of these patients had a response at cross-over Cycle 7 Day 1 corresponding to ORR of 47.8% (95% CI: 35.6%, 60.2%).

Overall, these results indicate a clinical benefit of ruxolitinib treatment also for SRcGvHD patients who failed treatment with BAT.

## Secondary efficacy results

## Failure free survival

The first key secondary endpoint, FFS, assessed the time from date of randomization to the earliest of i) relapse or recurrence of underlying disease or death due to underlying disease, ii.) non-relapse mortality, or iii.) addition or initiation of another systemic therapy for cGvHD

The study met the key secondary efficacy endpoint FFS at the interim analysis, with a HR of 0.315 (95% CI: 0.205, 0.486; one-sided p-value = &lt;0.0001).

P-valuederived from1-sidedstatifiedlog-ranktest.requiredsignificancelevelwasalpha=0.01176.Hazardratio obtained from stratified CoxmodelusingcGvHDseverity atrandomization asstrata. NE:notestimated

<div style=\"page-break-after: always\"></div>

Kaplan-Meier estimate of failure free survival (Full analysis set -Primary analysis)

|                             | RUX (N=165)          | BAT (N=164)          |
|-----------------------------|----------------------|----------------------|
| Number of events            | 60 (36.4%)           | 109 (66.5%)          |
| Number censored             | 105 (63.6%)          | 55 (33.5%)           |
| Log-rank test P-value*      | <0.0001              |                      |
| Hazard ratio (95% Cl)       | 0.370(0.268,0.510)   |                      |
| Median FFS (months)(95% Cl) | NE (18.6, NE)        | 5.7 (5.6, 6.5)       |
| KM estimates (95% Cl) at    |                      |                      |
| 6 months                    | 74.89 (67.48,80.85)  | 44.46 (36.46, 52.14) |
| 12 months                   | 64.00 (55.78,71.09)  | 29.62 (22.34, 37.23) |
| 18months                    | 60.73 (52.06, 68.31) | 27.04 (19.71,34.88)  |
| 24 months                   | 58.94(49.80,66.98)   | 20.28 (9.33,34.19)   |

*:P-value derived from 1-sided stratified log-rank test, as statistical significance has met at interim analysis.

Hazard ratio obtained from stratified Cox model using cGvHD severity atrandomization as strata

The superiority of FFS in the RUX arm compared to BAT was maintained at the primary analysis (n = 329), with HR=0.370 (95% CI: 0.268, 0.510; descriptive one-sided p&lt;0.0001. The 6-month FFS probability was 74.89% (95% CI: 67.48, 80.85) in the RUX arm and was 44.46% (95% CI: 36.46, 52.14) in the BAT arm. The median FFS time was not reached for RUX and was 5.7 months for BAT.

Kaplan-Meier estimate of failure free survival (Full analysis set -Primary analysis)

<!-- image -->

P value is obtalned from the log-rank test.

A pronounced drop in the BAT curve is seen around month 6, supposedly triggered by cross over from BAT to RUX treatment. Patients in the BAT arm could cross over not earlier than Cycle 7 Day 1 visit and only if they were non-responders.

The FFS endpoint is a composite of (i) relapse or recurrence of underlying disease or death due of underlying disease, (ii) non-relapse mortality, or (iii) addition or initiation of another systemic therapy for cGvHD. As anticipated, this endpoint is driven by item (iii), while there is no indication of any impact of treatment on items (i) and (ii). The data are generated in an open-label study, where the impact of the cross-over option results in a precipitate fall in the KM curve for the control arm. However, this key secondary endpoint, shows statistical significance (HR of 0.315 (95% CI: 0.205, 0.486; one-sided p-value = &lt;0.0001) in favor of ruxolitinib. The other items; NMR and MR, both each other's competing risk, had the similar cumulative incidence, hence gain in the one was not at the cost of the other.

<div style=\"page-break-after: always\"></div>

## Figure 14.2-1.2.1Page(1of 2) Failurefreesurvivalbytreatment Full analysis set

## Treatment=Ruxolitinib10mgBiD

FFSprobabilitieswereobtainedby1oo%-sumoftheprobabilitiesforTreatmentchange,RelapseandNRM.

<!-- image -->

Figure14.2-1.2.1Page (2of 2)

Fullanalysisset

Failurefreesurvival bytreatment

## Treatment=Best availabletherapy

<!-- image -->

## Total symptom score, TSS; Patient reported outcomes based on the total symptom score

The second key secondary endpoint TSS, (rate of responders as per improvement ≥ 7 points of total TSS from baseline of the modified Lee Symptom Scale (mLSS), did not meet statistical significance (stratified CMH test p = 0.0151) during the interim analysis (based on N = 196). The results from the primary analysis are shown below.

<div style=\"page-break-after: always\"></div>

## Responders at Cycle 7 Day 1 based on the TSS by the mLSS (Full analysis set- Primary analysis)

|                                             | RUX N=165   | RUX N=165    | BAT N = 164   | BAT N = 164   |                     |              |          |
|---------------------------------------------|-------------|--------------|---------------|---------------|---------------------|--------------|----------|
|                                             | n (%)       | 95%CI        | n (%)         | 95% CI        | Oddsratio (RUX/BAT) | 95%CI        | p- value |
| SubjectswithvalidTSSat baseline             | 149 (90.3)  |              | 141 (86.9)    |               |                     |              |          |
| SubjectswithvalidTSSat Cycle7Day1           |             |              |               |               |                     |              |          |
| AlI                                         | 92 (55.8)   |              | 87 (53.0)     |               |                     |              |          |
| Withoutpriorchangeof systemiccGvHDtreatment | 89 (53.9)   |              | 64 (39.0)     |               |                     |              |          |
| Responders(TSS reduction>= 7 points)        | 40 (24.2)   | (17.9, 31.5) | 18 (11.0)     | (6.6, 16.8)   | 2.62                | (1.42, 4.82) | 0.0011   |

SubjectswithchangeoforadditionofnewsystemiccGvHDtreatmentarecountedasnon-responders irrespectiveoftheTsSvalue.

Significant improvement in TSS, (cycle 7 day 1) was shown for the RUX arm compared to the BAT arm at the primary analysis. The odds ratio (ruxolitinib/BAT) was 2.62 (95% CI: 1.42, 4.82, stratified CMH test, p = 0.0011).

Given the significant impact of symptoms on quality of life (QoL) in patients with cGvHD, the change in a modified Lee symptom score was assessed as one of the key secondary objectives. However, given the open label nature of the study, there is a risk of bias that cannot be ascertained as to its magnitude.

Therefore, TSS data are not included in the product information.

- Other secondary endpoints

## Best overall response

BOR is defined as proportion of patients who achieved overall response (CR or PR) at any time point up to and including Cycle 7 Day 1 and before the start of additional systemic therapy for cGvHD. There was a statistically significant difference between the ruxolitinib and BAT (stratified CMH test p=0.0011, one-sided) with the odds ratio 2.17 (95% CI: 1.34, 3.52) for response in ruxolitinib arm compared to BAT arm. The rate of Non-responders in the RUX arm was 18.2% vs 28% in the BAT arm.

Best overall response up to Cycle 7 Day 1 (Full analysis set)

<div style=\"page-break-after: always\"></div>

|                                    | RUX N = 165   | RUX N = 165   | BAT N = 164   | BAT N = 164   |            |              |         |
|------------------------------------|---------------|---------------|---------------|---------------|------------|--------------|---------|
|                                    | n (%)         | 95% Cl        | n (%)         | 95% CI        | Odds ratlo | 95% CI       | p-value |
| Overallresponse                    |               |               |               |               |            |              |         |
| Responders                         |               |               |               |               |            |              |         |
| Complete Response (CR)             | 20 (12.1)     |               | 11 (6.7)      |               |            |              |         |
| Partlal Response (PR)              | 106 (64.2)    |               | 88 (53.7)     |               |            |              |         |
| Non-responders                     |               |               |               |               |            |              |         |
| Unchanged Response                 | 27 (16.4)     |               | 33 (20.1)     |               |            |              |         |
| Mixed response                     | 3 (1.8)       |               | 8 (4.9)       |               |            |              |         |
| Progresslon                        | 0             |               | 5 (3.0)       |               |            |              |         |
| Unknown                            | 9 (5.5)       |               | 19 (11.6)     |               |            |              |         |
| Death                              | 1 (0.6)       |               | 1 (0.6)       |               |            |              |         |
| Early discontinuation              | 0             |               | 6 (3.7)       |               |            |              |         |
| Missing visits                     | 8 (4.8)       |               | 12 (7.3)      |               |            |              |         |
| Overall Response Rate (ORR: CR+PR) | 126 (76.4)    | (69.1. 82.6)  | 99 (60.4)     | (52.4, 67.9)  | 2.17       | (1.34, 3.52) | 0.0011  |

n: Number of patients who are at the corresponding category.

N: The total number of subjects in the treatment group. It is the denominalor for percentage (%) calculation.

The 95% Cl for the response rate was calculated using Clopper Pearson exact method.

One-sided p-value,odds ratio and 95%Clare calculated using stratified CMH test.

Unknown:no valid post-baseline response assessment

BOR up to Cycle 7 Day 1 (RUX arm 76.4% vs BAT arm 60.4%) compared to the primary endpoint ORR at Cycle 7 Day 1 (RUX arm 49.7% vs BAT arm 25.6%) show a greater rate of loss of responses in the BAT arm than the RUX arm.

While there is a high BOR rate (ORR [CR + PR] at any time point up to and including Cycle 7 Day 1) observed in both treatment arms, it is also noticed a relatively high rate of 'lost responses' during the first 6 cycles (ruxolitinib and BAT treatment) as measured by the primary endpoint (i.e. ORR at Cycle 7, Day 1). However, early discontinuation, deaths, changes in systemic cGvHD treatment before Cycle 7 Day 1 or missing visits were the main reasons for the differences in BOR and ORR therefore, not necessarily meaning loss of response in all cases or treatment failure. For the RUX arm, 34.9% with BOR (CR or PR) had `no response´ at Cycle 7 D1 and the corresponding number for the BAT arm was 57.5%.

In addition, the probability of maintaining a response 12 months from the first documented response was 68.5% in the RUX arm and 40.3% in the BAT arm.

## Best overall response during Cross-over treatment with ruxolitinib

In the Cross-over analysis set, 44 out of 61 patients had a duration of exposure to ruxolitinib longer than 24 weeks, i.e., completed 6 cycles of treatment. The ORR for the cross-over treatment period was 78.7% compared to 74.4% ORR for the RUX arm in the randomized treatment period.

## Overall survival

At the time of primary analysis there were 31 deaths in the RUX arm and 27 deaths in the BAT arm (based on Cycle 7 Day 1 data). No statistical difference was observed between the arms (HR = 1.086 (95% CI: 0.648, 1.820), (log-rank p-value: 0.3764). The median OS estimated by Kaplan-Meier (K-M) was not reached at time of the analysis in either treatment arm.

## Kaplan-Meier curves of overall survival (Full analysis set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Given the study design, OS is primarily viewed as a safety endpoint. OS data are rather immature at the primary endpoint. An updated analysis of OS data has also been provided.

## Overall survival results in REACH-3

| Data cut-off   | Events(Deaths) n (%)   | Events(Deaths) n (%)   | Hazard ratio（Ruxvs BAT)   | Hazard ratio（Ruxvs BAT)   | Logrank test   |
|----------------|------------------------|------------------------|---------------------------|---------------------------|----------------|
|                | Rux N=165              | BAT N=164              | HR                        | 95%CI                     | P-value\"       |
| 08-May-2020    | 31 (18.8)              | 27 (16.5)              | 1.086                     | (0.648,1.820)             | 0.3764         |
| 25-Jun-2021    | 37 (22.4)              | 36 (22.0)              | 0.956                     | (0.604,1.512)             | 0.4230         |

* Nominal p-value derived from one-sided stratified logrank test with cGvHD severity as strata

## Kaplan-Meier estimate of overall survival

<!-- image -->

The results remain immature, as is expected in the setting of cGvHD. Updated HR for OS shows a HR just below 1 (0.956 vs. 1.086 with previous analysis) with a CI still crossing 1. Updated results for primary cause of death did not show any new safety signals compared to the primary analysis results.

<div style=\"page-break-after: always\"></div>

It is agreed that a detrimental effect on OS of ruxolitinib cannot be concluded based on available immature data. Mature OS data should be submitted post-marketing.

The allowance of cross-over creates a bias towards unity with regards to the impact of treatment on OS. In REACH-3 study, 61 (37.2%) of 164 subjects switched from BAT to ruxolitinib after completion of Cycle 6. The rank-preserving structural failure time (RPSFT) model was applied post-hoc to investigate what would have been the OS analysis had patients not crossed over to ruxolitinib. After adjustment for cross-over with the RPSFT model, the HR estimate was 0.967 (95% CI: 0.692, 1.352) compared to 0.956 (95% CI: 0.604, 1.512) obtained in the pre-planned ITT analysis. Thus, the RPSFT results do not indicate any impact of cross-over on overall survival.

## Duration of Response

DOR was only measured in patients who achieved a CR or PR at or before Cycle 7 Day 1 (BOR). Median DOR was not reached in the RUX arm, while median DOR in the BAT arm was 6.2 months (95% CI: 4.7 to 13.3). Furthermore, the 6-, 12-, 18- and 24-months probability of maintaining a response, was in favor of the RUX arm.

Kaplan-Meier curve of duration of response (Full analysis set)

<!-- image -->

Include patients with BOR=CR and PR only

<!-- image -->

| Table 14.2-1.8.1 (Page 1 of 1) Duration of response Full analysis set   |
|-------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

## Non-relapse mortality

NRM curves for the RUX and BAT arms were overlapping (cumulative incidence) indicating similar event rates over time. The competing risk (hematological disease relapse/progression) was low in both treatment arms (9/165 and 8/164).

The number of patients censored was high in both treatment arms (129/165 and 134/164), indicating a high proportion of patients who were alive and had no relapse/progression.

## Cumulative incidence of Non-Relapse Mortality (NRM) by treatment (Full analysis set)

<!-- image -->

## Incidence of Malignancy Relapse/ Recurrence

There were 156 patients in the ruxolitinib arm and 160 patients in the BAT arm who had underlying malignant disease at baseline. With regard to these patients, events of malignancy relapse/progression were low in both arms (9/156 in the ruxolitinib arm; 8/160 in the BAT arm).

Estimated cumulative event rates were 2.59% (95%CI: 0.85, 6.08) and 2.65% (95%CI: 0.87, 6.21) in respective treatment arms at 6 months and 4.94% (95%CI: 2.16, 9.45) and 5.80% (95%CI: 2.68, 10.65) at 12 months. Thus, indicating that the choice of cGvHD treatment has little or no significance for malignancy relapse, however data are still immature.

## Cumulative incidence of Malignancy relapse/recurrence by treatment (Full analysis set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Reduction of daily corticosteroid dose and successful tapering of all corticosteroids treatment

Tapering of corticosteroids was not recommended before 2 weeks after achieving a CR and tapering of CNI and/or ruxolitinib was not to be initiated until the patient was off corticosteroids and completed the assessments for Cycle 7 Day 1.

A comparable proportion of patients in both treatment arms had prior systemic therapy with steroids + CNI (RUX arm: 41.2%, BAT arm: 42.1%). As a consequence of successful tapering of steroids, subsequent tapering of CNI was to be initiated.

During the time interval of Day 155 to Day 168 (end of Cycle 6), patients with ≥ 50% reduction of corticosteroid dose (body weight-normalized) from baseline occurred in 71.2% (84 out of 118) of patients in the ruxolitinib arm and in 69.6% (80 out of 115) of patients in the BAT arm. The mean dose intensity of steroid was lower in ruxolitinib than BAT, starting from Cycle 2 and the trend of slightly larger reduction of steroid dose in the ruxolitinib arm remained during the study.

Patients with no steroids during the interval occurred in 31.4% (37) of patients in the RUX arm and 27.8% (32) of patients in the BAT arm.

## Average bi-weekly weight-standardized steroid up to Cycle 7 Day 1 (Safety set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

Data concerning duration of CNI treatment and change of CNI exposure by time interval up to Cycle 7 Day 1, by treatment arm and by type of CNI treatment (Cyclosporin or Tacrolimus) has been provided, showing similar exposure, between the arms, over time.

## Patient-reported outcomes (FACT-BMT and EQ-5D-5L) and Patient reported outcomes PGIS and PGIC

Although not defined as secondary endpoint, results of EQ-5D-5L and FACT-BMT questionnaires were presented. Completion rates as a percentage of available patients were similar between the two arms throughout the study.

Baseline scores were similar between both treatment arms. Higher scores of FACT-BMT assessment suggested a better the quality of life. The mean (SD) change from baseline at Cycle 7 Day 1 of the FACT-BMT score was 3.76 (15.028) in the RUX arm (n = 91) and 0.66 (16.816) in the BAT arm (n = 86). Change of EQ-5D-5L score from baseline was similar between the two arms, 0.07 (0.233) in the Rux arm (n = 90) vs. 0.00 (0.226) in the BAT arm (n = 84).

## Exploratory efficacy endpoints: Patient reported outcomes - PGIS and PGIC

At Cycle 7 Day 1 visit, Patient global impression of severity (PGIS) values from patients that reported moderate, severe and very severe symptoms reduced as compared to Cycle 1 Day 1 in both arms. The PGIS values were lower in the RUX arm as compared to the BAT arm. The values for no and mild symptoms increased from Cycle 1 Day 1 visit.

Patient global impression of change (PGIC) values from patients, that reported 'No change' at Cycle 2 Day 1, reduced at Cycle 7 Day 1 in the RUX arm from 20.9% to 7.1% and in the BAT arm from 28.6% to 22.4%. Numerically higher values of 'moderately better' and 'very much better' were reported in the RUX arm as compared to that in the BAT arm.

FACT-BMT up to Cycle 7, Day 1, measuring the mean change from baseline, a higher score suggests a better QoL. The mean change from baseline in the RUX arm is scores higher than that of the BAT arm.

<div style=\"page-break-after: always\"></div>

Data from the mLSS scoring (please refer to key secondary endpoint) is by comparison of greater importance since this is a validated tool for cGvHD assessment.

The EQ-5D-5L mean score change from baseline up to Cycle 7 Day 1 was similar between both treatment arms.

There was a decrease in number of patients available for evaluation with time in both arms and more reduced in the BAT arm, due to a higher number of FFS event in the BAT arm and to cross over, which was allowed after Cycle 7 Day 1.

The The EQ-5D-5L and FACT-BMT were secondary endpoints and PGIC and PGIS were exploratory endpoints. The study was an open label study and none of these endpoints were controlled for multiplicity.

In summary, the PRO outcomes for the RUX arm compared to the BAT arm are difficult to evaluate.

## Graft failure (Chimerism)

Only one patient, in the RUX arm, experienced graft failure and subsequently discontinued from study treatment, due to graft loss.

## Summary of main studies

The following table summarise the efficacy results from the two main studies supporting the present application in aGvHD and cGvHD. These summaries should be read in conjunction with the discussion on clinical efficacy as well as the benefit risk assessment (see later sections).

## Summary of Efficacy for trials CINC424C2301 (REACH2) and CINC424D2301 (REACH3)

| Study identifier          | allogeneic stem cell transplantation (INC424C2301) REACH2                                                                                                                                                                                                          | allogeneic stem cell transplantation (INC424C2301) REACH2                                                                                                                                                                                                          | allogeneic stem cell transplantation (INC424C2301) REACH2                                                                                                                                                                                                          |
|---------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Design                    | Open label, randomized (1:1), phase III                                                                                                                                                                                                                            | Open label, randomized (1:1), phase III                                                                                                                                                                                                                            | Open label, randomized (1:1), phase III                                                                                                                                                                                                                            |
| Design                    | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                     | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                                     | 24 weeks 0-28 days treatment taper could be delayed up to 2 years                                                                                                                                                                                                  |
| Hypothesis                | Superiority of Ruxolitinib over Best available therapy (BAT: anti-thymocyte globulin, extracorporeal photopheresis, mesenchymal stromal cells, low-dose methotrexate, mycophenolate mofetil, mTOR inhibitors [everolimus or sirolimus], etanercept or infliximab). | Superiority of Ruxolitinib over Best available therapy (BAT: anti-thymocyte globulin, extracorporeal photopheresis, mesenchymal stromal cells, low-dose methotrexate, mycophenolate mofetil, mTOR inhibitors [everolimus or sirolimus], etanercept or infliximab). | Superiority of Ruxolitinib over Best available therapy (BAT: anti-thymocyte globulin, extracorporeal photopheresis, mesenchymal stromal cells, low-dose methotrexate, mycophenolate mofetil, mTOR inhibitors [everolimus or sirolimus], etanercept or infliximab). |
| Treatments groups         | Experimental arm                                                                                                                                                                                                                                                   | Experimental arm                                                                                                                                                                                                                                                   | Ruxolitinib 10 mg BID                                                                                                                                                                                                                                              |
| Treatments groups         | Control arm                                                                                                                                                                                                                                                        | Control arm                                                                                                                                                                                                                                                        | BAT doses and administration were according to manufacturer's instructions and could be adjusted based on Investigator judgment                                                                                                                                    |
| Endpoints and definitions | Primary endpoint                                                                                                                                                                                                                                                   | ORR day 28 (overall response rate)                                                                                                                                                                                                                                 | proportion of patients in each arm demonstrating a complete response (CR) or partial response (PR) at Day 28 after randomization without requirement for additional systemic therapies for an earlier progression                                                  |
| Endpoints and definitions | Key Secondary endpoint                                                                                                                                                                                                                                             | Durable ORR day 56                                                                                                                                                                                                                                                 | proportion of all patients in each arm who achieved a complete response (CR) or partial response (PR) at Day 28 and maintain a CR or PR at Day 56.                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | BOR (best overall response)                                             | proportion of patients who had overall response, CR or PR, at any time point up to and including Day 28 and before the start of additional systemic therapy for aGvHD   |
|-----------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | ORR day 14                                                              |                                                                                                                                                                         |
| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | DoR (duration of response)                                              | evaluated in patients who achieved a CR or PR at or before Day 28                                                                                                       |
| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | Weekly cumulative steroid dose                                          | cumulative steroid dose for each patient up to Day 56 or end of treatment                                                                                               |
| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | OS (Overall survival)                                                   | the time from the date of randomization to the date of death due to any cause                                                                                           |
| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | EFS (Event- free survival)                                              | the time from the date of randomization to the date of hematologic disease relapse/progression, graft failure, or death due to any cause                                |
| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | FFS (Failure- free survival)                                            | hematologic disease relapse/progression, NRM or addition of new systemic aGvHD treatment, and the competing risk was cGvHD                                              |
| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | NRM (Non- relapse mortality)                                            | the time from date of randomization to date of death not preceded by hematologic disease relapse/progression                                                            |
| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | MR (Malignancy Relapse/Pro gression)                                    | time from date of randomization to hematologic malignancy relapse/progression (only patients with underlying hematologic malignant disease)                             |
| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | cGvHD                                                                   | diagnosis of any cGvHD, including mild, moderate, severe                                                                                                                |
| Other sec endpoints are not corrected for multiplicity.   | Other secondary endpoint                                                | OR up to and including Day 28                                           | proportion of patients who achieved OR (CR+PR) at any time point up to and including Day 28 and before the start of additional systemic therapy for aGvHD               |
| Database lock                                             | DCO for primary analysis 25-Jul-2019 and for secondary analysis 06-Jan- | DCO for primary analysis 25-Jul-2019 and for secondary analysis 06-Jan- | DCO for primary analysis 25-Jul-2019 and for secondary analysis 06-Jan-                                                                                                 |

## Results and Analysis

| Analysis description                           | Primary Analysis         | Primary Analysis         | Primary Analysis         | Primary Analysis         |
|------------------------------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Analysis population and time point description | Full analysis set (=ITT) | Full analysis set (=ITT) | Full analysis set (=ITT) | Full analysis set (=ITT) |
| Effect estimate per comparison                 | Treatment group          | Ruxolotinib              | BAT                      |                          |
| Effect estimate per comparison                 | Number of subjects       | 154                      | 155                      |                          |
| Effect estimate per comparison                 |                          |                          |                          | Odds ratio (RUX/BAT)     |
| Effect estimate per comparison                 | ORR d 28 ( %)            | 62,3                     | 39,4                     | 2,64 (1.65, 4.22)        |
| Effect estimate per comparison                 | (95% CI)                 | (54.2, 70,0)             | (31.6, 47.5)             | p<0.0001                 |
| Effect estimate per comparison                 | Durable OR Day 56 (%)    | 39.6                     | 21.9                     | 2,38 (1,43, 3,94)        |
| Effect estimate per comparison                 | (95% CI)                 | (31.8, 47.8)             | (15,7, 29,3)             | p=0,0007                 |

<div style=\"page-break-after: always\"></div>

|                                                         | ORR day 14                                                                              | 63.0                                                                                    | 47.1                                                                                    | 1,98 (1.24, 3.17)                                                                       |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|
|                                                         | (95% CI)                                                                                | (54.8, 70.6)                                                                            | (39.0, 55.3)                                                                            | p=0,0029*                                                                               |
|                                                         | BOR up to d 28                                                                          | 81,8                                                                                    | 60.6                                                                                    | 3.07 1.80, 5.25)                                                                        |
|                                                         | (95% CI)                                                                                | (74.8, 87.6)                                                                            | (52.5, 68.4)                                                                            | p<0.0001*                                                                               |
| Notes                                                   | *Results for ORR Day 14 and BOR are not corrected for multiplicity                      | *Results for ORR Day 14 and BOR are not corrected for multiplicity                      | *Results for ORR Day 14 and BOR are not corrected for multiplicity                      | *Results for ORR Day 14 and BOR are not corrected for multiplicity                      |
| Analysis description                                    | Second analysis                                                                         | Second analysis                                                                         | Second analysis                                                                         | Second analysis                                                                         |
| Analysis                                                | Full analysis set (=ITT)                                                                | Full analysis set (=ITT)                                                                | Full analysis set (=ITT)                                                                | Full analysis set (=ITT)                                                                |
| population Descriptive statistics/ estimate variability | Treatment group                                                                         | Ruxolotinib                                                                             | BAT                                                                                     |                                                                                         |
| population Descriptive statistics/ estimate variability | DoR (median/ Quartiles)                                                                 | 163 (78.0- 246.0)                                                                       | 101.0 (46.0-141.0)                                                                      | Only subjects with CR/PR at d28                                                         |
| population Descriptive statistics/ estimate variability | OS (median/ months, 95% CI)                                                             | 10.71                                                                                   | 5.82                                                                                    | HR: 0.83 (CI 0.62, 1.13) p=0.2331*                                                      |
| population Descriptive statistics/ estimate variability | EFS (median/ months, 95% CI)                                                            | 8.18                                                                                    | 4.17                                                                                    | HR: 0.80 (CI 0.60, 1.08) p=0.1431*                                                      |
| population Descriptive statistics/ estimate variability | FFS (median/ months, 95% CI)                                                            | 4.86                                                                                    | 1.02                                                                                    | HR: 0.49, 95% CI: 0.37, 0.63; p<0.0001*                                                 |
| population Descriptive statistics/ estimate variability | MR (%)                                                                                  | 10.9                                                                                    | 17.0                                                                                    |                                                                                         |
| population Descriptive statistics/ estimate variability | NRM (%)                                                                                 | 44.8                                                                                    | 45.2                                                                                    |                                                                                         |
| population Descriptive statistics/ estimate variability | Completely tapered steroid dose by day 56 (%, CI 95%)                                   | 22 (15.8, 29.5)                                                                         | 14.8 (9.6, 21.4)                                                                        | Odds Ratio: 1.63 (0.91, 2.92)                                                           |
| population Descriptive statistics/ estimate variability | Incid of cGvHD (%)                                                                      | 29.2                                                                                    | 18.7                                                                                    |                                                                                         |
| Notes                                                   | *None of the secondary endpoints in the second analysis are corrected for multiplicity. | *None of the secondary endpoints in the second analysis are corrected for multiplicity. | *None of the secondary endpoints in the second analysis are corrected for multiplicity. | *None of the secondary endpoints in the second analysis are corrected for multiplicity. |

| Pivotal study 2: A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogeneic stem cell transplantation.   | Pivotal study 2: A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogeneic stem cell transplantation.      | Pivotal study 2: A phase III randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory chronic graft vs. host disease after allogeneic stem cell transplantation.      |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Study identifier                                                                                                                                                                                                                           | REACH3                                                                                                                                                                                                                                        | REACH3                                                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                                     | Open label, randomized (1:1) phase III                                                                                                                                                                                                        | Open label, randomized (1:1) phase III                                                                                                                                                                                                        |
| Design                                                                                                                                                                                                                                     | Duration of main phase: Duration of Run-in phase: Duration of Extension phase:                                                                                                                                                                | 156 weeks (39 cycles) 0-28 days Cycle 7 to Cycle 39                                                                                                                                                                                           |
| Hypothesis                                                                                                                                                                                                                                 | Superiority of Ruxolitinib over Best available therapy (BAT: Extracorporeal photopheresis, low-dose methotrexate, mycophenolate mofetil, mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib or ibrutinib | Superiority of Ruxolitinib over Best available therapy (BAT: Extracorporeal photopheresis, low-dose methotrexate, mycophenolate mofetil, mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib or ibrutinib |
| Treatments groups                                                                                                                                                                                                                          | Experimental arm                                                                                                                                                                                                                              | Ruxolotinib 10 mg BID                                                                                                                                                                                                                         |
| Treatments groups                                                                                                                                                                                                                          | Control arm                                                                                                                                                                                                                                   | BAT doses and administration were according to manufacturer's instructions and could be adjusted based on Investigator judgment                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Endpoints and definitions                          | Primary endpoint                                                        | ORR (overall response rate)                                             | ORR (overall response rate)                                             | the proportion of patients in each arm demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier                                                                                             | the proportion of patients in each arm demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier                                                                                             | the proportion of patients in each arm demonstrating a complete response (CR) or partial response (PR) without the requirement of additional systemic therapies for an earlier                                                                                             |
|----------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|-------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Endpoints and definitions                          | Co-Secondary endpoints                                                  | FFS (failure free survival)                                             | FFS (failure free survival)                                             | progression time from date of randomization to the earliest of the following FFS events: 1) relapse or recurrence of underlying disease or death due to underlying disease or 2) non-relapse mortality or 3) addition or initiation of another systemic therapy for cGvHD. | progression time from date of randomization to the earliest of the following FFS events: 1) relapse or recurrence of underlying disease or death due to underlying disease or 2) non-relapse mortality or 3) addition or initiation of another systemic therapy for cGvHD. | progression time from date of randomization to the earliest of the following FFS events: 1) relapse or recurrence of underlying disease or death due to underlying disease or 2) non-relapse mortality or 3) addition or initiation of another systemic therapy for cGvHD. |
| Endpoints and definitions                          | Co-Secondary endpoints                                                  | TSS (total symptom score)                                               | TSS (total symptom score)                                               | the rate of patients with clinically relevant improvement of the modified Lee symptoms score at Cycle 7 Day 1 relative to baseline, as assessed by the rate of responders as per improvement ≥ 7 points of TSS from baseline of the modified Lee Symptom Scale             | the rate of patients with clinically relevant improvement of the modified Lee symptoms score at Cycle 7 Day 1 relative to baseline, as assessed by the rate of responders as per improvement ≥ 7 points of TSS from baseline of the modified Lee Symptom Scale             | the rate of patients with clinically relevant improvement of the modified Lee symptoms score at Cycle 7 Day 1 relative to baseline, as assessed by the rate of responders as per improvement ≥ 7 points of TSS from baseline of the modified Lee Symptom Scale             |
| Endpoints and definitions                          | Other secondary endpoint                                                | BOR (Best overall response)                                             | BOR (Best overall response)                                             | proportion of patients who achieved OR (CR+PR) at any time point (up Cycle 7 day 1 or the start of additional systemic therapy for                                                                                                                                         | proportion of patients who achieved OR (CR+PR) at any time point (up Cycle 7 day 1 or the start of additional systemic therapy for                                                                                                                                         | proportion of patients who achieved OR (CR+PR) at any time point (up Cycle 7 day 1 or the start of additional systemic therapy for                                                                                                                                         |
| Endpoints and definitions                          | Other secondary endpoint                                                | OR at Cycle 4 Day 1                                                     | OR at Cycle 4 Day 1                                                     | cGvHD) Proportion of patients who achieved OR (CR+PR) at Cycle 4 Day 1                                                                                                                                                                                                     | cGvHD) Proportion of patients who achieved OR (CR+PR) at Cycle 4 Day 1                                                                                                                                                                                                     | cGvHD) Proportion of patients who achieved OR (CR+PR) at Cycle 4 Day 1                                                                                                                                                                                                     |
| Endpoints and definitions                          | Other secondary endpoint                                                | DOR (Duration of response) therapies                                    | DOR (Duration of response) therapies                                    | for responders only; the time from first response until cGvHD progression, death, or the date of change/addition of systemic                                                                                                                                               | for cGvHD                                                                                                                                                                                                                                                                  | for responders only; the time from first response until cGvHD progression, death, or the date of change/addition of systemic                                                                                                                                               |
| Endpoints and definitions                          | Other secondary endpoint                                                | OS (Overall survival)                                                   | OS (Overall survival)                                                   | the time from the date of randomization to the date of death due to any cause                                                                                                                                                                                              | the time from the date of randomization to the date of death due to any cause                                                                                                                                                                                              | the time from the date of randomization to the date of death due to any cause                                                                                                                                                                                              |
|                                                    | Other secondary endpoint                                                | NRM (Non- relapse mortality)                                            | NRM (Non- relapse mortality)                                            | the time from date of randomization to date of death not preceded by underlying disease relapse/recurrence                                                                                                                                                                 | the time from date of randomization to date of death not preceded by underlying disease relapse/recurrence                                                                                                                                                                 | the time from date of randomization to date of death not preceded by underlying disease relapse/recurrence                                                                                                                                                                 |
|                                                    | Other secondary endpoint                                                | Reduction of daily steroid dose                                         | Reduction of daily steroid dose                                         | proportion of patients with ≥ 50% reduction in daily corticosteroid dose at Cycle 7 Day1                                                                                                                                                                                   | proportion of patients with ≥ 50% reduction in daily corticosteroid dose at Cycle 7 Day1                                                                                                                                                                                   | proportion of patients with ≥ 50% reduction in daily corticosteroid dose at Cycle 7 Day1                                                                                                                                                                                   |
|                                                    | Other secondary endpoint                                                | Tapering of all steroids all                                            | Tapering of all steroids all                                            | proportion of patients successfully tapered off corticosteroids at Cycle 7 Day 1                                                                                                                                                                                           | proportion of patients successfully tapered off corticosteroids at Cycle 7 Day 1                                                                                                                                                                                           | proportion of patients successfully tapered off corticosteroids at Cycle 7 Day 1                                                                                                                                                                                           |
|                                                    | Other secondary endpoint                                                | MR (Malignancy Relapse/Rec                                              | MR (Malignancy Relapse/Rec                                              | the time from date of randomization to hematologic malignancy relapse/recurrence (only patients with underlying hematologic                                                                                                                                                | the time from date of randomization to hematologic malignancy relapse/recurrence (only patients with underlying hematologic                                                                                                                                                | the time from date of randomization to hematologic malignancy relapse/recurrence (only patients with underlying hematologic                                                                                                                                                |
| Database lock                                      | Interim analysis Oct 2019 and the primary analysis 08-May-2020          | Interim analysis Oct 2019 and the primary analysis 08-May-2020          | Interim analysis Oct 2019 and the primary analysis 08-May-2020          | Interim analysis Oct 2019 and the primary analysis 08-May-2020                                                                                                                                                                                                             | Interim analysis Oct 2019 and the primary analysis 08-May-2020                                                                                                                                                                                                             | Interim analysis Oct 2019 and the primary analysis 08-May-2020                                                                                                                                                                                                             |
| Results and Analysis                               | Results and Analysis                                                    | Results and Analysis                                                    | Results and Analysis                                                    | Results and Analysis                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                       | Results and Analysis                                                                                                                                                                                                                                                       |
| Analysis description                               | Interim Analysis (based on 196 patients i.e., 60.5% of the targeted 324 | Interim Analysis (based on 196 patients i.e., 60.5% of the targeted 324 | Interim Analysis (based on 196 patients i.e., 60.5% of the targeted 324 | Interim Analysis (based on 196 patients i.e., 60.5% of the targeted 324                                                                                                                                                                                                    | Interim Analysis (based on 196 patients i.e., 60.5% of the targeted 324                                                                                                                                                                                                    | Interim Analysis (based on 196 patients i.e., 60.5% of the targeted 324                                                                                                                                                                                                    |
|                                                    | patients) FAS (Interim Analysis) = ITT                                  | patients) FAS (Interim Analysis) = ITT                                  | patients) FAS (Interim Analysis) = ITT                                  | patients) FAS (Interim Analysis) = ITT                                                                                                                                                                                                                                     | patients) FAS (Interim Analysis) = ITT                                                                                                                                                                                                                                     | patients) FAS (Interim Analysis) = ITT                                                                                                                                                                                                                                     |
| Analysis population Effect estimate per comparison | Treatment group                                                         | Treatment group                                                         | Ruxolotinib                                                             | Ruxolotinib                                                                                                                                                                                                                                                                | BAT                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                            |
| Analysis population Effect estimate per comparison | Number of                                                               | Number of                                                               | 97                                                                      | 97                                                                                                                                                                                                                                                                         | 99                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                            |
| Analysis population Effect estimate per comparison |                                                                         |                                                                         |                                                                         |                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                            | Odds ratio (RUX/BAT)                                                                                                                                                                                                                                                       |
| Analysis population Effect estimate per comparison | ORR at C7 D1                                                            | ORR at C7 D1                                                            | 50.5                                                                    | 50.5                                                                                                                                                                                                                                                                       | 26.3                                                                                                                                                                                                                                                                       | 2.98 (1.62,                                                                                                                                                                                                                                                                |
| Analysis population Effect estimate per comparison | (95% CI) Stratified CMH                                                 | (95% CI) Stratified CMH                                                 | (40.2, 60.8)                                                            | (40.2, 60.8)                                                                                                                                                                                                                                                               | (17.9, 36.1)                                                                                                                                                                                                                                                               | p=0.0003                                                                                                                                                                                                                                                                   |
| Analysis population Effect estimate per comparison | test                                                                    | test                                                                    | test                                                                    | test                                                                                                                                                                                                                                                                       | test                                                                                                                                                                                                                                                                       | HR                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                                                 | FFS (median/ months) (95% CI)                                       | NE                                                                  | 5.7                                                                 | 0.370 (0.268, 0.510)                                                |
|-------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|
|                                                 | Log Rank test                                                       |                                                                     |                                                                     | p<0.001                                                             |
| Analysis description                            | Primary Analysis (based on all randomized 329 patients.             | Primary Analysis (based on all randomized 329 patients.             | Primary Analysis (based on all randomized 329 patients.             | Primary Analysis (based on all randomized 329 patients.             |
| Analysis population                             | FAS (primary analysis) = ITT                                        | FAS (primary analysis) = ITT                                        | FAS (primary analysis) = ITT                                        | FAS (primary analysis) = ITT                                        |
|                                                 | Treatment group                                                     | Ruxolotinib                                                         | BAT                                                                 |                                                                     |
|                                                 | Number of subjects                                                  | 165                                                                 | 164                                                                 | Odds ratio (RUX/BAT)                                                |
|                                                 | ORR at C7 D1 (n(%);95% CI)                                          | 82 (49.7) 41.8, 57.6                                                | 42 (25.6) 19.1, 33.0                                                | 2.99 (1.86, 4.80) - p<0.0001                                        |
|                                                 | TSS ( by mLSS at C7 D1                                              | 24.2                                                                | 11.0                                                                | 2.62 (1.42, 4.82)                                                   |
|                                                 | Stratified CMH test                                                 | (17.9, 31.5)                                                        | (6.6, 16.8)                                                         | p=0.0011                                                            |
|                                                 | BOR up to C7 D1                                                     | 76.4                                                                | 60.4                                                                | 2.17 (1.34, 3.52)                                                   |
|                                                 | Stratified CMH test                                                 | (69.1, 82.6)                                                        | (52.4, 67,9)                                                        | p=0.0011                                                            |
|                                                 | ORR C4 D1                                                           | 54.5                                                                | 31.1                                                                | 2.77 (1.75, 4.39)                                                   |
|                                                 | Stratified CMH test                                                 | (46.6, 62.3)                                                        | (24.2, 38.8)                                                        | p<0.0001                                                            |
| Descriptive statistics and estimate variability | OS*                                                                 | NE                                                                  | NE                                                                  | HR: 1.09 (0.65, 1.82)                                               |
|                                                 | DOR (median/ months) (95% CI)                                       | NE (20.2, NE)                                                       | 6.24 (4.7, 13.3)                                                    | Include patients with CR/PR only                                    |
|                                                 | NRM                                                                 | 27/165                                                              | 22/164                                                              |                                                                     |
|                                                 | MR                                                                  | 9/156                                                               | 8/160                                                               | Patients with underlying malignancy only                            |
|                                                 | Reduction of Steroid dose ≥50%(%)                                   | 71.2                                                                | 69.6                                                                |                                                                     |
|                                                 | Tapering of all steroids (%)                                        | 31.4                                                                | 27.8                                                                |                                                                     |
| Notes                                           | * Updated OS results with DCO 25 Jun 2021; HR: 0,596 (0.604, 1.512) | * Updated OS results with DCO 25 Jun 2021; HR: 0,596 (0.604, 1.512) | * Updated OS results with DCO 25 Jun 2021; HR: 0,596 (0.604, 1.512) | * Updated OS results with DCO 25 Jun 2021; HR: 0,596 (0.604, 1.512) |

## Assessment of paediatric data on clinical efficacy

aGvHD In Study C2301, 5 adolescents were treated with RUX and 4 with BAT, with a median age of 15 (range 12-16) in the RUX arm. ORR was 80.0% (4/5) with RUX vs. 75.0% (3/4) with BAT. A total of 60% (3/5) patients in RUX arm and 75% (3/4) patients in BAT arm achieved a CR, and 20% (1/5) patients in RUX arm achieved a PR.

cGvHD In Study D2301, 4 adolescents were treated with RUX (youngest 13 years) and 8 with BAT. It is reassuring that responses with RUX were observed in 3 (75%, PR) out of 4 adolescents in the RUX arm. In comparison: 2 out of 8 adolescents (25%) in the BAT arm had a partial response up to Cycle 7 Day 1.

The inclusion of adolescents in REACH-2 and REACH-3 was based on an extrapolation concept as described in the EMA reflection paper (2017). The inclusion of adolescents was based on the following rationale:

<div style=\"page-break-after: always\"></div>

- The disease manifestation and progression of GvHD as well as treatment options are similar in adolescents and adults;
- Evidence for children treated with ruxolitinib already existed;
- Given the maturation of the cytochrome P450 system, the metabolism of ruxolitinib in adolescents is similar to that of adults;
- Non-clinical toxicity studies did not identify toxicities that would be expected in adolescents. The use of the same dose (10 mg BID) in adolescents as in adult patients was supported by safety and PK data of ruxolitinib from a Phase I study in pediatric patients with hematological malignancies (Loh et al 2015). As the exposure-response relationship was expected to be the same for adolescents and adults with GvHD, both allometric scaling and PBPK modelling approaches suggested that the dose for adolescents required to obtain similar exposure in terms of AUC and Cmax was similar to that of adults (20 mg BID in adults would constitute 16-18 mg BID in adolescents). In fact, the exposure in adolescents enrolled in REACH-2 and REACH-3 was in the range of the adult exposure. It was also shown that although BSA is a significant covariate, no clinically meaningful differences are to be expected in patients with a lower BSA such as adolescents.

Efficacy and safety were also expected to be similar between adolescents and adults with GvHD. Detrimental effects by ruxolitinib on bone formation and structure were not observed in toxicology safety studies using animals with a human equivalent age ≥ 12 years. Bone density measurement by dual energy x-ray absorptiometry (DEXA) were therefore not performed in REACH-2. In REACH-3, there was no clinically relevant change in bone mineral density in adolescents enrolled in the ruxolitinib arm. Overall, the safety profile was confirmed to be similar between adults and adolescents enrolled in REACH-2 and REACH-3 studies. No concerns with bone abnormalities were seen.

The rationale for extrapolation of adult data to adolescents has been adequately discussed based on disease manifestation, mode of action, non-clinical data, PK data and (expected) clinical efficacy and safety; and is acceptable.

In the product information, the recommended dose for paediatric patients with GvHD aged 12 years and older is the same as in adults, based on pivotal trials REACH 2 and REACH 3. The safety and efficacy of RUX have not been established in patients less than 12 years of age. The BSA dependent exposure is commented on in the PK section.

## Clinical studies in special populations

## Elderly

No specific dose adjustments are recommended in the product information for elderly patients.

## Renal impairment

In line with the existing recommendation for other indications, no specific dose adjustments are included in the product information for patients with mild or moderate renal impairment. In patients with severe renal impairment (creatinine clearance less than 30 ml/min) the recommended starting dose GvHD patients is 5 mg twice daily (in line with existing recommendations for patients with PV). Please refer to PK section of this report for raised uncertainty regarding this recommendation. There are limited data to determine the best dosing options for patients with end-stage renal disease (ESRD) on haemodialysis. For GvHD patients the recommended starting dose with ESRD on haemodialysis is a single dose of 10 mg or two doses of 5 mg given 12 hours apart, to be administered post-dialysis and only on the day of haemodialysis. This recommendation is similar to PV patients. No data is available for dosing patients who are undergoing peritoneal dialysis or continuous venovenous haemofiltration.

<div style=\"page-break-after: always\"></div>

## Hepatic impairment

Dose adjustments have been recommended in the product information for PV and MF patients. However, in patients with GvHD, mild, moderate or severe hepatic impairment was not found to have a significant impact on any parameter in the population pharmacokinetic model. Therefore, no starting dose adjustment is recommended for GvHD patients with mild, moderate or severe hepatic impairment, including liver GvHD. Please refer to PK section of this report for raised uncertainty regarding this conclusion. It is acknowledged that for patients with GvHD liver involvement and an increase of total bilirubin to &gt;3 x ULN, a recommendation has been included in the product information to monitor blood counts more frequently for toxicity and to consider a dose reduction by one dose level.

## Pregnancy and lactation

There are no data from the use of RUX in pregnant or lactating woman. Animal studies have shown that RUX is embryotoxic and foetotoxic. Available pharmacodynamic/toxicological data in animals have shown excretion of RUX and its metabolites in milk. As a precautionary measure, the use of Rux during pregnancy and lactation is contraindicated.

## 2.5.5. Discussion on clinical efficacy

## Design and conduct of clinical studies

The applicant has applied for a full marketing approval for the selective inhibitor of Janus Kinases (JAKs), JAK1 and JAK2, Jakavi (ruxolitinib) for the indication

Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1).

Since the initially proposed indication ( Jakavi is indicated for the treatment of patients with graft versus host disease aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies) differentiation of the two clinical settings (acute and chronic GvHD) has been implemented and refence to section 5.1 of the SmPC has been added to allow complementation of the concise indication with some further relevant information for the Health care professionals using ruxolitinib.

Overall, the eligibility criteria and exclusion criteria were acceptable for both studies

Ruxolitinib dose - For both main studies dose and regimen were based on data from published data on preliminary efficacy and safety generated in patients with SR GvHD and from the supportive phase II study INCB 18424-271 (REACH-1) SR aGvHD. In addition, publications have shown that adolescents have similar toxicity profiles, maximum tolerated doses, and PK parameters compared to adults. A 10 mg b.i.d. dose in adolescents is expected to provide a similar exposure as 10 mg b.i.d. dosing in adults. The dose-selection seems overall to be adequate, however, exposure is dependent on BSA, please refer to PK section.

GvHD type and grade Patients with higher grade acute and chronic GvHD were included in the pivotal trials with grading determined according to well established criteria. Patients with Grade I aGvHD or mild cGvHD were not eligible. In clinical practice these patients would rarely be offered (second or higher line) systemic treatment. Moreover, responses observed across GvHD stages did not indicate worse outcomes with lower grades. It is therefore considered acceptable not to specify the grade in the

<div style=\"page-break-after: always\"></div>

indication. For details with regard to GvHD grade and type (acute or chronic) of the studied population, a reference to SmPC section 5.1 is included in the indication.

Line of treatment Patients that had received more than one systemic treatment for SR GvHD were excluded, so eligible patients were in need of first- or second-line treatment for SR GvHD. The majority of aGvHD patients in Study C2301 (&gt;93%) and cGvHD patients in Study D2301 (&gt;54%) used corticosteroids and other prior systemic therapy for GvHD. The used definitions of steroid refractoriness are acceptable although this also referred to steroid-dependent patients, i.e., patients that were unable to taper corticosteroids but still responded to corticosteroids. It is reassuring that steroid-dependent patients were included with similar frequencies in both treatment arms (~28%). For acute GvHD, the definition of steroid dependency was stricter than currently recommended by the EBMT-NIH-CIBMTR Task Force position statement (Schoemans et al 2018). It could therefore be anticipated that a broader population of steroid-dependent aGvHD patients will be offered RUX treatment in clinical practice for which efficacy of ruxolitinib has not been established. Considering the persistent sensitivity to steroids in the steroid-dependent subgroup, it is anticipated that response rates in these patients will at least be similar compared to responses in steroid refractory patients or overall population. A cross reference in the indication to section 5.1 of the product information is provided, allowing prior and concomitant treatments in the studied population and used definitions of steroid refractoriness and dependency, to be captured in a concise indication.

Missing information Due to exclusion criteria for both pivotal trials, efficacy in patients with overlap syndrome or transition from active aGvHD to cGvHD wi thout tapering off corticosteroids ± CNI and any systemic treatment is unknown. Efficacy in acute or chronic GvHD after pre-emptive treatment of malignancy recurrence with donor lymphocyte infusion (DLI) and in patients who did not tolerate steroid treatment is unknown as well. This is specified in section 5.1 of the SmPC.

Protocol deviations In REACH-2, protocol deviations were observed in approximately 86% in both treatment arms. The most common deviation category was 'other deviations' (~63% in both arms). It has been clarified that the overall pattern of the most frequent subcategories of 'other deviations' was comparable between the two treatment arms in both studies, with the exception of PD 'organ staging assessment done per investigator criteria/judgement rather Harris', where there was a lower proportion of patients with recorded PD in the ruxolitinib arm (18.8%) compared to the BAT arm (34.2%) in REACH2. However, for key time points (baseline, Day 28 and Day 56) these were reported with low and similar rates. The additional supportive analyses for both studies with a subset of the patients in the FAS who were compliant with the requirements of the clinical study protocol indicated similar results to that observed with the FAS. No other imbalances in subcategories 'other deviations' have been observed.

In REACH-3, protocol deviations were observed in 213 (64.7%) patients overall (63.0% in ruxolitinib arm and 66.5% in BAT arm). The most common deviation category was 'Other deviations' (32.7% and 37.2%). Which included (ruxolitinib arm vs. BAT arm): Lee Symptom Scale not collected (13.9% vs. 17.1%); HBV and/or HCV viral load testing value missing at Cycle 1 Day 1 (9.7% vs. 7.9%); other deviations caused by COVID-19 pandemic as provided in Section 10.7.

A GCP inspection, proposed by the Rapporteur and Co-Rapporteur due to the concerns raised by the high numbers of protocol deviations, has been performed. The scope of the inspection were documentation and results concerning the consistency of reported data with source documents, protocol deviations relating to e.g., staging/grading of graft versus host disease (GvHD), response assessment and use of prohibited medication, and reporting of the data. Moreover, the compliance with ICH-GCP and applicable regulations was to be verified, in particular where it had an impact on the validity of the data.

<div style=\"page-break-after: always\"></div>

In total, the inspection revealed twelve major findings and one critical finding. None of the findings could be directly related to the specific triggers. The only critical finding concerned the violation of patients' rights; race and ethnicity were captured in the electronic case report form (eCRF) without a sound rationale in the study protocols. This finding is considered as non-compliance to ICH-GCP and for the EU trial participants not in accordance with the GDPR.

During inspection, it was observed that a significant number of important protocol deviations (PDs) occurred due to lack of clarity of the study protocol and its amendments. The process for PD management was not robust enough and should have been improved earlier in order to enhance a timely resolution.

Mostly due to occurrence of PDs, for the REACH 2 clinical trial, 56 (36.4%) trial participants in the ruxolitinib arm and 68 (43.9%) in the BAT arm were excluded from the per protocol set. For the REACH 3 clinical trial 69 (41.8%) trial participants in the ruxolitinib arm and 72 (43.9%) trial participants in the BAT arm were excluded from the per protocol set.

Sensitivity analysis was conducted to assess the impact of some of these PDs on primary and key secondary efficacy endpoints as defined in the statistical analysis plans and reported in the respective clinical study reports. The results of these sensitivity analyses confirmed the results of the primary analysis.

mLSS - The second key secondary endpoint Total symptom score, TSS (rate of responders from baseline of the modified Lee Symptom Scale [mLSS]) was not validated prior to start of the trial and data are derived from an open-label study. The risk of bias due to this, cannot be measured or determined. Furthermore, it did not meet statistical significance during the interim analysis. The Applicant has agreed not to include the results in the SmPC, as requested by the Rapporteurs

BAT - The sponsor did not require documentation as detailed for BAT as for IMP (investigational medical products). The classification of IMP or non-IMP in EU member states is based on the local implementation in national law of Directive 2001/20/EC, which provides the definition. However, also for these, certain minimum documentation requirements apply. As the documentation requirement of the Sponsor failed to assure for non-IMP appropriate traceability and compliance, even these lower standards were not fulfilled.

In the worst scenario for the REACH-2, 12% of the trial participants and for the REACH-3, 41% of the trial participants receiving BAT, treatment compliance was not/insufficiently monitored.

The approximately 12% of patients without drug accountability for BAT in acute GvHD Study REACH-2 still allows sufficient interpretation of clinical study results, as impact is considered low.

For BAT in chronic GvHD study REACH-3, max 41% of patients had no data on drug accountability. Novartis conducted additional exploratory analyses to assess the primary efficacy response of the different types of BATs. This is possible as at any time point, patients in the BAT arm were administered one single BAT on top of the backbone therapy of corticosteroids and CNI.

Importantly, it is considered unlikely that all 41% of BAT treated patients were indeed non-compliant considering the severity of symptoms and known positive impact of the BAT treatment for patients. However, it cannot be excluded that (a proportion of the) patients in the BAT arm, or their treating physicians preferred a switch from BAT to Jakavi in this open label study as Jakavi was already prescribed off label in clinical practice and anticipated to be more active. This physician's/patient's preference, could have, in a worst-case scenario, influenced BAT treatment compliance in order to urge a cross-over to the ruxolitinib arm and thereby potentially have influenced treatment outcomes for ORR and durability of response.

ORR was measured at Cycle 7 Day 1, prior to the possibility for BAT treated patients to cross-over to

<div style=\"page-break-after: always\"></div>

ruxolitinib. Now ORR results have been provided per BAT, and the observed ORR for each individual BAT is lower than the response rate reported in patients treated with ruxolitinib, regardless of the administration route and/or clinical setting i.e., in hospital versus at home. Importantly, the in-hospital BATs, which have high drug accountability (due to the setting), and the at-home BATs showed similar ORR per BAT. These exploratory results together are suggestive of a limited (if any) impact of the potential lower BAT compliance (worst case) in the at-home setting.

Regarding the time to event endpoints, demonstration of at least non-detriment in OS is considered necessary for registration in cGvHD, as discussed in the previous rounds of assessment.

As OS is multifactorial, for which BAT compliance is only one parameter of interest, it remains difficult to establish whether potential non-compliance in the BAT arm has substantially influenced OS outcomes. It is reassuring that with the latest OS update no sign of detriment was observed.

Finally, even if outcomes would have been comparable to BAT, ruxolitinib could still be acceptable as new treatment modality for chronic GvHD. Therefore, despite some remaining uncertainties on the impact of potential non-compliance on the efficacy results due to the exploratory nature of the additional analyses, the B/R of ruxolitinib is considered positive in chronic GvHD as well.

It is, however, acknowledged that patients with GvHD enrolled in the studies per study protocols were treated according to institutional guidelines, which represents local standard of care in real world practice. Transplanted patients are closely monitored by designated and experienced physicians working in specialized transplant units.

In summary, it can be concluded that in general the conduct of the REACH 2 and REACH 3 clinical trials was partially ICH-GCP compliant. Nevertheless, despite the deviation described with respect to ethics and patients´ rights in the inspections report, the REACH 2 and REACH 3 clinical trials were still considered to be conducted within internationally accepted ethical standards. The inspectors considered the data of the REACH 2 and REACH 3 clinical trials, as reported in the interim CSRs, to be acceptable and the impact of the use of the non-validated mLSS and the mostly lacking documentation on BAT accountability and treatment compliance on the benefit-risk balance is referred to the assessors.

According to the inspectors, the observed findings are unlikely to have a significant impact on data integrity within the inspected clinical trials. The inspection team did not identify any restrictions on the usability of the reported trial data, and therefore it was the recommendation of the inspectors that the data of the REACH-2 and REACH-3 clinical trials could be used for evaluation and assessment of the application. The Rapporteurs shares this view and therefore concludes that the findings are unlikely to have had any significant impact on the benefit-risk balance with regard to both aGvHD and cGvHD.

Endpoints ORR at day 28 after starting treatment in aGvHD and 6-month ORR in cGvHD patients are acceptable primary endpoints. Start of additional therapy before the primary endpoint is reached is considered non-response (composite strategy) and so is missing data. By design, only the primary endpoints (ORR at day 28 for aGvHD or ORR at cycle 7 day 1 for cGvHD) cannot be affected by crossover. Cross-over changes the interpretation of other endpoints and is handled by treatment policy. This may bias the effect compared to the situation when cross-over had not occurred. Under the assumption that RUX still has effect after BAT, the estimate will be conservative. Planned cross-over impacts the possibility to have reliable long-term efficacy data but should at least indicate no detrimental effect.

Censoring - Information with regard to censoring and competing risk for each of the endpoints was summarized on request. The definitions were largely the same for REACH2 and REACH3, except for DoR and FFS where onset of cGvHD was a competing event (in REACH2). These are more supportive than pivotal endpoints, so this is not critical for the B/R.

<div style=\"page-break-after: always\"></div>

Statistical analysis methods The statistical tests and analysis models were standard. Multiple testing procedures used control the type I error adequately. Of note: in aGvHD Study C2301, only the primary endpoint ORR at Day 28 and key secondary endpoint ORR at Day 56 were formally tested. In cGvHD Study D2301, the primary endpoint ORR at Cycle 7 Day 1 and key secondary endpoints FFS and Lee Symptom Score were formally tested. This D2301 study also included an interim analysis, at which the hypotheses for the first two endpoints (primary + FFS) were already rejected.

BAT subgroups The choice of BAT, were the patient to be randomized to the BAT arm, was decided before randomisation. Results per the particular BATs have been provided. Furthermore, the BAT accountability has been described and commented on in the inspection report as reported above.

Changes during the study - Most notably in both study REACH 2 and REACH 3 a data monitoring committee was added during the trial conduct (this was late in the study conduct of REACH 2, to address the Study Steering Committee's request to be informed on the balance of safety events between treatment arms, while maintain blinding of the Study Steering Committee; and early in REACH 3). This is not considered to impact the results or interpretation of the endpoints. The analysis plans were not changed.

## Efficacy data and additional analyses

## Efficacy results for INC424C2301, aGvHD REACH-2

Baseline characteristics -Overall, baseline characteristics were generally comparable between treatment arms and reflect a steroid refractory/steroid dependent population in need of first- or second-line systemic treatment (after first line corticosteroids) for aGvHD.

Response rates - REACH-2 demonstrated a statistically significant higher ORR (primary endpoint) for patients in the RUX arm (62.3%) compared with those in the BAT arm (39.4%) (Odds ratio [HR] 2.64; 95% confidence interval [CI] 1.65, 4.22; p &lt; 0.0001), thus meeting the primary endpoint, ORR (CR+PR) at Day 28. The primary endpoint results were confirmed by an analysis using PPS with an ORR at Day 28 of 63.9% in the ruxolitinib arm and 39.1% in the BAT arm. Furthermore, the robustness of primary endpoint results was confirmed by sensitivity analysis performed without stratification factor using the Fisher's exact method with an ORR at Day 28 (Odds ratio: 2.55; 95% CI: 1.61, 4.03).

Improvements in signs and symptoms were observed across all organs involved for aGvHD (skin, liver, lower GI and upper GI) at Day 28; these improvements were more pronounced in the ruxolitinib arm than in the BAT arm.

Cross over population Among the 49 patients who crossed over to RUX treatment between Day 28 and Week 24, the ORR at Crossover Day 28 was consistent with the primary analysis in the RUX arm: 67.3% (95% CI: 52.5, 80.1). The CR rate was higher compared with the primary analysis: 46.9%.

The key secondary endpoint, durable ORR at Day 56 (proportion of patients that achieved response at Day 28 and maintained their response up to Day 56) showed statistically significant higher response rate in the RUX arm (39.6%) compared to the BAT arm (21.9%) (Odds ratio of 2.38, 95% CI: 1.43, 3.94; p=0.0005). Analysis of durable ORR at Day 56 using PPS was consistent with that observed using FAS.

Time-dependent endpoints The magnitude of ORR and durability of response indicate activity of RUX. No nominally statistically significant differences in OS, EFS or NRM were observed, but results are impacted by the large proportion of cross-over from BAT to RUX (31.6%). It is acknowledged that results suggest no detrimental effect either and median OS and EFS were still numerically longer in the

<div style=\"page-break-after: always\"></div>

RUX arm (primary analysis OS: 11.14 vs. 6.47 months with BAT; EFS: 8.28 vs. 4.17 months). Given the high ORR in RUX after BAT (see cross-over population), it also seems reasonable to assume that RUX has beneficial effects after BAT. For FFS, where addition of new systemic aGvHD treatment was defined as event, results obtained were numerically in favour of RUX (4.99 months vs. 1.02 months with BAT; HR: 0.46, 95% CI: 0.35, 0.60), but this endpoint was not part of the confirmatory testing strategy. The favourable effect on FFS is largely driven by less additional systemic therapy for aGvHD in the ruxolitinib arm.

Subgroups - Responses were observed across all included aGvHD severities, all categories of SR refractoriness/dependency and most combinations of prior therapies (steroid only, steroid + CNI, and most subgroups with prior steroid + CNI + other systemic treatment). In some subgroups, firm conclusions regarding efficacy cannot be drawn. considering the limited number of patients in these respective subgroups. For elderly, OR point estimate approximates to 1 suggesting similar efficacy of RUX and BAT. Even if this would be the case, RUX might still offer a valuable (registered and well characterized) treatment option that does not seem to come with additional risks compared to BAT but provides an alternative option with a different safety profile.

cGvHD A higher proportion of patients in the RUX arm developed chronic GvHD (29.2% vs. 18.7% secondary analysis, 24.7% vs. 16.8% primary analysis) in the context of similar/better competing events (MR and NMR) for RUX. It is acknowledged that this primarily concerned lower grade events, and RUX treatment was not continued for cGvHD or overlap syndrome in the clinical trial.

## Supportive study 271

Single arm, open-label Phase II study 271 provided supportive data in SR acute GvHD. The study included 71 patients with Grade II-IV SR acute GvHD that had received corticosteroids alone or in combination with 1 or more additional agents as first-line therapy for aGVHD. RUX treatment started at a lower 5 mg b.i.d. dose. Results for the primary endpoint ORR at day 28 (56.3%) were in line with results for RUX in the confirmatory Phase 3 trial (62.3%). Median OS was lower (232 days, ~7.6 months) than observed in the pivotal trial (11.14 months), but the RUX dose in this supportive trial was lower and a non-detrimental effect vs. BAT has been confirmed in the Phase 3 Study REACH-2 (C2301).

## Efficacy results for the Pivotal study, INC424D2301, cGvHD REACH-3

Baseline characteristics Overall, baseline characteristics were generally comparable between treatment arms and reflect a steroid refractory/steroid-dependent population in need of first- or second-line systemic treatment (after first line corticosteroids) for cGvHD.

Responses - At the time of the Primary Analysis, the median duration of study follow-up (from randomization to the data cut-off date) was approximately 13 months.

The proportion of patients achieving response (CR or PR) at the interim analysis at Cycle 7 Day 1 in the RUX arm (50.5%) compared to the BAT arm (26.3%) was statistically significant, with an odds ratio of 2.98 (95% CI: 1.62, 5.48) in favour of the RUX arm. The result was maintained at the primary analysis, 49.7% in the RUX arm and 25.6% in the BAT arm; odds ratio of 2.99 (95%CI: 1.86, 4.80) (p&lt;0.0001). The primary endpoint results at the PA using FAS, was confirmed for the supportive analysis using PPS.

CR rates were low: 6.7% vs. 3% (RUX vs BAT). While a CR would provide most benefit to patients, it is acknowledged that the patient reported outcome (PRO) modified Lee symptom score (response rate 24.2% vs. 11%) could indicate clinical benefit in cGvHD as well, although interpretation of PRO data is hampered by the open-label study design.

<div style=\"page-break-after: always\"></div>

Results favouring the RUX arm was seen across majority of pre-defined baseline characteristics and prognostic subgroups including gender, race, cGvHD severity (moderate/severe) at randomization, and regardless of prior diagnosis of aGvHD (odds ratio &gt;1 for ORR at Cycle 7 Day 1). Since heterogeneity in allowed previous as well as concomitant treatment and prophylaxis regimes for GvHD makes it difficult to interpret these subgroup results. For REACH-3, only 14 patients (10 in RUX arm vs. 4 in BAT arm) had been enrolled with multiple prior therapies, and consequently ORR subgroup analyses showed large confidence intervals. It is acknowledged that it is not possible to draw firm conclusions due to the small numbers.

Cross over population - The ORR at Cycle 7 Day 1 for the cross-over population was slightly lower (39.3%) compared to the overall study population at Cycle 7 D1 (49.7%) although results became more similar with longer follow-up, 47.8% (at DCO 25-Jun-2021 used for the later OS analysis performed). These results suggest that responses can still be obtained for SR-cGvHD patients who failed treatment with BAT, to an (almost) similar level as in patients who received RUX for SR-cGvHD at an earlier stage.

The primary key secondary endpoint, FFS, showed a statistically significant difference, at the IA (N=196), between the treatment arms, with a HR of 0.315 (95% CI: 0.205, 0.486) (stratified Cox model using cGvHD severity at randomization as strata, p-value was &lt;0.0001). Therese results were confirmed at the Primary Analysis (HR of 0.370 (95% CI: 0.268, 0.510), p&lt;0.0001). The gain in FFS was driven by less change of therapy in the ruxolitinib arm and in lesser extent the other components of this composite endpoint, i.e., (i) relapse or recurrence of underlying disease or death due to underlying disease and (ii) non-relapse mortality. Of note: no competing risks are defined for FFS in this study, facilitating interpretation of the data. NMR and MR, both each other's competing risk, had the similar cumulative incidence, hence gain in the one was not at the cost of the other.

The second key secondary endpoint, improvement in mLSS score at Cycle 7 Day 1 did not meet statistical significance at the Interim Analysis. However, the rate of responders with improvement of ≥ 7 points in TSS at Cycle 7 Day 1, from baseline reached statistical significance, with 24.2% responders in the ruxolitinib arm and 11.0% in the BAT arm (odds ratio of 2.62 (95% CI: 1.42, 4.82) (one-sided p=0.0011) in favor of the RUX arm.

Time-dependent endpoints. At the primary data cut-off 08 May 2020, OS and NRM medians were not reached, and results showed overlapping KM curves. For OS, there was a slightly higher number of deaths (n=31, 18.8%) in the RUX arm vs. BAT (n=27 deaths, 16.4%) in the first 6 months of treatment, and HR of 1.086 (95% CI: 0.648, 1.820). Updated OS data (25 JUN 2021) is provided, and the results remain immature, as is expected in the setting of cGvHD. The updated HR for OS shows a HR just below 1 (0.956 vs. 1.086 with previous analysis) with a CI still crossing 1. The updated results for primary cause of death did not show any new safety signals compared to the primary analysis results. Interpretation of OS analysis is hampered by cross over from the BAT to the RUX arm. A detrimental effect on OS of ruxolitinib cannot be concluded based on available immature data. Final OS data should be submitted post-marketing.

## 2.5.6. Conclusions on the clinical efficacy

Both pivotal studies, aGvHD and cGvHD, met their primary endpoints, showing statistical significance for the RUX arm compared to the BAT arm in terms of ORR and spared the use of other immunosuppressive treatments. This is considered clinical benefit per se, as it is anticipated to be associated with a lower symptom burden. Despite ORR not being an established trial-level surrogate for long term outcomes, efficacy is considered established.

<div style=\"page-break-after: always\"></div>

## 2.6. Clinical safety

## Introduction

All patients who received at least one dose of study treatment were included in the safety analysis (Safety Set).

## Overview of clinical studies that contributed to safety data

| Population   | Studies                 | Study description                                                                                                                                                                                  | Dose schedule   | Numberof patients enrolled/treated                                                                      | Data-cut- off date                |
|--------------|-------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------|---------------------------------------------------------------------------------------------------------|-----------------------------------|
| AcuteGvHD    | CINC424C230 1 (REACH 2) | A phase Ill randomized open-label multi-center study of ruxolitinib versus best available therapy in patients with corticosteroid-refractory acute GvHD after allogeneic stem cell transplantation | 10 mg b.i.d.    | 309/302 Rux: 154/152 BAT:155/150(49 cross-over) Total number of patients exposed to Rux: 201 (51.8 PTY) | 06-Jan- 2020 (Secondary analysis) |

| Population   | Studies                  | Study description                                                                                                                                                                         | Dose schedule                                                         | Number of patients enrolled/treated                                                                      | Data-cut- off date              |
|--------------|--------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|---------------------------------|
|              | CINCB018424 271(REACH 1) | A single-cohort, Phase Il Study ofruxolitinibin combination with corticosteroids for the treatment of steroid- refractoryacuteGvHD                                                        | 5 mg b.i.d. with possibility to increase to 10 mg b.i.d. after 3 days | 71 (25.6 PTY)                                                                                            | 05-Jun- 2019 (LPLV)             |
| Chronic GVHD | CINC424D230 1 (REACH 3)  | A phase Ill randomized open-labelmulti-center studyofruxolitinibvs.best available therapy in patients with corticosteroid-refractory chronicGvHDafter allogenic stem cell transplantation | 10 mg b.i.d.                                                          | 329/323 Rux:165/165 BAT:164/158 (61 cross-over) Total number of patients exposed to Rux: 226 (195.1 PTY) | 08-May- 2020 (Primary analysis) |

Data-cut-off date: when all patients completed 6 months of treatment or discontinued from study participation in D2301

## Sources of safety data and safety presentation

For this presentation, no pooling of data from the studies was performed due to the differences in the study populations, study designs, duration of treatment exposure and frequency, and severity and seriousness of AE data observed across the studies during the entire treatment period.

The study population in acute GvHD and chronic GvHD are different. They differ with regard to aspects of the underlying pathophysiology, pathology, clinical manifestations, timing of transplant and disease management.

In addition, the duration of ruxolitinib treatment exposure was longer in chronic GvHD (median exposure of 41.4 weeks in REACH-3 study) compared to acute GvHD (median exposure of 8.9 weeks in REACH-2, 6.6 weeks in REACH-1).

Furthermore, the frequency and severity of adverse events was higher in REACH-2 study, compared to REACH-3 in both ruxolitinib and comparator arms, as expected in view of the recent transplant procedure and its complications in acute GvHD population. In addition, due to the differences in study design (single arm and randomized controlled study) and differences in the frequency and severity of AEs, REACH-1 and REACH-2 studies were not pooled.

<div style=\"page-break-after: always\"></div>

## Patient exposure

## Duration of exposure to ruxolitinib in acute and in chronic GvHD (Safety set)

|                                      | Acute GvHD                           | Acute GvHD        | Chronic GvHD                    |
|--------------------------------------|--------------------------------------|-------------------|---------------------------------|
|                                      | Study C2301 Rux overall 1 N=201      | Study271 Rux N=71 | Study D2301 Rux overall 1 N=226 |
| Duration ofexposure (weeks)          |                                      |                   |                                 |
| Mean (SD)                            | 13.4 (12.60)                         | 18.8 (26.24)      | 45.1 (30.95)                    |
| Median                               | 6'8                                  | 6.6               | 41.4                            |
| Q1-Q3                                | 3.3-23.9                             | 2.1-33.9          | 17.4-68.1                       |
| Min - Max                            | 0.3-66.1                             | 0.6-115.9         | 0.7-127.3                       |
| Duration ofexposure categories-n (%) | Duration ofexposure categories-n (%) |                   |                                 |
| ≤4 weeks                             | 57 (28.4)                            | 29 (40.8)         | 11 (4.9)                        |
| >4 to 8 weeks                        | 38 (18.9)                            | 14 (19.7)         | 12 (5.3)                        |
| >8 to 12weeks                        | 27 (13.4)                            | 2 (2.8)           | 16 (7.1)                        |
| >12 to 16 weeks                      | 10 (5.0)                             | 4 (5.6)           | 12 (5.3)                        |
| >16 to 20 weeks                      | 7 (3.5)                              | 2 (2.8)           | 9 (4.0)                         |
| >20 to 24 weeks                      | 23 (11.4)                            | 2 (2.8)           | 11 (4.9)                        |
| >24to36weeks                         | 27 (13.4)                            | 2 (2.8)           | 29 (12.8)                       |
| >36 to 48 weeks                      | 8 (4.0)                              | 8 (11.3)          | 29 (12.8)                       |
| >48weeks                             | 4 (2.0)                              | 8 (11.3)          | 97 (42.9)                       |
| Patient-Treatment-Years              | 51.8                                 | 25.6              | 195.1                           |

Patient Treatment-Years (PTY) is the sum of each patient's treatment exposure in years

1 Includes the total number of patients at the time of data cut-off including the patients after crossover.

## Exposure to BAT

## Acute GvHD

Duration of exposure to BAT varied widely. The overall exposure of BAT (total exposure of BAT options used in the randomized treatment period) was 19.0 patient years (the median exposure to BAT was 29 days; range: 1.0 to 188.0). The BAT administered the longest was everolimus, followed by extracorporeal photopheresis (ECP).

## Chronic GvHD

Also, in cGvHD the duration of exposure to the different regimen of BAT varied widely. The overall exposure to BAT was 24.1 weeks (range: 0.6 to 108.4) (total exposure of BAT options used in the randomized treatment period). The BAT administered the longest was ECP, followed by mycophenolate mofetil (MMF) The total exposure to ECP was 432.7 patient years.

## Post-marketing exposure

Ruxolitinib was first approved for treatment of MF on 16-Nov-2011. The estimated cumulative postmarketing exposure until the end of reporting period of recent PSUR (with data cut-off of 22-Feb-2020) was estimated to be 152,580 PTY.

Due to the differences in study populations in acute GvHD and chronic GvHD the clinical manifestation and time elapsed since transplant, the extent of exposure is markedly different between the diagnoses. This accounts for both the RUX arm and for the BAT arm.

## Dosage

RUX - In study REACH-2, the mean RDI up to Days 28 and 56 was 91.2% and 86.7%, with majority of patients receiving &gt;90 to 110% of their assigned doses in both epochs. The total daily dose was 20 mg in majority of patients up to both Day 28 and Day 56 (99.3%) the majority of patients received a RUX

<div style=\"page-break-after: always\"></div>

daily dose of 20 mg during the randomised treatment period (99.3%) and during the crossover period (91.8%).

In the supportive REACH-1 (study 271), per protocol the dosing was lower, 5 mg bid with the possibility to increase towards 10 mg b.i.d. The median daily dose received was 10.2 mg (5.1-19.7).

In study REACH-3, mean RDI (relative dose intensity) for RUX was 87.4% up to Cycle 7 Day 1 and was 83.4% for the Main treatment period. During the Cross-over period, mean (SD) dose intensity for the 61 patients was 17.8 (3.53) mg/day and mean RDI for RUX was 88.8%.

BAT - The safety sets with respect to the BAT arm for study REACH-2 functioning as the comparator set for ruxolitinib consist of 9 subsets, also there were 17 patients receiving more than one BAT treatment either simultaneously or replacing BAT 1. The safety sets with respect to the BAT arm for study REACH-3 consist of 10 subsets, also there were 16 patients receiving more than one BAT treatment either simultaneously or replacing the first BAT.

## Dose adjustments for RUX

aGVHD: Majority of patients required at least one dose change or interruption of RUX (82.9%), and the primary reason was AEs (57.2%). Other frequent reasons for dose change or interruption were protocol requirements (39.5%), or dose tapering (28.9%), or by physician decision (19.1%). RUX dose interruptions occurred in 46.1% patients. In the Cross-over treatment period, all 49 patients had a dose change, and 63.3% patients had a dose interruption. Physician decision (91.8%) was the major reason for dose changes, followed by dose tapering (69.4%), AEs (61.2%), and per protocol requirements (46.9%). The CRFs did not collect the reason for the physician decision and as such the reason for dose change or dose interruption cannot be analysed for approximately 20% of the study population. Dose reescalation occurred in 38.8% patients, which was allowed as per protocol. Majority of patients (79.3%) received only one BAT post-randomisation; 18% of patients received two lines of BAT and 2.7% patients received more than 2 lines of BAT. The most common initial BAT administered to 27.3% patients was extracorporeal photopheresis (ECP). Other frequently administered BAT was mycophenolate mofetil (MMF) (16.7%) and etanercept (14.7%).

cGvHD: Up to the data cut-off date during the Main treatment period, the majority of patients required at least one dose reduction or interruption of RUX (74.5%), and the primary reason was due to AEs (47.3%). Other frequent reasons for dose change or interruption were protocol requirements (25.5%), physician decision (23.0%) and dose tapering (13.9%). RUX dose changes occurred in 69.1% patients and dose interruptions occurred in 43.0% patients.

During the Crossover treatment period, 52.5% patients required at least one dose reduction or interruption of RUX, 47.5% had a dose change, and 31.1% patients had a dose interruption. AEs (31.1%) were the major reason for dose changes, followed by physician decision (19.7%). Dose reescalation occurred in 9.8% patients, which was allowed as per protocol. The majority of patients (80.4%) received only one BAT post-randomisation; 17.7% of patients received two lines of BAT and 1.9% patients received more than 2 lines of BAT. The most common initial BAT, administered to 55 (34.8%) patients was ECP, followed by MMF (35, 22.2%) and ibrutinib (27, 17.1%).

The comparator arms in REACH-2 study and REACH-3 study are presented below.

<div style=\"page-break-after: always\"></div>

## REACH-2

<!-- formula-not-decoded -->

InitialBAT-n(&amp;)

Extracorporeal photopheresis

(ECP)

Mycophenolate mofetil(MMF)

Etanercept

Infliximab

Anti-thymocyte globulin (ATG)

Mesenchymal stromalcells(MSc)

Low-doseMethotrexate(MTx)

Sirolimus

Everolimus

Numberof BAT

1

&gt;2

-n

2

CINC424c2301-SecondaryCSR

## REACH 3

<!-- formula-not-decoded -->

```
BAT N=158 Initial BAT treatment -n (%) Extracorporeal photopheresis (ECP) 55 (34.8) Mycophenolate mofetil (MMF) 35 (22.2) Ibrutinib 27 (17.1) Low-dose Methotrexate  (MTx) 10 (6.3) Imatinib 8 (5.1) Sirolimus 7 (4.4) Rituximab 6 (3.8) Everolimus 5 (3.2) Infliximab 5 (3.2) Numberof BAT treatmentsstarted beforeCycle7Day1-n(%) 1 127 (80.4) 2 28 (17.7) >2 3 (1.9) CINC424D2301- Primary CSR
```

## Patient disposition in Study REACH-2 and REACH-1 (aGvHD)

In addition, 49 patients randomized to BAT, crossed over to ruxolitinib treatment, whereof 36 (73.5%) patients discontinued crossover treatment period, the most common reason for discontinuation was AEs (in 24.5% of patients crossed over of whom 27 (55.1%) entered long term follow-up phase.

BAT

N=150

4 1

25

(27.3)

22

17

20

15

3

5

2

11 9

27

4

(14.7)

(16.7)

(13.3)

(11.3)

(10.0)

(2.0)

(3.3)

(1.3)

(79.3)

(18.0)

(2.7)

<div style=\"page-break-after: always\"></div>

## Patient disposition-Study REACH-2 (FAS)

|                                                              | Rux N=154 n (%)   | BAT N=155 n (%)   | All Patients N=309 n (%)   |
|--------------------------------------------------------------|-------------------|-------------------|----------------------------|
| Patients randomized                                          |                   |                   |                            |
| Treated                                                      | 152 (98.7)        | 150 (96.8)        | 302 (97.7)                 |
| Not treated                                                  | 2 (1.3)           | 5 (3.2)           | 7 (2.3)                    |
| Treatment ongoing'                                           | 3 (1.9)           | 0                 | 3 (1.0)                    |
| Completed treatment period?                                  | 35 (22.7)         | 21 (13.5)         | 56 (18.1)                  |
| Discontinuedfrom treatmentperiod                             | 116 (75.3)        | 134 (86.5)        | 250 (80.9)                 |
| Reasonfordiscontinuatlon                                     |                   |                   |                            |
| Lack of elficacy                                             | 32 (20.8)         | 69 (44.5)         | 101 (32.7)                 |
| Adverse event                                                | 27 (17.5)         | 6 (3.9)           | 33 (10.7)                  |
| Death                                                        | 25 (16.2)         | 21 (13.5)         | 46 (14.9)                  |
| Failure to meet protocol continualion criteria               | 12 (7.8)          | 9 (5.8)           | 21 (6.8)                   |
| Disease relapse                                              | 8 (5.2)           | 13 (8.4)          | 21 (6.8)                   |
| Physician decision                                           | 6 (3.9)           | 9 (5.8)           | 15 (4.9)                   |
| Patient/guardian decision                                    | 4 (2.6)           | 6 (3.9)           | 10 (3.2)                   |
| Graft loss                                                   | 2 (1.3)           | 0                 | 2 (0.6)                    |
| Lost to follow-up                                            | 0                 | 0                 | 0                          |
| Pregnancy                                                    | 0                 | 0                 | 0                          |
| Protocol devialion                                           | 0                 | 0                 | 0                          |
| Study terminated by sponsor                                  | 0                 | 0                 | 0                          |
| Technical problems                                           | 0                 | 1 (0.6)           | 1 (0.3)                    |
| Continued into next phase at the end of randomized treatment |                   |                   |                            |
| Crossover treatment                                          | 0                 | 49 (31.6)         | 49 (15.9)                  |
| Entered long-term follow-up3                                 | 96 (62.3)         | 51 (32.9)         | 147 (47.6)                 |

1Ongoing at the time of the data cut-off date 06-Jan-2020, 2Treatment period: from Day 1 until the dosing schedule for ruxolitinib or BAT is complete or patients met any criteria for discontinuation, *Long term followup: from EoT to Month 24

## Patient disposition -Study 271 REACH-1

At the time of data cut-off (05-Jun-2019), 3 patients (4.2%) who were still receiving RUX, were transferred to commercial product and 68 patients (95.8%) discontinued the study.

## Patient disposition in Study REACH3 (cGvHD)

## Patient disposition - REACH-3 (FAS)

|                                                           | Rux N=165 n (%)   | BAT N=164 n (%)   | All Patients N=329 n (%)   |
|-----------------------------------------------------------|-------------------|-------------------|----------------------------|
| Patlents randomized                                       |                   |                   |                            |
| Treated                                                   | 165 (100)         | 158 (96.3)        | 323 (98.2)                 |
| Not treated                                               |                   | 6 (3.7)           | 6 (1.8)                    |
| Treatment ongolng'                                        | 83 (50.3)         | 42 (25.6)         | 125 (38.0)                 |
| Discontinued from treatment period                        | 82 (49.7)         | 122 (74.4)        | 204 (62.0)                 |
| Reason for discontinuation                                |                   |                   |                            |
| Adverse events                                            | 28 (17.0)         | 8 (4.9)           | 36 (10.9)                  |
| Lack of efficacy                                          | 24 (14.5)         | 70 (42.7)         | 94 (28.6)                  |
| Dlsease relapse                                           | 9 (5.5)           | 7 (4.3)           | 16 (4.9)                   |
| Death                                                     | 8 (4.8)           | 7 (4.3)           | 15 (4.6)                   |
| Fallure to meet protocol continuation criteria            | 4 (2.4)           | 5 (3.0)           | 9 (2.7)                    |
| Physician decision                                        | 4 (2.4)           | 14 (8.5)          | 18 (5.5)                   |
| Patient/guardian decision                                 | 4 (2.4)           | 11 (6.7)          | 15 (4.6)                   |
| Lost to follow-up                                         | 1 (0.6)           | 0                 | 1 (0.3)                    |
| Continued intonextphase at the end ofrandomized treatment |                   |                   |                            |
| Crossover treatment                                       | 0                 | 61 (37.2)         | 61 (18.5)                  |
| Entered survival follow-up?                               | 61 (37.0)         | 37 (22.6)         | 98 (29.8)                  |

Ongoing at the time of the data cut-off date 08-May-2020, 2 Survival follow-up: followed approximately every 3 months by telephone call for survival and reporting of new cGvHD theraples until 39 cycles completed.

<div style=\"page-break-after: always\"></div>

There were 61 (37.2%) patients initially randomized to BAT that crossed over to ruxolitinib treatment. At DCO, 15 (24.6%) patients had discontinued the crossover treatment period with the most common reasons AEs and lack of efficacy each in 4 (6.6%) patients.

## Adverse events

## REACH-2

AEs considered related to the study treatment (all grades/grade ≥3) are considerably more frequent in the RUX arm compared to the BAT arm, however, for SAEs the frequencies are more or less similar.

AEs leading to treatment discontinuations and dose adjustments/interruptions was 11.32% and 36.8% in the RUX arm and 4.0% and 9.3% in the BAT arm, displaying a large difference with respect to tolerability between the study arms in aGvHD up to Day 28 (primary endpoint).

## Overview of adverse events up to Day 28 visit (Safety set)

|                                                             | RUX N=152        | RUX N=152      | BAT N=150        | BAT N=150     |
|-------------------------------------------------------------|------------------|----------------|------------------|---------------|
| Category                                                    | AlI grades n (%) | Grade 23 n (%) | AlI grades n (%) | Grade23 n (%) |
| Adverse events                                              | 146 (96.1)       | 119 (78.3)     | 142 (94.7)       | 119 (79.3)    |
| Study Treatment-related                                     | 79 (52.0)        | 62 (40.8)      | 43 (28.7)        | 30 (20.0)     |
| SAEs                                                        | 57 (37.5)        | 55 (36.2)      | 51 (34.0)        | 47 (31.3)     |
| Study Treatment-related                                     | 17 (11.2)        | 17 (11.2)      | 12 (8.0)         | 11 (7.3)      |
| Fatal SAEs                                                  | 12 (7.9)         | 12 (7.9)       | 18 (12.0)        | 18 (12.0)     |
| Study Treatment-related                                     | 2 (1.3)          | 2 (1.3)        | 3 (2.0)          | 3 (2.0)       |
| AEs leading to discontinuation                              | 17 (11.2)        | 17 (11.2)      | 6 (4.0)          | 6 (4.0)       |
| Sludy Treatment-related                                     | 10 (6.6)         | 10 (6.6)       | 2 (1.3)          | 2 (1.3)       |
| AEs leading to study treatment dose adjustment/interruption | 56 (36.8)        | 51 (33.6)      | 14 (9.3)         | 8 (5.3)       |
| AEs requiring additional therapy                            | 139 (91.4)       | 108 (71.1)     | 131 (87.3)       | 104 (69.3)    |

Numbers (n) represent counts of patients.

CNl/corticosteroid) and/or indistinguishable.

MedDRA version 22.1, CTCAE version 4.03.

Ruxolitinib treatment up to data cut-off (including cross-over period) show that a majority of the patients (98.5%) experienced at least one AE and 66.2% of patients had AEs (all grades) related to study treatment. SAEs were reported in 69.2% of patients and treatment related SAEs were reported in 26.9% of patients. Fatal SAEs, AEs leading to discontinuation, and AEs leading to dose adjustment/interruption occurred in 23.9% of patients, 29.4% of patients, and 53.7% of patients, respectively.

## REACH-3

## Overview of adverse events up to Cycle 7 Day 1 (Safety set)

<div style=\"page-break-after: always\"></div>

|                                             | RUX N=165        | RUX N=165      | BAT N=158        | BAT N=158      |
|---------------------------------------------|------------------|----------------|------------------|----------------|
| Category                                    | AII grades n (%) | Grade ≥3 n (%) | AII grades n (%) | Grade ≥3 n (%) |
| Adverse events                              | 161 (97.6)       | 94 (57.0)      | 145 (91.8)       | 91 (57.6)      |
| Treatment-related                           | 104 (63.0)       | 56 (33.9)      | 45 (28.5)        | 23 (14.6)      |
| SAEs                                        | 55 (33.3)        | 49 (29.7)      | 58 (36.7)        | 53 (33.5)      |
| Treatment-related                           | 27 (16.4)        | 25 (15.2)      | 16 (10.1)        | 12 (7.6)       |
| Fatal SAEs                                  | 12 (7.3)         | 12 (7.3)       | 8 (5.1)          | 8 (5.1)        |
| Treatment-related                           | 7 (4.2)          | 7 (4.2)        | 4 (2.5)          | 4 (2.5)        |
| AEs leading to discontinuation              | 27 (16.4)        | 20 (12.1)      | 11 (7.0)         | 8 (5.1)        |
| Treatment-related                           | 16 (9.7)         | 12 (7.3)       | 6 (3.8)          | 5 (3.2)        |
| AEs leading to dose adjustment/interruption | 62 (37.6)        | 38 (23.0)      | 26 (16.5)        | 12 (7.6)       |
| AEs requiring additional therapy            | 138 (83.6)       | 72 (43.6)      | 131 (82.9)       | 74 (46.8)      |

Numbers (n) represent counts of subjects.

MedDRA version 23.0,CTCAE version 4.03

A subject with multiple severity grades for an AE is only counted under the maximum grade.

Ruxolitinib treatment up to data cut-off (including cross-over period) display similar rates of the different AE categories as reported for the period up to cycle 7, Day1.

## Overview of adverse events in acute and chronic GvHD (Safety set) (at time of DCO including cross-over)

|                                            | Study C2301 Rux overall N=201   | Study C2301 Rux overall N=201   | Study C271 Rux N=71   | Study C271 Rux N=71   | Study D2301 Rux overall' N=226   | Study D2301 Rux overall' N=226   |
|--------------------------------------------|---------------------------------|---------------------------------|-----------------------|-----------------------|----------------------------------|----------------------------------|
| Category                                   | AlI grades n (%)                | Grade 23 n (%)                  | AII grades n (%)      | Grade 23 n (%)        | AlI grades n (%)                 | Grade 23 n (%)                   |
| Adverse events                             | 198 (98.5)                      | 183 (91.0)                      | 71 (100)              | 69 (97.2)             | 214 (94.7)                       | 139 (61.5)                       |
| Treatment-related                          | 133 (66.2)                      | 113 (56.2)                      | 54 (76.1)             | 46 (64.8)             | 136 (60.2)                       | 82 (36.3)                        |
| SAEs                                       | 139 (69.2)                      | 134 (66.7)                      | 59 (83.1)             | 55 (77.5)             | 94 (41.6)                        | 86 (38.1)                        |
| Treatment-related                          | 54 (26.9)                       | 52 (25.9)                       | 19 (26.8)             | 17 (23.9)             | 43 (19.0)                        | 42 (18.6)                        |
| Fatal SAEs                                 | 48 (23.9)                       | 48 (23.9)                       | 28 (39.4)             | 28 (39.4)             | 17 (7.5)                         | 17 (7.5)                         |
| Treatment-related                          | 14 (7.0)                        | 14 (7.0)                        | 2 (2.8)               | 2 (2.8)               | 8 (3.5)                          | 8 (3.5)                          |
| AEs leading to discontinuation             | 59 (29.4)                       | 53 (26.4)                       | 23 (32.4)             | 20 (28.2)             | 41 (18.1)                        | 30 (13.3)                        |
| Treatment-related                          | 35 (17.4)                       | 32 (15.9)                       | 7 (9.9)               | 5 (7.0)               | 24 (10.6)                        | 18 (8.0)                         |
| AEsleading todose adjustmentinterruption   | 108 (53.7)                      | 96 (47.8)                       | 46 (64.8)             | 42 (59.2)             | 90 (39.8)                        | 57 (25.2)                        |
| AEs requiring additional therapy195 (97.0) |                                 | 172 (85.6)                      | 70 (98.6)             | 63 (88.7)             | 193 (85.4)                       | 111 (49.1)                       |

1 includes the total number of patients at the time of data cut-off including the patients after cross-over

## Adverse events by system organ class and by PT

## aGvHD:

In REACH-2, the difference in incidence of all AEs (all grades and grade ≥ 3) between the two treatment arms (RUX arm vs. BAT arm) was ≤ 10% with the exception of blood and lymphatic system disorders (all grades: 58.6% vs. 44.7% and grade 3/4 AEs: 47.4% vs. 34.7%).

The most frequent AEs by SOCs (ruxolitinib treatment up to data cut-off including cross-over period) were infections and infestations (78.6% of patients), blood and lymphatic system disorders (69.2% of patients).

The incidence (at least one event) of AE Gr ≥3 was 91% in the RUX overall t reatment group of REACH2 of and 97.2% in REACH-1.

<div style=\"page-break-after: always\"></div>

There was an increase in the cumulative incidence of most AEs by SOC, between Day 28 vs overall population in acute GvHD patients receiving ruxolitinib.

Up to Day 28, the frequently observed AEs by PT ( ≥ 20% in either treatment arm) were primarily those of cytopenias, including thrombocytopenia (32.9% vs. 18.0%), and anaemia (30.3% vs. 28.0%), followed by cytomegalovirus infection (25.7% vs. 20.7%). The difference in incidence of AEs by PT in both treatment arms was ≤ 10%, except for thrombocytopenia which was observed in more patients in the RUX arm (32.9%) than in BAT arm (18.0%). Up to the data cut-off date, the frequently observed AEs by PT ( ≥ 20% in either treatment arm) were those of cytopenias (including anaemia [40.1% vs. 31.3%], thrombocytopenia [36.2% vs.20.0%], neutropenia [25.0% vs. 14.7%] and platelet count decreased [20.4% vs. 16.0%]), followed by cytomegalovirus infection (30.9% vs. 26.7%), oedema peripheral (24.3% vs. 21.3%), hypokalaemia (21.1% vs. 18.7%), and pyrexia (20.4% vs. 16.7%). The difference in incidence of all AEs by PT in both treatment arms was ≤ 10%, except for thrombocytopenia (36.2% vs. 20.0%) and neutropenia (25.0% vs. 14.7%) which were observed in more patients in the RUX arm compared to BAT arm. The incidence of Grade ≥ 3 AEs by PT was similar between the two treatment arms (90.1% vs 86.7%). The grade ≥ 3 AEs that were more frequent ( ≥ 10% difference) in RUX arm than BAT arm were anaemia (34.2% vs 24.0%), thrombocytopenia (32.9% vs 16%) and neutropenia (22.4% vs 12%). The frequent ( ≥ 5% in either treatment arm) nonhaematological Grade ≥ 3 AEs by PT (RUX vs BAT) were cytomegalovirus infection (9.2% vs 12.0%), hypokalaemia (9.2% vs 11.3%), diarrhoea (6.6% vs 5.3%), hypertension (6.6% vs 4.7%), hypoalbuminemia (5.3% vs 6.7%), sepsis (8.6% vs 11.3%) and hypoglycaemia syndrome (3.3% vs 6.0%).

Hence, the most pronounced difference (&gt;10%) in AEs between the RUX and the BAT arm up to Day 28, was seen for thrombocytopenia (all grades and grad e ≥ 3) in aGvHD. There were also more CMV infections/reactivations in the RUX arm compared to the BAT arm, 22.4% vs 5.6% (all grades).

## REACH-2 AEs by PT up to DCO

The most frequent hematological AEs by PT ( ≥ 10% of patients) were anemia (37.8%), thrombocytopenia (35.3%), and neutropenia (23.4%), platelet count decreased (18.4%), white blood cell count decrease (11.9%), and neutrophil count decrease (11.4%).

Nonhematological AEs reported in ≥ 15% were hypokalemia (22.4%), cytomegalovirus infection reactivation (22.4%), pyrexia (21.4%), edema peripheral (20.9%), and nausea (16.4%).

Frequent non-hematological AEs by PT ( ≥ 10% in either treatment arm) were hypertension (15.8% vs. 12.7%), pyrexia (15.8% vs. 9.5%) and ALT elevation (15.2% vs. 4.4%), blood creatinine increased (13.9% vs 4.4%), pneumonia (10.9% vs 8.9%), cough (10.3% vs 7.0%), diarrhea (10.3% vs 13.3%), and fatigue (10.3% vs 7.6%).

In line with what is a known ADR for ruxolitinib, a higher incidence of CMV infections/reactivation is recorded in aGvHD.

Study 271: Per PT, all patients experienced at least one AE and majority of patients (97.2%) had at least one AE grade ≥ 3. Exposure adjusted incidence of all grade AEs and grade ≥ 3 AEs were 11950.6 events/100 PTY and 1666.8 events /100 PTY, respectively. All (71, 100.0%) patients experienced at least one AE and majority of them (97.2%) had at least one grade ≥ 3 event. Anaemia, platelet count decreased, neutrophil count decreased were the most frequently reported haematological AEs, and hypokalaemia and peripheral oedema were the most frequent non-haematological AEs.

<div style=\"page-break-after: always\"></div>

## Adverse events up to Day 28 visit, regardless of study treatment relationship in at least 10% patients in either treatment arm (all grades column), by preferred term (Safety set)

| Preferred term                             | All grades n (%)   | Grade 23 n (%)   | All grades n (%)   | Grade 23 n (%)   |
|--------------------------------------------|--------------------|------------------|--------------------|------------------|
| Number of subjects with at least one event | 145 (95.4)         | 118 (77.6)       | 140 (93.3)         | 117 (78.0)       |
| Thrombocytopenia                           | 50 (32.9)          | 41 (27.0)        | 27 (18.0)          | 23 (15.3)        |
| Anaemia                                    | 46 (30.3)          | 33 (21.7)        | 42 (28.0)          | 28 (18.7)        |
| Cytomegalovirus infection'                 | 39 (25.7)          | 11 (7.2)         | 31 (20.7)          | 12 (8.0)         |
| Oedema peripheral                          | 28 (18.4)          | 2 (1.3)          | 26 (17.3)          | 1 (0.7)          |
| Platelet count decreased                   | 26 (17.1)          | 22 (14.5)        | 21 (14.0)          | 20 (13.3)        |
| Neutropenia                                | 24 (15.8)          | 20 (13.2)        | 19 (12.7)          | 14 (9.3)         |
| Hypokalaemia                               | 20 (13.2)          | 9 (5.9)          | 25 (16.7)          | 9 (6.0)          |
| Hypertension                               | 16 (10.5)          | 9 (5.9)          | 14 (9.3)           | 6 (4.0)          |
| Hypoalbuminaemia                           | 16 (10.5)          | 6 (3.9)          | 15 (10.0)          | 10 (6.7)         |
| Pyrexia                                    | 16 (10.5)          | 2 (1.3)          | 17 (11.3)          | 2 (1.3)          |
| Hypomagnesaemia                            | 15 (9.9)           |                  | 20 (13.3)          | 1 (0.7)          |
| Diarrhoea                                  | 14 (9.2)           | 7 (4.6)          | 15 (10.0)          | 5 (3.3)          |

1: a distinction between cytomegalovirus infection and reactivation was not made due to MedDRA limitations (CMV reactivation coded to CMV infection).

Numbers (n) represent counts of subjects.

Preferred terms are sorted within each category in descending frequency, as reported in the all grades for the RUX treatment arm.

A subject with multiple severity grades for an AE was only counted under the maximum grade. Adverse events occurring outside the on-randomized-treatment period or after Day 31 were not summarized

MedDRAversion 22.0,CTCAE version 4.03.

cGvHD: In REACH-3, the difference in incidence of all AEs (all grades and grade ≥ 3) between the two treatment arms (RUX arm vs. BAT arm) was ≤ 10% with the exception of blood and lymphatic system disorders (41.8% vs. 22.2%, all grades) and investigations (50.3% vs. 32.3%, all grades).

In the RUX overall treatment group, the most frequent AEs by SOCs, were infections and infestations (68.6% of patients), blood and lymphatic system disorders (42.5% of patients).

Other frequent AEs by SOCs ≥ 30% of patients) were investigations (49.1%), metabolic and nutrition disorders (39.8%), general disorders and administration site conditions (39.4%), gastrointestinal disorders (38.5%), respiratory, thoracic and mediastinal disorders (38.1%), and musculoskeletal and connective tissue disorders (31.4%)).

There was a similar cumulative incidence for most in AEs by SOC in the RUX population up to Cycle 7 Day 1 and in the overall period, in cGvHD patients receiving ruxolitinib, however, an increase of the cumulative incidence of AEs by SOC was obvious in infections/infestations, eye disorders, musculoskeletal and connective tissue disorders and neoplasms benign/malignant.

Up to Cycle 7 Day 1, the most frequently observed AEs by PT (≥15% in either treatment arm) were anemia (29.1% vs. 12.7%), followed by hypertension (15.8% vs. 12.7%), pyrexia (15.8% vs. 9.5%) and ALT elevation (15.2% vs. 4.4%). Of note, the exposure to RUX was much longer than to BAT up to the data cut-off.

## REACH-3 AEs by PT up to DCO

The most frequent hematological AEs by PT ( ≥ 10% of patients) were anemia (28.8%), neutropenia (13.3%), and thrombocytopenia (11.5%). With the exception of pyrexia (18.1%), all other nonhematological AEs were reported in ≤ 15%.

The frequencies of AEs were similar between Cycle 7 Day 1 and up to DCO were similar.

<div style=\"page-break-after: always\"></div>

With regard to Hematological and non-hematological AEs, up to DCO for the main treatment period, the frequently observed AEs by PT ( ≥ 15% in either treatment arm) were anemia (32.1% vs. 13.9%), pyrexia (20.0% vs. 10.8%), ALT increase (17.6% vs. 4.4%), hypertension (17.6% vs. 13.3%), blood creatinine increased (15.8% vs. 4.4%), diarrhea (15.8% vs. 15.8%), and pneumonia (15.8% vs. 13.3%).

CMV infections/reactivations were seen in 5.5 % (Gr≥3: 1.2%) vs. 8.2 % (Gr≥3: 0%) in the RUX and the BAT arm respectively.

## Adverse events ( ≥ 5% of all grades in either arm) up to Cycle 7 Day 1 regardless of study treatment relationship, by preferred term (Safety set)

|                                            | RUX N=165        | RUX N=165      | BAT N=158        | BAT N=158     |
|--------------------------------------------|------------------|----------------|------------------|---------------|
| Preferred term                             | All grades n (%) | Grade ≥3 n (%) | All grades n (%) | Grade≥3 n (%) |
| Number of subjects with at least one event | 161 (97.6)       | 94 (57.0)      | 145 (91.8)       | 91 (57.6)     |
| Anaemia                                    | 48 (29.1)        | 21 (12.7)      | 20 (12.7)        | 12 (7.6)      |
| Hypertension                               | 26 (15.8)        | 8 (4.8)        | 20 (12.7)        | 11 (7.0)      |
| Pyrexia                                    | 26 (15.8)        | 3 (1.8)        | 15 (9.5)         | 2 (1.3)       |
| Alanine aminotransferase increased         | 25 (15.2)        | 7 (4.2)        | 7 (4.4)          | 0             |
| Blood creatinine increased                 | 23 (13.9)        | 0              | 7 (4.4)          | 1 (0.6)       |
| Neutropenia                                | 18 (10.9)        | 14 (8.5)       | 8 (5.1)          | 6 (3.8)       |
| Pneumonia                                  | 18 (10.9)        | 14 (8.5)       | 20 (12.7)        | 15 (9.5)      |
| Thrombocytopenia                           | 18 (10.9)        | 17 (10.3)      | 14 (8.9)         | 9 (5.7)       |
| Cough                                      | 17 (10.3)        | 0              | 11 (7.0)         | 0             |
| Diarrhoea                                  | 17 (10.3)        | 1 (0.6)        | 21 (13.3)        | 2 (1.3)       |
| Fatigue                                    | 17 (10.3)        | 1 (0.6)        | 12 (7.6)         | 3 (1.9)       |
| Platelet count decreased                   | 17 (10.3)        | 8 (4.8)        | 9 (5.7)          | 7 (4.4)       |
| Aspartate aminotransferase increased       | 16 (9.7)         | 3 (1.8)        | 4 (2.5)          | 1 (0.6)       |
| Dyspnoea                                   | 16 (9.7)         | 3 (1.8)        | 10 (6.3)         | 2 (1.3)       |
| Hypertriglyceridaemia                      | 16 (9.7)         | 8 (4.8)        | 13 (8.2)         | 6 (3.8)       |

<div style=\"page-break-after: always\"></div>

| Gamma-glutamyltransferase increased    | 15 (9.1)   | 11 (6.7)   | 5 (3.2)   | 3 (1.9)   |
|----------------------------------------|------------|------------|-----------|-----------|
| Nausea                                 | 15 (9.1)   | 0          | 16 (10.1) | 2 (1.3)   |
| Headache                               | 14 (8.5)   | 2 (1.2)    | 12 (7.6)  | 1 (0.6)   |
| Upper respiratory tract infection      | 14 (8.5)   | 0          | 13 (8.2)  | 2 (1.3)   |
| Hyperglycaemla                         | 13 (7.9)   | 8 (4.8)    | 5 (3.2)   | 3 (1.9)   |
| Hypokalaemia                           | 13 (7.9)   | 3 (1.8)    | 16 (10.1) | 7 (4.4)   |
| Blood cholesterol increased            | 12 (7.3)   | 4 (2.4)    | 7 (4.4)   | 3 (1.9)   |
| Constipation                           | 12 (7.3)   | 0          | 8 (5.1)   | 0         |
| Oedema peripheral                      | 12 (7.3)   | 1 (0.6)    | 14 (8.9)  | 0         |
| Vomiting                               | 12 (7.3)   | 0          | 10 (6.3)  | 2 (1.3)   |
| Amylase increased                      | 11 (6.7)   | 5 (3.0)    | 3 (1.9)   | 0         |
| Back paln                              | 11 (6.7)   | 1 (0.6)    | 11 (7.0)  | 0         |
| Insomnia                               | 11 (6.7)   | 0          | 6 (3.8)   | 0         |
| Myalgia                                | 11 (6.7)   | 0          | 5 (3.2)   | 0         |
| Urinary tract infection                | 11 (6.7)   | 1 (0.6)    | 5 (3.2)   | 2 (1.3)   |
| Arthralgia                             | 10 (6.1)   | 0          | 8 (5.1)   | 0         |
| Lipase increased                       | 10 (6.1)   | 4 (2.4)    | 2 (1.3)   | 1 (0.6)   |
| Nasopharyngitis                        | 10 (6.1)   | 0          | 6 (3.8)   | 0         |
| BK virus infection                     | 9 (5.5)    | 1 (0.6)    | 2 (1.3)   | 0         |
| Cytomegalovirus infection reactivation | 9 (5.5)    | 2 (1.2)    | 13 (8.2)  | 0         |
| Hypercholesterolaemia                  | 9 (5.5)    | 2 (1.2)    | 2 (1.3)   | 1 (0.6)   |
| Hyperkalaemia                          | 9 (5.5)    | 3 (1.8)    | 4 (2.5)   | 1 (0.6)   |
| Hypomagnesaemia                        | 6 (3.6)    | 0          | 11 (7.0)  | 0         |
| Tremor                                 | 6 (3.6)    | 0          | 8 (5.1)   | 口         |
| Abdominal pain                         | 2 (1.2)    | 2 (1.2)    | 8 (5.1)   | 0         |

Numbers (n) represent counts of subjecls.

A subject with multiple severity grades for an AE Is only counted under the maximum grade.

MedDRA vcrslon 23.0, CTCAE vorslon 4.03.

## Adverse events suspected to be related to the study drug

In REACH-2 aGvHD, the most frequent AEs by PT (all grades) suspected to be related to study treatment ( ≥ 5% patients) in the RUX arm were haematological in nature, cytopenia including thrombocytopenia (19.1%), anemia and platelet count decreased (11.2% each), neutropenia (7.2%), WBC count decreased (5.9%), neutrophil count decreased (5.3%). All other non-haematological AEs were reported in ≤ 5%. Similarly, grade ≥ 3 AEs suspected to be related to RUX were also haematological AEs with the most frequent PTs including thrombocytopenia (14.5%), platelet count decreased (10.5%), anaemia (7.9%), neutropenia (5.9%), WBC count decreased (5.3%), and neutrophil count decreased (5.3% each). In the BAT arm, with the exception of platelet count decrease, white blood cell count decrease, and cytomegalovirus infection (which occurred in 4.7% of patients each), all other AEs by PT (all grades) suspected to be related to study treatment occurred in &lt; 4%. Grade ≥ 3 AEs suspected to be related to study treatment were infrequent (&lt;2%) with the exception of platelet count decreased (4.7%), decreased white blood cell count and thrombocytopenia (4.0% each), and anaemia (2.0%). Up to data cut-off (including cross-over period): AEs (all grades) and grade ≥ 3 AEs suspected to be related to study drug were reported in 66.2% and in 56.2% of patients. Similar to the frequencies observed up to Day 28, the most frequent AEs by PT (all grades) suspected to be related to study treatment ( ≥ 5% patients) in the RUX arm were haematological AEs. Exposure adjusted incidence of all grade AEs suspected to be related to study drug were 506.1 events/100 PTY. The most frequent exposure-adjusted incident rates (per 100 PTY) of AEs (all grades) were thrombocytopenia (85.4) and anaemia (58.6). Exposure adjusted incidence of grade ≥ 3 AEs suspected to be related to study drug were 320.1 events/100 PTY with thrombocytopenia (72.7) and anaemia (43.4) being the most frequent AEs.

<div style=\"page-break-after: always\"></div>

Study 271: AEs (all grades) and grade ≥ 3 AEs suspected to be related to study drug were reported in 76.1% and in 64.8% of patients, respectively. Exposure adjusted incidence of all grade AEs and grade ≥ 3 suspected to be related to study drug were 722.5 events/100 PTY and 383.7 events/100 PTY.

REACH-3 cGvHD : Up to Cycle 7 Day 1: In Study D2301, the most frequent ( ≥ 5% patients) AEs by PT (all grades) suspected to be related to study treatment in the RUX arm were haematological AEs. Up to Cycle 7 Day 1, the most frequent (in ≥ 5% patients) AEs by PT (all grades) reported as related to study treatment in the RUX arm were anaemia (21.7%), neutropenia (10.2%) and thrombocytopenia (8.4%), ALT (8.0%), and pneumonia (5.8 %). The most frequent grade ≥ 3 AEs suspected to be related to RUX by PTs were also occurred with anaemia (9.7%), thrombocytopenia (7.1%), and neutropenia (6.6%). In Study D2301, RUX treatment up to data cut-off (including cross-over period) was similar to the frequencies observed up to Cycle 7 Day 1. During the Crossover treatment period, 24 (39.3%) patients experienced at least one AE suspected to be related to study treatment, of whom 12 (19.7%) patients experienced grade ≥ 3 AEs. The frequently reported incidence ( ≥ 10 %) of AEs by SOC suspected to be related to RUX treatment were: blood and lymphatic system disorders (23.0% with all grades and 8.2% with grade ≥ 3 in severity), infections and infestations (14.8% with all grades and 8.2 % with grade ≥ 3), and gastrointestinal disorders (11.5% with all grades and 1.6% (n=1) with grade ≥ 3) (CSR study D2301).

With adjusted by exposure, the incidence rate of all grade AEs was higher in the RUX arm than in the BAT arm (1055.9 events/100 PTY vs. 863.3 events/100 PTY) with anaemia being the most frequent (42.9 vs 23.3 events/100 PTY), followed by pyrexia (24.4 vs 17.3) and ALT elevation (21.4 vs 6.9). (CSR study D2301). When adjusted for exposure, the incidence of grade ≥ 3 AEs was higher in the BAT arm (149.0 events/100 PTY) than in the RUX arm (123.7 events/100 PTY) with as most frequent in the RUX arm anaemia (16.9 vs. 11.9), pneumonia (14.6 vs. 15.7), neutropenia (13.5 vs. 5.8), thrombocytopenia (12.8 vs. 8.9).

## AEs by age

Differences were observed in the occurrence of AEs within the age subgroups (18 to 65 years old group and &gt;65 years old group) in the RUX treatment arm of REACH 2. Grade ≥ 3 AEs were similar across the subgroups but patients with SAEs were higher the &gt;65 years old group (82.8%) compared to the 18 to 65 years old group (66.9%). The comparison with BAT in the elderly age group shows that in Study C2301, patients older than 65 experience more grade 3 or higher AEs in RUX arm (95.2%) than in BAT (79.2%) and more were considered treatment related in the RUX arm. This was also confirmed with higher percentages SAE, AEs leading to discontinuation, AEs leading to dose adjustments and AEs requiring additional therapy (table 2-28), even though the sample size limits accurate definition of incidences. In REACH 3, in patients older than 65 experience numerical differences were noted but assessment is hampered by the limited number of subjects older than 65 years of age (18 vs 22).Serious adverse events and deaths

## Deaths aGvHD

For aGvHD and cGvHD, on-treatment deaths were defined as deaths from date of first administration of randomised treatment to 30 days after the last administration of randomised treatment or end of randomised treatment period, whichever is later.

REACH-2 - Up to Day 28: Up to Day 28, there were a total of 36 on-treatment deaths (RUX 15 (9.9%) vs BAT 21 (14.0%)). The primary reason for death was reported as study indication (including complications of the disease that were attributed to aGvHD itself or to its treatments) (5.9% RUX vs 11.3% BAT).

<div style=\"page-break-after: always\"></div>

Up to data cut-off (including cross-over period), in RUX treated patients 62 on-treatment deaths (30.8%) were reported, of which in 29 patients (14.4%), the primary reason for death was reported as study indication (including complications of the disease that were attributed to aGvHD itself or to its treatments).

Study 271: Of the 30 deaths, 25 (35.2%) were on-treatment deaths. Seven (9.9%) were due to study indication and 18 were due to other reasons. Of note, for this study, no primary reason for death was collected. Instead, all AEs with fatal outcome were summarized. Therefore, a patient can have more than one reason for death.

## On-treatment deaths in acute GvHD (Safety set including cross over)

| Category Preferred term             | Study C2301 Rux overall1 N=201 n (%)   | Study 271 Rux N=71 n (%)   |
|-------------------------------------|----------------------------------------|----------------------------|
| On-treatment deaths                 | 62 (30.8)                              | 25 (35.2)                  |
| Primary reason: Study indication    | 29 (14.4)                              | 7 (9.9)                    |
| Acute graft versus host disease     | 29 (14.4)                              | 0                          |
| GvHD Progression                    | 0                                      | 7 (9.9)                    |
| Primaryreason:Other                 | 33 (16.4)                              | 18 (25.4)                  |
| Sepsis                              | 4 (2.0)                                | 1 (1.4)                    |
| Respiratory failure                 | 3 (1.5)                                | 3 (4.2)                    |
| Multiple organ dysfunction syndrome | 2 (1.0)                                | 2 (2.8)                    |
| Cardiac arrest                      | 2 (1.0)                                | 1 (1.4)                    |
| Disease progression                 | 2 (1.0)                                | 1 (1.4)                    |
| Septic shock                        | 2 (1.0)                                | 0                          |
| Pulmonary haemorrhage               | 1 (0.5)                                | 1 (1.4)                    |
| Acute myeloid leukaemia             | 1 (0.5)                                | 0                          |
| Acute myeloid leukaemia recurrent   | 1 (0.5)                                | 0                          |
| Adenovirus infection                | 1 (0.5)                                | 0                          |
| Cardiopulmonary failure             | 1 (0.5)                                | 0                          |
| Cerebrovascular accident            | 1 (0.5)                                | 0                          |
| Coma                                | 1 (0.5)                                | 0                          |
| Condition aggravated                | 1 (0.5)                                | 0                          |
| Death                               | 1 (0.5)                                | 0                          |
| General physical condition abnormal | 1 (0.5)                                | 0                          |
| Idiopathicpneumoniasyndrome         | 1 (0.5)                                | 0                          |

<div style=\"page-break-after: always\"></div>

| Category Preferred term            | Study C2301 Rux overall1 N=201 n (%)   | Study 271 Rux N=71 n (%)   |
|------------------------------------|----------------------------------------|----------------------------|
| Infection                          | 1 (0.5)                                | 0                          |
| Lung disorder                      | 1 (0.5)                                | 0                          |
| Pneumonitis                        | 1 (0.5)                                | 0                          |
| Renal impairment                   | 1 (0.5)                                | 0                          |
| Respiratory disorder               | 1 (0.5)                                | 0                          |
| Respiratory tract infection        | 1 (0.5)                                | 0                          |
| Viral infection                    | 1 (0.5)                                | 0                          |
| Pneumonia                          | 0                                      | 2 (2.8)                    |
| Candida infection                  | 0                                      | 1 (1.4)                    |
| Device related infection           | 0                                      | 1 (1.4)                    |
| Fungaemia                          | 0                                      | 1 (1.4)                    |
| Graft versus host disease in liver | 0                                      | 1 (1.4)                    |
| Hepatic failure                    | 0                                      | 1 (1.4)                    |
| Lower gastrointestinal haemorrhage | 0                                      | 1 (1.4)                    |
| Peritonitis                        | 0                                      | 1 (1.4)                    |
| Pneumonia legionella               | 0                                      | 1 (1.4)                    |
| Pulselesselectrical activity       | 0                                      | 1 (1.4)                    |
| Staphylococcal sepsis              | 0                                      | 1 (1.4)                    |
| Sudden death                       | 0                                      | 1 (1.4)                    |
| Venoocclusiveliverdisease          | 0                                      | 1 (1.4)                    |

MedDRA version 23.0

1 includes the total number of patients at the time of data cut-off including the patients after cross-over. In Study 271, no primary reason for death was collected. Instead, all AEs with fatal outcome are summarized. Therefore, a patient can have more than one reason for death.

## Deaths cGvHD

REACH-3- Up to Cycle 7 Day 1: A total of 13 (7.9%) patients in the RUX arm and 9 (5.7%) patients in the BAT arm died during the study. Of the 13 deaths in the RUX arm, 12 were due to study indication (including complications of the disease that were attributed to cGvHD itself or to its treatments), and one (1.6%) was due to general physical health deterioration (reported more than 30 days after last dose of RUX but before end of randomisation period).

- In Study REACH 3 up to data cut-off (including cross-over period), there were 19 deaths (8.4%) in RUX treated patients. Of these, 16 reported the primary reason for death as study indication (4 additional patients since cycle 7 day 1) (Table 7).

A more detailed description of the primary cause of death depicted as 'study indication' for cGVHD has been provided. An overview of corresponding fatal SAEs according to the primary cause of ontreatment death reported as study indication up to Cycle 7 Day 1 by treatment arm with suspected treatment relationship was presented. Review of the 13 fatal cases in the ruxolitinib arm showed that the status of underlying GvHD prior to / at onset of events was either partial response or stable disease in all cases. None showed GvHD progression. It is clarified that the fatal cases of pneumonia can also be attributed to primary cause of death 'study indication', of which one case was not related to study treatment and 7 cases were related to RUX and/or concomitant treatment versus 2 cases of pneumonia in the BAT arm. The relation to RUX, in the majority of the cases could not be distinguished due to the concomitant administration of prednisolone, tacrolimus, cyclosporin.

On-treatment deaths in chronic GvHD (Safety set)

<div style=\"page-break-after: always\"></div>

| Category Preferred term              | Study D2301 Rux overall N=226 n (%)   |
|--------------------------------------|---------------------------------------|
| On-treatment deaths                  | 19 (8.4)                              |
| Primaryreason:Study indication       | 16 (7.1)                              |
| Chronic graftversushost disease      | 16 (7.1)                              |
| Primary reason: Other                | 3 (1.3)                               |
| Generalphysical health deterioration | 1 (0.4)                               |
| Haemorrhage intracranial             | 1 (0.4)                               |
| Pseudomonal sepsis                   | 1 (0.4)                               |

1includes the total number of patients at the time of data cut-off including the patients after cross-over.

MedDRAversion23.0

## SAEs with fatal outcome

In REACH-2 up to Day 28, SAEs with a fatal outcome was 7.9% in RUX arm and 11.3% in BAT arm. The majority of the fatal SAEs up to Day 28 were not suspected to be related to study treatment. Fatal SAEs in 3.9% in the RUX arm and 8.7% in the BAT were due to the study indication (including complications of the disease that were attributed to aGvHD itself or to its treatments). Up to DCO (including cross-over period), a total of 48 (23.9%) ruxolitinib patients had SAEs with fatal outcomes, out of which 20 (10.0%) were attributed to study indication and 28 deaths due to other causes. The most common SAEs ( ≥ 1%) by PT with a fatal outcome due to other causes were respiratory failure (4 patients, 2.0%), sepsis (3 patients, 1.5%), and septic shock (3 patients, 1.5%). Study treatment related SAEs with fatal outcome were reported in 14 patients.

In REACH-1, a total of 28 (39.4%) patients had SAEs with fatal outcomes out of which 9 (12.7%) were due to study indication and 19 (26.8%) were due to other causes (most frequently reported were infections).

In REACH-3, SAEs with a fatal outcome were reported in 7.3% in the RUX arm and 5.1% in the BAT arm. Also, in REACH-3, study indication was reported to be the primary cause of fatal SAEs in 6.7% patients in the RUX arm, and 3.2% patients in the BAT arm. The most common SAE(s) ( ≥ 1%) by PT with a fatal outcome was pneumonia (3.0%) in the RUX arm and pneumonia and septic shock (1.3% each) in the BAT arm. Study treatment related SAEs with fatal outcome were reported in 4.2% and 2.5% patients in ruxolitinib and BAT arms, respectively.

## SAEs

REACH-2 A similar proportion of patients in the RUX arm (57; 37.5%) and the BAT arm (51; 34.0%) experienced an SAE up to day 28, regardless of relationship to study treatment. Grade ≥ 3 SAEs were reported in 36.2% of patients in the RUX arm and 31.3% in the BAT arm (Table 35). The incidence of Grade ≥ 3 SAEs was 36.2% in the RUX arm and 31.3% in the BAT arm. In the RUX arm, sepsis (5.3%) was the only Grade ≥ 3 SAE by PT observed in &gt;5% patients. In the BAT arm, cytomegalovirus infection (3.3%) and septic shock and respiratory failure (2.7% each), were the most frequent Grade ≥ 3 SAE by PT. Up to the data cut-off date, SAEs were observed in 65.1% patients in the RUX group and 52.7% patients in the BAT group. The difference was driven to some extent by the SOC of infections and infestations (38.2% in the RUX arm and 30.0% in the BAT arm).

Overall, when adjusted for exposure, the incidence of SAEs (all grades) was higher in the BAT arm (427.4 per 100 PTY) than in the RUX arm (330.8 per 100 PTY). The exposure-adjusted incidence rate (per 100 PTY) of SAEs by PT higher ( ≥ 10 events difference) in the BAT arm relative to the RUX arm were (BAT vs RUX): Sepsis (38.4 vs 26.7), Cytomegalovirus infection (28.8 vs. 13.5, and Pneumonia (27.6 vs. 13.4). The exposure-adjusted incidence rate (per 100 PTY) of Grade ≥ 3 SAEs by PT observed

<div style=\"page-break-after: always\"></div>

at a higher rate ( ≥ 10 events difference) in the BAT arm relative to the RUX arm (BAT vs RUX) were: Sepsis (38.4 vs 26.7), Cytomegalovirus infection (28.8 vs 13.5), Pneumonia (27.6 vs 13.4).

Serious adverse events in REACH-2, regardless of relationship to study treatment, in at least 2% patients in either treatment arm (all grades column), by preferred term (Safety set)

|                                            | RUX N=152        | RUX N=152     | BAT N-150        | BAT N-150      |
|--------------------------------------------|------------------|---------------|------------------|----------------|
| Preferred term                             | All grades n (%) | Grade23 n (%) | All grades n (%) | Grade 23 n (%) |
| Number of subjects with at least one event | 99 (65.1)        | 94 (61.8)     | 79 (52.7)        | 74 (49.3)      |
| Sepsis                                     | 12 (7.9)         | 12 (7.9)      | 11 (7.3)         | 11 (7.3)       |
| Septic shock                               | 10 (6.6)         | 10 (6.6)      | 8 (5.3)          | 8 (5.3)        |
| Pyrexia                                    | 9 (5.9)          | 4 (2.6)       | 6 (4.0)          | 3 (2.0)        |
| Diarrhoea                                  | 7 (4.6)          | 7 (4.6)       | 3 (2.0)          | 2 (1.3)        |
| Cytomegalovirus infection                  | 6 (3.9)          | 6 (3.9)       | 8 (5.3)          | 8 (5.3)        |
| Pneumonia                                  | 6 (3.9)          | 6 (3.9)       | 8 (5.3)          | 8 (5.3)        |
| Respiratory failure                        | 6 (3.9)          | 6 (3.9)       | 6 (4.0)          | 6 (4.0)        |
| Neutropenia                                | 4 (2.6)          | 4 (2.6)       | 3 (2.0)          | 3 (2.0)        |
| Acute kidney injury                        | 3 (2.0)          | 3 (2.0)       | 4 (2.7)          | 4 (2.7)        |
| Blood bilirubin Increased                  | 3 (2.0)          | 3 (2.0)       | 0                |                |
| Cylomegalovirus colitis                    | 3 (2.0)          | 3 (2.0)       | 0                | 0              |
| Febrile neutropenia                        | 3 (2.0)          | 3 (2.0)       | 2 (1.3)          | 2 (1.3)        |
| Pancytopenia                               | 3 (2.0)          | 3 (2.0)       | 0                | 0              |
| Multiple organ dysfunction syndrome        | 2 (1.3)          | 2 (1.3)       | 3 (2.0)          | 3 (2.0)        |
| Renal failure                              | 2 (1.3)          | 1 (0.7)       | 3 (2.0)          | 2 (1.3)        |
| Pseudomonal sepsis                         | 3 (2.0)          | 3 (2.0)       | 0                | 0              |
| Bacteraemia                                | 1 (0.7)          | 1 (0.7)       | 4 (2.7)          | 3 (2.0)        |
| Confusional state                          | 1 (0.7)          | 1 (0.7)       | 3 (2.0)          | 2 (1.3)        |
| Graft versus host disease                  | 1 (0.7)          | 1 (0.7)       | 3 (2.0)          | 3 (2.0)        |
| Platelet count decreased                   | 0                | 0             | 3 (2.0)          | 3 (2.0)        |

Numbers (n) represent counts of subjects.

Preferred tems are sorted within each category in descending frequency, as reported in the all grades for the RuX treatment arm.

A subject with multiple severity grades for an AE was only counted under the maximum grade.

Adverse events occuring outside the on-randomized-treatment period are not summarzed.

MedDRA version 22.0, CTCAE version 4.03.

## SAE related to study treatment:

REACH-2: Up to Day 28, the incidence of SAEs suspected to be related to study treatment was similar between the RUX arm and BAT arm (10.5% vs. 7.3%), with as most common SOC in either treatment arm: infections and infestations (5.9% RUX vs 4.0% BAT). All other SOCs were observed in &lt;2% patients in either treatment arm. The treatment related SOCs of cardiac disorders, general disorders and administrative site conditions, immune system disorders, hepatobiliary disorders and renal and urinary disorders were observed only in the BAT arm. Except for PT sepsis observed in 3 patients randomized to RUX arm, no other SAE by PT occurred in more than 1 or 2 patients each.

Up to the data cut-off date, the incidence of SAEs suspected to be related to study treatment was higher in the RUX arm compared to BAT arm (25.7% vs. 11.3%). Except for PT sepsis, observed in 5 patients randomized to RUX arm, no other SAE by PT occurred in more than 1 or 2 patients each. In all these 5 patients reported with sepsis, the events were attributed to both RUX and other study treatments (CNIs and/or steroids). The single SAE of graft loss in the RUX arm was observed at data cut-off. After crossover, the incidence (24.5%) and overall profile of SAEs suspected to be related to study treatment was consistent with that observed in patients randomized to RUX.

In the crossover period, 77.6% patients had SAEs and Grade ≥ 3 SAEs were reported in (75.5%) patients and the most common Grade ≥ 3 SAEs by PT were: sepsis (14.3%) and respiratory failure

<div style=\"page-break-after: always\"></div>

(12.2%). Up to the second analysis DCO, the incidence of SAEs suspected to be related to study treatment was higher in the RUX arm compared to BAT arm (27.0% vs. 12.0%), driven by higher incidence ( ≥ 5% difference) of the SOCs in the blood and lymphatic system disorders (5.3% vs 0.7%) and infections and infestations (14.5% vs. 6.7%) in the RUX arm relative to the BAT arm. After crossover, the incidence and overall profile of SAEs suspected to be related to study treatment was consistent with that observed in ruxolitinib arm at second analysis cutoff.

Study 271: SAEs were reported in 83.1% of patients. Exposure adjusted incidence of SAEs was 487.2 events/100 PTY. The most frequent SAEs by exposure adjusted incidence were pneumonia (33.9%), sepsis (33.5%), and pyrexia (31.8%).

## REACH-3

Up to Cycle 7 Day 1, a similar proportion of patients in the RUX arm (33.3%) and the BAT arm (36.7%) experienced an SAE. By PT, the frequent ( ≥ 2% patients in either treatment arm) SAEs (RUX vs. BAT) were: pneumonia (7.9% vs. 8.2%), pyrexia (4.8% vs. 1.9%), lower respiratory tract infection (2.4% vs. 0), and bronchopulmonary aspergillosis (1.2% vs. 2.5%). The incidence of grade ≥ 3 SAEs was 29.7% in the RUX arm and 33.5% in the BAT arm. Up to the data cut-off date for the Main treatment period, the overall SAE profile was similar to those up to Cycle 7 Day 1 with a slight increase in the incidence as expected due to longer exposure. SAEs were observed in 43.6% of patients in the RUX arm and 39.9% of patients in the BAT arm.

Overall, when adjusted for exposure, the incidence of SAEs (all grades) was higher in the BAT arm (76.6 per 100 PTY) than in the RUX arm (60.3 per 100 PTY). Similarly, the incidence of grade ≥ 3 SAEs was higher in the BAT arm (65.4 events/100 PTY) than in the RUX arm (51.6 events/100 PTY). The Exposure-adjusted incidence rate of most commonly observed (with &gt;5 per 100 PTY) all grades SAEs (by PT) in the RUX arm and the BAT arm (RUX and BAT, respectively) were: pneumonia (13.8 and 13.7 per 100 PTY) and pyrexia (7.3 and 3.9 per 100 PTY).

## SAE related to study treatment:

Up to Cycle 7 Day 1, the incidence of SAEs reported as related to study treatment was 16.4% in the RUX arm and 10.1% in the BAT arm. The most common SAE (by PT) reported as related to study treatment was pneumonia in 6.1% of patients in RUX arm and 2.5% of patients in the BAT arm, followed by pyrexia 2.4% (4 patients) in RUX arm vs. 0.6% (1 patient) in the BAT arm. Other SAEs by PT occurred in &lt; 2 patients in each arm. Up to the data cut-off date for the Main treatment period, the incidence of SAEs reported as related to study treatment was higher in the RUX arm compared to the BAT arm (21.2% vs. 10.1%). The incidence of SAEs (by PT) with pneumonia was higher in the RUX arm (n=12, 7.3%) compared to that in the BAT arm (n=4, 2.5%). Pyrexia was observed in 5 patients (3.0%) in the RUX arm vs. 1 patient (0.6%) in the BAT arm and lower respiratory tract infection was observed in 4 patients (2.4%). Other SAE by PT occurred in no more than 2 patients in each arm.

After cross over to RUX treatment, SAEs related to study treatment were reported in 8 (13.1%) patients with all grades and in 8 (13.1%) patients with grade ≥ 3. The most common ( ≥ 5%) SAEs suspected to be related to study treatment by SOC (all grade, grade ≥ 3) were: infections and infestations (8.2%, 8.2%) and blood and lymphatic system disorders (6.6%, 4.9%).

## AEs leading to treatment discontinuations

## REACH-2 aGvHD

Up to Day 28, AE(s) leading to permanent discontinuation of study treatment were reported in 11.2% and 4.0% patients in the RUX arm and BAT arm, respectively, of whom most were of Grade ≥ 3 in

<div style=\"page-break-after: always\"></div>

severity. The most common AEs ( ≥ 2%) by PT leading to discontinuation in RUX arm were anemia and thrombocytopenia. In the BAT arm, no single AE (by PT) occurred in more than one patient leading to discontinuation.

Up to the second DCO, AEs leading to discontinuation were observed in 27% in the RUX arm and 9.3% in the BAT arm. The majority of AEs leading to discontinuation in both arms were Grade ≥ 3 in severity (23.0% and 8.7%). The most common ( ≥ 2%) AEs leading to discontinuation in the ruxolitinib arm were neutropenia, sepsis (2.6% each) and anemia and thrombocytopenia (2.0% each).

Study 271 AEs (all grades) leading to discontinuation were reported in 32.4% of patients and grade ≥ 3 AEs in 28.2% matching the frequencies in REACH-2.

## REACH-3 cGvHD

Up to Cycle 7 Day 1, AEs leading to discontinuation were observed in 16.4% in the RUX arm and 7.0% in the BAT arm. The majority of the AEs were grade ≥ 3 and pneumonia was the only AE (all grades) leading to discontinuation in at least 2% patients in ruxolitinib arm (4.8%, grade ≥ 3: 3,6%). Discontinuations due to pneumonia were 1.3% in BAT arm.

## Adverse events, leading to study drug discontinuation, by PT (Safety Set) ( ≥ 2 patients)

| Preferred term                             | StudyD2301 Rux overallt N=226   | Grade 23 n (%)   |
|--------------------------------------------|---------------------------------|------------------|
|                                            | All grades n (%)                |                  |
| Number of patients with at least one event | 41 (18.1)                       | 30 (13.3)        |
| Pneumonia                                  | 9 (4.0)                         | 7 (3.1)          |
| Thrombocytopenia                           | 2 (0.9)                         | 2 (0.9)          |
| Haemorrhageintracranial                    | 2 (0.9)                         | 2 (0.9)          |
| Septic shock                               | 2 (0.9)                         | 2 (0.9)          |
| Alanine aminotransferase Increased         | 2 (0.9)                         | 1 (0.4)          |
| Pneumothorax                               | 2 (0.9)                         | 1 (0.4)          |
| Anaemia                                    | 2 (0.9)                         | 0                |

Numbers (n)represent countsofpatients.

1 includes the total number of patients at the time of data cut-off including the patients after crossover.

A patient with multiple severity grades for an AE is only counted under the maximum grade.

MedDRAversion23.0.CTCAEversion4.03

Up to DCO, AEs (all grades) leading to discontinuation were reported in 18.1% and grade ≥ 3 AEs in 13.3% of ruxolitinib treated patients.

In aGvHD most treatment discontinuations were due to hematological AEs while most treatment discontinuations in cGvHD were due to infections.

It should be noted that discontinuation criteria were outlined in protocol only for ruxolitinib treatment while discontinuation criteria of BAT treatments were left at INV's judgement per standard of care.

## AEs leading to dose adjustment and/or interruption

## REACH-2 aGvHD

Up to Day 28, 36.8% and 9.3% the RUX arm and BAT arm, respectively, experienced an AE leading to dose adjustment or interruption. Majority of the AEs leading to dose adjustment or interruption in both treatment arms were Grade ≥ 3 in severity (33.6% and 5.3%).

<div style=\"page-break-after: always\"></div>

The higher incidence of AEs leading to dose adjustment or interruption in the RUX arm compared to the BAT arm was driven by cytopenias (Thrombocytopenia: 14.5% vs. 1.3%, Neutropenia 11.8% vs. 0.7%, Platelet count decreased 11.2% vs. 2.7%, Leukopenia (5.3% vs. 0.7%).

Up to DCO, 54.6% of patients on ruxolitinib treatment experienced AEs (all grades) leading to dose adjustment or interruption, driven by cytopenias. In BAT arm 13.3% were dose adjusted or interrupted Most of the AEs were Grade ≥ 3 in severity in both treatment arms (50.0% and 9.3%).

In REACH-1, AEs (all grades) leading to dose adjustment or interruption were seen in 64.8% patients (grade ≥ 3: 59.2%) and cytopenias were the most common reason.

## REACH-3 cGvHD

Up to Cycle 7 Day 1, 37.6% (grade ≥ 3. 23.0%) in the RUX arm and 16.5% (grade ≥ 3: 7.6%) in the BAT arm experienced an AE leading to dose adjustment or interruption. In the RUX arm, anemia (7.9%) and blood creatinine increased (6.1%) were the most frequent AEs leading to dose adjustment or interruption ( ≥ 5%). In the BAT arm, except for pyrexia observed in 3 patients, no other PTs were observed in more than two patients.

Up to DCO for the main treatment period (including cross-over period) ruxolitinib treatment AEs lead to a dose adjustment or interruption in 43.0% (grade ≥ 3: 28.5%). In the BAT arm these events occurred in 18.4% (grade ≥ 3: 8.2%). In the RUX arm, AEs occurring ≥ 5% (all grades) and leading to dose adjustment or interruption were anemia (8.8%, grade ≥ 3: 4.0%), and neutropenia (6.6%). Most frequent ( ≥ 2%) grade ≥ 3 AEs were neutropenia (5.3%), anemia (4.0%), pneumonia (3.5%), thrombocytopenia (2.7%), and ALT increased (2.7%).

Criteria for dose adjustment/ interruption for ruxolitinib were outlined in the protocol, however with respect to BAT this was left at the Investigator's judgement.

## Adverse events of special interest

AESIs are defined based on known safety data.

The aggregated PTs used to identify the AESI were based on the standardized MedDRA Queries (SMQs) /or group of PTs using MedDRA version 22.1 for REACH-2 and version 23.0 for REACH-3.

Note that the AESIs, in the RUX arm and in the BAT arm, are presented up to Day 28 in REACH-2, aGvHD and up to Cycle 7 Day 1 in REACH-3, cGvHD.

Further, the safety data (AESI) for the entire treatment period up to cut-off date for ruxolitinib treated patients (including patients originally randomized to BAT and who crossed over to ruxolitinib) is presented (for aGvHD and cGvHD) followed by exposure adjusted analysis.

<div style=\"page-break-after: always\"></div>

## Overview of adverse events of special interest in acute and chronic GvHD

|                               | StudyC2301 Ruxoverall1 N=201   | StudyC2301 Ruxoverall1 N=201   | Study271 Rux N =71   | Study271 Rux N =71   | StudyD2301 Ruxoverall1   | StudyD2301 Ruxoverall1   |
|-------------------------------|--------------------------------|--------------------------------|----------------------|----------------------|--------------------------|--------------------------|
| Safety topic                  | AII n (%)                      | Grade23 n (%)                  | AII n (%)            | Grade≥3 n (%)        | AII grades n (%)         | Grade≥3 n (%)            |
| Infections                    |                                |                                |                      |                      |                          |                          |
| Infectionsexcluding           | 159 (79.1)                     | 104 (51.7)                     | 58 (81.7)            | 46 (64.8)            | 157 (69.5)               | 59 (26.1)                |
| Tuberculosis                  |                                |                                |                      |                      |                          |                          |
| Opportunistic infections      | 67 (33.3)                      | 26 (12.9)                      | 15 (21.1)            | 7 (9.9)              | 26 (11.5)                | 7 (3.1)                  |
| CMVinfeclion/disease          | 65 (32.3)                      | 23 (11.4)                      | 14 (19.7)            | 6 (8.5)              | 20 (8.8)                 | 3 (1.3)                  |
| Sepsis and septic shock       | 51 (25.4)                      | 44 (21.9)                      | 16 (22.5)            | 15 (21.1)            | 8(3.5)                   | 8(3.5)                   |
| Pneumonia                     | 36 (17.9)                      | 26 (12.9)                      | 17 (23.9)            | 15 (21.1)            | 47 (20.8)                | 36 (15.9)                |
| Urinary tract infeclions(uTl) | 36 (17.9)                      | 13 (6.5)                       | 10 (14.1)            | 6 (8.5)              | 21 (9.3)                 | 3 (1.3)                  |
| Herpes zoster                 | 4 (2.0)                        | 2 ( 1.0)                       | 0                    | 0                    | 4 (1.8)                  | 3(1.3)                   |
| HepatitisBreactivation        | 1 (0.5)                        | 0                              | 0                    | 0                    | 1 (0.4)                  | 0                        |
| Other infections              | 128 (63.7)                     | 60 (29.9)                      | 42 (59.2)            | 30 (42.3)            | 131 (58.0)               | 26 (11.5)                |
| Cytopenias                    |                                |                                |                      |                      |                          |                          |
| Thrombocytopenia              | 107 (53.2)                     | 94 (46.8)                      | 44 (62.0)            | 38 (53.5)            | 45 (19.9)                | 33 (14.6)                |
| Leukopenia                    | 89 (44.3)                      | 82 (40.8)                      | 42 (59.2)            | 35 (49.3)            | 50 (22.1)                | 37 (16.4)                |
| Erythropenia (Anemia)         | 78 (38.8)                      | 64 (31.8)                      | 46 (64.8)            | 36 (50.7)            | 65 (28.8)                | 31 (13.7)                |
| OtherCytopenias               | 18 (9.0)                       | 14 (7.0)                       | 0                    | 0                    | 2(0.9)                   | 1 (0.4)                  |
| Bleedingevents                |                                |                                |                      |                      |                          |                          |
| Bleeding(Haemorrhage)         | 74 (36.8)                      | 25 (12.4)                      | 35 (49.3)            | 14 (19.7)            | 26 (11.5)                | 6 (2.7)                  |
| Gl bleoding                   | 33 (16.4)                      | 16 (8.0)                       | 19 (26.8)            | 9 (12.7)             | 2 (0.9)                  | 2 (0.9)                  |
| Bruising                      | 21 (10.4)                      | 2 (1.0)                        | 10 (14.1)            | 1 (1.4)              | 9 (4.0)                  | 0                        |
| Intracranialhaemorrhage       | 2 (1.0)                        | 2 (1.0)                        | 1 (1.4)              | 0                    | 2 (0.9)                  | 2 (0.9)                  |
| Otherhaemorrhageevents        | 35 (17.4)                      | 5 (2.5)                        | 22 (31.0)            | 4 (5.6)              | 15 (6.6)                 | 2 (0.9)                  |
| Others                        |                                |                                |                      |                      |                          |                          |
| Hypertension                  | 27 (13.4)                      | 11 (5.5)                       | 16 (22.5)            | 10 (14.1)            | 34 (15.0)                | 13 (5.8)                 |
| ElevatedTransaminases         | 30 (14.9)                      | 13 (6.5)                       | 22 (31.0)            | 6 (8.5)              | 39 (17.3)                | 14 (6.2)                 |
| Thromboembolicevents          | 25 (12.4)                      | 14 (7.0)                       | 16 (22.5)            | 9 (12.7)             | 10 (4.4)                 | 5 (2.2)                  |
| Lipid abnormalities           | 21 (10.4)                      | 11 (5.5)                       | 9 (12.7)             | 3 (4.2)              | 40 (17.7)                | 13 (5.8)                 |
| Dizziness                     | 12 (6.0)                       | 0                              | 10 (14.1)            | 0                    | 7 (3.1)                  | 0                        |
| Fracture                      | 7 (3.5)                        | 3 (1.5)                        | 5 (7.0)              | 2 (2.8)              | 8 (3.5)                  | 1 (0.4)                  |
| Weight gain                   | 3 (1.5)                        | 0                              | 3 (4.2)              | 1 (1.4)              | 8 (3.5)                  | 0                        |
| Second Primary Malignancies   | 4 (2.0)                        | 3 (1.5)                        | 5 (7.0)              | 3 (4.2)              | 4 (1.8)                  | 1 (0.4)                  |
| Nonmelanomaskincancers        | 0                              | 0                              | 1 (1.4)              | 0                    | 3 (1.3)                  | 1 (0.4)                  |

ApatientwithmultipleseveritygradesforanAEisonlycountedunder themaximumgrade

1includesthe total numberofpatients at thetimeofdatacut-off includingthepatients aftercross-over

MedDRAversion23.0,CTCAEversion4.03,CaseRetrievalStrategyversionreleased2020-08-19.

It is noted that out of the selected AESIs, growth retardation, PML and tuberculosis, there were no patients under these safety topics in any of the three studies.

In addition, there were only four patients in each pivotal study developing herpes zoster and one patient in each study with a hepatitis B reactivation.

## Infections

Infection is major complication following an allo-transplant procedure. Furthermore, immunosuppressive agents given prophylactic for GvHD increase the risk of opportunistic viral and fungal pathogens as well as either a risk of reactivation of CMV or a de novo CMV infection (due to mis-match donor with respect to CMV status). Due to the transplant procedure all patients are also heavily myelosuppressed.

## REACH-2 aGvHD

Up to Day 28, the proportion of patients with infections were comparable in the RUX arm (61.2%) vs. the BAT arm (58.7%).

Up to data cut-off, the exposure adjusted overall incidence of infections in the RUX arm was 681.9/100 PTY and 787.0/100 PTY in the BAT arm.

<div style=\"page-break-after: always\"></div>

Up to DCO, ruxolitinib exposure adjusted overall incidence rate was 652.2/100 PTY. Treatment-related AEs and SAEs were noted in 24.9% and 39.8% respectively. At the time of data cut-off, in 57.7% AEs were recovered/resolved and in 34.3% not recovered/not resolved. The most frequent PTs ( ≥ 5%) were CMV infection reactivation (22.4%), sepsis (12.4%), pneumonia (10.4%), urinary tract infection (8.5%), CMV infection (7.5%), device related infection (7.0%), and septic shock (6.5%). The most common fatal AEs were sepsis (10 deaths), septic shock (7 deaths), pneumonia (2 deaths), and pseudomonal sepsis (2 deaths). The majority of infections occurred within the first 2 months of treatment.

Until the DCO, sepsis and septic shock was 24.3% in the RUX arm and 20.7% in the BAT arm (of which most were of Grade ≥ 3 in severity. Study treatment discontinuations and dose interruptions were recorded in 4.6% vs 2.0% and dose interruptions was 4.6% in the RUX arm. However, up to the Secondary analysis data cut off, the exposure-adjusted IR of PT sepsis (all grades) was lower in ruxolitinib arm (33.2 events/100 PTY) compared to BAT arm (66.1 events/100 PTY).

## REACH-3 cGvHD

Up to Cycle 7 Day 1: Proportion of patients with infections were comparable in the ruxolitinib arm (62.4%) vs. the BAT arm (58.2%).

Up to data cut-off (excluding cross-over), the exposure adjusted overall incidence rates was 169.0/ 100 PTY in the ruxolitinib arm and 185.0 /100 PTY in the BAT arm.

Up to DCO, ruxolitinib exposure adjusted overall incidence rate was 161.2/100 PTY. Treatment-related AEs and SAEs were noted in 26.5% and 27.0% respectively. At the time of data cut-off, 58.0% AEs were recovered/resolved (Table 2-15). The most frequent PTs ( ≥ 5%) were pneumonia (14.6%), upper respiratory tract infection (13.3%), influenza (8%), nasopharyngitis (7.1%), bronchitis, urinary tract infection (6.6% each), conjunctivitis and CMV reactivation (5.3%).

Majority of the infections occurred within the first 4 months of treatment.

## Infections excluding tuberculosis in acute and chronic GvHD

|                                                     | Study C2301 Rux overall1 N=201   | Study 271 Rux N=71    | Study D2301 Rux overall1 N=226   |
|-----------------------------------------------------|----------------------------------|-----------------------|----------------------------------|
| Number of patients with at least one event, n (%)   | 159 (79.1) (72.8,84.5)           | 58 (81.7) (70.7,89.9) | 157 (69.5) (63.0,75.4)           |
| 95%CI                                               |                                  |                       |                                  |
| Exposure-adjustedoverallincidence,n(EAIRper 100PTY) | 159 (652.2)                      | 58 (652.6)            | 157 (161.2)                      |
| Maximum grade, n (%)                                |                                  |                       |                                  |
| Grade 3 AEs                                         | 55 (27.4)                        | 26 (36.6)             | 42 (18.6)                        |
| Grade 4 AEs                                         | 23 (11.4)                        | 20 (28.2)             | 5 (2.2)                          |
| Grade 5 AEs                                         | 26 (12.9)                        | NA2                   | 12 (5.3)                         |
| Treatment-related AEs,n (%)                         | 50 (24.9)                        | 21 (29.6)             | 60 (26.5)                        |
| SAEs, n (%)                                         | 80 (39.8)                        | 36 (50.7)             | 61 (27.0)                        |
| Action taken, n (%)                                 |                                  |                       |                                  |
| Drug Withdrawn                                      | 17 (8.5)                         | 9 (12.7)              | 18 (8.0)                         |
| Dose Reduced                                        | 2 (1.0)                          | 2 (2.8)               | 11 (4.9)                         |
| Dose Increased                                      | 0                                | 0                     | 1 (0.4)                          |
| Drug Interrupted                                    | 20 (10.0)                        | 8 (11.3)              | 18 (8.0)                         |
| Dose Not Changed/NA/Unknown                         | 153 (76.1)                       | 46 (64.8)             | 148 (65.5)                       |
| Missing                                             | 0                                | 0                     | 0                                |
| Medication or therapy taken, n (%)                  | 150 (74.6)                       | 56 (78.9)             | 139 (61.5)                       |
| AE outcome, n (%)                                   |                                  |                       |                                  |
| Recovered/Resolved                                  | 116 (57.7)                       | 42 (59.2)             | 131 (58.0)                       |
| Recovering/Resolving                                | 11 (5.5)                         | 5 (7.0)               | 16 (7.1)                         |
| NotRecovered/NotResolved                            | 69 (34.3)                        | 29 (40.8)             | 32 (14.2)                        |
| Recovered/ResolvedWithSequelae                      | 5 (2.5)                          | 1 (1.4)               | 2 (0.9)                          |

<div style=\"page-break-after: always\"></div>

<!-- image -->

## Cumulative incidence of infections excluding tuberculosis in acute and chronic GvHD (Safety set)

<!-- image -->

Competing risks: death or discontinuation due to any reason

## Pneumonia/opportunistic infections

The proportion of patients with pneumonia during period up to Day 28 (aGvHD) or up to Cycle 7, Day 1 (cGvHD), were comparable between the treatment arms. The exposure-adjusted overall incidence (EAIR per 100 STY), was considerably higher in aGvHD compared to cGvHD.

The proportion of opportunistic infections during period up to Day 28 (aGvHD) was 27% vs 22% in the RUX vs BAT arm and for cGvHD, up to Cycle 7 Day 1, 11% vs 12% in the respective treatment arm. The exposure-adjusted overall incidence (EAIR per 100 STY), was considerably higher in aGvHD compared to cGvHD.

## Cumulative incidence of opportunistic infections in acute and chronic GvHD (Safety set)

<div style=\"page-break-after: always\"></div>

<!-- image -->

## CMV infection/disease and viral other infections

## REACH-2 aGvHD

Up to Day 28, CMV infections were reported in 28.3% in the RUX arm vs. 24.0% in the BAT arm and during the period up to data cut-off, in 35.5% (Grade ≥ 3: 12.5%) in the RUX arm and 32.0% (Grade ≥ 3: 14.0%) in the BAT arm.

The exposure adjusted overall incidence rate (excluding the crossover period), 154.0/100 PTY in the RUX arm and 214.5 /100 PTY in the BAT arm. At the time of data cut-off, in 21.4% AEs were recovered or resolved.

## REACH-3 cGvHD

Up to Cycle 7 Day 1: The proportions of patients with CMV infections were similar in the RUX arm (9.1%) vs. the BAT arm (10.8%). CMV disease (enteritis, pneumonia) was reported in 1.2% and 1.3% in the ruxolitinib arm and in the BAT arm, respectively.

Up to data cut-off (excluding cross-over), the exposure adjusted overall incidence rates was 10.7/100 PTY in the ruxolitinib arm and 18.4 /100 PTY in the BAT arm.

## CMV infection/disease in acute and chronic GvHD (Safety set)

<div style=\"page-break-after: always\"></div>

|                                                          | Study C2301 Rux overall N=201   | Study 271 Rux N=71    | Study D2301 Rux overall N=226   |
|----------------------------------------------------------|---------------------------------|-----------------------|---------------------------------|
| Number of patients with at least one event, n (%) 95% CI | 65 (32.3) (25.9,39.3)           | 14 (19.7) (11.2,30.9) | 20 (8.8) (5.5,13.3)             |
| Exposure-adjusted overall incidence,n (EAIR por 100 STY) | 65 (142.3)                      | 14 (55.5)             | 20 (10.0)                       |
| Maximum grado, n (%)                                     |                                 |                       |                                 |
| Grade 3 AEs                                              | 22 (10.9)                       | 6 (8.5)               | 3 (1.3)                         |
| Grade 4 AEs                                              | 1 (0.5)                         | 0                     | 0                               |
| Grade 5 AEs                                              | 0                               | NA                    | 0                               |
| Treatment-related AEs,n (%)                              | 14 (7.0)                        | 4 (5.6)               | 7 (3.1)                         |
| SAEs, n (%)                                              | 14 (7.0)                        | 1 (1.4)               | 4 (1.8)                         |
| Action taken, n (%)                                      |                                 |                       |                                 |
| Drug Withdrawn                                           | 2 (1.0)                         | 1 (1.4)               | 0                               |
| Dose Reduced                                             | 1 (0.5)                         |                       | 0                               |
| Dose Increased                                           | 0                               | D                     | 0                               |
| Drug Interrupted                                         | 2 (1.0)                         | 1 (1.4)               | 1 (0.4)                         |
| Dose Not Changed/NA/Unknown                              | 63 (31.3)                       | 12 (16.9)             | 20 (8.8)                        |
| Missing                                                  | 0                               | 0                     | 0                               |
| Modication or thorapy taken, n (%)                       | 64 (31.8)                       | 14 (19.7)             | 19 (8.4)                        |
| AE outcomo,n (%)                                         |                                 |                       |                                 |
| Recovered/Resolved                                       | 43 (21.4)                       | 9 (12.7)              | 17 (7.5)                        |
| Recovering/Resolving                                     | 6 (3.0)                         | 0                     | 0                               |
| Not Recovered/Not Resolved                               | 18 (9.0)                        | 5 (7.0)               | 2 (0.9)                         |
| Recovered/Resolved With Sequelae                         | 1 (0.5)                         | 0                     | 0                               |
| Fatal                                                    | 0                               | 0                     | 0                               |
| Unknown                                                  | 0                               | 0                     | 0                               |
| Missing                                                  | 0                               | 0                     | 1 (0.4)                         |

EAiR = exposure-adjusted Incidence rate: number of patlents with an event divided by the corresponding sum of the exposure duration for all patients, where duration of exposure in Patient-Treatment-Years (PTY) is counted up to the first qualifying event (or end of time at risk for patlents without event).

1 All patients treated with ruxolitinib including patients who switched to ruxolitinib after cross-over.

and/or indistinguishable.

MedDRA version 23.0,CTCAE version4.03,Case Retrieval Strategy version released 2020-08-19

## Cumulative incidence of CMV infections/disease in acute and chronic GvHD (Safety set)

<!-- image -->

| REACH 1 Rux REACH 2 Rux overall REACH 3 Rux overall   | 27 70   |   39 | 41   | 43   | 4格6   | 51   | 51   | 59   | 53 131   | 54 NA   | 54   | 54   | 54 NA   | 54 NA   | NA NA   |
|-------------------------------------------------------|---------|------|------|------|-------|------|------|------|----------|---------|------|------|---------|---------|---------|
|                                                       |         |   91 | 02   | 126  | 126   | 128  | 130  | 130  |          |         | NA,  | NA   |         |         |         |
|                                                       | 9       |   31 | 79   | 101  | 111   | 114  | 118  | 121  | 123      | 124     | 126  | 126  | 127     | 127     | 127     |
| REACH 2 Rux oversl REACH 1Rux                         | 31      |   19 | 16   | 14   | 11    | 6    |      |      |          |         |      |      | 1       |         |         |
|                                                       | 67      |   44 |      |      | rR    |      | 1    | 1    |          | ou      |      |      |         |         |         |
| REACH 5 Rux ovorall                                   | 504     |  178 |      | 8    |       | R    |      |      |          |         |      |      |         |         | 0 0 0   |

With respect to acute vs chronic GvHD, the increased susceptibility of opportunistic infections and CMV infections/reactivation in aGvHD patients on treatment, is clearly demonstrated.

AESI CMV infections were reported for REACH-3 in 9.1% (Grade ≥ 3: 1.8%) up to Cycle 7 Day 1 (Safety set) and approximately the same rate for the main treatment period. Furthermore, CMV infection using other PTs were also reported, in a lower frequency.

<div style=\"page-break-after: always\"></div>

## Adenovirus infections

A review of the available cases of Adenovirus infection (n=26) in patients treated with ruxolitinib for GvHD, has been provided, including cases from clinical studies REACH-2 and REACH-3, spontaneous reports and literature.

There were 11 paediatric cases and 15 cases reported in adults. All cases were either confounded with multiple immunosuppressant therapy or were poorly documented which precluded evaluation of cases. There was none case with ruxolitinib monotherapy or a case where causal association only with ruxolitinib was established or suspected. However, having considered multiple immunosuppressive treatment, occurrence or reactivation of infections, including viral, could be expected.

The available data does not allow to assess the role of ruxolitinib on the incidence of adenoviral infection in patients with SR GvHD.

## Other Viral infections

Proportion of aGvHD patients with viral infections, during the period up to Day 28, were higher in the RUX arm (39.5%, Grade ≥ 3 14.5%) compared to the BAT arm (32.0%, Grade ≥ 3 14.0%). The imbalance was mainly due to the differences among CMV infections.

However, in cGvHD, the higher proportion of patients with viral infections in the RUX arm (28.5%) vs the BAT arm (23.4%) up to Cycle 7 Day 1, was mainly due to the differences among BK virus infections.

## Urinary tract infections (UTIs)

REACH-2 aGvHD Up to Day 28: were reported in 9.9% in the RUX arm and 10.7% in the BAT arm, and up to DCO in 19.1% vs 14.0%.

REACH-3 cGvHD Up to Cycle 7 Day 1: were reported in 8.5% in the RUX arm and 6.3 in the BAT arm, and up to DCO in 19.9 vs 9.5%.

## Haematology/Cytopenias

## aGvHD

REACH-2 population: At baseline, consistent with the study population disease characteristics, majority of patients with aGvHD had low haemoglobin level (90.8% vs. 90.6%), and low platelet counts (79.6% vs. 82.0%) in the RUX arm and the BAT arm; majority of these laboratory abnormalities were CTC grade 1 or 2. The worst post-baseline of grade 3 haemoglobin was reported in similar proportion of patients (47.4% vs. 46.0%). The proportion of patients with worst post-baseline value of grade 3 decreased platelets was lower in the RUX arm (25.7% vs. 32.7%) while higher for grade 4 decreased platelets (53.9% vs. 46.0%). Worst post-baseline of grade 3 (16.4% vs. 19.3%) and grade 4 (21.7% vs. 16.7%) neutrophil count was similar between the two arms.

## Thrombocytopenia

Up to Day 28, 50.0% of the patients in the RUX arm and 32.7% of the patients in the BAT arm experienced at least one thrombocytopenia event. The incidence of Grade ≥ 3 thrombocytopenia was 41.4% in the RUX arm and 29.3% in BAT arm, no fatal events were reported.

<div style=\"page-break-after: always\"></div>

Up to the Secondary analysis data cut-off, the overall incidence of thrombocytopenia events increased to 56.6% (Grade ≥ 3: 50.7%) in RUX arm and 36.7% (Grade ≥ 3: 32.0%) in BAT arm. In 36.8% and 9.3%, in the RUX arm and the BAT arm, respectively the events were regarded as treatment related.

## Anemia

Up to Day 28, the overall incidence of anemia events was 30.3% (Grade ≥ 3: 22.4%) in the RUX arm and 28.0% (Grade ≥ 3: 20.0%) in BAT arm.

Up to the Secondary analysis data cut-off, the incidence of anemia events had increased to 40.8% (Grade ≥ 3: 36.2%) and 34.0% (Grade ≥ 3: 25.3%). In 16.4% and 5.3%, in the RUX arm and the BAT arm, respectively, the events were regarded as treatment related.

## Leukopenia

Up to Day 28, the overall incidence of leukopenia events was 32.9% (Grade ≥ 3: 28.9%) in the RUX arm and 26.7% (Grade ≥ 3: 22.0%) in BAT arm.

Up to the Secondary analysis data cut-off, the incidence of leukopenia events had increased to 46.7% (Grade ≥ 3: 42.2%) and 32.0% (Grade ≥ 3: 27.3%).

## cGvHD

REACH-3 population: At baseline, patients with cGvHD had low haemoglobin level (40.0% vs. 48.1%), and low platelet counts (39.4% vs. 34.9%) in the RUX arm and the BAT arm; majority of these laboratory abnormalities were CTC grade 1 or 2. Post-baseline values of CTC grade 3 haemoglobin decrease (17.6 vs. 9.5%) occurred more in the RUX arm than in the BAT arm. While post-baseline grade 3 neutrophil decrease (10.3% vs. 3.8%) was more frequent in RUX arm, grade 4 values were similar between the two arms (7.3% vs. 7.6%). Worst post-baseline platelet counts of grade 3 and grade 4was similar between the two arms [Study D2301 PA-Table 14.3-3.4]. More patients in the RUX arm had worst post-baseline grade 3 for haemoglobin decrease and neutrophil decrease.

## Anemia

Up to Cycle 7 Day 1, the overall incidence of anemia events was 29.7% (Grade ≥ 3: 12.7%) in the RUX arm and 12.7% (Grade ≥ 3: 7.6%) in BAT arm.

Up to DCO, the incidence of anemia events was 32.1% (Grade ≥ 3: 15.2%) in the RUX arm and 13.9% (Grade ≥ 3: 7.6%) in the BAT arm.

## Thrombocytopenia

Up to Cycle 7 Day 1, 21.2% of the patients in the RUX arm and 14.6% of the patients in the BAT arm experienced at least one thrombocytopenia event. The incidence of Grade ≥ 3 thrombocytopenia was 15.2% in the RUX arm and 10.1% in BAT arm.

Up to DCO, the overall incidence of thrombocytopenia was 23.0% (Grade ≥ 3: 17.6%) in RUX arm and 15.8% (Grade ≥ 3: 11.4%) in BAT arm.

<div style=\"page-break-after: always\"></div>

## Leukopenia

Up to Cycle 7 Day 1, the overall incidence of leukopenia events was 18.8 (Grade ≥ 3: 12.7%) in the RUX arm and 13.9 (Grade ≥ 3: 10.8%) in BAT arm.

Up to DCO, the incidence of leukopenia events was 23.6% (Grade ≥ 3: 18.8%) in the RUX arm and 14.6% (Grade ≥ 3: 11.4%) in the BAT arm.

## Bleeding

## aGvHD REACH-2

Up to Day 28, bleeding events were seen in 25.0% (Grade ≥ 3: 4.6%) and 22.0% (Grade ≥ 3: 2.6%) patients in the RUX arm and the BAT arm, respectively. There were no fatal events.

Up to the Secondary analysis data cut-off, the incidence of bleeding events was 40.1% (Grade ≥ 3: 12.5%) in the RUX arm and 28.0% (Grade ≥ 3: 7.3%) in BAT arm.

Corresponding exposure-adjusted IR of bleeding events were 158.2 and 174.3 per 100 PTYs in the RUX and the BAT arms respectively. One patient in ruxolitinib arm died due to lower GI hemorrhage in setting of aGvHD involving lower GI (stage 3). Events in 11.8% patients in ruxolitinib arm and 2.0% patients in BAT arm were regarded as treatment related. SAEs were observed in 6.6% patients in ruxolitinib and 5.3% patients in BAT arms. GI bleeding events occurred in 9.2% patients in the RUX arm and 6.7% patients in the BAT arm up. There were no fatal GI bleeding events. There was one intracranial haemorrhage reported, in each arm.

## cGvHD REACH-3

Up to Cycle 7 Day 1, haemorrhages were seen in 11.5% (Grade ≥ 3: 2.4%) vs 14.6% (Grade ≥ 3: 1.9%) in the RUX arm and the BAT arm, respectively.

Up to DCO, hemorrhage events were seen in 12.7% (Grade ≥ 3: 3.0%) vs 16.5% (Grade ≥ 3: 3.2%) in the RUX arm and the BAT arm, respectively. There was one intracranial hemorrhage reported, in the RUX arm.

More bleeding events occurred in both treatment arms in REACH-2 than reported for REACH-3, concurrent with time elapsed since allo-tx and the higher frequency of thrombocytopenia.

## Hypertension

## REACH-2

Up to Day 28, hypertension occurred in 10.5% patients in the RUX arm and 9.3% patients in the BAT arm. Grade 3 events were observed in 5.9% patients in the RUX arm and 4.0% patients in the BAT arm, with no Grade 4 or 5 events.

Up to the Secondary analysis data cut-off, the proportion of patients with hypertension increased to 13.8% in the RUX arm, and 12.7% in BAT arm.

## REACH-3

Up to Cycle 7 Day 1, hypertension occurred in 16.4% (Grade ≥ 3: 6.1%) and in 12.7% (Grade ≥ 3: 7.0%) RUX and BAT arms respectively.

Up to DCO, hypertension occurred in 18.2% (Grade ≥ 3: 6.7%) and in 13.3% (Grade ≥ 3: 6.7 %) RUX and BAT arms respectively.

<div style=\"page-break-after: always\"></div>

Hypertension rate increased by time on ruxolitinib and is an identified ADR for ruxolitinib.

## Malignancies, including non-melanoma skin cancer

REACH-2: Up to the Secondary analysis data cut-off, malignancy events occurred in 3 (2.0%) patients each in two treatment arms. Corresponding exposure-adjusted IR of malignancy events were 6.1 and 9.9 per 100 PTYs in RUX and BAT arms respectively.

The event in RUX arm was diffuse large B-cell lymphoma (grade 3). On review of this case, the patient had relapse of underlying diffuse large B-cell lymphoma. In the BAT arm, one patient each had recurrent AML (fatal), erythroleukaemia (grade 1), and recurrent leukaemia (grade 4), none of which were suspected to be related to study treatment. After crossover, one patient had grade SAE of central nervous system lymphoma which led to discontinuation of study treatment.

REACH-3: Malignancy events were reported in 2 patients in the RUX arm and was not considered related to study treatment. These malignancy events were non melanoma skin cancer (NMSC) events. The event of grade 2 squamous cell carcinoma of skin was still ongoing by data cut-off in the Main treatment period. The events were reported as not related. No dose change, interruption or discontinuation occurred. The event of grade 3 basal cell carcinoma was resolved by Cycle 7 Day 1. No events were reported in the BAT arm.

## Thromboembolic events

REACH-2: Up to Day 28, thromboembolic events occurred in 8.6% (Grade ≥ 3: 4.6%) and 6.7% (Grade ≥ 3: 4.7%) in RUX and BAT arms respectively.

Up to the Secondary analysis data cut-off thromboembolic events occurred in 12.5% (Grade ≥ 3: 7.2%) and 11.3% (Grade ≥ 3: 6.0%) in RUX and BAT arms respectively.

REACH-3: Up to Cycle 7 Day 1, thromboembolic events occurred in 4.8% (Grade ≥ 3: 2.4%) and 7.6% (Grade ≥ 3: 6.3%) in RUX and BAT arms respectively.

Up to DCO, thromboembolic events occurred in 6.1 (Grade ≥ 3: 3.0%) and 7.6% (Grade ≥ 3: 6.3%) in RUX and BAT arms respectively.

## Clinical chemistry

## Liver chemistry/Elevated Transaminases

## REACH-2

Elevation of ALT, AST, bilirubin and alkaline phosphatase was noted in many patients. Of note, the liver is one of the target organs of underlying aGvHD indication. In majority of patients, the worsening post-baseline was to grade 1 or 2. a total of 8 (5.3%) in ruxolitinib arm and 18 (12.0%) patients in BAT arm met the criteria for Hy's law (concurrent ALT or AST &gt;3x ULN and BILI &gt;2x ULN and ALP &lt;2x ULN). Confounders, like concomitant potentially hepatotoxic antibiotics or progressive liver GvHD, were found.

The following incidence data were reported for AEs by SOC in REACH-2 CSR:

Up to the DCO, 17.8% (Grade ≥ 3: 6.6%) patients in the RUX arm and 10.0% (Grade ≥ 3: 4.7%) patients in BAT arm had elevated transaminases. Events in 4.6% patients in ruxolitinib arm and 0.7% patients in BAT arm were suspected to be related to study treatment. There were dose reductions in

<div style=\"page-break-after: always\"></div>

3.3% and dose interruption in 0.7% of the patients in the RUX arm. Drug-induced liver injury (DILI) was reported as AE in 2 patients in ruxolitinib arm and 1 patient in BAT arm and all were assessed as non-serious events with Grade 2 severity.

## REACH-3

No liver enzyme abnormalities that met Hy ' s law were observed in the RUX arm. 4 patients in the BAT arm met the criteria for Hy ' s law. Out of these 4 patients, 3 of whom had baseline GvHD liver involvement and had significant elevation of liver tests indicating the elevation was pre-existing.

The following incidence data were reported for AEs by SOC in REACH-3 CSR:

Up to Cycle 7 Day 1 elevated transaminases were seen in 18.2% (Grade ≥ 3: 6.7%) of the patients in the RUX arm and 7.6% (Grade ≥ 3: 0.6%) in the BAT arm.

Up to DCO, elevated transaminases were seen in 20.6% (Grade ≥ 3: 8.5%) of the patients in the RUX arm and 7.6% (Grade ≥ 3: 0.6%) in the BAT arm.

## Lipid abnormalities

## REACH-2

Up to Day 28, lipid abnormalities were observed in 3.9% patients in ruxolitinib arm and 4.0% patients in BAT arm. Grade 3 abnormalities were observed in 1.3% patients each in both treatment arms. Treatment-related events occurred in 1.3% patients in the RUX arm only. One patient in BAT arm had a dose reduction. A total of 2.0% patients in each arm required medication in ruxolitinib arm and BAT arm.

Up to the Secondary analysis data cut-off, lipid abnormalities were observed in 9.9% patients in ruxolitinib arm and 7.3% patients in BAT arm.

## REACH-3

Up to Cycle 7 Day 1, lipid abnormalities were observed in 18.8% (Grade ≥ 3: 7.3%) of the patients in the RUX arm and 14.6% (Grade ≥ 3: 7.0%) in the BAT arm.

Up to DCO, lipid abnormalities were observed in 20.6 (Grade ≥ 3: 7.3%) of the patients in the RUX arm and 14.6% (Grade ≥ 3: 7.0%) in the BAT arm.

Lipid abnormalities were overall higher in the RUX arm compared to the BAT arm. Increased total cholesterol, high-density lipoprotein (HDL) cholesterol, LDL cholesterol and triglycerides are known adverse drug reactions (ADRs) with ruxolitinib therapy.

## Additional safety topics

Subgroup analyses for safety were conducted for aGvHD and cGvHD. The subgroups were by age, by gender, by race, by region, by baseline hepatic impairment status, by baseline renal impairment status, by concomitant cyclosporine treatment.

## Safety assessment by age

## REACH-2

Adolescents: There were 9 patients between 12 to &lt;18 years (5 in the RUX arm and 4 in BAT arm). The median duration of exposure to RUX remained longer (163 days; range: 11.0 to 242.0) than to BAT (58.0 days; range: 2.0 to 162.0) and in line with overall population. The AE profile of adolescent

<div style=\"page-break-after: always\"></div>

patients were similar to other age groups with minor differences. Cardiac disorders, vascular disorders, and immune system disorders were not observed in patients between 12 to 18 years treated with RUX. The profile of suspected AEs and SAEs were similar to other age groups. Among patients of 12 to &lt;18 years, one patient died due to progression of underlying hematological disease. No fractures were reported in the RUX arm. Three patients reported events of bone pain, musculoskeletal pain (grade 1 events) and osteoporosis (n=1 each) (grade 2). Osteoporosis reported on study day 106 was resolving after treatment and did not result in a change in RUX therapy due to the event. All these events were assessed as not related to RUX therapy.

All ages: Due to the difference in the number of patients across age groups, 9 patients of 12 to &lt;18 years (5 in the RUX arm and 4 in BAT arm), 248 patients of 18 to 65 years (126 in the RUX arm and 122 in BAT arm), and 45 patients of &gt;65 years (21 in in the RUX arm and 24 in BAT arm) direct comparisons cannot be done.

In the 18 to 65 years old, there were 47 deaths (28.3%) and in the &gt;65 years old group there were 14 deaths (48.3%).

## REACH-3

Adolescents: There were only 11 patients in the age group 12-18 evaluable for safety, 4 received RUX and 7 BAT arm, 1 patient randomised to the BAT arm never received BAT dosing. Up to Cycle 7, Day 1, the median duration of exposure to RUX (25.6 weeks, range: 25.6 to 25.6) and to BAT (24.0 weeks, range: 8.9 to 25.6) was balanced. AEs profiles by SOC and PT were similar as observed in all-age group. No treatment-related AEs, and deaths and no fractures or bone abnormalities were reported. Up to Cycle 7 Day 1, 3 (75%) patients in the RUX arm and 7 (100%) patients in the BAT arm experienced at least one AE, of which, 1 patient in RUX arm and 2 patients in BAT arm experienced grade ≥3 AEs. AEs profiles by SOC and PT were similar as observed in all age group. Nervous system disorders (in 3 patients) and blood and lymphatic system disorders (2 patients) only occurred in the BAT arm. Immune disorders were not observed in patients between 12 to &lt;18 years of age treated with RUX. SAE was reported in only one patient in the BAT arm with a nervous system disorders of grade 3 neuralgia and grade 2 transient ischemic attack. No death was reported for adolescent patients. No notable findings were observed in Tanner staging assessment for adolescent patients. Bone density measurement by DEXA scan were collected from adolescent patients. Results were not reported in this CSR. SAE was reported in only one patient No death was reported for adolescent patients.

All ages: Subgroup by age 18 to 65 years included 277 patients and subgroup by age ≥ 65 years included 40 patients. The AE profiles were similar between age groups with a few exceptions. A higher proportion of deaths were reported in the subgroup &gt;65 year of age and mostly due to study indication (cGvHD and complications attributed to the treatment of cGvHD).

## Safety analysis by organ involvement at randomization

The CSR for aGvHD summarizes that overall the profile of AEs was similar between the aGvHD organ involvements, except for the following differences: AEs by gastrointestinal disorders were more frequent in aGvHD patients with upper GI involvement and AEs by general disorders and administration site conditions were less frequent in aGvHD patients with liver involvement.

With respect to organ involvement at randomization in cGvHD, the overall population regardless of organs involved, the incidence of treatment-related AEs (any grade and grade ≥ 3), treatment related SAEs, AEs requiring dose adjustment/interruption, and AEs leading to discontinuation was higher in the ruxolitinib arm than in the BAT arm among patients with specific cGvHD organ involvement. However, this can be explained by the almost twice as high median total treatment exposure for the RUX arm.

<div style=\"page-break-after: always\"></div>

Overall, when adjusted for exposure, the incidence of SAEs (all grades) was higher in the BAT arm (76.6 per 100 PTY) than in the RUX arm (60.3 per 100 PTY).

With respect to organ involvement at randomization, the profile of AEs was in general consistent with that of the overall population regardless of organs involved.

## Vital signs

aGvHD: There were few notable changes in blood pressure or occurrence of increased pulse rate values are infrequent and comparable between treatment arms. Also changes in the weight were comparable between treatment arms. Decrease in weight was more frequent than weight gain in both treatment arms in aGvHD.

cGvHD: Changes in systolic blood pressure values was rare and comparable between treatment arms. However, the diastolic blood pressure changes were slightly different between 2 treatment arms: ≥ 105 mmHg and increase ≥ 15 mmHg occurred more frequently in ruxolitinib arm (4.8%, n=8) than in BAT arm (3.2%, n=5); ≤ 50 mmHg and decrease ≥ 15 mmHg occurred less frequently in ruxolitinib arm (3.0%, n=5) than in BAT arm (5.7%, n=9). This difference was enhanced in the Main treatment period up to the data cut-off.

The occurrence of increased pulse rate and corresponding AEs was comparable between two treatment arms and occurred in a low rate. Weight increase &gt;10% was more common in the RUX arm (22.4%) compared to the in the BAT arm up to Cycle 7 Day 1 and even more pronounced up to DCO in the Main treatment period, 30.3% in the RUX arm and 16.5% in BAT arm.

Increase in weight was more frequent than weight loss in both treatment arms in contrast to the aGvHD population.

## Exposure and AEs by age

REACH-2: There were 166 patients 18-65-year-old vs N=29 patients &gt;65 years old. The median duration of exposure of RUX was lower in &gt;65-year-old patients (4.3 weeks; range: 0.3-25.1) than in the 18 to 65 year-old group (9.9 weeks; range: 0.9 to 66.1). The corresponding exposure in PTY was 4.0 and 46.0 PTY. AEs by PT in all the subgroups were similar (18 to 65 years old group and &gt;65 years old group) with a few exceptions. In the 18 to 65 years old group, cardiac failure and tachycardia were reported in 4 patients, and sinus tachycardia was reported in 3 patients. In the &gt;65 years old group cardiac failure, tachycardia and sinus tachycardia were reported in one patient each. Occurrence of grade ≥ 3 AEs and occurrence of grade ≥ 3 suspected to study treatment were similar across the subgroups (18 to 65 years old group and &gt;65 years old group). Patients with SAEs were higher the &gt;65 years old group (82.8%) compared to the 18 to 65 years old group (66.9%). This was mainly due to infections and infestations (51.7%) (sepsis in 20.7% and pneumonia in 13.8%). Occurrence of all other SOCs and PTs were similar in the 18 to 65 years old group and in 65 years old group. In the 18 to 65 years old, there were 47 deaths (28.3%) and in the &gt;65 years old group there were 14 deaths (48.3%). Among the 47 deaths in the 18 to 65 years old, 22 (13.3%) were due to study indication and 25 (15.1%) were due to other reason. The applicant has not provided this comparison for the BAT arm.

For cGvHD REACH-3, the median duration of exposure of RUX was similar across the subgroups (41.4 weeks in the 18 to 65 years old group (N=193); 42.6 weeks in the &gt; 65 years old group (N=25). The AE profile was similar between age groups (12 to &lt;18 years old group (N=8), 18 to 65 years old group and &gt;65 years old group with few exceptions. Treatment related AEs (all grades and grade ≥ 3) were lower in 12 to &lt;18 years old group compared to other subgroups. The proportion of patients with at

<div style=\"page-break-after: always\"></div>

least one AE was 94.8% in 18 to 65 years old group, and 100% in &gt;65 years old group. The proportion of patients with grade ≥ 3 AEs or SAEs was similar across the age groups. In study D2301, there were 15 deaths (7.8%) in the 18 to 65 years old group and 4 deaths (16.0%) in the 65 years old group. The applicant has not provided this comparison for the BAT arm.

## Exposure and AEs by gender

REACH-2: the exposure duration in males (N=116) was 30.7 patient years and in females (N=85) was 21.1 patient. The AE profile (Occurrence of AEs related to study treatment, grade ≥ 3 AEs, SAEs, treatment related SAEs, fatal SAEs, AEs leading to discontinuation, AEs requiring dose adjustment/interruption, and AEs requiring additional therapy) was similar between the 2 genders. In REACH-1, the exposure in males (N=35) was 15.7 patient years and in females (N=36) was 9.9 patient years. The AE profile was similar between the 2 genders.

REACH-3: In Study D2301, the exposure duration in females (N=80) was 69.8 patient years and in males (N=146) was 125.3 patient years. The AE profile (Occurrence of AEs related to study treatment, grade ≥ 3 AEs, SAEs, treatment related SAEs, fatal SAEs, AEs leading to discontinuation, AEs requiring dose adjustment/interruption, and AEs requiring additional therapy) was similar between the 2 genders.

## Exposure and AEs by race

REACH-2: The exposure duration was 35.4 patient years in White (N=141), 8.7 patient years in Asian (N=26), and 7.7 patient years in Others (N=34). In Study C2301, AEs and treatment related AEs were similar between Whites and Asian and lower compared to Others (56.8%). G rade ≥3 AEs were higher in Whites (93.7%) and Asian (92.9%) compared to Others (86.5%), SAEs were higher in Whites (74.9%) and Others (70.3%) compared to Asians (60.7%). AEs leading to discontinuation were generally comparable in all three races.

REACH-3: The exposure duration was 139.4 patient years in White (N=170), 35 patient years in Asian (N=36), and 20.7 patient years in Others (N=20). AEs were slightly higher in Others (100%) and Asian (97.2%) compared to Whites (93.5%). treatment related AEs were higher in Asian (77.8%) compared to Whites (56.5%) and Ot hers (60.0%), grade ≥3 AEs were higher in Others (85%) compared to Whites (57.6%) and Asian (66.7%), SAEs were higher in Asian (55.6%) and Others (55.0%) compared to Whites (37.1%) AEs leading to discontinuation: higher in Asian (30.6%) compared to Whites (15.3%) and others (20.0%).

## Exposure and AEs by region

REACH-2: The exposure duration was 4.6 patient years in Asia (excluding Japan), 3.7 patient years in Japan, and 43.5 patient years in Rest of the World. The number of patients in Rest of the World was highest (176) compared to patients in Asia (10) and Japan (15). Due to the differences in patient numbers, no conclusions could be made on the AEs by region.

REACH-3: The exposure duration was 10.3 patient years in Asia region, 21.3 patient years in Japan and 163.6 patient years in Rest of the World. The number of patients in Rest of the World was higher (194) compared to patients in Asia (8) and Japan (24). Due to the differences in patient numbers, no conclusions could be made on the AEs by region.

<div style=\"page-break-after: always\"></div>

## By baseline hepatic impairment status

REACH-2: In aGvHD, in the RUX arm (including cross over), 130 patients had no hepatic impairment, 21 patients with mild hepatic impairment, 27 patients with moderate hepatic impairment, and 23 severe hepatic impairment. Proportion of patients with SAEs in the no hepatic impairment group was 67.7% (n=88) and comparable between mild (n=16, 76.2%), moderate (n=17, 63.0%), and severe (n=18, 78.3%) groups. The fatal SAEs were 39 cases (21.9%) in the no hepatic impairment group, and 7 cases (28.0%) in the mild group, 14 cases (37.0%) in the moderate group, and 9 cases (39.1%) in the severe group. AEs leading to discontinuation in the no hepatic impairment group was 30.3% (54 cases) whereas in the mild, moderate and severe groups, it was 20.0% (5 cases), 38.2% (13 cases), and 28.6% (10 cases) respectively. No new safety concerns identified when safety data including hematological abnormalities were evaluated between patients with hepatic impairment and with no hepatic impairment at baseline.

In REACH-1, no notable differences were observed in the AE profile, laboratory abnormalities and clinical chemistry in patients with mild, moderate and severe hepatic impairment at baseline.

REACH-3 In cGvHD, the RUX arm (including cross over), most of the patients (n=205) had no hepatic impairment, 14 patients with mild hepatic impairment, 4 patients with moderate hepatic impairment, and 3 severe hepatic impairment. The proportion of patients with SAEs in the no hepatic impairment group was in 41.5% and was 42.9% in the mild group. One out of 4 patients had SAEs in the moderate (25%) and 2 out of 3 patients in the severe group (66.7%). Fatal SAEs in no hepatic impairment group were noted in 6.3%. In the mild and severe groups fatal SAEs were in 21.4% and 33.3%. There were no cases of fatal SAEs in the moderate group. Proportion of patients with AEs leading to discontinuation in the no hepatic impairment was 18.0%. In mild and severe groups, it was noted in 14.3% and 66.7%, respectively. In the moderate group, none of the 4 patients had an AEs leading to discontinuation. As there are few patients in the moderate and severe groups, these results should be interpreted with caution. No new safety concerns were identified.

## By baseline renal impairment status

REACH-2: In aGvHD, 137 patients had no renal impairment at baseline, 49 in mild, 15 in moderate renal impairment groups. There were no patients with severe renal impairment. The proportion of patients with SAEs were 68.6% in no renal impairment group, similar to mild (69.4%) and moderate (73.3%) groups. The proportion of patients with fatal AEs were also similar across no renal impairment group (24.1%), mild (22.4%), and moderate (26.7%) groups. The AEs leading to discontinuation were in 28.5% in no renal impairment group, 34.7% in the mild group and in 20.0% in the moderate group.

REACH-3: In cGvHD, 117 patients had no renal impairment at baseline, 71 in mild, 35 moderate, and 2 severe renal impairment. The proportion of patients with SAEs were similar across the groups (41.9% in no renal impairment group, 38.0% in the mild group, and 42.9% in the moderate group), Also, the proportion of patients with fatal AEs were similar across the groups (8.5% in no renal impairment group, 7.0% in the mild group, and 5.7% in the moderate group). The AEs leading to discontinuation in the no renal impairment was 16.2%, similar to the moderate group (17.1%). In the mild group, AEs leading to discontinuation (22.5%) was slightly higher than in the no renal impairment.

## Safety in cross-over population

It is acknowledged that the cross over groups (n=49) are expected to have more advanced disease. There were no new safety concerns identified between RUX randomized arm and crossover group in either pivotal study. In REACH 2, a similar proportion of patients had at least one AE in the ruxolitinib

<div style=\"page-break-after: always\"></div>

arm (99.3%, grade ≥ 3: 91.4%) and in the cross -over group (95.9%, grade ≥3: 89.8%). The incidence of AEs, treatment related SAEs, and AEs requiring dose adjustment/interruption and additional therapy was also similar in the ruxolitinib arm and cross-over group. The incidence of SAEs, fatal SAEs and AEs leading to discontinuation were higher in the cross-over group than in the ruxolitinib randomized group but notably treatment related events were similar. In REACH 3 the incidence of SAEs, fatal SAEs, AEs leading to treatment discontinuation was lower to that of the ruxolitinib randomized arm. Thus overall, it can be concluded that in general the safety of the cross over group is similar for the cross over patients

## Post marketing experience

Published information on the safety of RUX is evaluated on an ongoing basis and is available in the PSURs for RUX, with PSUR 10 covering the period 23-Feb-2019 to 22-Feb-2020, please refer to section 5.

RUX was approved on 16 Nov 2011 for treatment of MF. An estimate of patient exposure is calculated based on worldwide sales volume in kilograms (kg) active substance sold during the reporting interval and the Defined Daily Dose of 30 mg. The sales volume of RUX cumulatively up to 22 Feb 2020 (PSUR 10 data cut off) since the IBD of the product was estimated to be approximately 1,670.75 kg active substance (Novartis 1175.20 kg and Incyte 495.55 kg). The estimated cumulative exposure was approximately 152,580 PTY as discussed in PSUR 10 (reporting period 23-Feb-2019 to 22-Feb-2020). The Risk Management Plan (RMP) continues to adequately describe the measures to manage risk.

## 2.6.1. Discussion on clinical safety

Due to the differences in study populations in acute GvHD and chronic GvHD, the clinical manifestation and time elapsed since transplant, the extent of exposure is markedly different between the diagnoses. This accounts for the RUX arm but also for the BAT arms. Many AEs can be difficult to distinguish from symptoms of aGvHD or by the transplant procedure itself. The exposure differed significantly between the acute GvHD studies and the chronic GvHD setting. In aGvHD (REACH-2) the median duration of exposure to RUX was 63.0 days (range: 6.0 to 396.0) and for BAT 29.0 days (range: 1.0 to 188.0). In contrast, in the chronic setting the median duration of exposure was 42.6 weeks (range: 21.7-74.6) in the RUX arm and 25.2 (range: 22.7-41.1) weeks in the BAT arm. Due to the differences in the study populations, study structure in the Phase 3 studies and differences in AE frequency and patterns, the safety data are separately presented for aGvHD and cGvHD. Overall, the exposure to RUX in presented studies was considered sufficient to allow for a primary assessment of safety in patients representative of the intended target population, long-term safety data has not been presented and is listed as missing information in the RMP.

It is noted that out of the selected AESIs, growth retardation, PML and tuberculosis, there were no patients under these safety topics in any of the three presented studies. Other selected AESIs, e.g., dizziness, headache, flatulence, constipation and facture, were either not reported or low and comparable between the treatment arms.

The comparator in respective study, consist of 9 and 10 subsets of treatment choices for aGvHD and cGvHD, respectively, of whom some treatment choices are the same and some are unique for the respective study.

In REACH-2 the rate of discontinuation until day 28 was acceptable with 11.2% discontinuing due to an AE (mostly grade 3) with as main AE anaemia and thrombocytopenia. The majority of patients with aGVHD required at least one dose change or interruption of RUX (82.9%), with as primary reason AEs

<div style=\"page-break-after: always\"></div>

(57.2%), additionally a large proportion of subjects had a dose interruption by physician decision (19.1%) thus not classified as a discontinuation due to AE or lack of efficacy. However, the CRFs did not collect the reason for the physician decision and as such the reason for dose change or dose interruption cannot be analysed for approximately 20% of the study population.

The side effects profile in the ruxolitinib arm is mainly characterised by hematological adverse events and infections, consistent with the mechanism of action of ruxolitinib and these are known ADRs for ruxolitinib. However, due to the new indications proposed, aGvHD and cGvHD, which are two populations much more vulnerable with respect to both cytopenias and infections, these ADRs are also the main ADRs in the comparator arm.

With respect to the short time, 28 days, to the primary endpoint in REACH-2 study compared to the time up to primary endpoint in the cGvHD study REACH-3, Cycle 7 Day 1, and in addition, for both studies the double median exposure time on ruxolitinib compared to the BAT arm, complicated by the variety of BAT choices, comparisons between the two studies and between treatment arms is challenging. Hence, incidence of AE up to the data cut-off should be viewed with consideration of duration of exposure, population studied as well as the spectrum of BAT treatments.

By time of Secondary analysis, DCO for aGvHD the most commonly affected AEs by SOC were infections and infestations (81.6% of patients) and blood and lymphatic system disorders (71.1% of patients) for the RUX arm and for the BAT arm, 71.3% and 51.3% for SOC infections and infestations and blood and lymphatic system disorders, respectively.

The pattern for cGvHD is similar, namely by time of DCO the Main treatment period for cGvHD the most commonly affected AEs by SOC were infections and infestations (71.5% of patients) and blood and lymphatic system disorders (46.1% of patients) for the RUX arm and for the BAT arm, 65.8% and 24.1% for SOC infections and infestations and blood and lymphatic system disorders, respectively. Analysis of AEs that were judged as permanent was based mainly on AEs that were not recovered/not resolved in patients who discontinued and who have finished their 30-day safety follow-up.

In both REACH-2 and RECAH-3, the most frequent AEs that were not resolved were cytopenias, all other SAEs were reported infrequent and with no specific pattern and not leading to new safety concerns.

Furthermore, there is a considerable difference with respect to SAEs, fatal SAEs, AEs leading to discontinuations and AEs leading to dose adjustment/interruption in relation to ruxolitinib treatments in acute and chronic GvHD.

Since the incidences of AEs by SOC and by PT differs, in some respects, from those for the already approved ruxolitinib indications, a separate ADR table presenting data for the two pivotal studies in GvHD and the frequencies (all grades and grade 3/4), is introduced in the SmPC. This is endorsed. Cross over from BAT towards RUX was allowed in the study and it is reassuring that the type of AEs for cross over patients was similar and there were no new safety concerns identified and therefore, inclusion in the table in SmPC 4.8 is acceptable.

The results for primary cause of death did not show any new safety signals compared to the primary analysis results. A detrimental effect on OS of ruxolitinib cannot be concluded based on still immature data (please refer to efficacy section).

The rate of malignancy relapse/progression was roughly similar for ruxolitinib and BAT in each of the pivotal trials.

Subgroups

<div style=\"page-break-after: always\"></div>

Subgroup analyses of patients with baseline hepatic or renal impairment in REACH - and REACH-3 were provided. There was no clear trend that patients with more severe baseline hepatic or renal impairment are at increased risk, but the assessment is hampered by sample size and numbers were not robust over the categories. Importantly, no new safety concerns were identified in patients with severe hepatic or renal impairment and the starting RUX dose will not be reduced, as the dose is already low, and there is a need to ensure an adequate dose for efficacy. For renal impairment no specific dose adjustments are advised for mild or moderate renal impairment, which is accepted.

The comparison with BAT in the elderly age group shows that in REACH 2, patients older than 65 experience more grade 3 or higher AEs in RUX arm (95.2%) than in BAT (79.2%) and more were considered treatment related in the RUX arm. This was also confirmed with higher percentages SAE, AEs leading to discontinuation, AEs leading to dose adjustments and AEs requiring additional therapy. However, the sample size limits accurate definition of incidences.

A conclusion of ruxolitinib safety evaluation in adolescents is not readily feasible due to the low number of participants. With respect to patients &gt;65 year of age, besides also a more limited number, these patients are already selected, with regard to few or any co-morbidities, before entering the allotransplant procedure. However, no data points towards a significant different AE profile between the age groups. The death rate is higher in patients &gt;65 years in both the aGvHD and cGvHD study.

## Long term safety aspects

In study REACH-2, one patient experienced a DLBCL (grade 3) up to data cut-off which was assessed not related to RUX treatment. In the chronic GvHD population REACH3, up to Cycle 7 Day 1, malignancy events were reported in 1.2%, judged as not related to RUX and no new events reported at the time of the data cut-off. Thus, within this reporting period the risk for malignancies is low even with prolonged exposure (as in cGvHD). Long-term safety data including secondary malignancies are listed in the RMP as missing information and relevant information are incorporated in SmPC section 4.4. and 4.8.

## Assessment of paediatric data on clinical safety

In study REACH-2, 3 patients reported events of bone pain, musculoskeletal pain and osteoporosis (n=1 each), with low grade and 1 patient reported osteoporosis as a grade 2 event (on study day 106) resolving after treatment and considered not related to RUX. In REACH-3, no notable findings were observed in Tanner staging assessment. The non-clinical data showed that ruxolitinib administration to juvenile rats (PND 21, roughly corresponding to 2-year-old children) was associated with reduced bone size (diameter and/or lengths). Serious adverse effects consisting of degeneration of the physis and physeal fractures have been observed at higher systemic exposures when starting to dose from PND 7 (corresponding to preterm/neonate). Results in adolescent patients with sequential DEXA scan results revealed no clinically relevant change in the bone mineral density during the study, although data was limited to 4 subjects in RUX arm and 4 subjects in BAT arm. Additionally, no clinically relevant change in the weight and height was noted, which is reassuring.

Thus, the available DEXA scans and data on growth and development in adolescents in REACH-2 and REACH-3 studies did not confirm the safety concerns associated with bone toxicity. Moreover, the clinical relevance of the non-clinical results for the current indication for adults and adolescents is limited. Considering the information available in paediatric patients (&lt;12 years) is very limited at this point in time, the applicant adds this information as missing information in the RMP. Overall, the safety profile in adolescents could be considered similar to adults, although uncertainties are identified with respect to the small number of subjects and reassurance on the potential for bone toxicity is needed. When available Tanner and bone density measures and preliminary safety assessment of ongoing

<div style=\"page-break-after: always\"></div>

paediatric studies (Study INC424F12201 [REACH-4] in aGvHD and Study INC424G12201 [REACH-5] in cGvHD) are requested.

## 2.6.2. Conclusions on clinical safety

The overall safety profile of RUX-treated patients in both acute and chronic is consistent with its established safety profile and as expected in the study population. The safety profile of Jakavi is mainly characterised by cytopenias and infections. No new safety concerns were identified in the present GvHD studies with ruxolitinib therapy; however, ruxolitinib may be less tolerable in the GvHD setting compared to that of myelofibrosis or PV but appears to be manageable with the dose modification guidance.

## 2.6.3. PSUR cycle

The requirements for submission of periodic safety update reports for this medicinal product are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.

## 2.7. Risk management plan

The MAH submitted an updated RMP version with this application.

The CHMP received the following PRAC Advice on the submitted Risk Management Plan:

The PRAC considered that the risk management plan version 14.0 is acceptable.

The CHMP endorsed this advice without changes.

The CHMP endorsed the Risk Management Plan version 14.0 with the following content:

## Safety concerns

## Summary of safety concerns

| Important identified risks   | Serious infections                                                                                         |
|------------------------------|------------------------------------------------------------------------------------------------------------|
| Important potential risks    | Developmental toxicity Non-melanoma skin cancer (including basal, squamous and Merkel cell carcinoma)      |
| Missing information          | Long-term safety data, including secondary malignancies Safety in pediatric patients ≥12 years (GvHD only) |

## Pharmacovigilance plan

## Ongoing and planned additional pharmacovigilance activities

| Study Status                                                                                                               | Summary of objectives                                                                                                      | Safety concerns addressed                                                                                                  | Milestones                                                                                                                 | Due dates                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization | Category 1 - Imposed mandatory additional pharmacovigilance activities which are conditions of the marketing authorization |
| None                                                                                                                       |                                                                                                                            |                                                                                                                            |                                                                                                                            |                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| Study Status                                                                                                                                                                                                               | Summary of objectives                                                                                                                                                                                                                                                                            | Safety concerns addressed                                                                                                                                                                                                  | Milestones                                                                                                                                                                                                                 | Due dates                                                                                                                                                                                                                  |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances                                                                       | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances | Category 2 - Imposed mandatory additional pharmacovigilance activities which are Specific Obligations in the context of a conditional marketing authorization or a marketing authorization under exceptional circumstances |
| None                                                                                                                                                                                                                       |                                                                                                                                                                                                                                                                                                  |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |                                                                                                                                                                                                                            |
| Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                                                                                                    | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              | Category 3 - Required additional pharmacovigilance activities                                                                                                                                                              |
| Interventional study Study INC424F12201 Ongoing                                                                                                                                                                            | Phase I primary objective: To assess PK parameters (i.e. AUC, Cmax, T1/2, Ctrough) of ruxolitinib for patients with aGvHD and SR-aGvHD. Phase II primary objective: To measure the activity of ruxolitinib in patients with grade II-IV aGvHD or grade II-IV SR-aGvHD assessed by ORR at Day 28. | Safety in pediatric patients ≥12 years (GvHD only).                                                                                                                                                                        | Date of initiation Final CSR                                                                                                                                                                                               | Feb-2019 31-Mar-2024                                                                                                                                                                                                       |
| Interventional study Study INC424G12201 Ongoing                                                                                                                                                                            | To evaluate the activity of ruxolitinib added to standard dose corticosteroids, ± CNI, in pediatric subjects with moderate or severe treatment naive- cGvHD or SR-cGvHD                                                                                                                          | Safety in pediatric patients ≥12 years (GvHD only).                                                                                                                                                                        | Date of initiation Final CSR                                                                                                                                                                                               | May-2020 31-Dec-2025                                                                                                                                                                                                       |

## Risk minimisation measures

## Summary of risk minimization activities by safety concerns

| Safety concern             | Risk minimization measures                                                                                                                                                                                                                                     |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Important identified risks |                                                                                                                                                                                                                                                                |
| Serious infections         | Routine risk minimization measures: SmPC Section 4.4: Precaution for monitoring, treatment and description of risk factors and nature of risk. Section 4.8: The ADRs of UTI, HZ, pneumonia and sepsis are listed. Additional risk minimization measures: None. |
| Important potential risks  |                                                                                                                                                                                                                                                                |
| Developmental toxicity     | Routine risk minimization measures: SmPC Section 4.1 Section 4.2                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| Safety concern                                          | Risk minimization measures                                                                                                                                                                                                              |
|---------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                         | Section 4.3 Section 4.6 Section 5.3 There are no data from the use of ruxolitinib in pregnant women. Additional risk minimization measures: None.                                                                                       |
| Missing information                                     |                                                                                                                                                                                                                                         |
| Long-term safety data, including secondary malignancies | Routine risk minimization measures: The safety profile of ruxolitinib is described in SmPC Section 4.8. Currently available data do not support the need for additional risk minimization. Additional risk minimization measures: None. |
| Safety in pediatric patients ≥12 years (GvHD only)      | Routine risk minimization measures: SmPC Section 4.2: The ruxolitinib dose in pediatric patients with GvHD aged 12 years and older is the same as in adults. Additional risk minimization measures: None.                               |

## 2.8. update of the Product Information

As a consequence of this new indication, sections 4.1, 4.2, 4.4,  4.8, 5.1 and 5.2 of the SmPC have been updated with regards to acute and chronic GvHD. The Package Leaflet  has been updated accordingly. In addition, the list of local representatives in the PL has been revised to amend contact details for the representative of The Netherlands.

Please refer to Attachment 1 which includes all agreed changes to the Product Information.

## 2.8.1. User consultation

A justification for not performing a full user consultation with target patient groups on the package leaflet has been submitted by the MAH and has been found acceptable for the following reasons:

The information proposed in the Package leaflet maintain the currently approved layout and format and are not considered to require further consultation with target patient groups. The key information remain the same as for the currently approved PL or contain editorial changes only.

<div style=\"page-break-after: always\"></div>

## 3. Benefit-Risk Balance

## 3.1. Therapeutic Context

## 3.1.1. Disease or condition

Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment option for a variety of hematologic malignancies and also several non-malignant hematologic diseases.

Acute GvHD develops in 50% to 70% of patients after alloSCT with conventional prophylaxis and is one of the major barriers to successful transplant outcomes. The median time to onset (grade II-IV) of 2025 days after engraftment.

The pathogenesis of aGVHD is complex and is initiated when alloreactive donor immune cells recognize immunologically disparate antigens in the host. The risk of developing aGVHD depends on the degree of HLA match, recipient age, graft source, underlying disease diagnosis, intensity of conditioning regimen and GVHD prophylaxis used.

The clinical manifestations are seen primarily in three organs: the skin (maculopapular erythematous skin rash, erythroderma), the liver (cholestasis, hyperbilirubinemia, and/or jaundice), and the lower and upper gastrointestinal tract (nausea, abdominal pain, vomiting, anorexia with weight loss, secretory diarrhea, GI bleeding and/or ileus).

Patients who develop steroid-refractory acute graft-versus-host disease (SR-aGVHD) after allogeneic hematopoietic cell transplantation have poor prognosis. Systemic corticosteroids are the recommended first-line treatment of grades II to IV aGVHD, but less than 50% of patients achieve durable responses. The reported 6-month survival estimate for patients with steroid-refractory aGVHD is approximately 50%, with 30% or less of patients surviving beyond 2 years

Chronic GvHD is a major long-term complication after alloSCT, occurring most frequently after 100 days post-transplant with a median time to onset reported as 162 days post-transplant. While aGvHD is mainly a mature donor T cell-mediated inflammatory disease, cGvHD is characterized by the activation of complex signalling pathways in both T and B cells, reduced levels of circulating regulatory B cells (Bregs) and CD4+ Tregs

Among patients who undergo alloSCT, cGvHD occurs in 30% to 70% of patients. The occurrence of cGvHD varies depending on the donor type. Approximately 30% of cGvHD are de novo without any preceding aGvHD.

Chronic GvHD is a leading cause of non-relapse mortality and morbidity in patients surviving more than 2 years after transplantation and unfavourably affects physical and functional well-being as well as quality of life of most of the patients who are otherwise cured for their underlying disease after HSCT. Mild cGvHD is associated with a good prognosis whereas moderate and severe disease are associated with higher treatment-related mortality and lower survival. The 2-year overall survival (OS) reported for mild, moderate, and severe disease is 97%, 86%, and 62%, respectively.

Children are at less risk for GVHD than adults; however, that risk is still significant especially when using alternative donor sources. The incidence of grade II-IV aGvHD in children ranges from 28 to 56%, depending on the degree of histocompatibility, recipient age, underlying condition, and conditioning regimen used. The mortality in adolescent patients ≥ 12 years of age is, however, similar to that in adults (49% survive beyond 6 months). Grade II-IV SR-aGvHD adult

Chronic GvHD usually involves not only the epithelial target tissues affected in classic aGvHD (GI tract,

<div style=\"page-break-after: always\"></div>

liver, skin,) but also additional organ systems including lungs, muscles, fascia, joints, genitalia, eyes, and nails.

The final approved indication is:

Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies.

## 3.1.2. Available therapies and unmet medical need

There are no uniformly used, second-line treatments following corticosteroid resistance or sustained need, in SR-GvHD. Ibrutinib has been approved by FDA and Health Canada for the treatment of adult patients with cGvHD after failure of one or more lines of systemic therapy. Ruxolitinib is registered for the treatment of aGvHD in the US since 2019, and therefore, practices vary as to the selection of various systemic therapies but also depending on availability (e.g., ECP). There are no products approved for steroid refractory GVHD in the EU.

## 3.1.3. Main clinical studies

The Applicant provided two pivotal studies to support the two claimed indications,

- CINC424C2301 (REACH-2): A phase III randomized open-label multi-centre study of ruxolitinib versus BAT in patients with corticosteroid-refractory acute graft vs. host disease after allogeneic stem cell transplantation. Initiated 10-Mar-2017 and a DCO of 25-Jul-2019 for the primary analysis and 06Jan-2020, DCO for second analysis. The study is ongoing.

- CINC424D2301 (REACH-3): A phase III randomized open-label multi-centre study of ruxolitinib versus BAT in patients with corticosteroid-refractory chronic graft vs. host disease after allogeneic stem cell transplantation. Study initiation date: 29-Jun-2017 and DCO 08-May-2020 for the primary analysis. The study is ongoing.

A supportive Phase 2 study, INCB 18424-271 (REACH-1) was performed in SR-aGvHD.

The choice of best available therapy (BAT) for the control group in the two presented pivotal studies, was decided by the Investigator, from a list defined in the protocol before randomization in respective study.

Some treatment options were the same for aGvHD and cGvHD (Extracorporeal photopheresis (ECP)low-dose methotrexate (MTX) mycophenolate mofetil (MMF) mTOR inhibitors (everolimus or sirolimus) infliximab, while the choices anti-thymocyte globulin (ATG), mesenchymal stromal cells (MSC) and etanercept were unique for REACH-2 (aGvHD); and rituximab, pentostatin, imatinib and ibrutinib were unique choices for REACH-3 (cGvHD).

## 3.2. Favourable effects

## Pivotal study REACH-2; ruxolitinib versus vs BAT in SR-aGvHD

- ORR on Day 28 (primary endpoint, primary analysis) was 62.3% (95% CI: 54.2, 70.0) in the RUX arm and 39.4% (95% CI: 31.6, 47.5) in the BAT arm (p&lt;0.0001, stratified CochraneMantel-Haenszel test, one-sided, odds ratio: 2.64 with 95% CI: 1.65, 4.22). The results were maintained at the Second analysis.

<div style=\"page-break-after: always\"></div>

Subgroup analysis (follow-up data up + 6 months) indicated consistent results with that of the Primary analysis results. The OR favoured ruxolitinib across most of baseline characteristics subgroups.

- Durable ORR at Day 56 (key secondary endpoint, primary analysis) were in favour of ruxolitinib (OR: 2.38; 95% CI: 1.43, 3.94; p=0.0005). Results were maintained at the second analysis.
- Median DOR was longer in RUX arm (163 days, range: 22.0 to 623.0) than in BAT arm (101 days, range: 10.0 to 456.0).
- At Day 56, more patients in ruxolitinib arm (22.1%) had tapered off corticosteroids than in BAT arm (14.8%)

## Pivotal study REACH-3; ruxolitinib vs BAT in SR-cGvHD

- The ORR (Cycle 7 Day 1, primary endpoint, primary analysis) was 49.7% (95%CI: 41.8, 57.6) in the RUX arm and 25.6% (95%CI: 19.1, 33.0) in the BAT arm, odds ratio = 2.99 (95% CI: 1.86, 4.80) (stratified CMH test p&lt;0.0001, one-sided).
- FFS (failure free survival) showed a hazard ratio = 0.370 (95% CI: 0.268, 0.510), p&lt;0.0001 in favour of the RUX arm. The 6-months FFS probability was 74.89% (95% CI: 67.48, 80.85) in the RUX arm and 44.46% (95% CI: 36.46, 52.14) in the BAT arm.
- Significant improvement in TSS, cycle 7 day 1 (second Key secondary endpoint) was shown for the RUX arm compared to the BAT arm at the primary analysis. The odds ratio (RUX/BAT) was 2.62 (95% CI: 1.42, 4.82, stratified CMH test, p = 0.0011).
- Up to Cycle 7 Day 1, a numerically larger proportion of patients in the RUX arm (24.2%) had completely tapered off corticosteroids vs. 16.8% in the BAT arm.

In GvHD paediatric patients (12 years of age and older), the safety and efficacy of Jakavi are supported by evidence from the randomised phase 3 studies REACH2 and REACH3 (see section 4.2 for information on paediatric use). In REACH2, responses were observed at day 28 in 4/5 adolescent patients with acute GvHD (3 had CR and 1 had PR) in the ruxolitinib arm and in 3/4 adolescent patients (3 had CR) in the BAT arm. In REACH3, responses were observed at cycle 7 day 1 in 3/4 adolescent patients with chronic GvHD (all had PR) in the ruxolitinib arm and in 2/8 adolescent patients (both had PR) in the BAT arm.

## 3.3. Uncertainties and limitations about favourable effects

Both of the pivotal studies are characterised by high numbers of protocol deviations (PD), relating e.g., to aGVHD grading/staging, response assessment and the use of prohibited medication, which raised concerns, not least due to the open-label nature of the studies.  For REACH-2, 36.4% of the participants in the RUX arm and 43% in the BAT and for REACH 3, 41.8% in the RUX arm and 43.9% in the BAT arm, were excluded from the sensitivity analyses. A GCP inspection found that the process for PD management was not robust enough and should have been improved in order to enhance a timely resolution of PD, e.g., related to prohibited medication and organ staging assessment done per investigator criteria/judgement rather Harris.

Furthermore, with regard to BAT treatment accountability, which was not mandatory per study protocols, the inspection found that the Applicant failed to assure for non-IMP appropriate traceability and compliance (i.e., not compliant with the Guidance documents applying to clinical trials guidance on investigational medicinal products (IMPs) and 'non investigational medicinal products' (NIMPs) (rev. 1,

<div style=\"page-break-after: always\"></div>

March 2011)\"). In the worst scenario for the REACH 2, 12% of the trial participants and for the REACH 3, 41% of the trial participants receiving BAT, treatment compliance was not/insufficiently monitored. This introduces some uncertainty about estimates.

## aGVHD

For the primary endpoint of REACH-2, patients were assigned as failing to reach OR, if there was a need to intensify immunosuppression. Thus, it is presently unclear whether to understand the contribution of Jakavi to the treatment armamentarium is mainly as an alternative treatment option, and to what extent it contributes to a greater total treatment efficacy

Most responses noted at ORR Day 28, had already occurred at Day 14 (other secondary endpoint). However, ORR Day 56 (Durable ORR at Day 56) reveal that ORR dropped by 37% in the RUX arm and by 44% in the BAT arm between these two datum points, i.e. early responses, but for at large subset of responding patients, a short duration. Thus, there is some uncertainty about the extent of benefit shown.

## cGVHD

Even though an updated OS analysis has been performed, data are still immature,

For the primary endpoint, patients were assigned as failing to reach OR, if there was a need to intensify immunosuppression. Thus, it is unclear whether to understand the contribution of Jakavi to the treatment armamentarium is mainly as an alternative treatment option or to what extent it contributes to a greater total treatment efficacy.

FFS is a composite endpoint, as described above. As anticipated, this endpoint is driven by impact on addition or initiation of another systemic therapy, while there is no indication of any impact of treatment on relapse of underlying disease or non-relapse mortality.

For REACH 3 most responses noted for the primary endpoint ORR Cycle 7 Day 1, had already occurred at Cycle 4 Day 1 (other secondary endpoint). The endpoint BOR shows that one third of the initial responses to ruxolitinib were no longer recorded at the timepoint of the primary endpoint in cGvHD. However, early discontinuation, deaths, changes in systemic cGvHD treatment before Cycle 7 Day 1 or missing visits were the main reasons for the differences in BOR and ORR therefore, not necessarily meaning treatment failure or loss of response in all cases.

The patient reported outcome TSS (second key secondary endpoint) derives from an open-label study. The risk of bias due to this cannot be measured or ascertained. Furthermore, the 'mLSS' symptom scale on which TSS was based, according to the GCP inspectors, was not validated prior to start of the trial.

## REACH-2 and REACH-3

Efficacy in patients with low grade GvHD and in patients who received more than one prior systemic treatment for SR GvHD has not been investigated (for both pivotal trials).

The number of investigated adolescent patients is very limited (n=9 in total for both pivotal trials), emphasizing the need for extrapolation of adult data.

Response rates seem similar to BAT or even more in favour of BAT in small subgroups of patients &gt;65 years of age (aGvHD), region Asia (a+cGvHD) and some subgroups with prior steroid + CNI + other systemic therapy for a or cGvHD. With regard to this last subgroup, heterogeneity in previously

<div style=\"page-break-after: always\"></div>

allowed as well as concomitant treatment and prophylaxis regimes for GvHD make it difficult to interpret results.

The impact of RUX in terms of OS is uncertain since interpretation of data is hampered by cross-over in &gt;30% of patients in both trials.

Efficacy in patients with overlap syndrome, GvHD after pre-emptive treatment of malignancy recurrence with donor lymphocyte infusion and patients that did not tolerate steroid treatment is unknown.

## 3.4. Unfavourable effects

## aGvHD REACH-2

The side effects profile by SOC is mainly characterised by hematological adverse events and infections. Other AEs by SOC frequently seen in were investigations, GI-disorders, general disorders, metabolism and nutrition and respiratory, thoracic and mediastinal disorders.

- AEs leading to treatment discontinuations Up to Day 28: 11.2% and 4.0% in the RUX arm and BAT arm, respectively.

Up to the second DCO, AEs leading to discontinuation were observed in 27% in the RUX arm and 9.3% in the BAT arm.

- AEs leading to Dose adjustment or interruption up to Day 28, 36.8% and 9.3% the RUX arm and BAT arm, respectively.

Up to DCO AEs (all grades) leading to dose adjustment or interruption, was 54.6% in the RUX arm and 13.3% in the BAT arm Most of the AEs were of grade ≥ 3 in severity (in (50.0% and 9.3%), driven by cytopenias.

- Deaths up to Day 28: there were 9.9% and 14.0% on-treatment deaths recorded in RUX arm and the BAT arm, respectively. The primary reason for death was aGvHD.

Up to DCO there were a total of 168 deaths, 53.9% deaths in the RUX arm and 57.3% deaths in the BAT arm. Deaths due to aGvHD occurred in 24.3% in the RUX arm and 25.3% in the BAT arm.

- SAEs Up to Day 28: 37.5% in the RUX arm and 34.0% in the BAT arm. By SOC: Infections and infestations (21.7% vs. 17.3%) and by PT, Sepsis (5.3% vs. 2.0%), CMV infection (2.6% vs. 3.3%), Respiratory failure and septic shock (2.6% vs. 2.7%, each) and Pneumonia (2.0% each)

SAEs Up to DCO were reported in 66.4% patients in RUX arm and 53.3% in BAT arm. The difference was mainly driven by the SOC of infections and infestations (38.2% in the RUX arm and 30.0% in the BAT arm)

## AESIs

- Hematological AEs up to Day 28, with respect to hematological events, were recorded in 58% (Gr ≥3: 47.4%) in the RUX arm and 44.7% (Gr ≥3: 4.7%) in the BAT arm.

AEs by PT, up to Day 28, were thrombocytopenia (50.0% vs. 32.7%) anemia (30.3% vs 28.0%), leukopenia (32.9% vs 26.7%) neutropenia (15.8% vs. 12.7%) and neutrophil count decreased (6.6% vs 10.0%) in the RUX arm and the BAT arm, respectively.

<div style=\"page-break-after: always\"></div>

Up to the Secondary analysis DCO, the overall incidence of thrombocytopenia events increased to 56.6% (Grade ≥ 3: 50.7%) in RUX arm and 36.7% (Grade ≥ 3: 32.0%) in BAT arm the overall incidence of anemia 40.8% (Grade ≥ 3: 36.2%) in the RUX arm and 34.0% (Grade ≥ 3: 25.3%) in the BAT arm leukopenia in 46.7% (Grade ≥ 3: 42.2%) and 32.0% (Grade ≥ 3: 27.3%) in the RUX arm and the BAT arm, respectively.

- AEs Infections Up to Day 28, were reported in 61.2% the RUX arm vs 58.7% the BAT arm. The proportion of opportunistic infections during period up to Day 28 was 27% vs 22% in the RUX vs BAT arm and cytomegalovirus infection (25.7% vs. 20.7%).

AE pneumonia up to Day 28 was seen in 27% vs 22% in the RUX vs BAT arm and CMV infections were reported in 28.3% in the RUX arm vs. 24.0% the BAT arm.

## cGvHD REACH-3

Similar to aGvHD as well as the other studied indications, the side effects profile is mainly characterised by hematological adverse events and infections. Other AEs by SOC frequently seen in were investigations, GI-disorders, general disorders, metabolism and nutrition and respiratory, thoracic and mediastinal disorders as in the pivotal for aGvHD.

- AEs leading to Treatment discontinuations: Up to Cycle 7 Day 1: AEs leading to study treatment discontinuation were 16.4% vs. 7.0% in the BAT arm. Pneumonia was the most common (≥ 2% patients) AE leading to discontinuation in both arms.

Up to DCO, AEs (all grades) leading to discontinuations were reported in 18.1% and grade ≥ 3 AEs in 13.3% of ruxolitinib treated patients.

- AEs leading to Dose adjustment or interruption up to Cycle 7 Day 1: AEs leading to dose adjustment or interruption were 37.6% vs. 16.5% in the RUX arm and the BAT arm respectively.

AEs leading to Dose adjustment or interruption Up to DCO for the main treatment period occurred in 43.0% in the RUX arm and 18.4% in the BAT arm.

- Deaths Up to Cycle 7 Day 1: 7.9% patients in the RUX arm and 5.7% patients in BAT arm died on treatment. Study indication, cGvHD, was the main cause of death.

Deaths Up to the DCO were 18.8% in the RUX arm and 16.5% in the BAT arm.

- SAEs Up to Cycle 7 Day 1, were observed in 33.3% in the RUX arm and 36.7% in the BAT arm. By PT, the most frequent SAEs were pneumonia, pyrexia, lower respiratory tract infection, and bronchopulmonary aspergillosis.

SAEs Up to DCO were seen in 43.6% of patients in the RUX arm and 39.9% in the BAT arm.

## AESIs

- Hematological AEs up to Cycle 7, Day 1, were recorded in 41.8% (Gr ≥3 23.0%) in the RUX arm and 22.2% (Gr ≥3 15.8%).

AEs by PT, up Cycle 7 Day 1, subjects with at least one event of thrombocytopenia were 21.2% vs. 14.6%, anemia 29.7% vs 12.7%, leukopenia 18.8% vs 13.9%) in the RUX arm and the BAT arm, respectively.

Up to the Secondary analysis DCO, events of thrombocytopenia were 23.0% (Grade ≥ 3: 17.6%) in the RUX arm and 15.8% (Grade ≥ 3: 11.4%) in the BAT arm, the overall incidence of anemia was 32.1% (Grade ≥ 3: 15.2%) in the RUX arm and 13.9% (Grade ≥ 3: 7.6%) in the

<div style=\"page-break-after: always\"></div>

BAT arm, leukopenia in 23.6% (Grade ≥ 3: 18.8%) and 14.6% (Grade ≥ 3: 11.4%) in the RUX arm and the BAT arm, respectively.

- AEs Infection Up to Cycle 7 Day 1, were reported for 62.4% vs. 58.2% in the RUX arm and the BAT arm respectively.

The most frequently reported infectious events by PT (RUX vs BAT arm) were pneumonia (10.9% and 12.7%), upper respiratory tract infection (8.5% and 8.2%), urinary tract infection (6.7% and 3.2%), nasopharyngitis (6.1% and 3.8%), BK virus infection (5.5% and 1.3%), CMV infection (5.5% and 8.2%), influenza (4.8% and 3.8%), and conjunctivitis (4.8% and 2.5%).

- AE pneumonia up to up to Cycle 7, Day 1 was seen in 11% vs 12% in the respective treatment arm (RUX vs BAT) and CMV infections in 9.1% in the RUX arm vs. 10.8% in the BAT arm. Other PT CMV infections were also separately reported.

## 3.5. Uncertainties and limitations about unfavourable effects

Assessment of the safety profile of ruxolitinib and the crude incidence of AEs is challenging in a setting of immune compromised patients with severe underlying disease and concomitant use of corticosteroids and CNI bringing uncertainties with respect to the assessment of treatment-related AEs.

The latest updated OS data are 25 Jun 2021 for REACH-3 (22.4% vs 22.0% for the RUX and the BAT arm respectively). The allowance of cross-over in both studies creates a bias towards unity with regards to the impact of treatment on OS.

A proportion of treatment related AEs in REACH2 were not resolved at data cut-off, however, this was based on AEs that were not recovered/not resolved in patients who discontinued and who have finished their 30-day safety follow-up. In both REACH 2 and REACH 3 the most frequent AEs that were not resolved were cytopenias, all other SAEs were reported infrequent and with no specific pattern and not leading to new safety concerns.

The requested indication includes adolescents. The AE profile was largely similar to adults with some exceptions. Nevertheless, RUX treatment is studied in a limited dataset (5 patients with aGVHD, 4 patients with cGvHD).

A significant proportion of subjects in study REACH 2 (19.1%) and REACH 3 (23%) discontinued RUX treatment due to physician decision (thus not classified as discontinuation due to lack of efficacy or due to an AE), it is unclear what the primary reason for discontinuation is and further information was not captured in the CRFs.

## 3.6. Effects Table

## Effects Table for Jakavi (ruxolitinib)

<!-- image -->

| Effect                                                                                                                 | Short descriptio n Unit                                                                                                | Treatment Ruxolitinib 10 mg BID                                                                                        | Control BAT                                                                                                            | Uncertainties / Strength of evidence References                                                                        |
|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------|
| Favourable Effects REACH-2 aGvHD: Data cut offs: 25-Jul-2019 (Primary analysis, PA), 06-Jan-2020 (second analysis, SA) | Favourable Effects REACH-2 aGvHD: Data cut offs: 25-Jul-2019 (Primary analysis, PA), 06-Jan-2020 (second analysis, SA) | Favourable Effects REACH-2 aGvHD: Data cut offs: 25-Jul-2019 (Primary analysis, PA), 06-Jan-2020 (second analysis, SA) | Favourable Effects REACH-2 aGvHD: Data cut offs: 25-Jul-2019 (Primary analysis, PA), 06-Jan-2020 (second analysis, SA) | Favourable Effects REACH-2 aGvHD: Data cut offs: 25-Jul-2019 (Primary analysis, PA), 06-Jan-2020 (second analysis, SA) |
|                                                                                                                        |                                                                                                                        | N=154                                                                                                                  | N=155                                                                                                                  | One-sided p- values                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Effect                              | Short descriptio n                           | Unit   | Treatment Ruxolitinib 10 mg BID   | Control BAT              | Uncertainties / Strength of evidence      | References                                                                         |
|-------------------------------------|----------------------------------------------|--------|-----------------------------------|--------------------------|-------------------------------------------|------------------------------------------------------------------------------------|
| ORR by INV, at Day 28               | Overall response rate (CR + PR)              | %      | 62.3 95% CI (54.2, 70.0)          | 39.4 95% CI (31.6, 47.5) | OR: 2.64: 95% CI (1.65, 4.22). p<0.0001   | Primary endpoint (PA)                                                              |
| Durable ORR at Day 56               | responders only                              | %      | 39.6 95% CI (31.8, 47.8)          | 21.9 95% CI (15.7, 29.3) | OR: 2.38: 95% CI (1.43, 3.94) p=0.0005.   | Key secondary endpoint (PA)                                                        |
| BOR Best overall response by Day 28 | ORR at any time point up to and incl. Day 28 | %      | 81.8 95% CI (74.8, 87.6)          | 60.5 95% CI (52.5, 68.4) | OR*: 3.07: 95% CI (1.80, 5.25) p<0.0001   | Other secondary endpoints (PA) goes for all endpoints below                        |
| DoR Duration of response (Median)   | Composite endpoint a                         | Days   | 163 range: 22.0 to 623.0          | 101 range: 10.0 to 456.0 | NS*                                       | Only pat who had a CR or PR at or before Day 28 (SA, goes for all endpoints below) |
| OS (Median)                         | Overall Survival                             | months | 10.71                             | 5.82                     | HR: 0.83 (0.62, 1.13) P=0.2648 NS*        |                                                                                    |
| EFS Event free survival (Median)    | Composite b endpoint                         | months | 8.18                              | 4,17                     | HR: 0.80 (0.60, 1.08) NS*                 |                                                                                    |
| FFS Failure free survival (Median)  | Composite c endpoint                         | months | 4.86                              | 1.02                     | HR: 0.49, 95% CI: 0.37, 0.63) Descriptive |                                                                                    |

## Favourable Effects REACH-3 cGvHD:

## Data cut-off: 08-May-2020 Primary Analysis (PA)

|                                           |                                     |        | N=165                   | N=164                   |                                           |                                    |
|-------------------------------------------|-------------------------------------|--------|-------------------------|-------------------------|-------------------------------------------|------------------------------------|
| ORR at Cycle 7 Day 1                      | (CR + PR)                           | %      | 49.7 95%CI (41.8, 57.6) | 25.6 95%CI (19.1, 33.0) | OR: 2.99 95% CI (1.86, 4.80) p<0.0001     | Primary endpoint (PA)              |
| FFS Failure free survival Median          | Composite endpoint                  | months | NE (18.6, NE)           | 5.7 (5.6, 6.5)          | HR: 0.370 95% CI (0.268, 0.510) p<0.0001. | First Key secondary endpoint (PA)  |
| TSS PRO based on the total symptom score, | Based on modified Lee symptom scale |        | 24.2 (17.9, 31.5)       | 11.0 (6.6, 16.8)        | OR: 2.62 (95% CI: 1.42, 4.82) p = 0.0011  | Second Key secondary endpoint (PA) |
| BOR up to Cycle 7 Day 1                   |                                     | %      | 76.4 (69.1, 82.6)       | 60.4 (52.4, 67.9)       | 2.17 (95% CI: 1.34, 3.52)*                |                                    |
| OS                                        |                                     | n/N    | 37/165                  | 36/164                  | HR: 0,956 ((95% CI: 0.604, 1.512)*        | (updated 25 Jun 2021               |
| DOR                                       |                                     | months | NE (20.2,               | 6.2 (4.7,               | Descriptive                               | Measured only                      |

<div style=\"page-break-after: always\"></div>

| Effect                                                                | Short descriptio n                                                                                                    | Unit                         | Treatment Ruxolitinib 10 mg BID                                                  | Control BAT                                                                       | Uncertainties / Strength of evidence   | References                                            |
|-----------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|------------------------------|----------------------------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------|-------------------------------------------------------|
| (Median)                                                              |                                                                                                                       |                              | NE)                                                                              | 13.3)                                                                             |                                        | pat who had a CR or PR at or before Cycle 7, Day (PA) |
| Unfavourable Effects REACH-2                                          | Unfavourable Effects REACH-2                                                                                          | Unfavourable Effects REACH-2 | Unfavourable Effects REACH-2                                                     | Unfavourable Effects REACH-2                                                      | Unfavourable Effects REACH-2           | Unfavourable Effects REACH-2                          |
|                                                                       | Up to SA data cut- off                                                                                                | %                            | N=154                                                                            | N=155                                                                             |                                        |                                                       |
| Any AE AE Gr ≥ 3 AE leading to dose adjustment /interrupt. AE leading |                                                                                                                       |                              | 99.3 91.4 54.6 27                                                                | 98.7 87.3 13.3 9.3                                                                |                                        |                                                       |
| TEAEs ≥ 40 %                                                          | Infections Blood and lymphatic disorder G-I disorder Investigati ons General                                          | %                            | 81.6 71.1 63.8 58.6 53.9                                                         | 71.3 51.3 50.0 46.0 50.0                                                          |                                        |                                                       |
| AEs by PT >20%                                                        | Metabolism /nutrition Anemia Thrombocy topenia Neutropen. CMV infect. Oedema peripheral Hypokalem ia Pyrexia Platelet | Any/Gr ≥3 (%)                | 50.0 40.1/35.5 36.8/33.6 24.3/21.7 30.9/9.2 24.3/2.0 22.4/9.9 22.9/2.0 20.4/17.8 | 53.3 32.0/24.0 20.7/16.7 14.7/12.0 26.7/12.0 21.3/2,0 21.3/2.0 21.3/2.0 16.0/15.3 |                                        |                                                       |
| Treatment related AEs (suspected)                                     | Blood and lymphatic disorder Investigati                                                                              | All/Gr≥ 3 (%)                | 40.1/36.2 28.9/22.4                                                              | 10.0/8.7 12.7/9.3                                                                 |                                        |                                                       |

<div style=\"page-break-after: always\"></div>

| Effect                             | Short descriptio n                                                                                                                                                                                   | Unit                         | Treatment Ruxolitinib 10 mg BID                                         | Control BAT                                                            | Uncertainties / Strength of evidence   | References                   |
|------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------|-------------------------------------------------------------------------|------------------------------------------------------------------------|----------------------------------------|------------------------------|
| AESI Gr≥ 3 >10%                    | GI disorder Nerv. System disorders Trombocyt openia Leucopenia Anemia Infection (excl Tb)** CMV infect ion (any grade/ Gr≥3 ) Sepsis/cho ck Pneumonia Opportun. Infections Other infections Bleeding |                              | 13.8/5.3 7.9/2.6 50.7 42.8 36.2 52.0 30.9 (9.2) 20.4 11.8 7.9 27.0 12.5 | 3.3/1.3 4.0/1.3 32.0 27.3 25.3 47.3 26.7 (12.0) 18.0 14.0 4.7 24.0 7.3 |                                        |                              |
| SAEs                               |                                                                                                                                                                                                      | %                            | 66.4                                                                    | 53.3                                                                   |                                        |                              |
| SAE Gr≥ 3                          | Sepsis Septic chock                                                                                                                                                                                  | %                            | 63.8 5.3 4.6                                                            | 50.0 2.7 2.7                                                           |                                        |                              |
| Fatal SAEs Deaths up to DCO        |                                                                                                                                                                                                      | %                            | 21.7 53.9                                                               | 21.3 57.3                                                              |                                        |                              |
| Deaths (on treatment)              |                                                                                                                                                                                                      | %                            | 28.3                                                                    | 24.0                                                                   |                                        |                              |
| Deaths due to aGvHD                |                                                                                                                                                                                                      | %                            | 13.8                                                                    | 14.0                                                                   |                                        |                              |
| Deaths (suspect treatment related) |                                                                                                                                                                                                      | N                            | 10                                                                      | 4                                                                      |                                        |                              |
| Unfavourable Effects REACH-3       | Unfavourable Effects REACH-3                                                                                                                                                                         | Unfavourable Effects REACH-3 | Unfavourable Effects REACH-3                                            | Unfavourable Effects REACH-3                                           | Unfavourable Effects REACH-3           | Unfavourable Effects REACH-3 |
| cGvHD                              | During the Main treatment period                                                                                                                                                                     | %                            | N=165                                                                   | N=164                                                                  |                                        |                              |
| Any AE AE Gr ≥ 3 AE                |                                                                                                                                                                                                      |                              | 98.2                                                                    | 92.4 58.9 18.4                                                         |                                        |                              |
| leading to dose                    |                                                                                                                                                                                                      |                              | 66.1 43.0                                                               |                                                                        |                                        |                              |

<div style=\"page-break-after: always\"></div>

| Effect                 | Short descriptio n                                                                                                                                                                                  | Unit      | Treatment Ruxolitinib 10 mg BID                                                                                                                 | Control BAT                                                                                                                        | Uncertainties / Strength of evidence   | References   |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------|
| adjustment /interrupt. |                                                                                                                                                                                                     |           |                                                                                                                                                 |                                                                                                                                    |                                        |              |
| AE leading to discont. |                                                                                                                                                                                                     |           | 20.6                                                                                                                                            | 8.9                                                                                                                                |                                        |              |
| TEAEs ≥ 40 % By SOC    | Infections Investigati ons Blood and lymphatic disorder Metabolism /nutrition Respiratory etc GI disorder                                                                                           | Any/Gr ≥3 | 71.5/26.1 56.4/29.7 46.1/28.5 44.2/21.2 43.6/12.1 42.4/6.1                                                                                      | 65.8/22.2 34.8/17.7 24.1/16.5 38.0/15.2 34.8/9.5 42.4/9.5                                                                          |                                        |              |
| AEs by PT >10%         | disorders Anemia Pyrexia ALT increase Hypertensi on Blood creatin. Increase Diarrhoea Pneumonia Cough Neutropenia Fatigue Trombocyto penia Nausea Dyspnoea Platelets decrease AST increased GammaGT | Any/Gr ≥3 | 32.1/15.2 20.0/3.0 17.6/6.1 17.6/5.5 15.8/0 15.8/1.2 15.8/13.3 13.9/0.6 13.9/12.1 12.1/0.6 12.1/11.5 11.5/0 10.9/1.8 10.9/6.1 10.3/1.8 10.3/7.3 | 13.9/7.6 10.8/1.3 4.4/0 13.3/7.0 4.4/0.6 15.8/1.9 13.3/10.1 8.9/0 5.1/3.1 10.1/1.9 8.9/5.9 7.0/1.9 7.0/1.9 7.0/5.7 2.5/0.6 3.8/2.5 |                                        |              |
| Treatment              |                                                                                                                                                                                                     | Any/Gr    |                                                                                                                                                 |                                                                                                                                    |                                        |              |
| related AEs (susp) >5% | Anemia Neutropen. ALT increased Trombocyt openia Platelet count decreased Pneumonia AST increased Blood creatin.                                                                                    | ≥3        | 23.6/10.3 10.9/8.5 10.3/4.2 9.1/8.5 6.1/3.0 7.3/6.7 5.5/0.6 5.5/0                                                                               | 3.2/1.3 3.271.3 0.6/0 3.8/1.3 1.9/1.3 3.2/2.5 0.6/0 0.6/0                                                                          |                                        |              |

<div style=\"page-break-after: always\"></div>

| Effect                | Short descriptio n                                                                                                                                                                                              | Unit          | Treatment Ruxolitinib 10 mg BID                                                                                           | Control BAT                                                                                                          | Uncertainties / Strength of evidence   | References   |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|---------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------|----------------------------------------|--------------|
| AESI >10%             | increased Infection (excl Tb)** Pneumonia Opportun. Infections UTI CMV infec tion (any grade) Other infections Anemia Leucopenia Trombocyt openia Bleeding events Elevated ALT/AST Lipid abnormal Hypertensi on | Any/Gr ≥3     | 72.1/26.7 23.6/18.2 12.7/3.6 10.9/1.8 5.5/1.2 58.8/10.9 32.1/15.2 23.6/18.8 23.0/17.6 12.7/3.0 20.6/8.5 20.6/7.3 18.2/6.7 | 65.8/22.2 17.7/14.6 13.3/3.8 9.5/1.9 8.9/0 53.2/10.8 13.9/7.6 14.6/11.4 15.8/11.4 16.5/3.2 7.6/0.6 14.6/7.0 13.3/7.0 |                                        |              |
| SAEs                  |                                                                                                                                                                                                                 | Any/Gr ≥3 (%) | 43.6/40.0                                                                                                                 | 39.9/36.1                                                                                                            |                                        |              |
| >5%                   | Pneumonia Pyrexia                                                                                                                                                                                               |               | 12.7/12.1 6.7/3.0                                                                                                         | 8.9/7.6 2.5/1.3                                                                                                      |                                        |              |
| Fatal SAEs            |                                                                                                                                                                                                                 |               | 9.1                                                                                                                       | 6.3                                                                                                                  |                                        |              |
| Deaths                |                                                                                                                                                                                                                 |               | 18.8                                                                                                                      | 16.5                                                                                                                 |                                        |              |
| Deaths (on treatment) |                                                                                                                                                                                                                 |               | 9.7                                                                                                                       | 5.7                                                                                                                  |                                        |              |
| Deaths due to cGvHD   |                                                                                                                                                                                                                 |               | 8.5                                                                                                                       | 4.4                                                                                                                  |                                        |              |

*Not corrected for multiplicity

** No Tb cases reported

Abbreviations: OR=Odds ratio, NS=not significant, HR= Hazard ratio, NE= not estimated, NRM=nonrelapse mortality, PA=primary analysis, SA=second analysis, IA=interim analysis

## Notes:

- a i ) Progression of aGvHD ii ) addition of systemic therapy for aGvHD after D28. Competing risk: death without prior observation of aGvHD and onset of cGvHD
- b i ) Hematol disease relapse ii ) graft failure or death due to any cause
- c i ) hematologic disease relapse/progression ii ) NRM iii ) addition of new systemic aGvHD treatment. Competing risk: cGvHD

d i ) relapse or recurrence of underlying disease or death due to underlying disease ii ) non-relapse mortality iii ) addition or initiation of another systemic therapy for cGvHD.

<div style=\"page-break-after: always\"></div>

## 3.7. Benefit-risk assessment and discussion

## 3.7.1. Importance of favourable and unfavourable effects

The applicant has selected objective response rate as primary endpoint in each of its studies on acute and chronic GvHD. While this is anticipated to confer symptomatic benefit, the applicant claims it is a surrogate for long term outcomes. The applicant has provided statistically robust evidence of the effects of ruxolitinib on this endpoint as defined. However, intensification of immunosuppressive treatment was considered failure to reach an objective response in the primary analysis. Thus, it remains unclear to what extent this is due to an overall increase in regimen efficacy, and to what extent this is due to sparing of other drugs through substitution. In either case, this is considered clinical benefit.

The safety profile of Jakavi is similar to what has been seen in the previously approved indications and is dominated by cytopenias and increased risk of infection. There was no apparent increase in the risk of relapse or progression of malignancy.

No effects on OS have been shown, which may be impacted by the cross-over option which creates bias towards unity.

The proposed indication does not specify GvHD type or grade and allows treatment of patients that are first line steroid refractory as well as patients that have received multiple systemic therapies for GvHD. A reference to section 5.1 in the indication has therefore, been provided with regard to detailed information of the studied population.

Overall, despite one critical finding and several major findings identified during the GCP inspection which showed that on several key aspects the processes were not robust for a sound conduct of the study and/or failing to prevent deviations from ICH-GCP, it was the recommendation of the inspectors that the data of the REACH-2 and REACH-3 clinical trials were of sufficient quality to be used for evaluation and assessment of the application, though the inspectors deferred to the assessors for the final conclusion on the impact of the lacking documentation on best available therapy (BAT) accountability in REACH- 2 and REACH-3.

Notably, the study protocols for the REACH-2 and REACH-3 clinical trials explicitly warranted drug accountability for ruxolitinib only, but according to the most conservative assessment of the inspection team, for 12% out of 150 trial participants for REACH-2 and 41% out of 159 patients for REACH-3, BAT treatment compliance was insufficiently monitored. For a cute GvHD the approximately 12% of patients without drug accountability for BAT in REACH-2 still allows sufficient interpretation of clinical study results, allowing for a positive B/R.

Additional exploratory analyses to assess the primary efficacy response of the different types of BAT used in the chronic GvHD study REACH-3 showed for each independent BAT a lower ORR than the response rate reported in patients treated with RUX, regardless of the administration route and/or clinical setting, i.e. in hospital / at home. Furthermore, the in-hospital BATs, which have high drug accountability (due to the setting), and the at-home BATs showed similar ORR per BAT. These exploratory results together are suggestive of a limited (if any) impact of the potential lower BAT compliance (worst case) in the at-home setting.

As OS is multifactorial, for which BAT compliance is only one parameter of interest, it remains difficult to establish whether potential non-compliance in the BAT arm has substantially influenced OS outcomes. It is reassuring that with the latest OS update no sign of detriment was observed.

<div style=\"page-break-after: always\"></div>

Finally, even if outcomes would have been comparable to BAT, ruxolitinib could still be acceptable as new treatment modality for chronic GvHD. Therefore, despite some remaining uncertainties on the impact of potential non-compliance on the efficacy results due to the exploratory nature of the additional analyses, the B/R of ruxolitinib is considered positive in chronic GvHD as well.

## 3.8. Conclusions

The B/R of Jakavi is positive in acute GvHD and chronic GvHD. Final OS data from REACH-3, including modelling of the impact of cross-over, should be provided as a post marketing recommendation.

## 4. Recommendations

## Outcome

Based on the review of the submitted data, the CHMP considers the following variation acceptable and therefore recommends the variation to the terms of the Marketing Authorisation, concerning the following change:

| Variation accepted   | Variation accepted                                                                                                             | Type    | Annexes affected   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------|---------|--------------------|
| C.I.6.a              | C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one | Type II | I and IIIB         |

Extension of indication to include treatment of patients with acute and chronic GvHD aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies for Jakavi; as a consequence, sections 4.1, 4.2, 4.4, 4.8. 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 14.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representative for The Netherlands in the Package Leaflet.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).

## Amendments to the marketing authorisation

In view of the data submitted with the variation, amendments to Annex(es) I and IIIB and to the Risk Management Plan are recommended.

## Paediatric data

Furthermore, the CHMP reviewed the available paediatric data of studies subject to the agreed Paediatric Investigation Plan EMEA-000901-PIP03-16-M01 and EMEA-000901-PIP04-17-M01and the results of these studies are reflected in the Summary of Product Characteristics (SmPC) and, as appropriate, the Package Leaflet.

<div style=\"page-break-after: always\"></div>

## 5. EPAR changes

The EPAR will be updated following Commission Decision for this variation. In particular the EPAR module \" steps after the authorisation \" will be updated as follows:

## Scope

Please refer to the Recommendations section above.

## Summary

Please refer to Scientific Discussion 'Jakavi-H-C-2464-II-0053'